AU758249B2 - Radiopharmaceuticals for imaging infection and inflamation - Google Patents

Description

P/00/011 Regulation 3.2

AUSTRALIA

Patents Act 1990 COMPLETE SPECIFICATION FOR A DIVISIONAL PATENT 0 ORIGINAL Name of Applicant: Actual Inventor(s): Address for Service: Invention Title: TO BE COMPLETED BY APPLICANT DUPONT PHARMACEUTICALS COMPANY John Andrew Barrett; Edward Hollister Cheesman; Thomas David Harris; Milind Rajopadhye CALLINAN LAWRIE, 711 High Street, Kew, Victoria 3101, Australia RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND

INFLAMMATION

The following statement is a full description of this invention, including the best method of performing it known to me:- 29/05/01,cfl2100.fcl

TITLE

RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION FIELD OF THE INVENTION The present invention provides novel radiopharmaceuticals useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis. The radiopharmaceuticals bind in vivo to the leukotriene B4 (LTB4) receptor on the surface of leukocytes which accumulate at the site of infection and inflammation. The reagents provided by this invention are also useful for the treatment of diseases associated with infection and inflammation.

S'BACKGROUND OF THE INVENTION 20 The rapid diagnosis of diseases associated with focal infection and inflammation is a currently unmet clinical need.

Inflammation is the result of the detection of an abnormality in the body, such as infection, by leukocytes. Leukocytes become activated and gravitate toward the site of the 25 abnormality. When the leukocytes become fully activated they degranulate and release proteolytic enzymes as well as chemoattractants resulting in a chemotactic gradient and as a oo consequence the recruitment of additional leukocytes. The result is a concentration of activated leukocytes at the site.

This localization provides a means for diagnosing diseases associated with infection and inflammation through the use of leukocytes labeled with an externally detectable radioisotope and gamma scintigraphy.

Two approaches have been taken to utilize this mechanism for imaging infection and inflammation. The first involves isolating leukocytes from a patient, labeling the leukocytes with a radioisotope and then reinjecting the radiolabeled autologous leukocytes into the patient. This approach has several drawbacks including the effect of the labeling methodology on the biological activity of the leukocytes manifest as a diminished number of competent leukocytes, and the hazards and inconvenience of handling the patient's blood.

The second approach involves injecting into the patient a radiopharmaceutical that binds to activated leukocytes in vivo.

An example of the in vivo labeling approach is the use of radiolabeled monoclonal antibodies or fragments thereof that are directed against a leukocyte activation marker, as described in Morgan, Jr., U.S. Patent 5,376,356. A leukocyte activation marker is an antigen on the surface of the leukocyte that is poorly expressed or not expressed at all until activation of the leukocyte. This approach suffers from the disadvantages associated with the use of many Sproteinaceous radiopharmaceuticals as diagnostics, namely, generally slow blood clearance which results in high :background activity unless an inconveniently long period of time is allowed to pass between injection and imaging, and the 20 possibility of an allergic reaction by the patient to a foreign protein.

It has been proposed that these problems can be overcome by using radiolabeled peptides that bind in vivo to surface receptors on activated leukocytes (Fischman et. al., Semin.

Nucl. Med., 1994, 24, pp 154-168). The chemotactic peptide, fMLF, labeled with In-1ll or Tc-99m have been shown to accumulate at sites of infection in experimental animal models. However, the peptide fMLF is a potent agonist for the leukocytes and thus has limited clinical applicability in a diagnostic radiopharmaceutical. The limitations include the potential for serious deleterious effects to the patient, such as a severe drop in white blood cell count, resulting from the activation of the leukocytes upon injection of even small amounts of the potent agonist peptide.

Another alternative approach has been described by Rubin et. al. in U.S. Patent 4,926,869 involving the use of a radiolabeled immunoglobulin or fragment thereof. The immunoglobulin accumulates at the site of infection or inflammation by a non-specific mechanism attributed to the leakage of labeled immunoglobulin from the circulation into the greatly expanded protein space at the site. However, this approach suffers from the same disadvantages associated with the use of a proteinaceous substance as described above.

Therefore, there remains a need for new radiopharmaceuticals for imaging infection and inflammation that have improved pharmacokinetics, especially faster blood clearance, and do not cause serious side-effects in patients.

Leukotriene B4 (LTB4) is synthesized from arachidonic acid by the action of 5-lipoxygenase and leukotriene A4 hydrolase. LTB4 is released by polymorphonuclear leukocytes (PMN), macrophages, mast.cells, basophils and monocytes with each cell type having an LTB4 surface receptor. Endothelial cells, eosinophils and platelets do not generate LTB4. The binding of .LTB4 to its surface receptor promotes chemotaxis in PMN's, macrophages and eosinophils. It also induces PMN aggregation, adherence of PMNs to vascular endothelium and PMN diapedesis.

20 LTB4 in conjunction with PMN, macrophages, mast cells, basophils and monocytes has been implicated in a variety of diseases which involve undesirable inflammatory responses in diverse tissues, including infection, tissue injury and transient ischemia. In the case of reperfusion injury and 25 transplant rejection, LTB4 together with PMN, macrophages and mast cells have been causally demonstrated to play a major role in the inflammatory processes associated with these phenomena. In addition, LTB4 in conjunction with PMN, macrophages, mast cells, basophils plays a pivotal role in the development of inflammatory bowel disease. Colonic mucosal scrapings from inflammatory bowel disease patients generate 6 fold more LTB4 than from corresponding normal subjects. Thus a radiopharmaceutical which binds to the LTB4 receptor at sub-therapeutic levels should be able to rapidly detect inflammatory disease processes throughout the body.

In the present invention it has been found that radiopharmaceuticals capable of binding to the LTB4 receptor are useful for imaging sites of infection and inflammation.

SUMMARY OF THE INVENTION The present invention provides novel radiopharmaceuticals useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis. The radiopharmaceuticals bind in vivo to the leukotriene B4 (LTB4) receptor on the surface of leukocytes which accumulate at the site of infection and inflammation. The reagents of this invention are also useful in the treatment of diseases associated with infection and inflammation.

The radiopharmaceuticals of the present invention are small molecules and so do not suffer from the disadvantages associated with radiolabeled proteins or antibodies. As antagonists, the radiopharmaceuticals have significantly diminished risk of producing side-effects. The 20 radiopharmaceuticals of the present invention have utility in the rapid detection of inflammatory or infectious diseases such as inflammatory bowel, fever of unknown origin, reperfusion injury and transplant rejection. The reagents of this invention are useful in the treatment of diseases 25 associated with infection and inflammation.

DETAILED DESCRIPTION OF THE INVENTION Inafirst embodiment, the present invention provides a novel compound having the formula: We'.01 CR 54

R

55 )ka-Yf; wherein, W.e is selected from the group: 6 ri and wherein,

R

47 is selected from the group:

C

1

-C

6 alkyl substituted with 0-3 R 50

*C

1

-C

6 alkoxy substituted-with 0-3 A 50 aryl substituted wi th 0-3 R 51 and heter6CyCle substituted with 0- 3

R

51

R

4 8 and R 4 9 are selected from the group: Cl-C 3 alkyl,

C

2

-C

3 alkenyl,*cyclopropyl Cyclopropylmethyl, and aryl substituted with D -3 R 51

R

50 is'independently selected from the group:

-F,

-Cl,

-N(R

52

(R

5 3 and -CF 3

R

51 is-independently selected from the group:

-F,

-Cl, -Br, -N(R 5 2

(R

5 3

-CF

3

C

1

-C

3 alkyl, cl-c 3 alkoxy, and methylenedioxy; :5:R 5 2 and R 5 3 are independently H or Cl-C 3 alkyl;

R

54 and R 55 are independently selected at each occurrence from the group: H, C 1

-C

5 alkyl, and Cl-C 5 alkoxy, or alternatively,

R

54 and R 55 may be taken together to form a 3-6 membered cycloalkyl; k" is 4-7; Y' is selected from the group: C(0)NHR 5 6 NHiC(=0)R 5 6 and NHC(=0)NHR5 7

R

56 is selected from the group: aromatic heterocycle substituted with 0-3 R 5 8 aryl substituted with 0-3

R

5 8 and C 1

-C

5 alkyl substituted with 1-3 R 59

R

57 is selected from the group: heterocycle substituted with 0-3 R 5 8 aryl substituted with 0-3 R 58 and C 1

C

5 alkyl substituted with 0-3 R 60

R

58 is independently selected at each occurrence from the group: -Cl, -Br,

COOR

61

OR

6 1 C(=O)N(R61) 2 and C 1

-C

3 alkyl substituted with 0-3 R 62

R

59 is independently selected at each occurrence from the group: -Cl, -Br, COOR 6 1

OR

6 1

C(=O)N(R

6 1 2

N(R

6 1 2 and NHC(=O)R 63 provided that at least one R 5 9 is NH(C=O)R 63

R

60 is independently selected at each occurrence from the group: -Cl, -Br, COOR 6 1

OR

6 1 20

C(=O)N(R

61 2

N(R

61 2 and NHC(=O)R 63

R

61 is independently selected at each occurrence from the group: H, and CI-C 5 alkyl; 25

R

6 2 is independently selected at each occurrence from the group: -Cl, -Br, COOR 6 4

OR

64

C(=O)N(R

64 2 and NH(C=0)R 64

R

63 is independently selected at each occurrence from the group: aryl substituted with 0-3 R 65 and heterocycle substituted with 0-3 R 65

R

64 is independently selected at each occurrence from the group: H, and C 1

-C

5 alkyl;

R

65 is independently selected at each occurrence from the group: -Cl, -Br,

COOR

6 6

OR

6 6 and

C(=O)N(R

6 6 2 and

R

66 is independently selected at each occurrence from the group: H, and C 1

-C

5 alkyl; and pharmaceutically acceptable salts thereof.

In another preferred embodiment, the present invention provides a novel compound, wherein:

R

50 is independently selected from the group: -Cl,

-N(R

5 2

)(R

53 and -CF 3

R

51 is independently selected from the group: -Cl, -CF3 Ci-C3 alkyl, C 1

-C

3 alkoxy, and methylenedioxy;

R

54 and R 55 are independently selected at each occurrence from the group: H, C 1

-C

3 alkyl, and C 1

-C

3 alkoxy; k" is 5-6;

R

56 is selected from the group: pyridine substituted with 0-3 R 5 8 aryl substituted with 0-3 R 5 8 and CI-

C

3 alkyl substituted with 1-3 R 59 25

R

57 is selected from the group: pyridine substituted with 0-3 R 58 aryl substituted with 0-3 R 5 8 and C 1

C

3 alkyl substituted with 0-3 R 6 0

R

58 is independently selected at each occurrence from the r group: -Cl,

COOR

6 1

OR

61 and C(=O)N(R 6 1 2

R

59 is independently selected at each occurrence from the group:

COOR

6 1

OR

6 1

C(=O)N(R

6 1 2 and NHC(=0)R 63 provided that at least one R 59 is

NH(C=O)R

6 3

R

6 0 is independently selected at each occurrence-from the group: COOR61,

OR

6 1

C(=O)N(R

61 2 and NHC (=0)R 6 3

R

61 is independently selected at each occurrence from the group: H, and Ci-C 5 alkyl;

R

63 is independently selected at each occurrence from the group: phenyl substituted with 0-3 R 65 and pyridine substituted with 0-3 R 65 and,

R

65 is independently selected at each occurrence from the group: -Cl, COOR 6 6 and OR 6 6 In another more preferred embodiment, the present invention provides a novel compound, wherein: oeo R 47 is phenyl or p-fluorophenyl;

R

48 is phenyl substituted with 0-1 R 51

.R

49 is C 2

-C

3 alkyl;

R

5 1 is -F or methylenedioxy;

R

5 4 and R 55 are independently H or methyl;

R

56 is selected from the group: pyridine substituted with 0-1 R 5 8 phenyl substituted with 0-1 R 5 8 and C 1

-C

3 alkyl substituted with 1-3 R 59

R

57 is selected from the group: pyridine substituted with 0-1 R 5 8 phenyl substituted with 0-1 R 5 8 and C 1

-C

3 alkyl substituted with 0-3 R 6 0

R

58 is independently selected at each occurrence from the group: COOH, and OH;

R

59 is independently selected at each occurrence from the group: COOH, OH, and NHC(=O)R 63 provided that at least one R 5 9 is NH(C=O)R 63

R

6 0 is independently selected at each occurrence from the group: COOH, OH, C(=O)NH 2 and NHC(=O)R 6 3;

R

61 is independently selected at each occurrence from the group: H, and CI-C 3 alkyl;

R

63 is independently selected at,each occurrence from the group: phenyl substituted with 0-1 R 65 and pyridine substituted with 0-1 R 65 and

R

65 is independently selected at each occurrence from the group: -Cl, COOH, and OH.

-20 In another even more preferred embodiment, the compounds is selected from: :N 0

N

a N N

NH

COOH

and, N,

COOH

o-y 0-/ Ina second embodiment, the present invention provides a novel method of treating disease in a mammal associated with infection and inflamation comprising administering to said mammal a therapeutically effective amount of a previously described compound.

When any variable occurs more than one time in any constituent or in any formula, its definition on each occurrence is independent of its definition at every.other occurrence. Thus, for example, if a group is:shown to be substituted with 0-2 R 52 then said group may optionally be substituted with up to two R 52 and R 52 at each occurrence is 15 selected independently from the defined list of possible R 52 Also, by way of example, for the group -N(R 53 2 each of the .two R 53 substituents on N is independently selected from the defined list of possible R 53 Combinations of substituents and/or variables are permissible only if such combinations 20 result in stable compounds.

By "reagent" is meant a compound of this invention capable of direct transformation into a radiopharmaceutical of this invention. Reagents may utilized directly for the preparation of the radiopharmaceuticals of this invention or may be a component in a kit of this invention.

The term "binding agent" means a radiopharmaceutical of this invention having affinity for and capable of binding to LTB4. The binding agents of this invention have Ki 1000nM.

By "stable compound" or "stable structure" is meant herein a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious diagnostic agent.

The term "substituted", as used herein, means that one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom's or group's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto then 2 hydrogens on the atom are replaced.

The term "bond", as used herein, means either a single or double bond.

The term "salt", as used herein, is used as defined in the CRC Handbook of Chemistry and Physics, 65th Edition, CRC Press, Boca Raton, Fla, 1984, as any substance which yields ions,_other than hydrogen or hydroxyl ions.

As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms; "cycloalkyl" or "carbocycle" is intended to include saturated and partially unsaturated ring groups, including mono-,bi- or poly-cyclic ring systems, such as cyclopropyl, cyclobutyl, 20 cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and adamantyl; "bicycloalkyl" is intended to include saturated bicyclic ring groups such as 3 4 3 .0]bicyclononane, 4 4 .0]bicyclodecane (decalin), 2 2 2 ]bicyclooctane, and so forth.

25 As used herein, the term "alkene" or "alkenyl" is intended to include both branched and straight-chain groups of the formula CnH2n-1 having the specified number of carbon atoms.

As used herein, the term "alkyne" or "alkynyl" is intended to include both branched and straight-chain groups of the formula CnH2n-3 having the specified number of carbon atoms.

As used herein, "aryl" or "aromatic residue" is intended to mean phenyl or naphthyl, which when substituted, the substitution can be at any position.

As used herein, the term "heterocycle" or "heterocyclic ring system" is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 14-membered bicyclic or tricyclic heterocyclic ring which may be saturated, partially unsaturated, or aromatic, and which consists of carbon atoms and from 1 to 4 heteroatoms selected independently from the group consisting of N, O and S and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. Examples of such heterocycles include, but are not limited to, benzopyranyl, thiadiazine, tetrazolyl, benzofuranyl, benzothiophenyl, indolene, quinoline, isoquinolinyl or benzimidazolyl, piperidinyl, 4-piperidone, 2-pyrrolidone, tetrahydrofuran, tetrahydroquinoline, tetrahydroisoquinoline, decahydroquinoline, octahydroisoquinoline, azocine, triazine (including and 1,3,5-triazine), 6H-1,2,5thiadiazine, 2H,6H-1, 5, 2-dithiazine,- thiophene, tetrahydrothiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, xanthone, phenoxathiin, 2H-pyrrole, pyrrole, imidazole, pyrazole, thiazole, isothiazole, oxazole (including 1,2,4- and 1,3,4-oxazole), isoxazole, triazole, 25 pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, 3H-indole, indole, 1H-indazole, purine, 4Hquinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, 4aH-carbazole, carbazole, 9-carboline, phenanthridine, acridine, perimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, isochroman, chroman, chromanone, pyrrolidine, pyrroline, imidazolidine, imidazoline, pyrazolidine, pyrazoline, piperazine, indoline, isoindoline, quinuclidine, or morpholine. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

As used herein, the term "alkaryl" means an aryl group bearing an alkyl group of 1-10 carbon atoms; the term ."aralkyl". means an alkyl group of 1-10 carbon atoms bearing an aryl group; the term "arylalkaryl" means an aryl group bearing an alkyl group of 1-10 carbon atoms bearing an aryl group; and the term "heterocycloalkyl" means an alkyl group of 1-10 carbon atoms bearing a heterocycle.

A "polyalkylene glycol" is a polyethylene .glycol, polypropylene glycol or polybutylene glycol having a molecular weight of less than about 5000, terminating in either a hydroxy or alkyl ether moiety.

A "carbohydrate" is a polyhydroxy aldehyde, ketone, alcohol or acid, or derivatives thereof, including polymers thereof having polymeric linkages of the acetal type.

A "cyclodextrin" is a cyclic oligosaccharide. Examples of cyclodextrins include, but are not limited to, acyclodextrin, hydroxyethyl-a-cyclodextrin, hydroxypropyl-acyclodextrin, P-cyclodextrin, hydroxypropyl-p-cyclodextrin, carboxymethyl-0-cyclodextrin, dihydroxypropyl--cyclodextrin, hydroxyethyl-P-cyclodextrin, 2,6 di-O-methyl-p-cyclodextrin, S. sulfated-P-cyclodextrin, y-cyclodextrin, hydroxypropyl-y- 20 cyclodextrin, dihydroxypropyl-y-cyclodextrin, hydroxyethyl-ycyclodextrin, and sulfated y-cyclodextrin.

As used herein, the term "polycarboxyalkyl" means an alkyl group having between two and about 100 carbon atoms and a plurality of carboxyl substituents; and the term 25 "polyazaalkyl" means a linear or branched alkyl group having between two and about 100 carbon atoms, interrupted by or substituted with a plurality of amine groups.

A "reducing agent" is a compound that reacts with the radionuclide, which is typically obtained as a relatively unreactive, high oxidation state compound, to lower its oxidation state by transfering electron(s) to the radionuclide, thereby making it more reactive. Reducing agents useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to stannous chloride, stannous fluoride, formamidine sulfinic acid, ascorbic acid, cysteine, phosphines, and cuprous or ferrous salts. Other reducing agents are described in Brodack et. al., PCT Application 94/22496, which is incorporated hereinby reference.

A "transfer ligand" is a ligand that forms an intermediate complex with the radionuclide that is stable enough to prevent unwanted side-reactions but labile enough to be converted to the radiopharmaceutical. The formation of the intermediate complex is kinetically favored while the formation of the radiopharmaceutical is thermodynamically favored. Transfer ligands useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to. gluconate, glucoheptonate, mannitol, glucarate, N,N, N',N'-ethylenediaminetetraacetic acid, pyrophosphate and methylenediphosphonate. In general, transfer ligands are comprised of oxygen or nitrogen donor atoms.

The term "donor atom" refers to the atom directly attached to a metal by a chemical bond.

"Ancillary" or "co-ligands" are ligands that are incorporated into the radiopharmaceutical during its 20 synthesis. They serve to complete the coordination sphere of the radionuclide together with the chelator or radionuclide bonding unit of the reagent. For radiopharmaceuticals *000 comprised of a binary ligand system, the radionuclide coordination sphere is composed of one or more chelators or 25 bonding units from one or more reagents and one or more S0-0* ancillary or co-ligands, provided that there are a total of two types of ligands, chelators or bonding units. For example, a radiopharmaceutical comprised of one chelator or bonding unit from one reagent and two of the same ancillary or coligands and a radiopharmaceutical comprised of two chelators or bonding units from one or two reagents and one ancillary or co-ligand are both considered to be comprised of binary ligand systems. For radiopharmaceuticals comprised of a ternary ligand system, the radionuclide coordination sphere is composed of one or more chelators or bonding units from one or more reagents and one or more of two different types of ancillary or co-ligands, provided that there are a-total of three types of ligands, chelators or bonding units. For example, a radiopharmaceutical comprised of one chelator or bonding unit from one reagent and two different ancillary or co-ligands is considered to be comprised of a ternary ligand system.

Ancillary or co-ligands useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals are comprised of one or more oxygen, nitrogen, carbon, sulfur, phosphorus, arsenic, selenium, and tellurium donor atoms. A ligand can be a transfer ligand in the synthesis of a radiopharmaceutical and also serve as an ancillary or co-ligand in another radiopharmaceutical. Whether a ligand is termed a transfer or ancillary or cb-ligand depends on whether the ligand remains in the radionuclide coordination sphere in the 15 radiopharmaceutical, which is determined by the coordination S chemistry of the radionuclide and the chelator or bonding unit of the reagent or reagents.

A "chelator" or "bonding unit" is the moiety or group on a reagent that binds to a metal radionuclide through the formation of chemical bonds with one or more donor atoms.

The term "binding site" means the site in vivo or in vitro that binds a biologically active molecule.

A "diagnostic kit" or "kit" comprises a collection of components, termed the formulation, in one or more vials 25 which are used by the practising end user in a clinical or pharmacy setting to synthesize the radiopharmaceutical. The kit provides all the requisite components to synthesize and S use the radiopharmaceutical except those that are commonly available to the practising end user, such as water or saline for injection, a solution of the radionuclide, equipment for heating the kit during the synthesis of the radiopharmaceutical, if required, equipment necessary for administering the radiopharmaceutical to the patient such as syringes and shielding, and imaging equipment.

A "buffer" is a compound that is used to control the pH of the kit during its manufacture and during the synthesis of the radiopharmaceutical.

A "lyophilization aid" is a component that has favorable physical properties for lyophilization, such as the glass transition temperature, and is added to the diagnostic kit to improve the physical properties of the combination of all the components of the kit for lyophilization.

A "stabilization aid" is a component that is added to the radiopharmaceutical or to the diagnostic kit either to stabilize the radiopharmaceutical once it is synthesized or to prolong the shelf-life of the kit before it must be used.

Stabilization aids can be antioxidants, reducing agents or radical scavengers and can provide improved stability by reacting preferentially with species that degrade other components or the radiopharmaceutical.

A "solubilization aid" is .a component that improves the 15 solubility of one or more other components in the medium required for the synthesis of the radiopharmaceutical.

*i A "bacteriostat". is a component that inhibits the growth of bacteria in the diagnostic kit either during its storage before use of after the kit is used to synthesize the radiopharmaceutical.

In one embodiment this invention is a radiolabeled LTB4 antagonist radiopharmaceutical. The radiolabel is a suitable radioisotope having an emission that can be detected outside the body after injection of the radiolabeled LTB4 antagonist 25 into a mammal. Detection using a gamma camera results in an image of the areas of localization of white blood cells bearing the LTB4 receptor to which is attached the radiopharmaceutical. Our approach in designing LTB4 antagonist radiopharmaceuticals was to identify common features in compounds known to have potential therapeutic uses, and then, assisted by a 3 -dimensional map of the LTB4 receptor we developed, design radiopharmaceuticals having such features.

A number of therapeutic LTB4 compounds are known. These display a wide variety of structural types. One similarity shared by many of these compounds is the presence of two key regions in the molecule, described in the literature as the eastern and western ends of the molecule, connected by a flexible tethering group. Recent reviews of LTB4 antagonists include Djuric et. al., Drugs of the Future, 1992, 17, pp 819- 830; Cohen, N. and Yagaloff, Curr. Opin. Invest. Drugs, 1994, 3, pp. 13-22; and Brooks, C. and Summers, J. Med.

Chem., 1996, 39, pp 2629-2654, the disclosures of which are herein incorporated py reference in their entirety.

We have identified two concepts for designing radiolabeled LTB4 antagonists. In one concept the radioisotope bonding unit is incorporated into the structure in such a way that it participates in the binding of the compound to the receptor site even when bound to the radioisotope. In the second concept, the radioisotope bonding unit. is incorporated into a site on the molecule which is not part of the recognition site, and is removed enough from the 15 recognition site that its presence does not interfere with the binding of the compound to the receptor.

An example of the first concept is to design a LTB4 radiopharmaceutical wherein either the eastern or western end of a potential therapeutic LTB4 antagonist is replaced with an appropriate radionuclide bonding unit bound to Tc-99m or a radiohalogen substituent. Scheme 1 shows the potential S therapeutic LTB4 antagonist, which has excellent affinity for the LTB4 receptor (Sawyer et al.; J. Med. Chem., 1995, 38, 4411-32). In the tetrazole substituent serves as a 25 hydrogen bonding acceptor, thereby promoting binding of the compound to the receptor. When the tetrazole is absent, the compound has no affinity (7 pM) for the LTB4 receptor. Also shown in Scheme I is radiopharmaceutical which is a LTB4 receptor antagonist labeled with Tc-99m. In this radiopharmaceutical, the tetrazole group of is replaced with the HYNIC metal chelator complexed to Tc, whose coordination sphere is completed by two ancillary ligands.

(II) retains good activity for the LTB4 receptor. (II) can be prepared from reagent (IIa), which bears a hydrazone protected hydrazonicotinamide group, by reaction of (IIa) with Tc-99m in the presence of a suitable reducing agent and appropriate ancillary ligands. (IIa) retains very good affinity for LTB4 (Ki 8 nM compared to 3 nM for I).

F -OH NH

N

F

OH

OH

N

-TPPTS

H

OH

Scheme 1 An example of the second approach is shown in Scheme 2.

Compound III is an active LTB4 antagonist (Ki 41 nM). This compound was elaborated into a reagent of this invention.

This was accomplished by conjugation of a hydrazone protected hydrazinonicotinamide group via a three carbon tether to the tyrosine hydroxyl oxygen to provide a reagent for preparing a Tc-99m radiopharmaceutical of the present invention, reagent IV. Reagent with Ki 52nM, has essentially the same affinity for LTB4 as does (III). Reagent IV is readily converted to the radio-labeled analog using the methods described below.

The tyrosine aromatic ring of (III) can also be radioiodinated to form a radiopharmaceutical of the present invention.

Scheme 2 In the reagents of the present invention, compounds IIa and IV shown above, the three common structural features are: a western end comprised of a hydrogen bond acceptor, either phenolic oxygen or the pyridine nitrogen, and an aromatic substituent; a spacer or tether; and an eastern end comprised of a hydrogen bond acceptor, a carbonyl oxygen. Some examples of alternative western end moieties are shown in Scheme 3.

Scheme 3 Some examples of alternative spacers or -tethers include acyclic alkyl, either stragtcano rnhdad heterocycloalkyl. Some exazplesof alternative eastern ends bearing an optional second spacer o r tether and a chelator or metal-bonding unit are shown in Scheme 4.

N~ H9 rH 2 0 IQJH 2 N *0 N

N

s\6 3S6 H W r.tCo2H N

HN

NN OH H 1 N" NNHN; H 0H 2 +SH

H

Scheme 4 The second spacer or tether provide a means of incorporating a pharmacokinetic modifier into the radiopharmaceuticals of the present invention. The pharmacokinetic modifier serves to direct the biodistibution of the portion of the injected radiopharmaceutical that does 10 not become associated with white blood cells. A wide variety S of functional groups can serve as pharmacokinetic modifiers, Sincluding, but not limited to, carbohydrates, polyalkylene glycols, peptides or other polyamino acids, and cyclodextrins.

The modifiers are generally characterized by a plurality of atoms selected from oxygen and nitrogen, which provide enhanced hydrophilicity to the radiopharmaceuticals and can thus affect their rate of blood clearance and the route of elimination. Preferred pharmacokinetic modifiers are those that result in moderate blood clearance and enhanced renal 20 excretion.

Other radiopharmaceuticals of the present. invention are comprised of more compact LTB4 antagonist moieties to which are attached an optional spacer or tether and a chelator or metal bonding unit. Examples of these compact LTB4 antagonist moieties are shown in Scheme Scheme .Synthesis of Radiopharmaceuticals The radiolabeled LTB4 antagonist compounds of the present invention can be synthesized using standard synthetic methods S known to those skilled in the- art, using radioisotopes of halogens (such as chlorine, fluorine, bromine and iodine), 10 technetium and indium, as well as others. Preferable radioisotopes include 1231, 125i, 131i, 99 mTc, and 1 1 lln.

The LTB4 antagonist compounds of the invention may be labeled either directly (that is, by incorporating the radiolabel directly into the compounds) or indirectly (that is,'by incorporating the radiolabel into the compounds through a chelator which has been incorporated into the compounds.

For direct labeling, as those skilled in the art will recognize, the labeling may be isotopic or nonisotopic. With isotopic labeling, one group already present in the cyclic 20 compound is substituted with (exchanged for) the radioisotope.

With nonisotopic labeling, the radioisotope is added to the cyclic compounds without substituting with (exchanging for) an already existing group.

Generally, labeled compounds are prepared by procedures which introduce the labeled atom at a late stage of the synthesis. This allows for maximum radiochemical yields, and reduces the handling time of radioactive materials. When dealing with short half-life isotopes, a major consideration is the time required to conduct synthetic procedures, and purification methods. Protocols for the synthesis of radiopharmaceuticals are described in Tubis and Wolf, Eds., "Radiopharmacy", Wiley- Interscience, New York (1976); Wolf, Christman, Fowler, Lambrecht, "Synthesis of Radiopharmaceuticals and Labeled Compounds Using Short-Lived Isotopes", in Radiopharmaceuticals and Labeled Compounds, Vol 1, p. 345-381 (1973), the disclosures of each of which are hereby incorporated herein by reference, .in their entirety.

Various procedures may be employed in preparing the radiolabeled compounds of the invention where the radiolabel is a halogen. Some common synthetic methodologies for isotopic halogen labeling of aromatic compounds such as the type present here are iododediazonization, iododeborobation, iododestannylation, iododesilation, iododethallation, and halogen exchange reactions. The most common synthetic methodology for nonisotopic halogen labeling of aromatic compounds such as the type present here is iododeprotonation oor electrophilic aromatic substitution reactions. These methods and additional procedures are described in Merkushev, Synthesis, 923 (1988), and Seevers et al, Chem. Rev., 82: 575 (1982), the disclosures of each of which are hereby incorporated herein by reference, in their entirety.

Alternatively, such compounds may prepared by way of isotopic labeling from the unlabeled bromo or iodo derivatives by various two step reaction sequences, such as through the 25 use of trialkylsilyl synthons as described in Wilson et at J.

Org.-.Chem., 51: 483 (1986) and Wilbur et al J. Label.

Compound. Radiopharm., 19: 1171 (1982), the use of trialkylsilyl synthons as described in Chumpradit et al J.

Med. Chem., 34: 877 (1991) and Chumpradit et al J. Med. Chem., 32: 1431 (1989), and the use of boronic acid synthons as described in Kabalka et al J. Label. Compound. Radiopharm., 19: 795 (1982) and Koch et al Chem. Ber., 124:2091 (1991).

The unlabeled iodo compounds are versatile precursors which can be converted to the labeled derivatives by any of the two step reaction sequences described above. Useful functionality to incorporate into the LTB4 antagonists includes the bromo, the nitro, the trialkylsilyl, the trialkyltin, and the boronic acid groups. The synthesis and application of each of these precursors is described in the references cited above.

The least complex means of radioiodination of the cyclic compounds of the present invention via isotopic labeling during the final stages of their preparation is the substitution of radioactive iodide for a stable iodine atom already present in the molecule. This can often be done by heating the compound with radioactive iodide in an appropriate solvent as described in Ellis et al., Aust. J. Chem., 26: 907 (1973). When applied to aromatic iodides, the extremely small quantities and low concentration of radioactive iodide employed leads to the incorporation of only modest specific activity.

The LTB4 antagonist compounds may also be isotopically 15 iodo-labeled during the final stages of their preparation from the anilines by the Sandmeyer reaction as described in Ellis et al., Aust. J. Chem., 26: 907 (1973). This approach leads to a labeled cyclic compound with high specific activity. To avoid complications in the synthesis of the LTB4 antagonist compound, the nitro group provides an ideal synthon for the aniline.

Labeled iodo derivatives may also be readily prepared nonisotopically from the amino, hydroxy, or methoxy substituted cyclic compounds as described in Arora et al J.

25 Med. Chem., 30:918 (1987). Electrophilic aromatic substitution reactions are enhanced by the presence of such electron-donating substituents.

Various procedures may also be employed in preparing the radiolabeled compounds of the invention where the radiolabel is a metal, such as where the radiolabel is technetium or indium. Exemplary procedures for such technetium or indium labeling are disclosed, for example, in Cerqueira et al., Circulation, Vol. 85, No. 1, pp. 298-304 (1992), Pak et al., J. Nucl. Med., Vol. 30, No. 5, p. 793, 36th Ann. Meet. Soc.

Nucl. Med. (1989), Epps et al., J. Nucl. Med., Vol. 30, No. p. 794, 36th Ann. Meet. Soc. Nucl. Med. (1989), Pak et al., J.

Nucl. Med., Vol. 30, No. 5, p. 794, 36th Ann. Meet. Soc. Nucl.

Med. (1989), and Dean et al., J. Nucl. Med., Vol. 30, No. p. 794, 36thAnn. Meet. Soc. Nucl. Med. (1989), the disclosures of each of which are hereby incorporated herein by reference, in their entirety.

Preferred reagents of the present invention are comprised of chelators or radionuclide bonding units which are diaminedithiols, monoamine-monoamidedithiols, triamidemonothiols, monominemonothiolsonothiols, diaminedioximes, or hydrazines. The chelators are generally tetradentate with donor atoms selected from nitrogen, oxygen and sulfur. More preferred reagents are comprised of chelators having amine nitrogen and thiol sulfur donor atoms and hydrazine bonding units. The thiol sulfur atoms and the hydrazines may bear a protecting group which can be displaced either prior to using the reagent to synthesize a radiopharmaceutical or preferrably 15 in situ during the synthesis of the radiopharmaceutical.

Exemplary thiol protecting groups include those listed in Greene and Wuts, "Protective Groups in Organic Synthesis" John Wiley Sons, New York (1991), the disclosure of which is hereby incorporated by reference. Any thiol protecting group known in the art can be used. Examples of thiol protecting groups include, but are not limited to, the following: acetamidomethyl, benzamidomethyl, 1-ethoxyethyl, benzoyl, and triphenylmethyl.

Exemplary protecting groups for hydrazine bonding units are hydrazones which can be aldehyde or ketone hydrazones having substituents selected from hydrogen, alkyl, aryl and heterocycle. Particularly preferred hydrazones are described in co-pending U.S.S.N. 08/476,296 the disclosue of which is herein incorporated by reference in its entirety.

The hydrazine bonding unit when bound to a metal radionuclide is termed a hydrazido, or diazenido group and serves as the point of attachment of the radionuclide to the remainder of the radiopharmaceutical. A diazenido group can be either terminal (only one atom of the group is bound to the radionuclide) or chelating. In order to have a chelating diazenido group at least one other atom of the group must also be bound to the radionuclide. The atoms bound to the metal are termed donor atoms.

S

a. a 4 The transition metal radionuclide is selected from the group: technetium-99m, rhenium-186 and rhenium-188. For diagnostic purposes Tc-99m is the preferred isotope. Its 6 hour half-life and 140 keV gamma ray emission energy are almost ideal for gamma scintigraphy using equipment and procedures well established for those skilled in the art. The rhenium isotopes also have gamma ray emission energies that are compatible with gamma scintigraphy, however, they also emit high energy beta particles that are more damaging to living tissues. These beta particle emissions can be utilized for therapeutic purposes, for example, cancer radiotherapy.

The coordination sphere of the radionuclide includes all the ligands or groups bound to the radionuclide. For a transition metal radionuclide to be stable it typically has a 15 coordination number (number of donor atoms) comprised of an integer greater than or equal to 4 and less than or equal to 8; that is there are 4 to 8 atoms bound to the metal and it is said to have a complete coordination sphere. The requisite coordination number for a stable radionuclide complex is determined by the identity of the radionuclide, its oxidation state, and the type of donor atoms. If the chelator or bonding unit does not provide all of the atoms necessary to stabilize the metal radionuclide by completing its coordination sphere, the coordination sphere is completed by 25 donor atoms from other ligands, termed ancillary or coligands, which can also be either terminal or chelating.

A large number of ligands can serve as ancillary or coligands, the choice of which is determined by a variety of considerations such as the ease of synthesis of the radiopharmaceutical, the chemical and physical properties of the ancillary ligand, the rate of formation, the yield, and the number of isomeric forms of the resulting radiopharmaceuticals, the ability to administer said ancillary or co-ligand to a patient without adverse physiological consequences to said patient, and the compatibility of the ligand in a lyophilized kit formulation. The charge and lipophilicity of the ancillary ligand will effect the charge and lipophilicity of the radiopharmaceuticals. For example, the use of 4 ,5-dihydroxy-1 3 benzene disulfonate results in radiopharmaceuticals with an additional two anionic groups because the sulfonate groups will be anionic under physiological conditions. The use of N-alkyl substituted 3,4hydroxypyridinones results in radiopharmaceuticals with varying degrees of lipophilicity depending on the size of the alkyl substituents.

Preferred radiopharmaceuticals of the present invention are comprised of a hydrazido or diazenido bonding unit and an ancillary ligand, AL1, or a bonding unit and two types of ancillary ALI and AL2, or a tetradentate chelator comprised of two nitrogen and two sulfur atoms. Ancillary ligands ALI are comprised of two or more hard donor atoms such as oxygen and amine nitrogen (sp 3 hydribidized). The donor atoms occupy at least two of the sites in the coordination sphere of the S radionuclide metal; the ancillary ligand AL1 serves as one of the three ligands in the ternary ligand system. Examples of S. ancillary ligands AL1 include but are not limited to dioxygen **ligands and functionalized aminocarboxylates. A large number of such ligands are available from commercial sources.

Ancillary dioxygen ligands include ligands that coordinate to the metal ion through at least two oxygen donor atoms. Examples include but are not limited to: glucoheptonate, gluconate, 2 -hydroxyisobutyrate, lactate, 25 tartrate, mannitol, glucarate, maltol, Kojic acid, 2,2bis (hydroxymethyl)propionic acid, 4,5-dihydroxy-1, 3-benzene disulfonate, or substituted or unsubstituted 1,2 or 3,4 hydroxypyridinones. (The names for the ligands in these examples refer to either the protonated or non-protonated forms of the ligands.) Functionalized aminocarboxylates include ligands that have a combination of amine nitrogen and oxygen donor atoms.

Examples include but are not limited to: iminodiacetic acid, 2, 3 -diaminopropionic acid, nitrilotriacetic acid, N,N'ethylenediamine diacetic acid, N,N,N'-ethylenediamine triacetic acid, hydroxyethylethylenediamine triacetic acid, and N,N'-ethylenediamine bis-hydroxyphenylglycine. (The names for the ligands in these examples refer to either the protonated or non-protonated forms of the ligands.) A series of functionalized aminocarboxylates are disclosed by Bridger et. al. in U.S. Patent 5,350,837, herein incorporated by reference, that result in improved rates of formation of technetium labeled hydrazino modified proteins.

We have determined that certain of these aminocarboxylates result in improved yields of the radiopharmaceuticals of the present invention. The preferred ancillary ligands ALl functionalized aminocarboxylates that are derivatives of glycine; the most preferred is tricine (tris(hydroxymethyl)methylglycine).

The most preferred radiopharmaceuticals of the present invention are comprised of a hydrazido or diazenido bonding unit and two types of ancillary designated ALl and AL2, or a t diaminedithiol chelator. The second type of ancillary ligands S AL2 are comprised of one or more soft donor atoms selected from the group: phosphine phosphorus, arsine arsenic, imine nitrogen (sp 2 hydridized), sulfur (sp 2 hydridized) and carbon (sp hybridized); atoms which have p-acid character. Ligands :AL2 can be monodentate, bidentate or tridentate, the denticity is defined by the number of donor atoms in the ligand. One of the two donor atoms in a bidentate ligand and one of the three S. donor atoms in a tridentate ligand must be a soft donor atom.

We have disclosed in co-pending U.S.S.N. 08/415,908, and U.S.S.N. 60/013360 and 08/646,886, the disclosures of which are herein incorporated by reference in their entirety, that radiopharmaceuticals comprised of one or more ancillary or coligands AL2 are more stable compared to radiopharmaceuticals that are not comprised of one or more ancillary ligands, AL2; that is, they have a minimal number of isomeric forms, therelative ratios of which do not change significantly with time, and that remain substantially intact upon dilution.

The ligands AL2 that are comprised of phosphine or arsine donor atoms are trisubstituted phosphines, trisubstituted arsines, tetrasubstituted diphosphines and tetrasubstituted diarsines. The ligands AL2 that are comprised of iminenitrogen are unsaturated or aromatic nitrogen-containing, or 6-membered heterocycles. The ligands that are comprised of sulfur (sp 2 hybridized) donor atoms are thiocarbonyls, comprised of the moiety C=S. The ligands comprised of carbon (sp hybridized) donor atoms are isonitriles, comprised of the moiety CNR, where R is an organic radical. A large number of such ligands are available from commercial sources.

Isonitriles can be synthesized as described in European Patent 0107734 and in U. S. Patent 4,988,827, herein incorporated by reference.

Preferred ancillary ligands AL2 are trisubstituted phosphines and unsaturated or aromatic 5 or 6 membered heterocycles. The most preferred ancillary ligands A2 are trisubstituted phosphines and unsaturated 5 membered heterocycles.

15 The ancillary ligands AL2 may be substituted with alkyl, aryl, alkoxy, heterocycle, aralkyl, alkaryl and arylalkaryl groups and may or may not bear functional groups comprised of heteroatoms such as oxygen, nitrogen, phosphorus or sulfur.

Examples of such functional groups include but are not limited to:- hydroxyl, carboxyl, carboxamide, nitro, ether, ketone, amino, ammonium, sulfonate, sulfonamide, phosphonate, and p* hosphonamide. The functional groups may be chosen to alter the lipophilicity and water solubility of the ligands which may affect the biological properties of the 25 radiopharmaceuticals, such as altering the distribution into non-target tissues, cells or fluids, and the mechanism and rate of elimination from the body.

The radiopharmaceuticals of the present invention comprised of a hydrazido or diazenido bonding unit can be easily prepared by admixing a salt of a radionuclide, a reagent of the present invention, an ancillary ligand AL1, an ancillary ligand AL2, and a reducing agent, in an aqueous solution at temperatures from 0 to 100 The radiopharmaceuticals of the present invention comprised of a tetradentate chelator having two nitrogen and two sulfur atoms can be easily prepared by admixing a salt of a radionuclide, a reagent of the present invention, and a reducing agent, in an aqueous solution at temperatures from 0 to 100 OC.

When the bonding unit in the reagent.of the present invention is present as a hydrazone group, then it must first be converted to a hydrazine, which may or may not be protonated, prior to complexation with the metal radionuclide. The conversion of the hydrazone group to the hydrazine can occur either prior to reaction with the radionuclide, in which case the radionuclide and the ancillary or co-ligand or ligands are combined not with the reagent but with a hydrolyzed form of the reagent bearing the chelator or bonding unit, or in the presence of the radionuclide in which case the reagent itself is combined with the radionuclide and the ancillary or co-ligand or ligands. In the latter case, the pH of the reaction mixture must be neutral or acidic.

Alternatively, the radiopharmaceuticals of the present invention comprised of a hydrazido or diazenido bonding unit *can be prepared by first admixing a salt of a radionuclide, an ancillary ligand ALl, and a reducing agent in an aqueous •solution at temperatures from 0 to 100 °C to form an intermediate radionuclide complex with the ancillary ligand 20 ALI then adding a reagent of the present invention and an ancillary ligand AL2 and reacting further at. temperatures from 0 to 100 °C.

Alternatively, the radiopharmaceuticals of the present .invention comprised of a hydrazido or diazenido bonding unit 25 can be prepared by first admixing a salt of a radionuclide, an ancillary ligand ALl, a reagent of the present invention, and a reducing agent in an aqueous solution at temperatures from 0 to 100 o C to form an intermediate radionuclide complex, and then adding an ancillary ligand AL2 and reacting further at temperatures from 0 to 100 OC.

The total time of preparation will vary depending on the identity of the radionuclide, the identities and amounts of the reactants and the procedure used for the preparation. The preparations may be complete, resulting in 80% yield of the radiopharmaceutical, in 1 minute or may require more time. If higher purity radiopharmaceuticals are needed or desired, the products can be purified by any of a number of techniques well known to those skilled in the art such as liquid chromatography, solid phase extraction, solvent extraction, dialysis or ultrafiltration.

The technetium and rhenium radionuclides are preferably in the chemical form of pertechnetate or perrhenate and a pharmaceutically acceptable cation. The pertechnetate salt form is preferably sodium pertechnetate such as obtained from commercial Tc-99m generators. The amount of pertechnetate used to prepare the radiopharmaceuticals of the present invention can range from 0.1 mCi to 1 Ci, or more preferably from 1 to 200 mCi.

The amount of the reagent of the present invention used to prepare the radiopharmaceuticals of the present invention can range from 0.01 gg to 10 mg, or more preferably from jg to 200 gg. The amount used will be dictated by the amounts 15 of the other reactants and the identity of the radiopharmaceuticals of the present invention to be prepared.

The amounts of the ancillary ligands ALl used can range from 0.1 mg to 1 g, or more preferrably from 1 mg to 100 mg.

The exact amount for a particular radiopharmaceutical is a function of identity of the radiopharmaceuticals of the present invention to be prepared, the procedure used and the S amounts and identities of the other reactants. Too large an amount of ALl will result in the formation of by-products comprised of technetium labeled ALl without a biologically 25 active molecule or by-products comprised of technetium labeled biologically active molecules with the ancillary ligand ALl but without the ancillary ligand AL2. Too small an amount of ALI will result in other by-products such as technetium labeled biologically active molecules with the ancillary ligand AL2 but without the ancillary ligand ALl, or reduced hydrolyzed technetium, or technetium colloid.

The amounts of the ancillary ligands-AL 2 used can range from 0.001 mg to 1 g, or more preferrably from 0.01 mg to mg. The exact amount for a particular radiopharmaceutical is a function of the identity of the radiopharmaceuticals of the present invention to be prepared, the procedure used and the amounts and identities of the other reactants. Too large an amount of AL2 will result in the formation of by-products comprised of technetium labeled AL2 without a biologically active molecule or by-products comprised of technetium labeled biologically active molecules with the ancillary ligand AL2 but without the ancillary ligand ALl. If the reagent bears one or more substituents that are comprised of a soft donor atom, as defined above, at least a ten-fold molar excess of the ancillary ligand AL2 to the reagent of formula 2 is required to prevent the substituent from interfering with the coordination of the ancillary ligand AL2 to the metal radionuclide.

Suitable reducing agents for the synthesis of the radiopharmaceuticals of the present invention include stannous salts, dithionite or bisulfite salts, borohydride salts, and formamidinesulfinic acid, wherein the salts are of any 15 Pharmaceutically acceptable form. The preferred reducing agent is a stannous salt. The amount of a reducing agent used can range from 0.001 mg to 10 mg, or more preferably from 0.005 mg S. to 1 mg.

The specific structure of a radiopharmaceutical of the present invention comprised of a hydrazido or diazenido bonding unit will depend on the identity of the reagent of the present invention used, the identity of any ancillary ligand ALl, the identity of any ancillary ligand AL2, and the identity of the radionuclide. Radiopharmaceuticals comprised 25 of a hydrazido or diazenido bonding unit synthesized using concentrations of reagents of <10Q gg/mL, will be comprised of one hydrazido or diazenido group. Those synthesized using >1 mg/mL concentrations will be comprised of two hydrazido or diazenido groups from two reagent molecules. For most applications, only a limited amount of the biologically active molecule can be injected and not result in undesired side-effects, such as chemical toxicity, interference with a biological process or an altered biodistibution of the radiopharmaceutical. Therefore, the radiopharmaceuticals which require higher concentrations of the reagents comprised in part of the biologically active molecule, will have to be diluted or purified after synthesis to avoid such sideeffects.

The identities and amounts used of the ancillary ligands ALl and AL2 will determine the values of the variables y and z. The values of y and z can independently be an integer from 1 to 2. In combination, the values of y and z will result in a technetium coordination sphere that is made up of at least five and no more than seven donor atoms. For monodentate ancillary ligands AL2, z can be an integer from 1 to 2; for bidentate or tridentate ancillary ligands AL2, z is 1. The preferred combination for monodentate ligands is y equal to 1 or 2 and z equal to 1. The preferred combination for bidentate or tridentate ligands is y equal to 1 and z equal to Another aspect of the present invention are diagnostic kits for the preparation of radiopharmaceuticals useful as imaging agents for the inflammation and infection. Diagnostic kits of the present invention comprise one or more vials i containing the sterile, non-pyrogenic, formulation comprised of a predetermined amount of a reagent of the.present invention, one or two ancillary and optionally other .components such as reducing agents, transfer ligands, buffers, lyophilization aids, stabilization aids, solubilization aids and bacteriostats. The inclusion of one or more optional components in the formulation will frequently improve the ease of synthesis of the radiopharmaceutical by the practising end 25 user, the ease of manufacturing the kit, the shelf-life of the kit, or the stability and shelf-life of the radiopharmaceutical. The one or more vials that contain all part of the formulation can independently be in the form of a sterile solution or a lyophilized solid.

Buffers useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to phosphate, citrate, sulfosalicylate, and acetate. A more complete list can be found in the United States Pharmacopeia.

Lyophilization aids useful in the preparation of diagnostic kits useful for the preparation of radiopharmaceuticals include but are not limited to mannitol, lactose, sorbitol, dextran, Ficoll, and polyvinylpyrrolidine(PVP).

Stabilization aids useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to ascorbic acid, cysteine, monothioglycerol, sodium bisulfite, sodium metabisulfite, gentisic acid, and inositol.

Solubilization aids useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to ethanol, glycerin, polyethylene glycol, propylene glycol, polyoxyethylene sorbitan monooleate, sorbitan monoloeate, polysorbates, poly(oxyethylene)poly(oxypropylene)poly(oxyethylene) block copolymers (Pluronics) and lecithin. Preferred solubilizing aids are polyethylene glycol, and Pluronics.

Bacteriostats useful in the preparation of •radiopharmaceuticals and in diagnostic kits useful for the *.preparation of said radiopharmaceuticals include but are not 20 limited to benzyl alcohol, benzalkonium chloride, chlorbutanol, and methyl, propyl or butyl paraben.

.o A component in a diagnostic kit can also serve more than one function. A reducing agent can also serve as a stabilization aid, a buffer can also serve as a transfer 25 ligand, a lyophilization aid can also serve as a transfer, ancillary or co-ligand and so forth.

The predetermined amounts of each component in the formulation are determined by a variety of considerations that are in some cases specific for that component and in other cases dependent on the amount of another component or the presence and amount of an optional component. In general, the minimal amount of each component is used that will give the desired effect of the formulation. The desired effect of the formulation is that the practising end user can synthesize the radiopharmaceutical and have a high degree of certainty that the radiopharmaceutical can be safely injected into a patient and will provide diagnostic information about the disease state of that patient.

Another aspect of the present invention contemplates a method of imaging the site of infection or inflammation in a patient involving: synthesizing a radiopharmaceutical using a reagent of the present invention capable of localizing at sites of infection or inflammation; administering said radiopharmaceutical to a patient by injection or infusion; (3) imaging the patient using either planar or SPECT gamma scintigraphy.

The radiopharmaceuticals are administered by intravenous injection, usually in saline solution, at a dose of 1 to 100 mCi per 70 kg body weight, or preferably at a dose of 5 to mCi. Imaging is performed using known procedures.

-EXAMPLES

The materials used to synthesize the following examples of the present invention were obtained from commercial sources or prepared as described in the following references.

"Substituted (E)-3-[6-(arylthiomethyl) 2 -phenylethoxy) 2 -pyridinyl]-2-propenoic acid and substituted 3-[6- (arylthiomethyl)-3- (2-phenylethoxy)- 2 -pyridinyl]propanoic acid derivatives useful as intermediates in the synthesis of the compounds of the invention are prepared using standard .procedures, for example, as described in Daines et al., J.

Med. Chem, 39: 3837 (1996); Daines et al J. Med. Chem, 37: 25 3327 (1994); Daines, PCT International Application

WO

95/15752; Daines, PCT International Application WO 95/15950.

[3-(4-Phenylbenzyl)- 4 -hydroxychroman-7-yl]cyclopentane carboxylic acid derivatives useful as intermediates in the synthesis of the compounds of the invention are prepared using standard procedures, for example, as described in Koch et al., J. Med. Chem, 37: 3197 (1994); Koch et al., PCT International Application WO 93/15066; Koch et al., PCT International Application WO 93/15067.

5-Allyl-6-hydroxy-l-tetralone derivatives useful as intermediates in the synthesis of the compounds of the invention are prepared using standard procedures, for example, as described in Cohen et al., Bioorg. Med. Chem. Lett., 4: 2883 .(1994); Cohen et al., PCT InternatiQnal Application wo 95/'15956.

.6-Bromo-2, 2 -dimethylhexanenitriie was synthesized as described by Larcheveque, M. et. al., Bull. Soc. Chin. Fr., 1974, 1710-1714.

4, 6E-Diphenyl 2-pyri done, 4- 4 -Methylenedioxyphenyl) -6diphenyl-2-pyridone, 6- L(4, 6-diphenyl-2-pyridinyl)ox] -2,2dime thyihexaneni tri le, 6- (2H-2, 3,4, 5-tetraazolyl) methyihexyloxy) 4 -diphenylpyridine and 6- (2H-2, 3,4,5tetraazolyl) -5-methylhexyloxy) 4 -diph~enylpyridine were synthesized as described by Labaudiniere, R. et. al., J. Med.

Chem., 1992, 35, 4315-4324.

t-Butyl 4 -bromobutyrate was synthesized as described by Morin,. C.'et. Tetrahedron, 1992, 48, 9277-9282.

ll-Amino-3,6,9-trioxaundecanol, 2 2 2 -(3-aza-3dizpo--eyoyehoyehx.)ta--lwere synthesized as described by Bertozzi, C. R.et. al., J.'Org. Chem., 1991, 56, 4326'4329.

2-Hydroxy-6. [(S5-hydroxypentyi ).oxy] benzenepropanoic -acid methyl ester and -naphthalen-i-one were synthesized as described by Cohen,-N., European Patent Application EP 0531823A1.

was prepared according to US Patent 4,204,870.

25 N-Methyl-N-phenethyl2.. 5-benzyloxy-3- (2carboxyvinyl)indo1.lyiaceamide was prepared according to- F.C. Huang et al., POT International Application WO 92/04321.

7- (2-Ethyl-4- 4 -flurophenyl) (phenylmethoxy) phenoxy) propoxy) 8 -propylchromne-2 -carboxylic acid was prepared according to Sawyer, et al., J.Med.Chem., 1995, 38, 4411.

A mixture of 4-ethyl-2 (l-methyl-Hpyrazols..yl) oxy] phenol and 4-ethyl-2 (1-methyl-1Hpyrazol-3-yl) -5-f -ehy--ynoeylxype was prepared as described in R.W. Harper, et al., J.Med.Chem., 1994, 37, 2411.

N- f 4- (Carboxy)benzyl] -bis 2 -triphenylmethylthio) ethyllglycinamide N-hydroxysuccinimide ester was synthesized as described by Harris, T. D.et. al., Bioorg. Med. Chem.

Lett. 1996, 6, 1741-1746.

N- 2 -Aminoethoxy) ethoxy) etho,) ethyl) (texrtbutoxy)formamide (5.87 g, 20 inmol) was prepared as described by Levenson, US Patent 4,803,297.

6 -Deoxy- 6-amino-p- cyclodextrin was prepared as described by Petter, R.C. et. al., J. Am. Chem. Soc, .1990., 112, 3860- 3868.

Tetraf luorophenyl bis-S- (l-ethoxyethy3mercaptoacetyl)pentanoate .was prepared as described in Fritzberg,

A.

et. al., Proc. Natl. Acad.. Sci. 1988,- 85, 4025.

Abbreviations used in this section: T7EA:. triethylaxnine DCM: dichioromethane ACN: acetonitrile Z: benzyloxycarbony.

mesyJlate TFA: trifluoroacetic acid.

DIEA: diisopropylethyandn.e H1ATU: O-( 7 -azabenzotriazo1-1y)13, 3..

.tetramethyluronium Hexafluorophosphate HBU 0- (Benzotriazol-1..yl) 3 -tetramethyluronium Hexafluorophosphate TMSI: -6rimethylsilyliodide TP T :ti -slo*oh ny*h sh n oi m sl TPPTS: tis (3-suf onatophenyl )phphosphine, dsodium salt TPPMS: 3 -sulfonatophenyl)diphenylphosphine, monosodium salt TFP: tris furanyl )phosphine Excample 1 Synthesis of 4-ethyl-2- (4-fluorophenyl) -[S-[5,5-dimethyl-6- U 2 -sulfonylphenyl)*methylenelhydazino]..3 pyridinyl Icarbonyl] amino] hexy-l] oxy] phenol Step A: Preparation of 4- (benzyloxy) cyanohexyl)oxy]-benzophenone *9 A solution of 4-benzyloxy-2-hydroxyacetophenone (2.45 g), potassium carbonate (3.25 potassium iodide (0.42 and (2.6g) in dimethylformamide 10 (40 mL) was heated at 90"C for 22 hours under nitrogen. The slurry was cooled, poured into water (150 mL) and extracted with ethyl acetate. The combined extracts were washed with water, dried (MgS04),, filtered, and concentrated under reduced pressure to an orange oil. This was purified by flash chromatography (ethyl acetate:hexane) to afford the product (2.4g) as a clear oil. NMR(CDC1 3 1.37, s 1.64, m 1.89, m 2.58, s 4.03, t 5.09, s 6.50, s 6.58, d 7.37, m (5 7.81, d Mass Spec (GC-MS) m/z 365 Step B: Preparation of 4 -(benzyloxy)-2-[(5-methyl-5cyanohexyl)oxy]-ethylbenzene 9 .9 9 The acetophenone (2.4 g) was dissolved in carbon tetrachloride (6 mL) and trifluoroacetic acid (6 mL) and triethylsilane (5.9 mL) added. The solution was stirred for 2 hours and poured into saturated sodium bicarbonate and ethyl acetate. The layers were separated and the organic layer was washed with saturated bicarbonate until washings remained basic, dried (MgSO 4 filtered, and concentrated under vacuum to a reddish oil (2.6 This was purified by flash chromatography (hexane:ethyl acetate) to afford the product (2.0g) as a clear Oil. NMR (CDC1 3 1.15, t 134., s 1. 9, M (6H) 2.55, q 3.94, t 5.02, 6.48, m (2H) 7.02, d 7.37, mn Mass Spec (GC-MS) m/z 351 Step C: Preparation of l-bromo-2- (benzyloxy) -5-ethyl-4- oxy] benzene BzI Brf The ethylbenzene g) was dissolved in carbon tetrachloride int) and N-bromosuccjnimide (1.16 g) added. The solution was stirred 18 hours, diluted with dichloromethane (50 xnL), washed with water, dried (MgSO 4 filtered and concentrated under vacuum to an orange solid. This was recrystallized from hexane/ethyl acetate to yield the product as a white solid (1.65 NMR (CDC1 3 1.14, .t -1.35, s I(6H) 1. 9, in 2.52, q (2H1); 3.88, t (2H1) 5.12, s (2H); 6.45, s 7.2 mn MS m/z =454.2 20 (M+Na).

Step D Preparation of 1-(benzyloxy)-4-ethyl-2-(4fluorophenyl) (5-methyl-5-.cyanohexyl) oxy] -benzene F 4 -fluorophenylboronic acid (0.84 g) was added to ethanol To this was added toluene (15 mL), the broinonitril~e (1.29g), 1.82N sodium carbonate solution (4.9 inL), and tetrakis-triphenylphosphine palladium (0.35 g) under a nitrogen atmosphere. The mixture was heated at reflux for 18 hours, cooled, and poured into ethyl acetate (50 inL). The layers were separated and the organics washed with saturated ammonium chloride solution, dried (MgSO 4 filtered, and concentrated under vacuum to afford a green oil (1.75 g).

This was purified by flash chromatography to afford the product (1.13 g) as a clear oil. NMR (CDCl 3 1.19, t (3H); 1.36, s (6H) 1.5 1.9, m 2.612, q 3.97, t 5.02, s 6.55, s 7.06, m 7.32, m 7.50, dd MS (EI) m/z 468.2 (M+Na).

Step E: Preparation of 1-(benzyloxy)-4-ethyl-2-(4fluorophenyl)-5-[(5,5-dimethyl-6-aminohexyl)oxy]benzene

NH

2 0 15 Dry ether (10 mL) was added to anhydrous aluminum chloride (670 mg) at O'C under nitrogen and stirred until dissolution was complete. Lithium aluminum hydride (190 mg) was added in one portion and the solution heated to reflux. l-(benzyloxy)- 4-ethyl-2-( 4 -fluorophenyl)-5- benzene (1.05 g) dissolved in dry ether (5 mL) was added dropwise at reflux. The heat was removed and the mixture stirred at ambient temperature for 5 hours. The reaction was quenched by addition of water, followed by 6N sulfuric acid until a clear solution was obtained. This was extracted with 25 ether. The aqueous solution was cooled and treated with sodium hydroxide. The basic mixture was extracted with ether.

The organic layers were dried over magnesium sulfate, filtered, and concentrated under reduced pressure to afford 900 mg of l-(benzyloxy)-4-ethyl-2-(4-fluorophenyl)-5-[( 6 ,6dimethyl-6-aminohexyl)oxy]benzene as a white solid, which was not further purified but carried forward. NMR (CDCl 3 0.83 s 1.17, t 1.25, m 1.42, m 1.55 broad 1.77, m 2.47, s 2.61 q 3.95, t (2H); 5.00, s 6.55, s 7.03, d 7.08, s 7.31, m 7.50, d of d Mass Spec m/e =450.3

(M+H)

Step F Preparation of 4-ethyl-2-(4-fluorophenyl)-5-[ dimethyl-6-aminohexyl)oxyphenol l-(benzyloxy)-4-ethyl-2-(4-fluorophenyl)-5-[(5,5-dimethyl-6aminohexyl)oxy]benzene (900 mg) was dissolved in ethanol (7 mL) and added to a solution of 10% palladium on carbon (200 mg) in 10 mL ethanol. The flask was fitted with a balloon and pressurized with hydrogen gas to maintain inflation of the balloon. The reaction was stirred overnight. The solution was filtered through Celite and concentrated under reduced pressure to afford III as an amber oil, essentially pure by TLC. Trituration with 19:1' hexane/ethyl acetate afforded the product 4-ethyl-2- 4 -fluorophenyl)-5- [(6,6-dimethyl-7aminoheptyl)oxy]phenol (625 mg) as an. off white solid. NMR (CDCl 3 0.84, s, 1.17, t 1.24, m 1.76, m 2.43, s 2.57,-q 2.82, broad 3.95, t 6.45, s 6.96, s 7.11, d of d (2H); 7.43, d of d Mass Spec m/e 360.2 (M+H) Step G Preparation of Sodium pyrolidinyl)oxy]carbonyl] -2-pyridinyll hydrazono] methyl] benzenesulfonate 4N-010 *Na S 9** 5909$ S NaO3S6" To a solution of 2-formylbenzenesulfonic acid sodium salt (13.6 g) in dimethylformamide (400 mL) was added 2hydrazinonicotinic acid (10.0 g) and the mixture stirred for three hours. N-hydroxysuccinimide (7.52 g) and dicyclohexylcarbodiimide (27.6 g) were added to the reaction and it was stirred for 16 hours. The mixture was filtered through Celite and the filtrate concentrated under vacuum to a thick oil. This was triturated with ethyl acetate to afford a solid which was filtered to afford crude product 32 The solids were refluxed in hot methanol for 5 hours filtered, washed with methanol, and dried under vacuum to afford Sodium 2-[l[5-[[(2,5-dioxo-1-pyrolidinyl)oxy]carbonyll- 2 -pyridinyl] hydrazonojmethyl]-benzenesulfonate (21.2g) as a pale yellow solid. NMR (DMSO-ds): 2.88, s 7.36, m 7.79, d of d 8.10, m 8.79, t 9.16, s (1H); 11.90, s (1H).

Step H Preparation of 4-ethyl-2-(4-fluorophenyl)-[5-[ 5 5 dimethyl-6-[[6-l[[( 2 -sulfonylphenyl)methylene]hydrazino]-3pyridinyl]carbonyll]amino]heptyl]oxyphenol Dry dimethylformamide (7 mL)was charged to a flask under nitrogen. To this was added 4-ethyl-2-(4-fluorophenyl)-5- [(5,5-dimethyl-6-aminohexyl)oxy]phenol (180 mg) and sodium 2- [[[5-[[(2,5-dioxo-1-pyrolidinyl)oxylcarbonyl] -2-pyridinyl] hydrazono]methyll-benzenesulfonate (275 mg followed by diisopropylethylamine (97 mg) and 4-dimethylaminopyridine mg). The solution was stirred overnight. Solvent was concentrated under vacuumand the residual oil partitioned into water/ethyl acetate. The ethyl acetate was concentrated .*000 and the resulting solids triturated with hot ethanol. The crude product was purified by preparative HPLC (5 x 25cm Vydac Pharmaceutical C18 column, 0.1% trifluoroacetic acid in 25 water/acetonitrile gradient). NMR (DMSO-d 6 0.88, s (6 H); 1.11, t 1.33, m 1.48, m 1.73, m (2H); 2.50, m 3.16, d 3.93, t 6.52, s (1H); 6.99, s 7.16, t 7.19, m 7.45, m (2H); S 7.52, d of d 7.81, m 8.26, d 8.35, d 8.47, s 8.53, broad 9.33, broad (2H).

m/e 661.3 Example 2.

Synthesis of 4 -ethyl-2-(4-fluorophenyl)-[5-14-[[6-[[(2sulfonylphenyl)methylene I hydrazino I -3pyridinyl] carbonyl]amino]butyll oxy] phenol Step A Preparation of 4-(Benzyloxy)-2-[ 3 -cyanopropyl)oxy] acetophenone 2 -hydroxyl-4-benzyloxy-acetophenione (5 4bromobutyronitrile (3.66 powdered potassium carbonate (5.7 and potassium iodide (0.85 g) were added to dimethylformamide (100 mL) under nitrogen. The slurry was 0 heated with stirring at 100'C for 24 hours, cooled, and poured into water (200 mL) and ethyl acetate (50 mL). The layers were separated and the aqueous layer extracted with ethyl acetate. The combined organics were washed with sodium bisulfite solution and brine, dried over magnesium sulfate, 15 filtered and concentrated under vacuum to an orange solid (5.8 S This was recrystallized from ethanol to afford pure 4- (benzyloxy)-2- (3-cyanopropyl) oxy]-acetophenone (5.2g) NMR (DMSO-d 6 2.10, m 2.50, s (3 2.70, t (2H); 4.16, t 5.19, s 6.69, m 6.75, d (1H); 7.40, m (5 7.67, d Mass Spec m/e 310.1 Step B Preparation of 4-(Benzyloxy)-2- (3-cyanopropyl) oxy] 1-ethylbenzene 4-(Benzyloxy)-2-[(3-cyanopropyl)oxy]-acetophenone (5 g) was dissolved in carbon tetrachloride (12.5 mL) under nitrogen.

To this was added trifluoroacetic acid (15 mL) and triethylsilane (15.5 mL) with stirring. The solution was stirred for three hours and then poured into 0.1N. sodium hydroxide (190 mL)/ethyl acetate (50 mL) with cooling. The layers were separated and the aqueous reextracted with ethyl acetate. The combined organic layers were washed with sodium bicarbonate solution, brine, and dried over magnesium sulfate.

The solvent was removed under vacuum after filtration to afford an orange oil. This was purified by flash chromatography on silica gel using hexane/ethyl acetate (9:1) as an eluant. After concentration, 4-(Benzyloxy)-2-[ (3cyanopropyl)oxy]-l-ethylbenzene was obtained as a clear oil NMR (CDC1 3 1.16, t 2.16, m 2.56, m 4.03, t 5.03, s 6.50, m 7.04, d 7.37, m Mass Spec m/e 296.3 Step C Preparation of 1-(benzyloxy)-2-bromo-4-ethyl-5-[( 3 cyanopropyl)oxy]-benzene Carbon tetrachloride (30 mL) was used to dissolve 4- (Benzyloxy)-2- (3-cyanopropyl) oxy]-l-ethylbenzene (2.5

N-

bromosuccinimide (1.66 g) was added to the solution and it was stirred for 5.5 hours. The mixture was diluted with dichloromethane (50 mL), washed with water, dried over magnesium sulfate, filtered, and concentrated under vacuum.

The resulting oil was crystallized from hexane/ethyl acetate at -20'C to afford 1-(benzyloxy)-2-bromo-4-ethyl-5-[ (3cyanopropyl)oxy]-benzene as a white crystalline solid (1.5 g).

25 NMR (CDC1 3 1.14, t 2.14, m 2.55, m 3.98, t 5.12, s 6.45, s 7.37, m (6H).

Step D Preparation of l-Benzyloxy-2-(4-fluorophenyl)-4ethyl-5-[( 3 -cyanopropyl)oxy]-benzene 4 -fluorobenzene boronic acid (1.14 g) was dissolved in ethanol S(7 mL). To this was added l-(benzyloxy)-2-bromo-4-ethyl-5- 3 -cyanopropyl)oxy]-benzene (1.5 toluene (20 mL), tetrakis-triphenylphosphine palladium (470 mg), and 2M sodium carbonate solution (6.1 mL). The resulting mixture was heated to reflux and held there for 24 hours. The solution was cooled, diluted with ethyl acetate, and the layers separated.

The organic layer was washed with saturated ammonium chloride, dried over. magnesium sulfate, filtered, and concentrated to afford a green oil. This was purified by flash chromatography on silica using hexane/ethyl acetate The resulting fractions were concentrated under vacuum to afford 1- Benzyloxy-2-( 4 -fluorophenyl) -4-ethyl-- [(3-cyanopropyl) oxy] benzene (1.1 g) as a clear oil. NMR (CDC1 3 1.18, t (3H); 2.15, m 2.59, m (4 4.06, t 5.00, s (2H); 6.53, s 7.06, t 7.09, s 7.30, m 7.49, d of d (2H).

Mass Spec m/e 412.2 (M+Na).

Step E Preparation of l-Benzyloxy-2-(4-fluorophenyl)-4- 4 -aminobutyl)oxy]-benzene Bn 1 5 2 Dry ether (10 mL) was added to anhydrous aluminum chloride (693 mg) at O'C under nitrogen and stirred until dissolution :'was complete. Lithium aluminum hydride (197 mg) was added in 20 one portion and the solution heated to reflux. l-Benzyloxy-2- 4 -fluorophenyl)-4-ethyl-5-[(3-cyanopropyl)oxy]-benzene (1.05 g) dissolved in dry ether (5 mL) was added dropwise at reflux.

S The heat was removed and the mixture stirred at ambient temperature for 4.5 hours. The reaction was quenched by 25 addition of water, followed by 6N sulfuric acid until a clear solution was obtained. This was extracted with ether. The aqueous solution was cooled and treated with 50% sodium hydroxide. The basic mixture was extracted with ether. The organic layers were dried over magnesium sulfate, filtered, and concentrated under reduced pressure to afford 500 mg of l-Benzyloxy-2- 4 -fluorophenyl) -4-ethyl-5-[(4-aminobutyl)oxy] benzene as an oil, which was not further purified but carried forward. Mass Spec m/e 394.3 (M+H) Step F Preparation of 4-Ethyl-2-(4-fluorophenayl)-5-((4aminobutyl)oxy] phenol F 1

OH

O.NH2 A flask was charged with 10% palladium on carbon (200 mg), ethanol (20 mL), and 1-benzyloxy-2-(4-fluorophenyl)-4-ethyl-5- [(4-aminobutyl)oxy]-benzene (500 mg). The flask was fitted with a balloon and pressurized with hydrogen to fully inflate the balloon. The reaction was stirred 3.5 hours, filtered through Celite, and the filtrate concentrated under vacuum to afford 4-ethyl-2-(4-fluorophenyl)-5- (4-aminobutyl)oxy]phenol Sas a white powder (350 mg). HPLC showed that -25% starting material remained. It was not purified but carried directly 15 into the next step. Mass Spec m/e 304.1 d Step G Preparation of 4-ethyl-2-(4-fluorophenyl)-[5-[4-[[6- [[[(2-sulfonylphenyl methyleneihydrazino]- 3-: pyridinyl] carbonyl] amino]butyl] oxy] phenol 4-Ethyl-2-(4-fluorophenyl)-5-[(4-aminobutyl)oxy]phenol (300 mg) was dissolved in dimethylformamide (10 mL) under nitrogen. Sodium pyrolidinyl)oxy] carbonyl] -2-pyridinyl] hydrazono] methyl] benzenesulfonate (440 mg) and triethylamine (324 mg) were added and the reaction stirred overnight at ambient temperature. The solvent was removed under vacuum to afford a brown oil, which was purified by preparative HPLC (5 cm x cm Vydac.Pharmaceutical column, 0.1% trifluoroacetic acid/water 90% acetonitrile/water gradient, 50% B in 25 minutes) and the product fractions lyophilized to afford a white powder (120 mg) (decomposes 250'C). NMR (CDC1 3 1.11, t 1.79, m 2.50, q (2 3.36, m 3.97, t 6.53, s 6.99, s 7.18, m 7.49, m 7.83, m 8.28, d 8.38, d 8.46, s 8.78, m 9.36, s Mass Spec m/e 605.2 Example 3 Synthesis of 2-[[[5-[[(6-[(4,6-diphenyl-2-pyridinyl)oxy]-lhexanamino] carbonyl] -2 -pyidinyl] hydrazono] methyl] benzenesulfonic acid

NO

.N S03" Part A Preparation of 1-Amino-6-[(4,6-diphenyl-2pyridinyl)oxy]-hexane o* To a dry flask was added aluminum chloride (0.857 g, 6.42 15 rmol). The flask was cooled to less than 0 'C with an ice/ethanol bath. Ether (15 nmL) was added, and the reaction was stirred for 5 min until the aluminum chloride dissolved.

Lithium aluminum hydride (0.244 g, 6.42 mmol) was then added, and the reaction was heated to reflux. 6-[(4,6-Diphenyl-2pyridinyl)oxy]-hexanenitrile (1.0 g, 2.92 mmol) was dissolved in ether (5 mL) and added dropwise to the refluxing solution.

After addition was complete, the reaction was stirred overnight at room temperature. The reaction was then quenched with water. 6 N Aqueous sulfuric acid was added until a clear S 25 solution formed. This mixture was then extracted with ether The aqueous layer was then cooled in an ice bath and basified to pH 14 with 50% aq. NaOH. This was then extracted with ether The organic layer was then washed with saturated NaC1, dried over magnesium sulfate, and evaporated to give 0.7184 g of 1-amino-6-(4,6-diphenyl-2pyridinyl)oxy]-hexane as an oil. ESMS: Calcd. for C23H26N20, 346.20; Found, 347.3 1 49 Part B Preparation of 2- [15- (4,6-diphenyl-2pyridinyl) oxy] -1-hexanamino] carbonyl] -2pyridinyl]hydrazono]methyl] -benzenesulfonic acid 1-Amino-6- 4 ,6 -diphenyl-2 -pyridinyl) oxy]-hexane (0.

2 00g, 0.557 mol) was dissolved in DMF (5 mL). Triethylamine (232.9 iL, 1.67 mmol) was added, and the reaction was stirred for min. 2 ,5-Dioxo-l-pyrrolidinyi)oxy]carbonyl] -2pyridinyl i hydrazono] methyl] -benzenesulfonic acid, monosodium salt (294.3 mg, 0.668 mmol) was then added, and the reaction mixture was stirred under nitrogen for 3 days. The reaction mixture was concentrated to an oil and triturated with ethyl acetate. The crude product was purified by preparative

HPLC,

using the following method to give 133 mg of the purified title compound. ESMS: Calcd. for C36H35N505S, 649.23; Found, 648.3 1

S

HPLC Method 1 Instrument: 20 Column: Detector: Flow Rate: Column Temp: Mobile Phase: Rainin Rabbit; Dynamax software Vydac C-18 (21.2 mm x 25 cm) Knauer VWM 15 mL/min

RT

A: 0.05 M ammonium acetate B: 90% ACN, 10% 0.05 M ammonium acetate Time (min) %A %B 0 80 0 100 0 100 31 80 Gradient: Example 4 Synthesis of 2 -[[[5-[[2,2-dimethyl-6-[ (6-fluorophenyl-4phenyl-2-pyridinyl) oxy] -1-hexanamino] carbonyl] -2pyridinyl ]hydrazono] methyl] -benzenesulfonic acid Part A Preparation of 2,2-Dimethyl-6- (4-fluorophenyl)- 4-phenyl-2-pyridinyl) oxy] -hexanenitrile 6-( 4 -Fluorophenyl)-4-phenyl-2-pyridone (1.0 g, 3.77 mmol) was dissolved in toluene. Silver carbonate (1.04 g, 3.77 mmol) and 6-bromo-2,2-dimethyl-hexanenitrile (1.15 g, 5.66 mmol) were added, and the reaction was heated to reflux and kept in the dark for 2 days. The reaction was filtered and concentrated. The resulting residue was purified by flash column chromatography using 9:1 hexane:ethyl acetate to give 1.110 g of the purified nitrile. ESMS: Calcd. for C25H25FN 2 0, 388.20; Found, 388 GCMS Part B Preparation of l-Amino-2,2-dimethyl-6-[ (6fluorphenyl-4-phenyl-2-pyridinyl) oxy]-hexane

F

*I

N 0 15 To a dry flask was added aluminum chloride (0.754 g, 5.65 mmol). The flask was cooled to less than 0 C' with an ice/ethanol bath. Ether (10 mL) was added, and the reaction was stirred for 5 min until the aluminum chloride dissolved.

S Lithium aluminum hydride (0.214 g, 5.65 mmol) was then added, S. and the reaction was heated to reflux. 2,2-Dimethyl-6-[(6fluorophenyl)- 4 -phenyl-2-pyridinyl)oxy]-hexanenitrile (1.0 g, 2.57 mmol) was dissolved in ether (5 mL) and added dropwise to 25 the refluxing solution. After addition was complete, the reaction was stirred for 5 h at room temperature. The reaction was then quenched with water. 6N Aqueous sulfuric acid was added until a clear solution formed. This mixture was then extracted with ether The aqueous layer was then cooled in an ice bath and basified to pH 14 with 50% aq.

sodium hydroxide. The resulting solution was then extracted with ether The organic layer was then washed with saturated NaC1, dried over magnesium sulfate, and evaporated to give 1..2.g (119%) 1of the amine product as-an oil. jEsSS Calcd. for C25H2 9FN 2 392.23; Found, 393.2 Part C Preparation of 2-f[(5-t[2,2-dimethyl-6-u(6fluorophenyl-4 -phenyl-2-pyridinyl) oxy] -1-hexanaminol carbonyl] 2-pyridinyl] hydrazono] methyl) -benzenesulfonic acid 1-Amino-2, 2-dimethyl--[(6-f luorophenyl-4-phenyl-2pyrkidinyl)oxy]-hexane (0.200 g, 0.51 mmol) was dissolved in dimethylformamide (5 mL). Triethylamine (213.2 JIL, 1.53 mmcl) was added and the reaction was stirred for 5 min. oxy] carbonyl] -2pyridinyl] hydr!azono ]methyl] -benzenesulfonic acid, monosodium salt (269.5 mg. 0.612 mmol) was added and the reaction was stirred for 24 h under nitrogen. The reaction was then concentrated to an oil under high vacuum. The oil was triturated with ethyl'acetate. The crude product was then purified by the following method to give 10 mg of the title compound. ESMS: Calcd. for C38H38FN505S, 695.'26; Found, 696.4 (M+H)+l 00.

.0.

HPLC Method 2 Instrument: Column: Detector: Flow Rate: Column Temp: Mobile Phase: Gradient: Rainin Rabbit; Dynamax software Vydac C-18 (21.2 mm x 25 cm) Knauer VWM 15 mL/min

RT

A: 0.1% TFA in B: 0.l%TFA in ACN/H20 (9:1) Time (min) %A %B 0 80 0 100 0 100 31 80 Example Synthesis of 2 4 -fluorophenyl)-4-phenyl-2pyridinyl)oxy] -hexanoyl] -tyrosine-O- 3-propanamino] carbonyl 2 -pyridinyl]hydrazono]l-methyl}-benzenesulfonic acid

F

o COOH

NO

N

H

H

.O NO Part A Preparation of N-(6-[(6-(4-fluorophenyl)-4-phenyl-2pyridinyl)oxy]-hexanoyl]tyrosine S 10 To a teabag (5x5 cm polypropylene filters, 0.75 gm mesh) was added :0.30 g of Fmoc-Tyr(OtBu)-Wang Resin. The teabag was washed with the following (10 mL/bag): DMF 2 x 3 min, -piperidine in DMF 1 x 3 min, 20% piperidine in DMF 1 x 30 min, DCM 8 x 3 min, and DMF 3 x 3 min. About 2.5 equivalents of S. 15 4 -fluorophenyl)- 4 -phenyl-2-pyridinyl)oxy -hexanoic acid, five equivalents of each of the following; HBTU, HOBT, diisopropylethylamine(DIEA) and DMF (10 mL/bag) were added.

The bag was then shaken overnight for about i8 h. The bag was then washed with the following (10 mL/bag): DMF 3 x 3 min, 20 DCM 8 x 3 min. The bag was dried under high vacuum. The contents of the bag was then placed in a small erlenmeyer flask. To the flask was added 10 mL of cleavage cocktail trifluoroacetic acid, 2.5% triisopropylsilane, and water). The resin was allowed to sit for 2 h while occasionally being swirled. After each swirl the sides of the flasks were rinsed with additional cocktail until the total volume of cocktail added was 15 mL. After 2 h, the resin was filtered and washed with TFA (2x4 iL). The filtrates were then concentrated to an oil under high vacuum. The oils were then purified by prep HPLC using the method 2 described above, to give 36.2 mg of the title compound. ESMS: Calcd. for C32H31FN 2 0 5 542.22; Found, 543.4 (M+H) 1 Part B Preparation of N-[6-[(6-(4-fluorophenyl)-4-phenyl-2pyridinyl) oxy] -hexanoyl ]-O-(N-tert-butyloxycarbonyl-3aminopropyl] tyrosine

F

f 0 COOH

H

Boc-HN %O N- 4 -fluorophenyl) -4-phenyl-2-pyridinyl)oxy] hexanoyl]tyrosine was dissolved in dimethylformamide 0.5 mL) and cooled to 0 'C in an ice bath. Sodium hydride (2.2 equivalents) was added, and the reaction was stirred for 1 hour at 0 N-Boc-Bromopropylamine (1.1 equivalent) was dissolved in 0.2 mL of dimethylformamide and added dropwise to the solution. The reaction was stirred an additional 24 h under nitrogen. The reaction was then concentrated to an oil.

The resulting residue was brought up in ethyl acetate. This was acidified with 10% potassium hydrogen sulfate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated to give 45.3 mg of the crude product as an oil. ESMS: Calcd. for C40H46FN307S, 699.33; Found, 698.4 (M+H)+1 25 Part C Preparation of 2 -[[[5-[[N-[6-[(6-(4-fluorophenyl)-4phenyl-2-pyridinyl) oxy] -hexanoyl] -tyrosine-0- [3propanamino] carbonyl] -2-pyridinyl]hydrazono] -methyl] S benzenesulfonic acid To a solution of N-[6-[(6-(4-fluorophenyl)-4-phenyl-2pyridinyl) oxy] -hexanoyl] [N-tert-butyloxycarbonyl-3aminopropyl]tyrosine dissolved in 1 mL of dichloromethane was added trifluoroacetic acid (1 mL), and the reaction mixture stirred for 2 h. The reaction mixture was then concentrated to an oil under high vacuum. The crude Oil was'dissolved. in 1 mL of dimethylformamide. Triethylamine (3 equivalents) was added and the reaction stirred for 5 min. Dioxo-1-pyrrolidiny) oxy] carbonyl] -2-pyridinyl hydrazono methyl]-benzenesulfonic acid, monosodium salt (1.2 equivalents) was added and the reaction was stirred for 24 h under nitrogen. The reaction was then concentrated to an oil under high vacuum. The oil was triturated with ethyl acetate.

The crude product was then purified by method 2 described above to give 13.3 mg of the title .product. ESMS: Calcd. for C48H4-7FN60 9 S, 902.31; Found, 903.32 l Example 6 Synthesis of 2 ridinyl)oxy]hexanoyl]-tyrosine-o.[3 -propanamino] carbonyl.] -2pyridinyl]hydrazono -methyl-benzenesulfonic acid .0 0 COOH

NO

HH

2

N.

Part A Preparation of N-[6-[(,6-diphenyl-2-pyridinyl)oxy] hexanoylityrosine To a teabag (5x5 cm polypropylene filters, 0.75 pAm mesh) was added 0.30 g of Fmoc-Tyr(tBu)-Wang Resin. The teabag was washed with the following (10 mL/bag): DMF 2 x 3 min, piperidine in DNF 1 x 3 min, 20% piperidine in IbF 1 x 30 min, DCM 8 x 3 min, and DMF 3 x 3 min. 'About 2.5 equivalents of 6-[(4,G-Dipheny -2-pyridinyl) oxy] -hexanoic acid, five equivalents of each of the following; HBTU,

HOET,

diisopropylethylamine(DIFA) and DMF (10 mL/bag) were added.

The bag was then shaken overnight for about 18 h. The bag was then washed with the following (10 mL/bag): DMF 3 x 3 min, DCM 8 x 3 min. The bag was dried under high vacuum. The contents of the bag was then placed in a small erlenmeyer flask. To the flask was added 10 mL of cleavage cocktail trifluoroacetic acid, 2.5% triisopropylsilane, and water). The resin was allowed to sit for 2 h while occasionally being swirled. After each swirl the sides of the flasks were rinsed with additional cocktail until the total volume of cocktail added was 15 mL. After 2 h, the resin was filtered and washed with TFA (2x4 mL). The filtrates were then concentrated to an oil under high vacuum. The oils were then purified by prep HPLC method 2 described above, to give 43.6mg of N-(6-[(4,6-diphenyl-2-pyridinyl)oxy] hexanoyl]tyrosine. ESMS: Calcd. for C32H32N205, 524.23; Found, 525.4 (M+H)+1 Part B Preparation of (4,6-diphenyl-2-pyridinyl)oxy]hexanoyl] [N-tert-butyloxycarbonyl-3-aminopropyl tyrosine o 0 COOH

H

Boc-HN O (4,6-diphenyl-2-pyridinyl)oxy]-hexanoyl]tyrosine was dissolved in dimethylformamide 0.5 mL) and cooled to 0 25 C in an ice bath. Sodium hydride (2.2 equivalents) was added, and the reaction was stirred for 1 hour at 0 N- Boc-Bromopropylamine (1.1 equivalent) was dissolved in 0.2 mL of dimethylformamide and added dropwise to the solution. The reaction was stirred an additional 24 h under nitrogen. The reaction was then concentrated to an oil. The resulting residue was brought up in ethyl acetate. This was acidified with 10% potassium hydrogen sulfate. The organic layer was washed with brine, dried over magnesium sulfate, and %evaporated to give the crude product as an oil'. (35.0 rag) ESMS: Calcd. for C4QH47N30 7 681.34; Found, 680.4 (M.H)+l Part C Preparation of 2.-U[[5-[([N-[6-[(4,6-diphenyl2pyridinyl) oxy] -hexanoyl I-tyrosilne-O- [3 -propanamino] Icarbonyli 2 -Pyridinyllhydrazono] -methyl] -benzenesulfonic acid To a solution of N- 6-diphenyl-2-pyridinyl)oxy] hexanoyl]I-0- (N-te6rt-butyloxycarbonyl.3 -aminopropyl] tyrosine dissolved'in 1 znL of dichioromethane was'added trifluoroacetic acid (1 MWL, and the reacti on mixture stirred for*2 h.Thereaction mixture was then concentrated to an oil under high vacuum.+ The crude oil was dissolved in 1 niL of -dimethylformamide. Triethylamine (3 equivalents) was added and the reaction stirred for 5 min. 2-[([5-[-(2,5Dioxo_1 C*pyrrolidinyl) oxy] carbonyl] -2-pyridinyl] hydrazono] methyl] benzenesulfoni*c acid, monosodium salt'(1.2 equivalents) was added and the reaction was stirred for 24 h under nitrogen.

**The reaction.was then 'Concentrated to an oil under high vacuum. The oil was triturated with ethyl acetate. The crude product was then purified by method 2 described above to give mg of the product. ESMS: Calcd. for C48H48N60 9 S, 884.32; Found, 885.33 (M+H) 1 Example 7 'Synthesis of (3,4-methylenedioxyphenyl).6phenyl-2- pyridinyl) oxy] -hexanoyl] -tyrosine-0- [3-propanamino]

I-

carbonyl] -2 -pyridinyl] hydrazono] -methyl] -benzenesulfonic acid 0 COOH N0 N 0 .0s Part A Preparation of N-[6-[(4-(3,4-methylenedioxyphenyl)- 6-phenyl-2-pyridinyl)oxy]-hexanoyl]tyrosine To a teabag (5x5 cm polypropylene filters, 0.75 pm mesh) was added 0.30 g of Fmoc-Tyr(OtBu)-Wang Resin. The teabag was washed with the following (10 mL/bag): DMF 2 x 3 min, piperidine in DMF 1 x 3 min, 20% piperidine in DMF 1 x 30 min, DCM 8 x 3 min, and DMF 3 x 3 min. About 2.5 equivalents of 6-Diaryl-2-pyridinyl)oxy]-hexanoic acid, five equivalents of each of the following; HBTU, HOBT, diisopropylethylamine(DIEA) and DMF (10 mL/bag) were added.

The bag was then shaken overnight for about 18 h. The bag was then washed with the following (10 mL/bag): DMF 3 x 3 min, DCM 8 x 3 min. The bag was dried under high vacuum. The .contents of the bag was then placed in a small erlenmeyer flask. To the flask was added 10 mL of cleavage cocktail trifluoroacetic acid, 2.5% triisopropylsilane, and water). The resin was allowed to sit for 2 h while 20 occasionally being swirled. After each swirl the sides of the flasks were rinsed with additional cocktail until the total volume of cocktail added was 15 mL. After 2 h, the resin was filtered and washed with TFA (2x4 mL). The filtrates were then concentrated to an oil under high vacuum. The oils were 25 then purified by prep HPLC using method 2 described above, to give 35..3 mg of the desired product. ESMS: Calcd. for C33H32N 2 0 7 568.22; Found, 569.4 (M+H)+1 Part B Preparation of N-[6-[(4-(3,4-methylenedioxyphenyl)- 6-phenyl-2-pyridinyl)oxy]-hexanoyl]-O-[N-tertbutyloxycarbonyl-3-aminopropyl]tyrosine 0 COOH NO

N

O Boc-HN O o-/ N-[6-[(4-(3,4-Methylenedioxyphenyl) -6-phenyl-2-pyridinyl)oxy]hexanoyl]tyrosine was dissolved in dimethylformamide 0.5 mL) and cooled to 0 *C in an ice bath. Sodium hydride (2.2 equivalents) was added, and the reaction was stirred for 1 hour at 0 N-Boc-Bromopropylamine (1.1 equivalent) was dissolved in 0.2 mL of dimethylformamide and added dropwise to the solution. The reaction was stirred an additional 24 h under nitrogen. The reaction was then concentrated to an oil.

The resulting residue was brought up in ethyl acetate. This was acidified with 10% potassium hydrogen sulfate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated to give 39.2 mg of the crude product as an oil. ESMS: Calcd. for C41H47N309, 725.33; Found, 726.3 (M+H)+1

S

Part C Preparation of methylenedioxyphenyl) -6-phenyl-2-pyridinyl) oxy]-hexanoyl tyrosine-O- 3 -propanamino] ]-carbonyl] -2-pyridinyl]hydrazono] 20 methyll-benzenesulfonic acid To a solution of 4 (3,4-methylenedioxyphenyl)-6-phenyl- 2-pyridinyl)oxy]-hexanoyl]tyrosine dissolved in-1 mL of dichloromethane was added trifluoroacetic acid (1 mL), and the 25 reaction mixture stirred for 2 h. The reaction mixture was then concentrated to an oil under high vacuum. The crude oil was dissolved in 1 mL of dimethylformamide. Triethylamine (3 equivalents) was added and the reaction stirred for 5 min. 2- [[[5-[[(2,5-Dioxo-1-pyrrolidinyl)oxy]carbonyl]-2pyridinyl]hydrazono]methyl]-benzenesulfonic acid, monosodium salt (1.2 equivalents) was added and the reaction was stirred for 24 h under nitrogen. The reaction was then concentrated to an oil under high vacuum. The oil was triturated with ethyl acetate. The crude product was then purified by method 2 described above to give 3.8 mg of the product.

ESMS:

Calcd.for C49H48N 6 0 11 S, 928.31; Found, 929.32 (M+H)+1 Example 8 Synthesis of (4,6-diphenyl-2pyridinyl)oxy] -hexanoyl]-lysine-epsilon-N-amino]carbonyl]-2pyridinyl i hydrazono -methyl] -benzenesulfonic acid

OHN

L OON H N'

NN

s. N SO 3 -H O

H

2 Part A Preparation of alpha-N-[6-[(4,6-diphenyl-2pyridinyl)oxy] -hexanoyl lysine O

NH

2

TFA

I. H i

H

0 To the teabag (5x5cm polypropylene filters; 0.75 pm mesh) was added 0.88g of Fmoc-Lys(boc)-Wang Resin. The teabag was washed with the following (10 mL/bag) DMF 2 x 3 min, piperidine in DMF 1 x 3 min, 20% piperidine in DMF 1 x 30 min, DCM 8 x 3 min, and DMF 3 x 3 min. 2. 2 Equivalents of 6- 4 ,6-Diphenyl-2-pyridinyl)oxyl-hexanoic acid, five equivalents of each of the following; HBTU, HOBT, diisopropylethylamine(DIEA) and DMF (10 mL/bag) were added.

The bag was then shaken overnight for about 18 h. The bag was 20 then washed with the following (10 mL/bag): DMF 3 x 3 min, DCM 8 x 3 min. The bag was dried under high vacuum. The contents the bag was then placed in a small erlenmeyer flask.

To the flask was added 10 mL of cleavage cocktail trifluoracetic acid, 2.5% triisopropylsilane, and 2.5% water).

The resin was allowed to sit for two h while occasionally being swirled. After each swirl the sides of the flasks were rinsed with additional cocktail until the total volume of cocktail added was 15 mL. After 2 h, .the resin was filtered and washed with TFA (2x4 mL). The filtrate was then concentrated to an oil under high vacuum. The oil was then purif ied -by prep HPLC using the- method 2 described above, to give 115 mg of product. ESMS: Calcd. for C29H35N 3 0 4 ,.489.26; Found, 490.4 Part B -Preparation of 2 [a1pha-N-(6- 4,6-diphenyl.

2 pyridinyl) oxy] -hexainoyl] -lysine-epsilon-N-amino] carbonyL] -2pyridinyllhydrazono] -methyl] -benzenesullfonic acid The lysine derivative (30 mg, 0.061 nunol) was dissolved in niL of dimethylformamiide. Triethylamine (25.5 t.L, 0.183 mmol) was added and the reaction was stirred for 5 min. pyridinyl] hydrazono] methyl] -benzenesulfonic acid, monosodium salt (32-.2 mg, 0.073 nimol) was added and .the reaction was .15 -stirred for 24 h .under nitrogen. The reaction was then concentrated to an oil under high vacuum. The oil was triturated with ethyl acetate. The crude product was then.

*purified by method 2 described above to give 4.8 mg of the title compound. ESMS: Calcd. for C42H44N60 8 S, 792.29; Found,. 793'.30. (M+Hi)~ *Example 9 Synthesis of 4 -ethyl-2-(4-fluorophenyl) 5-dimethyl-6aminohexyl) oxylphenol N- (carboxy)benzyl] -bis (2thioethyl]...gycinmide Conjugate

H

HN-)

SHHS

Part A Preparation of S-rpeymty-2aiotaeho A solution of cysteamine hydrochloride (79.5 g, 0.7 mol) in TFA (500 ml) was treated with triphenylmethanol (182 g, 0.7 Mo1), and stirred at room temperature for one hour. TFA was removed under reduced pressure at a temperature of 45 0 C and the resulting dark orange oil was dissolved in EtOAc -700 ml).

The EtOAc solution was washed with cold 2N NaOH (3 X 350 ml),

H

2 0 (2 X 350 ml), saturated NaHCO 3 (350 ml), and saturated NaC1 (350 ml). The combined aqueous washings were back extracted with EtOAc (350 ml): The combined organic layers were dried (MgS04) and concentrated to a yellow solid.

Trituration with ether (500 ml) gave product (97.2 g, 43%) as a colorless solid, MP 90-92 0 C. Concentration of the ether triturant to a volume of 100 ml and cooling produced an additional 40.9 g of product, MP 89-91 0 C, for a combined yield of 62%.

Part B Preparation of N-2-Bromoacetyl-S-triphenylmethyl-2aminoethanethiol A solution S-triphenylmethyl-2-aminoethanethiol (48 g, 0.15 mol) and Et 3 N (20.9 ml, 0.15 mol) in DCM (180 ml) was slowly added to a stirred solution of bromoacetyl bromide (13.9 ml, 0.15 mol) in DCM (100 ml) at a temperature of -20 0 C. The reaction was allowed to warm to room temperature over a one hour period. The reaction was washed with 500 ml portions of

H

2 0, 0.2 N HC1, saturated NaHC03, and saturated NaC1. The organic solution was dried (MgS0 4 and concentrated to an oil.

This oil was crystallized from DCM-hexane to give product 25 (54.9 g, 83%) as a colorless solid, MP 137-139.5 0

C

Part C Preparation of N,N'-Bis[(2triphenylmethylthio)ethyl]glycinamide A solution of N- 2 -Bromoacetyl-S-triphenylmethyl-2aminoethanethiol (35.2 g, 0.08 mol), S-triphenylmethyl-2aminoethanethiol (25.5 g, 0.08 mol), and Et 3 N (16.7 ml, 0.12 mol) in DCM (375 ml) was kept at room temperature for 24 hours. The solution was washed with 200 ml portions of H 2 0 saturated NaHC03

H

2 0 and saturated NaCl dried (MgS0 4 and concentrated to give a viscous oil.

The oil was dissolved in 70:30 DCM:EtOAc (150 ml) and cooled in an ice bath. The solid which formed was removed by filtratioi. The filtrate was concentrated to a viscous oil.

This oil was purified by flash chromatography over 200-400 mesh, 60A silica gel using 70:30 DCM:EtOAc mobile phase to give product (34.4 g, 63%) as a colorless, amorphous foamy solid. 1 H NMR (CDC13) 7.42-7.18 30H), 3.12-3.01 4H), 2.48-2.27 6H).

Part .D Preparation of Methyl 4- (Methanesulfonylmethyl)benzoate A solution of methyl 4 -(hydroxymethyl)benzoate (10.8 g, 0.065 mol) and proton sponge (19.5 g, 0.091 mol) in DCM (200 ml) was treated with methanesulfonic anhydride (13.94 g, 0.08 mol) and stirred at room temperature for 20 hours. The reaction 15 mixture was washed with 100 ml portions of H 2 0 lN HC1

H

2 0 saturated NaHC0 3 and H 2 0 The organic phase was dried (MgS04) and concentrated to give 15.5 g of pale yellow solid. Recrystallization from CC1 4 (150 ml) using decolorizing carbon gave product (14.2 g, 90%) as colorless needles, MP 91-94 0

C.

Part E Preparation of N-[ 4 -(Carbomethoxy)benzyl]-NNbis[( 2 -triphenylmethylthio)ethyl]glycinamide 25 A solution of N,N'-Bis[( 2 -triphenylmethylthio)ethyl]glycinamide (16.27 g, 0.024 mol) and methyl 4- (methanesulfonylmethyl)benzoate (4.88 g, 0.02 mol) in ethylene dichloride (200 ml) was heated to reflux for 28 hours. The reaction was washed with 200 ml portions of saturated NaHCO 3 and H 2 0, dried (MgS0 4 and concentrated to a light brown oil This oil was purified by flash chromatography over 200-400 mesh, 60A silica gel using DCM:EtOAc mobile phase to give product (9.9 g, 60%) as a colorless, amorphous foamy solid. 1H NMR (CDC1 3 7.90 2H, J 6.5 Hz), 7.49-7.18 (m, 32H), 3.91 3H), 3.47 2H), 3.01 2H, J 6.2 Hz), 2.88 2H), 2.43 2H, J 6.2 Hz), 2.39-2.27 4H).

Part F Preparation of N-[4-(Carboxy)benzyl]-NN'-bis[(2triphenylmethylthio)ethyl]glycinamide A mixture of N-[ 4 -(carbomethoxy)benzyl]-N,N'-bis[(2triphenylmethylthio)ethyl]glycinamide (6.00 g, 7.26 mmol) in dioxane (65 ml) and IN NaOH (65 ml) was stirred at room temperature for 24 hours. The mixture was acidified with M citric acid (100 ml) and the gummy precipitate which formed was extracted into EtOAc (400 ml). The EtOAc solution was washed with H 2 0 (3 X 200 ml) and saturated NaCl (100 ml), dried (MgSO 4 and concentrated to give product (5.90-g, 100%) as a colorless, amorphous foamy solid. 1 H NMR (CDC1 3 7.96 2H, J 8.1 Hz), 7.40-7.16 32H), 3.71 3H), 3.49 2H), 3.00 2H, J 5.4 Hz), 2.91 2H), 2.44 2H, 15 J 5.4 Hz), 2.38-2.30. 4H).

Part G Preparation of N-[4-(Carboxy)benzyl]-N,N'-bis[( 2 triphenylmethylthio)ethyl]glycinamide N-Hydroxysuccinimide Ester A solution of N-[4-(carboxy)benzyl]-N,N'-bis[ (2-triphenylmethylthio)ethyl]glycinamide (450 mg, 0.55 mmol) and Nhydroxysuccinimide (76 mg, 0.66 mmol) in DCM (10 ml) was treated with a solution of WSCD.HC1 (122 mg, 0.66 mmol) in DCM (7 ml) and stirred at room temperature for 22 hours. The reaction mixture was concentrated and the solids redissolved in EtOAc (60 ml). The EtOAc solution was washed with H 2 0 (2 X ml), 0.1 N NaOH (35 ml), H 2 0 (2 X 25 ml), and saturated NaCI (35 ml), dried (Na 2

SO

4 and concentrated to give product (469 mg, 93%) as a colorless solid.

Part H Preparation of 4 -ethyl-2-(4-fluorophenyl)-5-[(5,5dimethyl-6-aminohexyl)oxy]phenol N-[4-(carboxy)benzyl]-N,N'bis[(2-triphenylmethylthio)ethyl]-glycinamide Conjugate 4-ethyl-2-( 4 -fluorophenyI)-5-[(5,5-dimethyl-6aminohexyl)oxylphenol (100 mg) was dissolved in dimethylformamide (5 mL) under nitrogen.- To this was added triethylamine (84 mg), N-[ 4 -(carboxy)benzy]-NiN-bis[ (2triphenylmethythic) ethyl)-glycinamide N-hydroxysuccinimid ester (254 mg), and 4 -dimethylaminopyridine* (7mg). The mixture was stirred overnight at ambient temperature. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate. The combined organics were dried (magnesium sulfate), filtered,*and concentrated to dryness to yield an oil (205 mg). This was purified by preparative

HPLC

cm x 25 cm Vydac Pharmaceutical column, 0.1% trifluoroacetic acid/water acetonitrile/water gradient,) and the fractions lyophilized to yield the product (118 mg) as a white powder. NMR (CDC13): 0.93, s (6H); 1.15, t 1.34, m 1.51; m 1.78, m 2.31, t 2.45, m 2.55, m 2.95, m (2H); 2.45, s 3.28, d 3.73, s 3.96, t (2H); 6.05, t 6.48, s 6.94, s 7.07, t (2H); 7.20, m (20H); 7.38, m. (15H); 7.56, d Mass Spec (El), i/e 1154.7 Part I Preparation of 4 -ethyl-2-(4-fluorophenyl)-5-[(5,5dimethyl-6-aminohexyl)oxyiphenol N-[4-(carboxy)benzyl]-N,N'bis[ 2 -thioethyl]-glycinamide Conjugate 4-ethyl-2-( 4 -fluorophenyl)-5-[(5,5-dimethyl-6aminohexyl)oxylphenol N-[4-(carboxy)benzyl] N'-bis[ (2triphenylmethylthio) ethyl]-glycinamide Conjugate (92 mg) was mixed with trifluoroacetic acid (4.6 mL) and triethylsilane (36 mg) and stirred for 3 hours under nitrogen. The solution was filtered and concentrated under vacuum. The resulting solid was dissolved in chloroform, loaded onto a SepPak® (Sio 2 and flushed with chloroform (5 mL). It was then flushed with methanol and the methanol collected and concentrated under vacuum to afford the product (25 mg). NMR (CDC1 3 0.97, s 1.15, t 1.36, m 1.49, m 1.80, m 2.58, m 2.78, t 2.97, t 3.31, m 3.39, m 3.91, s 3.97, t 6.16, t 6.48, s 6.96, s 7.11, t 7.43, m 7.69, d 7.79, b Mass Spec m/e 670.3 Example Synthesis of Benzenesulfonic Acid, 4 ,6-diphenyl- 15 2-pyridinyl)oxy]-2,2-dimethyl-l-hexyl]aza]carbonyl]-2pyridinyl]hydrazono]methyl] ON

N

H

NH

2

N

-03S 20 Part A Preparation of 6-[(4,6-Diphenyl-2-pyridinyl)oxy]- 2 2 -dimethyl-l-hexylamine A stirred suspension of NaBH 4 (255 mg, 6,75 mmol) in THF (4 mL) was treated with TFA (52 ul, 6.75 mmol). To the resulting solution was added dropwise a solution of 6-[(4,6-diphenyl-2pyridinyl)oxy]-2, 2 -dimethylhexanenitrile (500 mg, 1.35 mmol) in THF (5 mL). The solution was stirred at ambient temperatures for 4 hr, and the excess reagent was decomposed at 0°C by the cautious addition of water. The solution was concentrated to dryness and the residue was partitioned between DCM (30 mL) and water (30 mL). The aqueous layer was further extracted with DON x 30. mL). The combined'_DCM extracts were washed with water (50 mL) and sat. NaCi (50 ml), dried (MgSO 4 and concentrated' to give a yellow oil.

Purification by preparative HPLC- on a Vydac C-18 column (21.2 x 25 cm) using a l.35%/min gradient of 50 to 80% ACN containing 0.1% TFA at a flow rate of 15 mL/min gave the title compound as* a colorless oil (321 mg, 1 H. NMR (CDCl1 3 8.00-7.93 (in, 7.71-7.62 (mn, 2H), 7.56-7.41 (mn, 7H), 6.96 1H), 4.64-.4.38 (mn, 4H), 2.82-2.70 (in, 2H), 1.90-1.75 (in, 2H), 1.58-1.32 (m 4H), 0.97'(s, 6H); MS: m/e 375.2 Part B Preparation of Benzenesulfonic Acid, (6- 6 -dipheny1-2-pyridinyl)oxyI 2-dimethyl-lhexyl Iaza] carbonyl) -2-pyridinyl] hydrazono] methyl] A solution of 4 ,E-diphenyl-2-pyridiny)oxyI 2,2-diethy..

1 -hexylaniine (64.8 ing, 0.17 mniol), benzenesulfonic acid, 2- Is- 2 ,5-dioxo-1 pyrrolidinyl)oxy1ronl..2.

pyridinyllhydrazonolinethyl.] .(76.2 mng, 0.17 inmol), and TEA (96 20 ul, 0.53 mmol) in DMF (2 niL) was stirred at ambient *.temperature under nitrogen for 24 h. The DNF was rem oved .under vacuum and the residue was purified by preparative

HPLC

on a Vydac 0-18 column (21.2 x 25 cm) using a l.8%/min *..gradient of 20 t o 90% ACN containing 0.05 M NH 4 0H at a flow rate of 15 mL/inin. A second HPLC purification On the same column and gradient using-ACN gave the title compound as a colorless oil (9.6 mng, ES-NS: Wne 676.3 fM-H].

Example 11 Synthesis of 4 ,6-Diphenyl-2-pyridiny)oxy..

hexanoyl] -4-sulfonaiidyl] benzylamino] carbonyl] -2-pyridinyl

I-

hydrazonolmethyl] -benzenesulfonic acid Part A Preparation of 4 -(tert-butyl-aminomethyl)benzene sulfonamide Commercially available 4 -aminomethylbenzene sulfonamide hydrochloride hydrate (0.5 g, 2.25 mmol) was dissolved in dioxane (10 mL). Triethylamine (0.627 mL, 4.5 mmol) was added and the reaction was stirred for 5 min. Di-tert-butyldicarbonate (0.490 g, 2.25 mmol) was added, and the reaction was stirred overnight at room temperature. The reaction was then concentrated under high vacuum. The resulting oil was brought up in water and extracted with dichloromethane. The organic layer was then washed with brine, dried over magnesium sulfate, and evaporated to a small volume. Hexane was added 15 and the product precipitated. The product was filtered, washed with hexane, and dried to give 0.476 g of 4- (tert-butyl-aminomethyl)benzene sulfonamide.

ESMS: Calcd. for C12H18N20 4 S, 286.10; Found, 285.1 (M-H)-1 Part B Preparation of 4 -(Aminomethyl)-benzosulfonimide of 6-[(4,6-Diphenyl-2-pyridinyl)oxy)-hexanoic acid, trifluoroacetic acid salt 0 e. I -SS.' N I 4 O H NH 2

.TFA

6-f(4,6-Diphenyl-2-pyridinyl)oxyhexanoic acid (0.100 g, 0.276 mmol) was dissolved in dichloromethane (8 mL). 4- Dimethylaminopyridine (43.8 mg, 0.358 mmol), 1-(3dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (50.9 mg, 0.276 mmol), and 4 -(Tert-butyl-aminomethyl)benzene sulfonamide (79.0 mg, 0.276 mmol) were added. 4A Molecular sieves were added, and the reaction was stirred overnight for 22 h. The reaction was then filtered, and washed with dichioromethane. The- filtrate was washed with *IN HCl (1x), water saturated NaCI dried over magnesium sulfate, and concentrated to give a white solid which was recrystallized from hexane/ethyl acetate to give 106.7 mg of the boc protected sulfonimide product.

ESMS: Calcd. for C35H39N30 6 S, 629.26; Found, 628.3 (M-H)-l The boc protected product (97.3 mg, 0.154-mmol) was then dissolved in dichioromethane (1.5 niL). -TrifluoroAcetic acid niL) was added, and the. reaction was stirred for 2 h at room temperature. The reaction mixture was then concentrated to an oil and- triturated with ether. -The product was filtered, washed with ether, and dried to give,9-7.2 mg (11*9%) of 4- (aminomethyl) -benzosulfonimide of -6-[(4-,6-Dipheny1-2.- .pyridinyl')oxyJ]-hexanoic acild, trifluoroacetic acid salt.

15 ESMS: Calcd. for C30H3lN3Q 4 S,'529..20; Found, -53:0.2 (M+H)+l Part C Prep~aration hof 2 6 -[(4,,6-Diphenyl2.

o Pyridinyl) oxy] hexanoyll 4 -sulfonanidyllbenzylapinolcarbon11 2 -pyridinyl J -hydrazonolmethyl] -benzenesulfonic acid 0 The sulfonimido-mne (0.080 g, 0.124, rmol) was dissolved in dime thyl f ormaide (3 niL). Triethylamine (51.8g1, 0.372 nimol) was added and the reaction was stirred for 5 minutes.

000 a 2 ,ISDioxo-1-pyrrolidinyl)oxyl-carnyl.

2 25 pyridinyljhydrazno]methyl..benzenesulfonic. acid, monosodium.

salt (65.5 mg, 0..149 nimol) was added and the reaction was stirred for 36 h under nitrogen. The reaction was then p pconcentrated to an oil. under high vacuum. The oil was triturated with ethyl acetate to give 100.9 mig of the title compound. ESMS: Calcd. for C43H40N6O8S 2 832.23; Found, Example 12 Synthesis of 4-ethyl-2- 4 -fluorophenyl) 6-dimethyl-7- [(6-111 2 -sulfonylphenyl)methylene]hydrazin 0 J-3pyridinyl]I carbonyl]I amino]J heptyl]I oxy] phenol Part A Preparation of 1-(benzyloxy)-4-ethyl-2-(4f luorophenyl) (6-methyl-6-cyanoheptyl) oxy] -benzene 1- (Benzyloxy) -4-ethyl-2- (4-flu'orophenyl t(6-methyl-6cyanoheptyl)oxy]- benzene was prepared as described in Example V,00. 1.for the synthesi's of l-(b:enzyloxy)-4-ethyl-2-(4fluorophenyl) (-methyl-5-cyanohexyl) oxy] -benzene substituting E-cyano- 6 -methyl-1-bromoheptane for methyl-l-bromoh'exane..

Part B Preparation of 4 -et hyl-2-(4-fluoropheny.)-5.[(6,6dimethyl-7-aminoheptyl) oxyiphenol F

OH

NH

2 l-(benzyloxy)4-ethyl-2-(4-fluorophenyl)...[ (6-methyl'-6cyanoheptyl)oxy]-benzene (485 mg) was dissolved in ethanol rnL) and added to a solution of platinum oxide (20 mg) in 10 niL ethanol in a Parr bottle. The bottle was pressurized to psi with hydrogen and shaken for 20 hours. Additional catalyst (120 mig) was added and bottle shaken at 55 psi of hydrogen for an additional 18 hours. The solution was filtered through Celite and concentrated under vacuum to afford crude 4-ethyl-2- (4-fluorophenyl) 6-dimethyl-7aminoheptyl)oxylpheno. (475 mig) as an oil. It was purified by chromatography on silica gel with chloroform/methanol eluant.

The product fractions were combinedabd concentrated under vacuum (120 mg). NNR (CDC1 3 1.00, s, 1.15, t (3H); 1.33, m 1.44, m 1.77, m 2.55, q (2H); 2.74, s 3.92, t 6.52, s 6.96, s (1H); 7.11, d of d 7.43, d of d Mass Spec m/e 374.3 Part C Preparation of 4-ethyl-2- (4-fluorophenyl)-[5-[6,6dimethyl-7-[[6-[[[(2 -sulfonylphenyl)methylene]hydrazino].3pyridinyil carbonyl] amino] heptyl] oxy] phenol' Dry."dinethyl formamide (5 nL) was charged to a flask under nitrogen. To this was added 4 -ethyl-2-(4-fluoropheny)5" f(EIG-dimethyl-7-aminoheptyl) oxylphenol (85 mg) and sodium 2hydrazono]methyl]-benzen(sulfonate (100 mg) followed b.

.diisopropylethylaine (94 mg) and 4 -dimethylaminopyridine mg). The solution was stirred overnight. Solvent was concentrated under vacuum and the residual oil purified by preparative HPLC (5 x 25cm Vydac C18 pharmaceutical column, 0.1% trifluoroacetic acid in water/acetonitrile gradient) and lyophilized to afford the product (30 mg) as an off-white powder. NMR (DMSO-d 6 0.88, s (6 1.10, t 3H); 1.33, m 1.76,.m 250, m 3.16, d 3.93, t 6.52, s 6.99, s 7.16, t 7.19, m 7.41, m 7.53, d of d 7.80, m 8.19, b 8.51, s 9.18, broad 9.33, broad (11).

Mass Spec Wie 675.3 Example 13 Preparation of 4-ethyl-2-(5-pyrazolyl)-[5-5,5-dimethyl-6-([6- 2 -sulfonylphenyl)iethylene]hydrazino]-3pyridinyl] carbonyl] amino] hexyl] oxy phenol Part A Preparation of 2-hydroxy-5-ethyl-4-[(5-methyl.5cyanohexyl) oxy] -acetophenone A solution of 2 ,4.-dihydroxy-5-ethyi-acetophenone (2.65 g), potasIS-Ium.?carbonate (3.6 potassium iodide .(0.49 (3.0 g) in dimethylsuif oxide (4 niL) and 2-butanone (15 niL) was heated at 110'C for 18 hours under nitrogen.. The mixture was cooled, diluted with water nL), and extracted with toluene'. The combined organics were washed with water, dried (magnesium sulfate), filtered, and tes concentrated under vacuum to a yellow oil (3.6 g) This was flash chromatographed (6:1 hexane/ethyl acetate) and the 15 combined fractions concentrated to afford the product as an *too**oil NMR (CDCl 3 1.17, t 1.35, s 1.6- 1.9, mi 2.55, s 2.56, q 4.01, t (2H); to.

*00 0 6.35, s 7.41, s 12.69, s Mass Spec e9os *000 .(GC/MS) m/e 303 o Part B Preparation of 3-II(5-methyl-5-cyanohexyl)oxy]-4ethyl-6-pyrazoyl-phenol:

OH

N.

2-hydroxy-5-ethyl-4- t(5-mhethyl-5-cyanohexyl) oxy] -acetophenone g) was mixed with dimethylforniamide dimethylacetal (1.6 g) and heated in a 100'C oil bath, where the solid dissolved.

After 3 hours, a yellow precipitate had formed and the volatiles were.removed under vacuum. The solids were suspended in ethanol (20 mL) and hydrazine hydrate (375 mg) added. The mixture was stirred for 18 hours at ambient temperature and then for 24 hours at reflux. The solution was filtered and the filtrate concentrated to an oil which was purified by flash chromatography (Hexane/chloroform/acetonitrile/ methanol, The desired fractions were combined and concentrated to afford the product as an oil (600 mg). NMR (CDCl 3 1.19, t (3H); 1.35, s 1.6-1.9, m 2.60, q 4.01, t (2H); 6.51, s 6.62, d 7.31, s 7.60, d (1H); 10.2, b Mass Spec m/e 326.2 Part C Preparation of 3-[(5,5-dimethyl-6-aminohexyl)oxy]-4ethyl- 6 -pyrazoyl-phenol

OH

N

H

NH

3-((5-methyl-5-cyanohexyl)oxy)- 4 -ethyl-6-pyrazoyl-phenol (285 mg) was dissolved in methanol (25 mL) in a Parr bottle and platinum oxide (100 mg) and concentrated hydrochloric acid (270 L) added. The vessel was capped, pressurized at 54 psi of hydrogen and shaken for 24 hours. The reaction was filtered through Celite and the filtrate concentrated to afford the product as an oil (265 mg). NMR (DMSO-d 6 0.92, s 1.14, t 1.2-1.5, m 1.6-1.8, m (2H); 2.48, q 2.64, m 3.97, t 6.51, s (1H); 6.76, d 7.45, s 7.85, d Mass Spec (EI), m/e 332.2

(M+H)

Part D Preparation of 4 -ethyl-2-(5-pyrazolyl)-[5-[5,5dimethyl-6-[ 2 -sulfonylphenyl)methylene]hydrazino]-3pyridinyl] carbonyl amino] hexyl] oxy]phenol 5-dimethyl-6-aminohexyl )oxyl -4-ethyl-6-pyrazoyl-phenl (260 mg) was dissolved in diiethylformanide (12 mL) and triethylamine (230 mg) added, followed by sodium [[(2,5-dioxo-l-pyrolidinyl)oxy]carbonyl]-2-pyridinyl] hydrazonoliethyl].benzenesulfonate (398 mg) and dimethylaminopyridine (8 mg). The purple reaction was stirred overnight, concentrated under vacuum, and the resulting oil (840 mg) purified by preparative HPLC (5 cm x 25 cm Vydac Pharmaceutical column, 0.1% trifluoroacetic acid/water acetonitrile/water gradient). The fractions were lyophilized to yield the product as a grey powder (140 mg).

NMR (DMSO-d 6 NMR (DMSO-d 6 0,88, S 1.12, t (311); 1.

2 9,m 2.53, g 3.15, m 3.95, t (2H); 4.2, b 6.46, s 6.75, s 7.17, d (1H); 7.43, m 7.84, m 8.29, d 8.38, d (1H); 8.45, s (lH)8.54, t 9.734, s(lH); 13.10, Mass Spec m/e 633.2 0 00 Example 14 Synthesis ofthe Conjugate Between 2 -f6-((4,6-Diphenyl-.

pyridinyl) oxylpentyl] 8 -amino-5-aza-4-oxooctylxy)benzenepropanoic Acid and Benzenesulfonic Acid, Dioxo-l-pyrrolidinyl)oxy]carbonyl]-2-pyridinyl]hydrazono] methyl] N

N

COOH 0 NH 2 S 03%- Part A Preparation of 6-[(5-Hydroxypentyl)oxyl-2-(4-tbutoxy-4-oxobutyloxy) benzenepropanoic Acid Methyl Ester A mixture of 2-hydroxy-6-[ (5-hydroxypentyl) oxy]benzenepropanoic acid methyl ester (2.04 g, 7.23 mmol) as described by Cohen, N. EP Appi. 531,823), t-butyl 4bromobutyrate (1.93 g, 8.67 mnmol), and K 2 C0 3 (2.29 g, 16.6 mol). in DMSQ (60 m.L) was stirred at Ambient temperatures.

under nitrogen for 21 h. The solids were removed by filtration and the filtrate was diluted with water (100 niL), and extracted with EtOAc (3 x 100 inL). The combined organic extracts were washed with water and sat. NaCi, dried (M~gS0 4 and concentrated to give product as a yellow oil (2.98

A

portion (487 mig) was purified by silica gel flash chromatography (40:60 EtOAc/hexanes) to give the title compound as a colorless oil (367 ing, 1 H NMR (CDCl 3 7.08 J 8.2 Hz, 1H), 6.48 J 8.2 Hz, 4.0-0-3.89 (in, 4H), 3.70-3.62: 5H), 3.04-2.93 (mn, 21f), 2.50-2.39 (in, 4H, 2.11-1.99 1..88-1.75, 2H), 1.72-1.52 (in, 1. 43 9H);.MS: nile.447.3 [M+Na].

'Part B Preparation of 6-( 4 -t-Butoy4,oxobuto)-2.( 5 .(mthysufonl~oylentlloylenznepopnoi. Acid Methyl Ester solution-of 6-(5 hdo yeti 4-tbtxoxbtlX~ez-npoaoda methyl ester (1..68 g, 3.96 inmol) TEA .10 -ml, 11.8 mmol), and methanesulfonyl chloride (0.46- nL, 5.9 inmol) in DCM (30 niL) was stirred at ambient temperature under nitrogen for 1 hr. The solution was diluted with DCM (50 xnL) and water (30 niL), and the aqueous layer was further extracted with DCM (3 x 50 niL). The- combined

DCM

extracts were washed successively with 0.1N HCl (100 niL), sat..

NaHCO 3 (50 niL), and sat. NaCl (50 niL), dried -(MgSO 4 and concentrated to give product as a pale yellow oil (1.99 g, 100%) IH NI4R (CDCl 3 7.08 J 8.3 Hz, 1H) 6.48

J

=8.3 Hz, 2H), 4.25 J 6.4 Hz, 2H), 4.00-3.90 (mn, 4H), 3.67 3H), 3.01-2.91 SH), 2.50-2.37 (in, 4H), 2.13-2.00 (mn, 2H), 1.89-1.75 (mn, 4H), 1.68-1.56 (mn, 2H), 1.43 9H); MS: nile 520.3

[M+NH

4 Part C Preparation of 2 -(6-[(4,6-Diphenyl-2pyridinyl) oxylhexyl] 4 -t-butoxy-4oxobutoxy)benzenepropanoic Acid Methyl Ester A mixture of 6- 4 -t-butoxy-4-oxobutoxy)-2-[[5- (methylsulfonyl)oxy]pentyl]oxy]benzenepropanoic acid methyl ester (2.08 g, 3.6 mmol), 4 6 -diphenyl-2-pyridinone (0.89 g, 3.6 mmol), and K 2 CO3 (1.19 g, 8.64 mmol) in DMSO (40 mL) was stirred at ambient temperature under nitrogen for 23 h. The reaction mixture was diluted with water (50 mL) and extracted with,EtOAc (3 x 70 mL). The combined organic extracts were washed successively with water, and sat. NaC1, dried (MgSO 4 and concentrated to give a yellow oil. Purification by silica gel flash chromatography (1:6 EtOAc/hexanes) gave the title Scompound as a colorless oil (1.56 g, 1 H NMR (CDC1 3 8.07 J 6.7 Hz, 2H), 7.70-7.63 2H), 7.54-7.35 (m, 15 7H), 7.08 J 8.1 Hz, 1H), 6.89 1H), 6.52-6.43 (m, 1H), 4.50 J 6.3 Hz, 2H), 4.05-3.93 4H), 3.63 (s, 3H), 3.05-2.94 2H), 2.54-2.39 4H), 2.11-1.98 2H), 1.98-1.83 4H), 1.76-1.61 2H), 1.43 9H); MS: m/e 654.5 Part D Preparation of 2 -[6-[(4,6-Diphenyl-2pyridinyl)oxylhexyll-6-(3-carboxypropoxy)benzenepropanoic Acid Methyl Ester 25 A solution of 2 6 -[(4,6-diphenyl-2-pyridinyl)oxylhexyl]-6-(4-t-butoxy-4-oxobutoxy)benzenepropanoic acid methyl ester (200 mg, 0.3 mmol) and anisole (65 ul, 0.6 mmol) in TFA mL) was stirred at ambient temperatures for 2 h. The solution was evaporated to dryness and the residue was partitioned between EtOAc (40 mL) and H20 (40 mL). The aqueous layer was extracted with additional EtOAc (3 x 20 mL).

The combined organic extracts were washed successively with sat. NaHCO 3 (30 mL) and sat. NaCl (2 x 30 mL), dried (MgSO 4 and concentrated to give a colorless solid. Lyophilization from 70% ACN gave the title compound as a colorless solid (170 mg, High Resolution MS: Calcd for C3 6

H

39 N0 7 598.2805, Found: 598.2813.

Part E Preparation of 2 -[6-[(4,6-Diphenyl-2pyridinyl)oxyjhexyl]-(5-aza-8-t-butoxycarb oxooctyloxy)benzeneproparioij Acid Methyl Ester

H

N O,_'NH-Boc COOMe A solution of 2-[6-[(4,6-diphenyl-2-pyridiny)oy]hexyl]-6-(3-carboxypropoxy) benzenepropanoic acid methyl'ester 0 (118 mg, 0.197 mmol) in DMF (4 xL) was treated with HBTU (82 *o mg, 0.217 mmol). After 8 min a solution of mono-N-Boc-1,3- ':eoi 15 diaminopropane (34.3 mg, 0.197 mmc l) and DIEA (86 ul, 0.49 mmol) in DMF (1 mL) was added and stirring was continued at ambient. temperatures for 10 min. The DMF was removed by evaporation and the residue was dissolved in a mixture of EtOAc (40 mL) and H 2 0 (30 mL). The aqueous layer was adjusted to pH 2 with 0.2 N HC1 and the layers were thoroughly mixed.

The EtOAc layer was washed consecutively with sat. NaHCO 3 mL) and sat. NaCi (2 x 30 mL),dried (MgSO 4 and concentrated to give the title compound as a colorless oil (129 mg, 86.8%).

High Resolution MS: Calcd for C4 4

H

55

N

3 0 8 754.4067, Found: 25 754.4077.

Part F Preparation of 2 6 -[(4,6-Diphenyl-2pyridinyl) oxy]hexyl] 8 -amino-5-aza-4oxooctyloxy)benzenepropanoic Acid

H

KCOOHQO

A mixture of 4 ,6-diphenyl-2-pyridinyl)oxy]hexyl]-6-( 5 aza-8-t-butoxycarbonylamino-4-oxooctyloxy)benzenepropanoic acid methyl ester (120 mg, 0.159 mmol) and 3 M LiOH (0.77 mL, 2.3 mmol) in THF (7.6 mL) was stirred at ambient temperatures for 4 days. The THF and H 2 0 were removed by vacuum evaporation and the residue was taken up cautiously with cooling in TFA (4 mL). The resulting solution was stirred at ambient temperature for 70 min and the TFA was removed by evaporation. The residue was treated with EtOAc (30 mL) and sat. NaHCO 3 (30 mL) causing a colorless solid to form in the EtOAc layer. This solid/EtOAc mixture was washed with water (2 x 10 mL) and filtered to remove the solid. The solid was dried to give the title compound as a colorless solid (77 mg, High Resolution MS: Calcd for C 38

H

45

N

3 0 6 640.3387, Found: 640.3384.

Part G Preparation of Conjugate between 2 4 ,6-Diphenyl-2pyridinyl)oxy]hexyl] 8 -amino-5-aza-4-oxooctyloxy) 20 benzenepropanoic Acid and Benzenesulfonic Acid, Dioxo-1-pyrrolidinyl)oxy]carbonyl] -2-pyridinyl] hydrazono]methyl] A mixture of 2-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]-6-(8- 25 amino-5-aza-4-oxooctyloxy)benzenepropanoic acid (55 mg, 0.086 mmol), benzenesulfonic acid, 2 pyrrolidinyl) oxy]carbonyl]-2-pyridinyl]hydrazono]methyl] (45.4 mg, 0.103 mmol), and TEA (56 ul, 0.344 mmol) in DMF (0.6 mL) was stirred at ambient temperatures for 17 h. The reaction mixture was purified directly by preparative HPLC on a Vydac C-18 column (21.2 x 25 cm) using a 1.33%/min gradient of 40 to ACN containing 0.05 M NH40H at a flow rate of 15 mL/min.

Lyophilization of the product-containing fraction gave title compound as a colorless solid (50 mg, High Resolution MS: Calcd for C51H5 4 N6OloS: 943.3700, Found: 943.3701.

Example Synthesis of the Conjugate Between G-(lI-Amino-3,6,9.

trioxaundecyloxy) 5 (-oxo-1- (2propenyl) 5 6,7, 8 tetrahydro-2-naphthalenyl)oxy]pentyloxy]benzenepropanoic Acid and Benzenesulfonic Acid, [5-[[(2,5-Dioxo-lpyrrolidinyl)oxy] carbonylJ- 2 -PYridinyl] hydrazonoj methylI rH 2 Part A Preparati'n of l-Benzyloxycarbonylamino 3 6 9 trioxaundecanol, A solution of 1-amino-3,6,-trioxaundecanol .(6.56 g, 0.034 mol) and TEA (5.2 mL, 0.037 mol) in DCM (200 mL) was treated with benzyl. chioroformate (5.1 nL, 0.036 mol) in one- portion.

After 18 h the solution was concentrated to a Viscous oil and triturated with ether (3 x 100 mL) The combined triturants were concentrated to give an amber oil (9.4 Flash *chromatoraphy on silica gel MeOH/EtOAc) gave the title compound as a colorless viscous oil (7.0 g, 1 H NMR (CDCl 3 7.36-7.25 5H), 6.04 (bs, 1H), 5.08 2H), 3.72-3.48 14H), 3.41-3.31 2H).

Part B Preparation of ll-Benzyloxycarbonylamino-3,6,9trioxaundecyl Mesylate A solution of 11-benzyloxycarbonylamino 3 6, 9 -trioxaundecanol (2.10 g, 6.4 mmol), TEA (2.7 mL, 19.2 nmol), and methanesulfonyl chloride (0.8 mL, 10.2 mmol) in DCM (20 mL).

After 2 h the solution was diluted with DOM (80 mL), washed successively with 0.2 M HCl (40 mL), water (40 mL), sat.

NaHCO 3 (40 mL) and sat. NaCl (2 x 40 mL), and dried (MgSO 4 Concentration gave the title compound as a viscous oil (2.3 g, 1 H NMR (CDCl 3 7.37-7.23 5H), 5.34 (bs, 1H), 5.08 2H), 4.35-4.26 2H), 3.72-3.50 12H),-3.41-3.32 2H), 3.02 3H); MS: m/e 406.2 Part C Preparation of N-Benzyloxycarbonyl-11-iodo-3, 6,9trioxaundecylamine A mixture of 11-benzyloxycarbonylamino-3,6,9 -trioxaundecyl mesylate (3.0 g, 7.4 mmol) and Nal (2.2 g, 14.8 mmnol) in ACN mL)- was heated at 80 0 C with stirring for 3 h. The mixture was partitioned between ether (140 mL) and water (80 mL). The aqueous phase was further extracted with ether (2 x 100 mL).

The combined ether extracts were washed successively with water (60 mL), 10% sodium thiosulfate (60 and sat. NaCl (2 x 60 mL). The ether solution was dried (MgSO4) and concentrated to give the title compound as a colorless oil (3.20 g, 1 H NMR (CDC1 3 7.39-7.26 5H), 5.35 (bs, 1H), 5.08 2H), 3.73-3.50 12H), 3..42-3.32 2H), 3.27-3.16 2H); MS: m/e 438.1 0 to Part D Preparation of 6-[(5-Hydroxypentyl)oxy]-2-(11benzyloxycarbonylamino-3,6, 9 -trioxaundecyloxy) benzenepropanoic Acid Methyl.Ester HO' O

H-Z

COOMe :A mixture of 2-hydroxy-6-[(5-hydroxypentyl)oxylbenzenepropanoic acid methyl ester (1.39 g, 4.93 mmol), Nbenzyloxycarbonyl-11-iodo-3,6, 9 -trioxaundecylamine (1.96 g, 4.48 mmol), and K 2

C

3 (1.24 mg, 8.96 mmol) in DMSO (6 mL) was stirred at ambient temperature under nitrogen for 6 d. The reaction mixture was used directly for purification on a Vydac C-18 column (21.2 x 25 cm) using a 1.5%/min gradient of 30 to ACN at a flow rate of 15 niL/min. The product fractions from nine injections were collected together and lyophilized to give the title compound as a colorless oil (626 mg, 23.6%).

1 H NMR (CDC13): 7.34-7.25 5H), 7.07 J 8.3 Hz, 1H), 6.48. J= 8.3:Hz 1H), -6-.46 J. 83 Hz, 1H), 5.4 (s, 1H), 5.08 2H), 4.07-3.35 23H), 2.98 J 8.1 Hz, 2H), 2.48 J 8.1 Hz, 2H), 1.83-1.61 8H); MS: m/e 592.3 Part E Preparation of 6-(ll-benzyloxycarbonylamino-3,6, 9 trioxaundecyloxy) (methylsulfonyl) oxyjpentyl] oxylbenzenepropanojc Acid Methyl Ester A solution of (5-hydroxypentyl)oxy3 (ll-benzyloxy.

carbonylamno-3,6, 9 -trioxaundecyloxy) benzenepropanoic acid methyl ester (75 mg, 0.13 nmol), TEA 0.51 rniol), and methanesulfonyl chloride (29 mg; 0.25 mmol) in.DCM (1.0 mL) was stirred at ambient temperatures for 1 h. The solution was diluted with DCM (6 znL), and washed successively with water (3 niL), pH 2.0 HC1 (3 mL), sat. NaHCO 3 (3 ML), and sat. NaCi (2 x 3 mL). The DCMsolution was dried (MgSO 4 and concentrated to give product as a-viscous oil (67 mg, MS: m/e 670.3 '2 0 Part F Preparation of 6-(ll-Benzyloxycarbonylamino-3,6,9 trioxaundecyloxy) -2[5-[(5-oxo---(2-propenyl)-56,7t8tetrahydro-2-naphthalenyl)oxy]pentyloxy]benzenepropanoic Acid :25 Methyl Ester 'o-Y(~OV

H.Z

A mixture of the mesylate prepared in Part C (67 mg, 0.10 nmol), 6-hydroxy-5-( 2 -propenyl)-1,2,3, 4 -tetrahydronaphthaien.

1-one (22.5 mg, 0.11 nmol), and anhydrous K2C03 (27 mg, 0.20 imol) in DMSO (500 ul) was stirred at ambient temperature under nitrogen for 96 h. The reaction solution was used directly for preparative HPLC purification on a Vydac C-18 column (21.2 x 25 cm) using a 1.8%/min gradient of--2-7 to 81% ACN at a flow rate of 15 iL/min. Lyophilization of the product fraction gave the title compound.as a viscous oil (38 mg, 1 H NMR (CDC1 3 7.99 J 8.8 Hz, 1H),-7.4 0 7.20 5H), 7.08 J 8.3 Hz, IH), 6.83 J 8.8 Hz, 1H), 6.49 J 8.3 Hz, IH), 6.46 J 8.3 Hz, IH), 5.94-5.79 1H), 5.35 1H), 5.08 2H), 4.97-4.87 (m, 2H), 4.07-3.94 6H), 3.80-3.38 18H), 2.98-2.85 4H), 2.59-2.48 4H), 2.08-1.65 8H); 1 3C NMR (CDC1 3 197.74, 174.06,160.64, 157.62, 157.44, 156.40, 144.39, 136.61, 135.50, 128.43, 128.05, 128.00, 127.800, 127.16, 126.30, 125.19, 117.34, 114.72, 109.14, 104.59, 70.86, 70.63, 70.49, 70.24, 69.96, 69.73, 68.00, 67.91, 66.57, 51.31, 40.86, 38.43, 33.32, 29.86, 28.98, 28.86, 26.31, 22.87, 22.73,.18.84;

DCI-

MS: m/e 793.6

[M+NH

4 High Resolution MS: Calcd for C44H 58

N

1 0 11 776.4010, Found: 776.4011.

Part G Preparation of 6-(ll-Benzyloxycarbonylamino-3,6,9trioxaundecyloxy)-2-[5-f (5-oxo-l-(2-propenyl)-5,6,7,8tetrahydro-2-naphthalenyl) oxy]pentyloxy] benzenepropanoic Acid Or o O

NH-Z

The ester prepared in Part C (28.5 mg, 0.037 mmol) was treated with THF (1.8 mL) and 3N aqueous LiOH (0.18 mL). The mixture was stirred at ambient temperatures under nitrogen for 6 d. The resulting yellow solution was concentrated to dryness, the residue was treated with water (4 mL), and adjusted to pH 2 with IN HC1. The milky solution was extracted with EtOAc (3 x 8 mL). The combined organic layers were washed with water (20 mL), and then sat. NaCl (15 mL), dried (MgS0 4 and concentrated to give the title compound as a colorles oil (27.0 mg, DCI-MS: m/e 779.5

[M+NH

4 High Resolution MS: Calcd for C43H 55

NO

11 762.3853, Found: 762.3859.

Part H Preparation of 6- (ll-Amino-3, 6, 9 -trioxaundecyo,) (S-oxo-l-(2-propenyl)..5,678.tetrahydro-2 naphthalenyl) oxy]pentyloxybenznepropanoic Acid A solution of 6 -(ll-enzyloxycarbonylamfl36 9 trioxaundecyloxy)-2.2[ (5-oxo-1-(2-propenyl)..5,67 8 tetrahydro-2 -naphthalenyl) oxylpentyloxy] benzenepropanoic acid (22 mg,'.0.0289 nunol) and TMSI (58 ul,. 0.0458 inmol) in ACN (1 m.L) was stirred at ambient temperatures for 30*mmn. 1{PLC analysis indicated approximately 50% starting mate rial remaining and additional TMSI-(58 ul) was added. After An additional 30 min the solution was concentrated and the' residue was partitioned between 5i NaHCO 3 (10 m.L) and EtOAc znL).. The aqueous layer was extracted with additional 15 EtOAc (2 x 5 The combined EtOAc extracts-.were washed with 1.0%.sodium thiosulfate (5 niL),' dried (MgSO 4 and concentrated to give the title compound as a pale yellow oil (9.8 MS: W/e 628.4 Part I Preparation of- Conjugate Between E-(ll-Amino-3,6,9.

trioxaundecyloxy).2-.(5-oxo.((2-pro 1 (pnp) 5 6 7 tetrahydro-2 -naphthalenyl) oxy] pentyloxy] benzenepropanoic Acid and Benzenesulfonic Acid, 2-f S-Dioxo-l-pyrrolidinyl) xy] carbonyl] -2 -pyridinyl] hydrazono] methyl] A solution of 6- (ll-amino-3,6G;9-trioxaundecyloxy) oxo-l- 2 -propenyl) 8 -tetrahydro-2-naphthalenyl) oxy] *pentyloxylbenzenepropanoic acid (7 mg, 0.0111 nimol), benzenesulfonic acid,, 2-f ((5-f[(2,5-~dioxo-l-pyrrolidiny1)oxy] cabnl--yiiylyrznlehl (5.6 mg, 0.0134 mmol), and TEA (6.2 ul, 0.0444 inmol) in DMF (0.3 niL) was stirred at ambient temperatures for 16 h. The reaction mixture was purified directly by preparative HPLC on a Vydac C-18 column (21.2 x 25 cm) using a 2 .O%/min gradient of 20 to 80% ACN containing 0.05 M NH 4 0H at a flow rate of 15 rnL/niin.

Lyophilization of the product-containing fraction gave title compound as a colorless solid. MS: m/e 931.4 Example 16 Synthesis of 4 -ethyl-2-(4-fluorophenyl)-5-[6,6-dimethy.7.

[[I[Phenylmethylenejjhydrazino] -3pyridinyl] carbonyl] amino] heptyl] oxy Iphenol Step.A: Preparation of 2 ,5-dioxo-1-pyrolidiny1)oxy] carbonyl] -2 -pyridinyl] hydrazono] methyl] -benzene This was prepared in an identical fashion to Example 1, Part substituting benzaldehyde for 2 -formylbenzensulfonic acid.

15 Clean solid 2 carbonyl] -2-pyridinyl] hydrazono] methyl] -benzene was obtained by simple rotary evaporation without trituration. NMR (DMS0d 6 2.88, s 7.36, mn 7.79, d of d 8.10, m 8.79, t (lIH); 9.16, s 11.90, s Mass Spec (El) m/ (14+H-) Step B: Preparation of 4-ethyl-2- 4 -fluorophenyl) [6,6dimethyl-7- [[6-f[[[phenylmethylenelhydrazinobenzene] -3pyridinyl] carbonyl] amino] heptyl] oxy] phenol Pry dime thyl f ormaide (10 inL) was chargeda-to a flask under nitrogen. To this was added 4 -ethyl-2-(4-fluorophenyl)- 5 5-diiethy-6-aminoheyl) o,,jphenl (Example 1,'Part c) (188 mng) and 2 ,5-dioxo-....pyIrolidinyl) 0 carbonyl] 2 pyridinyl] hydrazonoj methyl I -benzene (200 mg) followed by diisopropylethylamine (231 mg) and 4di~ehyamno~jj~ (5 g) Tesolution was stirred 18 hours and then -concentrated under reduced pressure. The residual oil was partitioned into water/ethyl acetate. The ethyl acetate was concentrated and the resulting crude purified by preparative IiPLC (5 x 25cm Vydac C18 pharmaceutical column; water/acetonitrile/0 1%.

trifluoroacetic acid gradient) and lyophilized to yield 98- mg of product. NMR '(CDCl 3 0.96, s (6 1. 15, t (3H4) 1.37, mn 1.53, m 1.80, mn (2H1); 2.53, q 3.31, d 4.00, t (2H1); 6.50, s 6.92, s (1H); 6, t (2H1); 7.38, m 7.71, mn (31H); 8.21, in 3H); 13.81, b (1H1). LRMS inlz =583. 3 HR MS(FAB): OOO:*oCalc. for C35H 4

ON

4 0 3 F -58-3.3084; Found -583.3070 Example.17 Synthesis of (l-aza-2-phenylvinyl) aino) (3pyridyl) )sulfonyl) 2 -phenylethyl) carbamoyl)inethyl)

HS

0 0 N b

N

Step A: Preparation of Sodium 2 pyrolidinyl) oxy] carbonyl

I-

2 -pyridinylI hydrazonolmethyl] benz enesulfonate 2 -Hydrazino-5-sulfamoylpyridine (0.2 g, 1.06 mmol)', benzaldehyde (170 mg, 1.6 mmol), and DMF (3 niL) were combined and stirred Overnight. The solution was concentrated to a yellow solid, which was triturated with ethyl acetate, filtered, and dried'under vacuum to yield 240 mg of product as a yellow solid. NMR (DMSO-d 6 7.40,mr (6H); 7.75, 8.02,. dd 8.16, s (1Hi); 8.47, d (1H); 11.85, b (exchange). mass Spec (El),m/z =277.1 Step B: Preparation of N-(-(-za2peyviy m.o(3pyridyl) )sulfonyl). (2-phenylethyl) carbamoyl)methyl) (pheniylmethoxy) indol-3-yl)prop..2.enmide N-Methyl-Nphenethyl2-.[5-benzyloxy-3 -carboxyviny1) indol-1yllacetamide (70. mg, 0.15 mmol), sodium. 2 [(2,5-diox o..

~pyrolidinyl) oxy] carbonyl] -2-pyridinylI hydrazono] methyl] benzenesulfonate (43 mg, 0.155 mnmol), ethyldimethylaxninopropyl carbodiimide (EDO) (30.7 mg, 0.16 nimol). and 4dimethylaminopyridine (25 mng, 0.O2lmmol) were added to dry DMF (3 inL) in a dry flask under nitrogen with-stir ring.

*Additional EDO (31 Mg, 0.l6nm61) was added after 24 hours.

EAfter an additional 16 hr of stirring, water (1 5 mL) was added, and the mixture extracted with ethyl acetate. The combined organics were washed with 0.1N HC1, sat. NaHCO3, and brine. The solution was dried (MgSO 4 filtered, and concentrated to a yellow oil, which was purified by flash chromatography (ethyl acetate/hexane) to afford 21 mng of product. NMR(CDCl 3

D

2 2.88, m 2.94, d (3H); 3.58, m (2H1); 4.27, s, 4.82, d (2H) 4.86, d (2H); 6.01, dd Uli); 6.67, dd 6.91, s 6.94, s (1H); 7.17, mi 7.34, m (10H); 7.63, mn OH); 7.78, s (1H); 8.23, d 8.74, s, HRMS (FAB): Caic. for C41H39N605S 727.270266; Found- 727.271253.

Example 18 Synthesis of 2 -sulfonato-(2-aza-2-((5-carbamoyl(2pyridyl)amino)vinyl)benzene) ethyl 3 -(6-ethyl-4-(4fluorophenyl)-3-hydroxyphenoxy)propoxy)-8-propylchroman-2yl)carbonylamino)propanoate F OH

OH

Step A: Preparation of 2 -[N-(t-butoxycarbonyl)ethyl)3carbobenzyloyaminopropionate N-(t-butoxycarbonyl)-2-hydroxyethylamine (2.2 g, 13.7 mmol), SN-benzyloxycarbonyl- -alanine (3.05.g, 13.7 mmol), and 4dimethylaminopyridine (0.84 g, 6.85 mmol) were dissolved in dry DMF (45 mL) under nitrogen and cooled to Ethyl dimethylaminopropyl carbodiimide (2.9 g, 15.1 mmol) was added and the reaction allowed to warm to room temperature. It was stirred 18 hours, and diluted with water (300 mL). The mixture was extracted with ethyl acetate and the combined organics were washed with 10 citric acid, brine, dried (MgSO 4 filtered, and concentrated under vacuum. The resulting oil was purified by flash chromatography (hexane/ethyl acetate) to afford 3.7 g of product as a clear oil. NMR (CDC1 3 1.42, s 2.54, t 3.35, m 3.46, m 4.12, t 4.85, b 5.08, s 5.40, b 7.33, s Mass spec m/z 384.3

(M+NH

4 Step B: Preparation of 2 -[N-t-butoxycarbonylaminoethyl]-3aminopropionate acetate salt 2-lN-(t-butoxycarbonyl)ethyl).3-carbobenzyloxyaminopropionate (3.7 g, 10.1 mmol) was dissolved in ethanol (50 mL) with one equivalent of acetic acid and 10% palladium on carbon (500 mg). Hydrogen gas was bubbled into the slurry for four hours, the mixture filtered on Celite@, rinsed with ethanol, and concentrated under reduced pressure. The oil was taken up in toluene (50 mL) and reconcentrated to afford 2.4 g of a clear oil. NMR (CDC1 3 1.42, s 1.95, s 2.63, t 3.09, t 3.37, m 4.14, dd 5.38, b 6.32, s Mass spec m/z 233.0 Step C: Preparation of 2 -((tert-butoxy)carbonylamino)ethyl-3- ((7-(3-(2-ethyl-4-( 4 (phenylmethoxy)phenoxy)propoxy)-8-p propylchroman-2- S 15 yl)carbonylamino)propanoate OBn O NHBoc 0 7-(3-(2-ethyl-4-( 4 (phenylmethoxy)phenoxy)propoxy)-8 -propylchromane-2-carboxylic acid (200 mg, 0.33 mmol), 2 -fN-t-butoxycarbonylaminoethyll-3aminopropionate acetate salt (122 mg, 0.42 mmol), hydroxybenzotriazole (76.6 mg, 0.50 mmol), HBTU (190 mg, 0.50 mmol), and diisopropylethylamine (1.32 mmol, 233 gL) were added to dry DMF (1.7 mL) and stirred under nitrogen for 24 hours. An additional 50% of HOBT, HBTU, and diisopropylethylamine were added and the reaction stirredanother 24 hours. The mixture was added to water (7 mL) and extracted with ethyl acetate. The combined organics were washed with 0.1N HC1, bicarbonate, and brine, dried over MgSO 4 filtered, and concentrated under vacuum. The resulting oil was purified by flash chromatography (hexane/ethyl acetate) to afford 120 mg of product. Mass Spec (EI) m/z 830.6

(M+NH

4 Step Preparation of 2 -((tert-butoxy)carbony1amino)ethyl- 3 (G-ethyl-4- 4 -f luorophenyl) 3 -hydroxyphenoxy)propoxy)- 8 -propylchroman-2 -yl) carbonylaiino) propanoate F

OH

NH- J QO -N.NHBoc f lu 6rophenyl) 5- (phenylmethoxy) phenoxy) propoxy) -8 propylchroman-.2..yl) carbonylanino) propanoate .(110 ing) was dissolved in methanol /chlorof o 5 inL) with 10% Pd/c (24 mng) and hydrogen gas bubbled -in ~for 2.hours. The mixture was filtered through Celite®, rinsed with methanol, and concentrated-under vacuum to'afford 80 ing'of 2 -((tertbutoxy)carbonylamino)ethyl- 3 (6-ethyl-4- (4fluorophenyl) -3 -hydroxyphenoxy) propoxy) -8 -propylchronan-2 yl)carbonylarnino)propanoate. Mass Spec 723.5 Step E: Preparation. of 2 !-aminoeth yl-3- (6-ethyl-4- (4fluorophenyl) -3 -hydroxyphenoxy) propoxy) -8-propylchronan-2 yl)carbonylamino)propanoate e t b t x a b o y a i o e h l 3 3 t y 4 fluorophenyl) -3 -hydroxyphenoxy) propoxy) 8 -propylchroman-2 yl)carbonylamino)propanoate (55.4 mng, 0.07 nmmol) was added to dichloroinethane (4 inL), followed by'anisole (30 mng, 0.28 imol) and trifluoroacetic acid (4 inL). The solution was stirred-for 2 hours, concentrated under reduced pressure, and purified on a short silica column (chloroform/mnethan.ol) to afford 48 mng of product. NMR (CDCl 3 0.90, t 1.14, t 1.50, mn 1.62, mn 1.87, in 2.27, m(3H); 2.54, q.

2.58, in 3.42, b 4.14, mn 4.44, b 6.47, d 6.57, s 6.80, mn 6.95, s 7.10, dd 7.40: dd 8 81, b (3H) _Mass Spec m/z 623.4 Step F: Preparation of propyl 3 7 -(3-(6-ethyl-4- (4fluorophenyl) -3 -hydroxyphenoxy) propoxy) -8-propylchroman-2- Yl) carbonylamino) propanoate, 5-carbamoyl(2pyridyl) amino) vinyl) benzenesulfonic acid 2-aminoethyl-3-((7-(3-(6-ethyl-4-(4-fluorophenyl)-3hydroxyphenoxy) propoxy) -8-propylchroman- 2yl)carbonylazino)propanoate (43 mg, 0.072 nmol), Sodium 2- [[(5-([(2,5-dioxo-1-pyrolidinyl)oxy ]carbonyl] -2-pyridinylI hydrazono] methyl) -benzenesulfonate (32 mg, 0.08 mmol), and diisopropyethyaamine (23.4 mg, 0.18 nmol) were added to dry DMF (0.3 mL) and stirred 18 hr. The solution was diluted with water and acetonitrile and purified iby direct injection onto a Vydac C18 using acetonitrile/water/0.01% trifluoroacetic acid gradient. The collected fractions were lyophilized to afford 20 mg of product. NMR (DMSO-d6): 0.82, t 1.14, t 1.42, m 1.80, m 2.18, m 2.50, m 3.42, t 4.09, i 4.42, d 6.51, d 6.55, s 6.80, d 6.98, s 7.16, m 7.41, t 7.51, dd 7.72, t 7.79 d 8.21, b 8.50, s 8.72, b 9.35, d LRMS (El): m/z 926.5 ERMS (FAB): Calc. for C4 8

H

53

N

5 0 1

FS:

926.344633; Found: 926.346995 Example 19 Synthesis of 7 -(-(6-ethyl-4- (4fluorophenyl)-3hydroxyphenoxy) propoxy) 8 -propylchroman-2yl)carbonylamino)propyl-2-methylpropanoate 2-(2-aza-2 carbanoyl(2-pyridyl)amino)vinyl)benzenesulfonic acid Step A: 'Preparation of 3- (N-tert*-butoxycarbonylaminopropyl) (N-carbobenzyoxyamino) propionate The procedure used in example Example 18, Part A was followed, using N-abbny oylnn and 3- (N-tert-butoxycarbonyl) aminopropanol to afford.1.8 g of.3-(N-tertbutoxycarbonylaminopropyl) (M-carbobenzyoxyamino) propionate after flash 'Chromatography (ethyl acetate/hexane).

NMR

(CDCl 3 1.40, d O3H); 1.43, s 1.80,..t 3.1,5, Mn 4.14, t 4.35, m 4.68, b 5.09, s 5.38, b 7.33, s (514). Mass spec m/z 381.2 (MY+H-) *Step B: Preparation of 3 -aminopropyl .2-(N-carbobenzyloxW)aminopropionate trifluoroacetate

TFAH

2 N N-'sO NH 3- (N-tert-butoxycarbonylaminopropyl)

(N-

carbobenzyoxyamino)propionate (510 mg) was dissolved in S dichloromethane (10 mL) and trifluoroacetic acid (10 mL) added. The solution was stirred for 2.5 hours and concentrated under reduced pressure to a clear oil. NMR (CDCl3): 1.37, d 2.04, m 3.12, in 4.24, m 5.06, dd 5.44, b 7.32, m 12.67, s Mass Spec m/z 281.0 Step C: Preparation of 3 7 3 2 -ethyl-4-(4-fluorophenyl).

(phenylmethyloxy) phenoxy) propoxy) 8 -propylchroman-2 yl) carbonylamino) propyl 2- ((phenylmethoxy) carbonylamino) propanoate This was carried out in identical fashion to Example 18, Part C, using 3-mnpoy--Ncroenyoyaiorpoae to afford 125 mg of product. Mass Spec (El) m/z =861.5 (M+H) Step D: Preparationof 3-i 7 3 -(6-ethyl-4-(4-fJluorophenyl).

3 -hydroxyphenoxy) propoxy) -8 -propylchroman-2 yl) carbonylamino) propyl 2 -aminopropanoate 7 -(3-(2-ethv-4-4-fluorophe..r...

(phenylmethyloxy) phenoxy) propoxy) -8-propylchroman-2 yl)carbonylamino)-propyj. 2- ((phenylmethoxy)carbonylamino)propanoate (125 mg) is dissolved in methanol/chloroform 7 rnL) with 50 mg 10% Pd/C catalyst. Hydrogen gas is bubbled in for 3 hours, when the mixture is-filtered through. Celite® and concentrated to yield 88 mng of product as a .white crunchy foam. Mass Spec (El) m/z 20 +=637.5.(M+H) Step E: Preparation of 7 -(-(6-ethyl-4-(4-fluorophenyl)3.

hydroxyphenoxy) propoxy) -8-propylchroman-2 yl) carbonylamino)propyl-2-methylpropanoate, 2- (2-aza-2 carbamoyl (2-pyridyl) amino)vinyl) benzenesulfonic acid This procedure was carried out with 3 7 -(3-(6-ethyl-4- (4fluorophenyl) -3 -hydroxyphenoxy) propoxy) -8 -propylchroman-2 yl)carbonylamino)propyl 2-aminopropanoate as in Example 18, 30 Part F to afford 41 mg of product after lyophilization.

NMR

(DMSO-d 6 0.82, t 1.07, t 1.42, m 1.76, m 2.18, m 2.70, m 3.25, m 4.09, m 4.43, m 6.53, d 6.55, s 6.82, d 6.99, s 7.16, m 7.51, m "7.78, t 7.80 d 8.21, b 8.31, b 8.53, s 9.05, b 9.35, d Mass Spec m/z 940.4 Example Synthesis of 7 (3-(66-ethyl-4-(4-fluorophenyl) 3 hydroxyphenoxy) propoxy) 8 -propylchroma-2yl)carbonylamino)propyl)-2 -methylpropanamide, 2-(2-aza-2-((5carbamoyl( 2 -pyridyl))amino)vinyl)benzenesulfonic acid

OH

0 o oH .0

N

Step A; Preparation of N-'(3-((tertbutoxy) carbonylaxino) propyl)-2-( (phenylmethoxy)carbonylamino)- 2 -methylpropanamde

-NHZ

BOcHN"-^

'NA~

N-carbobenzyldxyala ine (1.3 g, 5.7 mmol), 3-(Ntertbutoxycarbonylamino)-1,3-propanediam (1 g, 5.7 mmol)hydroxybenzotriazole (0.88 g, 5.8 mmoJ), HBTU (2.4 g, 0.63 mmol), and diisopropylethylamine (1.48 g, 11.5 mmol) were added to dry DMF (25 xL) under nitrogen and stirred 16 hours, when the reaction was poured into water (100 mL) and extracted with ethyl acetate. The combined organics were washed with 0.1N HCl and saturated bicarbonate, dried over magnesium sulfate, filtered, and concentrated under reduced pressure.

The reaction mixturewas not further purified but carried directly into the next step. Mass Spec m/z 380.3

(M+H)

Step B: Preparation of N-(3-aminopropyl)-2- ((phenylmethoxy)carbonylamino)-2-methylpropanamide trifluoroacetate salt This procedure was carried out as in Example 19, Part B, using N- ((tert-butoxy) carbonylamino)propyl) -2- ((phenylmethoxy) carbonylanino) -2 -methyipropanamide (2 g) to yield 1.4 g N-(3-aminopropyl)-2- ((phenylmethoxy) carbonylamino) -2 -me thyipropanamide trifluoroacetate salt. Mass Spec (El) m/z =280.1 (M+H) Step C: Preparation of iluorophenyl) (phenylmethoxy) phenoxy) propoxy) -8propylchroman-2 -yl) carbonylamino) propy l) -2- ((phenylmethoxy) carbonylamino) -2 -me thyipropanamide F OBn

NHZ

*0 This procedure was carried out as in Example 18, Part C, using N- 3 -aminopropyl) ((phenylmethoxy) carbonylamino) -2- *methylpropanamide trifluor-oacetate salt (82 mg, 0.-3 Inmol) to yield 165 mg of product, which was not purified but carried forward directly. Mass Spec m/z 860.5 (M+H) Step D: Preparation of 2-amino-N-*(3-( (7-(3-(6-ethyl-4-(4fluorophenyl) -3 -hydroxyphenoxy) propoxy) -8-propylchroman-2 l) carbonylamino) propyl) -2 -methyipropanamide This step was carried out as in Example 19, Part D, using N- (2-ethyl-4- (4-fluorophenyl) (phenylmethoxy) phenoxy) propoxy) -8-propylchroman-2 yl) carbonylamino) propyl) ((phenylmethoxy) carbonylaiino) -2methylpropanamide (160 mg) to yield 100 mg of product, which was not purified but carried forward directly. Mass Spec (El) m/z 636.3 (M+H) Step E: Preparation of (7-(3-(6-ethyl-4-(4fluorophenyl) -3 -hydroxyphenoxy) propoxy) -8-propylchroman-2 yl) carbonylanino) propyl) -2 -methyipropanamide, 2- (2 -aza-2- carbamoyl (2 -pyridyl) amino) vinyl) benz .enesulfonic acid This procedure was carried out as in Example 18, Part F, using 2-ainoN- (3 (-etyl-- 4-fluorophenyl) -3hydroxyphenoxy) propoxy) -8-propylchronan-2yl) carbonylamino) propyl) -2 -methyipropanamide (100 mg) to afford 74 mg of product after lyophilization. NMR (DMSO-d6): 0.81, t 1.07, t 'd (2H) 1. 42., m (2H); 1.55, t 1.80, in 2.18, m. 2.70, m (6H); 3.09, in 4..09, mn 4.40, in 12H); 6.53, d (1H); 6 .54, s. 6.83, d .6.99, s. 7. 16, m O3H); 0 15 7.51, mn 7.80 mn 8.04, t 8.2-5, d (1H); -8.40, b 8.54, s 9.35, b Mass Spec (EI): m/z =956A4

(M+NH

4 0 Example 21 Synthesis of 2-(2-aza-2-( (5-(N-(6-(6-ethyl-3-hydleoxy-4-(1- 44:: methylpyrazol-5-yl)phenoxy) 2-dimethyihexyl) carbamoyl) (2pyridyl) )amino) vinyl) benzenesulfonic acid

OH

H0 3

S

Step A: Preparation of 4-Ethyl-2-(1-mnethyl-lH-pyrazo1-3-yl)- -dimethyl-6-aminohexylloxylpheno1 and 4-Ethyl-2- (1- 5-dimethyl-6aminohexyl] oxy) phenol A mixture of 4-ethyl-2(1-methyl-1H-pyrazol-5-yl)-5-f5 S-methyland 4-ethyl-2(1-methyl-1H-pyrazol-3- 5-methyl-5-cyanohexylloxyphenol (350 mg, 1.05 mmol) was added to methanol (20 mL) containing platinum oxide (120 mg, 0.53 mmol) in a Parr bottle. Four equivalents of conc.

hydrochloric acid were then added and the mixture hydrogenated at 55 psi for 18 hours. The slurry was filtered on Celite®, rinsed with methanol, and concentrated under reduced pressure to afford 318 mg of an off-white solid. Analysis by HPLC showed two peaks, in a ratio of 4:1, consisting of the two isomeric products. These.were not separated, but carried directly into the next reaction.

Step B: Preparation of 2 2 -aza-2-((5-(N-(6-(6-ethyl-3- 15 hydroxy-4-(1-methylpyrazol-5-yl)phenoxy)-22dimethylhexyl)carbamoyl)(2pyridyl))amino)vinyl)benzenesulfonic acid The mixture obtained in Step A (318 mg, 0.92 mmol) was reacted in the same manner as described in Example 18, Part

HPLC

000 purification (acetonitrile/water/0.1% trifluoroacetic acid, Vydac C18) afforded two clean products. The earlier eluting product (66 mg after lyophilization) was identified as the 1- *0" compound by NMR. NMR (DMSO-d6): 0.88, s 1.09, t 1.33, m 1.49, m 1.73, m 2.47, m 3.16, s 3.64, s 3.95, t 6.14, s 6.53, s 6.89, s 7.19, d 7.38, s 7.46, m 7.80 d 8.30, d 8.39, d 8.47, s 8.53, m 9.34, s 9.65, b LRMS(EI): m/z 647.3 HRMS(FAB): Calc. for C 33

H

41

N

6 0 6 S 649.2808; Found 649.2834.

Example 22 Synthesis of 2-(2-aza-2-((5-(N-(6-(6-ethyl-3-hydroxy-4-(1methylpyrazol-5-yl)phenoxy)-2,2-dimethylhexyl)carbamoyl)(2pyridyl))amino)vinyl)benzenesulfonic acid The l-inethyl-3-pyrazolyl isomer was isolated as the second eluting peak in Example 21, Part B (8 mg). NMR (DMSO-d6): 0.88, s 1.09, t 1.33, m 1.49, m 1.73, m 2.47, m 3.15, bs 3.83, s (3H); 3.95, t 6.14, s 6.44, s 6.68, s 7.17, d 7.38, s 7.46, m 7.75 m (1H); 8.30, d 8.39, d .8.53, m 9.34, s 9.65, b LRMS m/z 649.3

HRMS(FAB):

Calc. for C3 3

H

4 1

N

6 0 6 S 649.2808; Found 649.2831 Example 23 Synthesis of 2 2 -aza-2-((5-((3-((6-ethyl-4-(4-fluorophenyl)- *15 3-hydroxyphenoxy)methyl)piperidyl)carbonyl)(2pyridyl))amino)vinyl)benzenesulfonic acid

OH

.*F

N N-~

HO

3

S

20 Step A: Preparation of 2 -mesyloxy-4-benzyloxyacetophenone 4 -Benzyloxy-2-hydroxyacetophenone (25 g, 0.1 mol) and diisopropylethylamine (17.3 g, 0.134 mol) were dissolved in chloroform (200 mL). Methanesulfonyl chloride (14.2 g, 0.124 mol) was added slowly and the reaction stirred for 24 hours.

The chloroform was poured into water (150 mL), the layers seperated, and the organic layer washed with 0.1N NaOH, water, 0.1N HC1, water, dried over magnesium sulfate, filtered and concentrated to a crude brown solid. Flash chromatography (hexane:ethyl acetate) afforded 15.1 g of product as an orange solid. NMR (CDC13): 2.57, s 3.23, s, 5.11, s (2H) 6.94, dd 7. 01, d 7. 40, m 7.77, d Mass Spec (GCMS): 320 Step B: Preparation of 2-eyo. ezlxehlezn 2 -mesyloxy-4-benzyoxacetopenonel (15 g, 47 mrmol) is dissolved in carbon tetrachloride (40 mL). To this stirring solution under nitrogen is added trifluoroacetic acid (45 niL) and triethylsilane (4 5 mL) and the reaction stirred 24 hours.

The volatiles are removed-under reduced pressure and the residue redissolved in dichioromethane, washed with 0.1N NaOH, dried over sodium sulfate, filtered and concentrated to afford an orange oil which solidified to afford 10.8 g of a light orange solid. NNR (CDCl3),: 1.21, t, 2.66, q 3.14, s (3 H) 5.04, s (2H) 6.88, dd 6.95, d 7.19, d 7.38, m Mass Spec (GCMS): 306 Step C: Preparation of 2 bromoe thylbenz ene 2 -mesyloxy-4-benzyloxyethylbenzene (10.3 g, 33.7 mmol) is dissolved in carbon tetrachloride (25 mL) with stirring.

N-

bromosuccinimide (6.6 g, 37 mmol) is added and the reaction 25 stirred 18 hours under nitrogen. The slurry is diluted with dichloromethane (100 mL) and washed with water, dried over magnesium sulfate, filtered and concentrated. The crude solids are recrystallized from hexane to afford 6 g of 2mesyloxy- 4 -benzyloxy-5-bromoethylbenzene as an off-white solid. NNR (CDCl3): 1.20, t, 2.60, q 3.09, s 5.13, s 6.93, s 7.38, mn (6H1). Mass Spec (GCMS): 384 Step D: Preparation of 5-(4-fluorophenyl)-4-benzyloy-2 mesyloxyethylbenzene 4-Fluorophenylboronic acid (2.18 g, 15.6 mmol) is slurried in ethanol (13 mL). To this is added the 2 -mesyloxy-4-benzyloxy- 5-bromoethylbenzene dissolved in toluene (40 mL), followed by palladium tetrakistriphenylphosphine (150 mg) and a solution of sodium carbonate (0.2M, 12 mL). The mixture is heated to reflux under nitrogen and the temperature maintained for 24 hours. The mixture is cooled and diluted with ethyl acetate.

The organic layer is separated and washed with saturated ammonium chloride, dried over magnesium sulfate, filtered, and concentrated under reduced pressure to afford a light orange i solid, which was recrystallized from hexane to afford 5-(4- Sfluorophenyl)-4-benzyloxy-2-mesyloxyethylbenzene (2.5 g) as an 15 off-white solid. NMR (DMSO-d6): 1.17, t, 2.66 S(2H); 3.48, s 5.14, s 7.38, m 7.59, dd 7.83, dd Mass Spec (GCMS): 400 Step E: Preparation of 5-( 4 -fluorophenyl)-4-benzyloxy-2hydroxyethylbenzene Bn .do

OH

4 -fluorophenyl)-4-benzyloxy-2-mesyloxyethylbenzene g, 6.24 mmol) was dissolved in methanol (80 mL). To this was added sodium hydroxide (300 mg, 7.5 mmol) dissolved in water (20 mL). The solution was heated to reflux and heating maintained for 24 hours, when an additional equivalent of sodium hydroxide was added, and reflux maintained for an additional 16 hours. The mixture was cooled, acidified with IN HC1, and extracted with ethyl acetate. The organic layers were dried over magnesium sulfate, filtered, and concentrated under reduced pressure to afford an orange solid which was triturated with hexane to yield 5-( 4 -fluorophenyl)-4benzyloxy-2-hydroxyethylbenzene (1.4 g) as an off-white powder. NMR (DMSO-d6): 1.11, t, 2.50, q (2H1); 3.34, s 5.02, s 6.60, d 6.98, s 7.16, t 7.35, m 7.50, dd 9.44, s Mass Spec (GCMS): 322 Step F: Preparation of 3 -(methanesulfonyloxymethyl)-N- (tertbutoxycarbonyl)-piperidine 3 -Hydroxymethyl-N-(tert-butoxycarbonyl)-piperidine (4.3 g, mmol) was dissolved in dichloroethane (50 mL) with Proton Sponge® (6.08 g, 28.3 mmol). Triflic:anhydride (4.94 g, 28.4 mmol) was dissolved in dichloroethane (50 mL) and added dropwise to this solution. The reaction was stirred for 3 days, quenched with water (100 mL), the layers separated, and the combined organics washed with LN HC1, water, bicarbonate, water, and brine. The solution was dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford 3- (methanesulfonyloxymethyl) -N-(tertbutoxycarbonyl)-piperidine (6 g) as a yellow oil. NMR (CDC13): 1.39, m 1.42, s 1.65, m 1.85, m 2.77, m 2.89, t 2.99, s 3.81, m 3.92, m 4.06, m Mass Spec 316.10 (M+Na).

25 Step G: Preparation of tert-butyl 3-((2-ethyl-4-(4- *(phenylmethoxy)phenoxy)methyl)piperidinecarboxylate F OBn O,,Boc 3-(Methanesulfonyloxymethyl)-N-(tertbutoxycarbonyl)-piperidine (143 mg, 0.49 mmol) and 5-( 4 -fluorophenyl)-4-benzyloxy-2hydroxyethylbenzene (150 mg, 0.47 mmol) were added to methyl ethyl ketone (7 mL) followed by potassium carbonate (113 mg, 0.82 mmol), potassium iodide (15.5 mg, 93 mol), and dimethylsulfoxide (4 mL). The slurry was heated at reflux for hours, when it was cooled, diluted with water (50 mL) and extracted with ethyl acetate. The combined organic layers were dried over magnesium sulfate, filtered, and concentrated under reduced pressure to a clear oil which was not purified but used as is in the following step. Mass Spec 537.4

(M+NH

4 Step H: Preparation of 5-(4-fluorophenyl)-4-benzyloxy-2-[(3piperidinyl)methoxy]ethylbenzene The crude product of tert-butyl 3-((2-ethyl-4-(4-- (phenylmethoxy)phenoxy)methyl)piperidinecarboxylate (125 mg) was dissolved in ethanol (5 mL) containing 10% Pd/C catalyst 15 (55 mg). The slurry was hydrogenated at balloon pressure for 28 hours, filtered through Celite@, and concentrated under reduced pressure to afford 80 mg of an oil. This was dissolved in dichloromethane (5 mL) and trifluoroacetic acid (5 mL) added. The solution-was stirred 3 hours, and concentrated under reduced pressure to afford 85 mg of 5-(4fluorophenyl)-4-benzyloxy-2-[(3piperidinyl)methoxy]ethylbenzene as an oil. Mass spec.

(EI):

330.2 (M+H) 25 Step I: Preparation of 2 2 fluorophenyl) -3-hydroxyphenoxy) methyl) piperidyl) carbonyl) (2pyridyl))amino)vinyl)benzenesulfonic acid The crude 5-(4-fluorophenyl)-4-benzyloxy-2-[(3piperidinyl)methoxy]ethylbenzene (60 mg, -70 pure) was reacted according to the procedure in Example 18, Part F and purified by preparative HPLC (acetonitrile/water/0.1% trifluoroacetic acid gradient). The product fractions were combined and lyophilized to afford 20 mg of a yellow powder.

NMR (DMSO-d6): 0.86, b 1.08, m 1.43, m (2H); 1.72, m 1.85, m 2.06, m 2.21, m (1H); 2.45, m 3.06, m 3.88, m 6.42, m (1H); 6.93, m 7.15, m 7.45, m 7.78, s (1H); 7.79, d 7.97, d 8.13, s 8.24, m 9.19, s LRMS(EI): 631.1 HRMS(FAB): Calc. for C33H 34

FN

4 0 6 S 633.2183; Found 633.2160 Example 24 Synthesis of 2 4 -(N-(6-(4,6-Diphenyl(2-pyridyloxy))-2,2dimethylhexyl)carbamoyl)phenyl methyl) (2-sulfanylethyl)amino) N-(2-sulfanylethyl)ethanamide NO 0N N

HN

H N HN SH HS .Part A: Preparation of 2 4 -(N-(6-(4,6-Diphenyl(2pyridyloxy))-2, 2 -dimethylhexyl)carbamoyl)phenyl)methyl)(2triphenylmethylthio)ethyl)amino)-N-(2- 15 triphenylmethylthio)ethyl)ethanamide A solution of 6-f(4,6-diphenyl( 2 -pyridinyl)oxy -2,2dimethyl-l-hexylamine (37.6 mg, 0.077 mmol), N-[4- (carboxy)benzyl]-N,N'-bis( 2 -triphenylmethylthio)ethyl]- 20 glycinamide N-hydroxysuccinimide ester (70.0 mg, 0.077 mmol), and TEA (32 ul, 0.23 mmol) in DMF (1.0 mL) was stirred at ambient temperature for 18 h. The reaction solution was used directly for HPLC purification on a Vydac C-18 column (22 x 250 mm) using a 3 .6%/min gradient of 72 to 90% ACN containing 0.1% TFA followed by isocratic elution at 90% ACN containing 0.1% TFA at a flow rate of 15 iL/min to give the title compound as a colorless solid (27 mg, 1 H NMR (CDC1 3 8.11-8.03 2H), 7.70-7.12 43H), 6.88 1H), 5.96-5.85 1H), 4.53-4.43 2H), 3.44 2H), 3.33-3.25 2H), 3.08-2.96 2H), 2.86 2H), 2.48-2.24 6H), 1.90-1.73 2H), 1.61-1.22 4H), 0.91 6H); 1 3 C NMR (CDCl 3 6 170.23, 167.27, 164.34, 155.16, 151.97, 144.68, 144.63, 140.97, 139.24, 138.81, 134.25, 129.50, 129.06, 128.94, 128.84, 128.59, 127.92, 127.04, 126.80, 126.72, 111.69, 107.12, 66.86, 66.650 65.80, 58.17, 57.61, 53.31, 49.54, 39.86, 37.74, 34.63, 32.05, 29.96, 29.76, 29.68, 24.94, 20.66; MS: Wie 1191.8 High Resolution MS: Calcd for C77H 76

N

4 0 3

S

2 1169.5437, Found: 1169.5448.

Part B: Preparation of 2 4 -(N-(6(4,6-Diphenyl(2.

pyridyloxy))-2,2 -dimethylhexyl)carbamoyl)phenyl)methyl)(2sulfanylethyl ethanamide 2 4 -Diphenyl(2 -pyridyloxy))-2,2dimethyihexyl)carbanoyl)phenyl)methyl) (2-triphenylmethyl thio) ethyl)amino)-N-(2 -triphenylmethylthio- ethyl) ethananide (64-mg, 0.092 mmol) was dissolved in TFA (4 mL) along with triethylsilane (57 AL) and stirred under nitrogen atmosphere for 2 h at ambient temperatures. The precipitate of triphenylmethane was removed by filtration and the filtrate was concentrated. The crude product was purified by HPLC on a Vydac C-18 column (22 x 250 mm) using a 2 .1%/min gradient of 27 to 90% ACN containing 0.1% TFA at a flow rate of 15 iL/min to give the title compound asa colorless oil (18 mg, 28%).

MS: m/e 685.4 LM+H].

Example Synthesis of diphenyl(2-pyridyloxy))-1,1-dimethylpentyl) (1,2,3,5tetraazolyl)) pentanoylamino) propoxy) ethoxy) ethoxy) propyl)carbamoyl) (2-pyridyl)) amino) vinyl benzenesulfonic Acid N.N

H

NN

N

N'N

&NH

Part A: Preparation of Ethyl 5-(5-(5-(4,6-Diphenyl(2pyridyloxy)) -1,l-dimethylpentyl) -1,2,3,4tetraazolyl)pentanoate and Ethyl 5-(4-(5-(4,6-Diphenyl(2tetraazolyl.) pentanoate

N.H

NI 0

IN

A solution of 2 H-2,345-tetraazolyl)5.

methyihexyloxy) 4 -diphenylpyridine (880 mg, 2.13 mmlol), ethyl 5-broinovalerate (1.35 rnL, 8.51 mmcl),* and TEA (1 .3 1 m.L, 9.36 mmol) in ACN (50 mL) was heated to reflux under nitrogen for 3 h. The solution was concentrated and the residue'was Partitioned between EtOAc (150 inL) and water (50 The EtOAc layer was washed with 0.1 N HCl (50 inL), dried (MgSo 4 and concentrated to an amber oil. Flash chromatography on silica gel (25% EtOAc/hexanes) gave N2 isomer ethyl 6dpey 2prdlx)) -1,l1-dime thylpentyl).-1,2,3 5 tetraazolyl)pentanoate as a-colorless oil (925 mg, 1H NMR (CDC1 3 8.10-8.01 (mn, 2H), 7.69-7.61 (mn, 2H), 7.55-7-35 7H), 6.86 4.54 J 7.1 Hz, 2H), 4.42

J

6.6 Hz, 2H), 4.09 J 7.1 Hz, 2H), 2.'31 J 7.3 Hz, 2H), 2.09-1.95 (in, 2H), 1.90-1.70 (mn, 4H), 1.70-1.56 (mn, 2H), 1.45-1.28 (mn, 8H), 1. 21 J 7. 1 Hz, 3H) 1 3 C NMR (CDCl 3 173.50, 172-.81, 164.32, 155.12, 151.97, 139.18, 138.82, 128.94, 128.84, 128.57, 127.03, 126.81, 111.66, 107.10, 65.83, 60.40, 52.32, 42.40, 34.77, 3 3.32, 29.59, 28.63, 27.21, 21.74, 21.31, 14.18; MS: Wne 542.4 High Resolution MS: Calcd for C32H 4

ON

5 0 3 542.3131, Found: 542.3143; CIHN Calcd:

C,

70.95; H, 7.26; N, 12.93; Found: C, 71,.02; H, 6.89; N, 13.04.

After eluting the above compound fromn the flash column the eluting solvent was changed to 40% EtOAc/hexanes to give Ni isomer ethyl 4 ,6-diphenyl(2-.pyridyloxy) dimethylpentyl) 4 -tetraazolyl)pentanoate as a colorless oil (113 mng, 1 H NMR (CDC1 3 8.10-8.01 (mn, 2H), 7.69- 7.62 (mn, 2H), 7.55-7.36 (in, 7H), 6.85 iH), 4.43 J 6.3 Hz, 2H), 4..34 J 7.5 Hz, 2H), 4.09 j 7.1 Hz, 2H) 2.32 J 7.2 Hz, 2H) 2.07-1.92 (in, 2H), 1-.'91-1.60 8H), 1.50 6H), 1.21 J 7.1 Hz, 3H); MS: m/e 542.4 High Resolution MS: Calcd for C 32

H

4 0

N

5 0 3 542.3131, Found: 542.3140.

Part B: Preparation of 5-( 4 (5-(4,6-Diphenyl(2-pyridyloxy)) 1,1-dimethylpentyl) -1,2,3,5-tetraazolyl)pentanoic Acid N NO OH'- A mixture of ethyl 5-( 4 -(5-(4,6-diphenyl(2-pyridyloxy))- 1,l-dimethylpentyl)-1,2,3,5-tetraazolyl)pentanoate (464 mg, *."0.858 mmol), 3 M LiOH (3.0 mL), and THF (25 mL) was stirred at ambient temperatures for 45 h. The mixture was concentrated to a volume of 5 mL and partitioned between ether (25 mL) and water (75 mL). The layers were separated and the aqueous 15 layer was acidified to pH 4.0 with 1 N HC1. The aqueous layer was extracted with EtOAc (3 x 25 mL). The combined organic extracts were dried (MgSO 4 and concentrated to give the title compound as a colorless oil (418 mg, 1 H NMR (CDC1 3 8.04 J 6.8 Hz, 2H), 7.65 J 8.4 Hz, 2H), 20 7.55-7.31 7H), 6.84 1H), 4.53 J 6.9 Hz, 2H), 4.40 J 6.6 Hz, 2H), 2.40-2.25 2H), 2.09-1.94 (m, 2H), 1.86-1.70 4H), 1.70-1.52 2H), 1.50-1.25 8H).

SPart C: Preparation of Aminopropoxy) ethoxy) ethoxy) propyl) (tert-butoxy) formamide A 1 L 3-neck round bottom flask was fitted with a 500 mL addition funnel with nitrogen line, a thermometer, and a mechanical stirrer. The flask was charged with 4 7 1,1 3 -tridecanediamine (72.5 g, 0.329 mol), anhydrous THF (250 mL), and anhydrous MeOH (100 mL). The addition funnel was charged with a solution of di-tert-butyl dicarbonate (22.4 g, 0.103 mol) in anhydrous THF (100 mL). The contents of the addition funnel were added to the flask with rapid stirring at ambient temperatures over 30 min, causing a slight rise in temperature from 21 °C to 32 oC. The reaction was stirred an additional 3 h at ambient temperatures and the solvents were removed under reduced pressure. The resulting thick syrup was taken up in sat. NaC1 (1500 mL) and extracted with ether (5 x 1000 mL). The combined ether extracts were dried (MgS0 4 and concentrated to give a colorless oil (29.8 A 5.00 g sample of this oil was purified by flash chromatography on silica gel (DCM:MeOH:TEA, 20:15:0.75) to give the title compound as a colorless oil (4.00 g, 1 H NMR (CDCI 3 5.13 1H), 3.63-3.47 12H), 3.17 J 6.2 Hz, 2H), 2.75 J 6.7 Hz, 2H), 1.75-1.64 4H), 1.39 9H), 1.36 2H); MS: m/e 321.2 Part D: Preparation of N-( 3 Butoxy)carbonylamino)propoxy)ethoxy)ethoxy)propyl)-5-(4-(5- 4 ,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)(1,2,3,5tetraazolyl))pentanamide N

H

11N: NO

N

0 o A solution of 5-(4-(5-(4,6-diphenyl(2-pyridyloxy))-1,1dimethylpentyl)-1,2,3,5-tetraazolyl)pentanoic acid (185 mg (0.360 mmol) and-TEA (208 uL, 1.50 mmol) in anhydrous DMF 25 mL) was pre-activated by treatment with HBTU (218 mg, 0.576 mmol). After 5 min at ambient temperatures, a solution of N- (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)(tertbutoxy)formamide (180 mg, 0.562 mmol) in DMF (500 uL) was added and the solution was stirred at ambient temperatures for 2 h. The DMF was removed under reduced pressure and the resulting oil was partitioned between EtOAc (20 mL) and 0.1 N HC1 (5 mL). The organic phase was washed consecutively with 0.1 N HC1 (5 mL) and sat. NaHCO 3 (2 x 5 mL), dried (MgS04), and concentrated to give an amber oil (177 mg). This oil was purified by flash chromatography on silica gel (hexane:EtOAc:CHC1 3 to give the title compound as a pale yellow oil (162 mg, MS: 816.5 Part E: Preparation of (5-(4,'6-dipheny(2 -pyridyloxy))-1,1-dimethylpentyl)(1,2,3,5.

tetraazolyl))pentanoylamino) Propoxy)ethoxy)ethoxy)propyl)carbanoyl)(2pyridyl) )amino)vinyl)benzenesulfonic Acid N-(3-(2-(2-(3-((tert-Butoxy)carbonylamino)prp o xy)ethoxy) ethoxy) pr 6 -diphenyl(2 -pyridyloxy))- 1,l-dixethylpentyl)(1,2,3,5-tetraazolyl)) pentanamide (60 mg, 0.074 .mol) was dissolved in TFA and stirred at ambient temperatures for 45 min. The TFA was removed :under reduced pressure and the resulting thick oil was dissolved in anhydrous DMF (0.70 mL) and the solution was made basic to pH paper with TEA (82 uL, 0.588 mmol). The solution was treated with 2 2 ,5-dioxopyrrolidinyl)carbonyl) (2pyridyl) )amino)vinyl)benzenesulfonic acid (48.5 mg, 0.110 mmol) and stirred at ambient temperatures for 24 h. The DmF was removed under vacuum, and the resulting oil was dissolved in 80% ACN and purified by preparative HPLC on a Vydac C-18 column (22 x 250 mm) using a l.80%/min gradient of 18 to 72% ACN containing 0.05 M N{4OAc at a flow rate of 15 mL/min. The main product peak eluting at 26.3 min was -collected and lyophilized to give the title compound as a colorless powder (54.5 mg, MS: 1019.5 [MiH]; High Resolution

MS:

Calcd for C53H 6 7

N

1 0 0 9 S 1019.4813, Found: 1019.4842.

Example 26 Synthesis of diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)(1,2,3,4tetraazolyl))pentanoylamino) propoxy) ethoxy) ethoxy) propyl) carbamoyl) (2pyridyl))amino)vinyl)benzenesulfonic Acid Part A: Preparation of 5-(5-(5-(4,6-Diphenyl(2-pyridyloxy))- 1, 1-dimethylpentyl)-1,2,3, 4 -tetraazolyl)pentanoic Acid

N-N

N b 1y 0 N

OH

0 A mixture of ethyl 5-(5-(5-(4,6-diphenyl(2-pyridyloxy))- 1,1l-dimethylpentyl)-1,2,3, 4 -tetraazolyl)pentanoate (113 mg, 0.21 mmol), 3M LiOH (1.0 mL), and THF (6 mL) was stirred at ambient temperatures for 45 h. The mixture was partitioned between EtOAc (50 mL) and water (25 mL). The aqueous layer S was acidified to pH 3.0 with 1 N HC1 and the layers were separated. The aqueous layer was extracted with EtOAc mL). The combined organic extracts were dried (MgSO 4 and 15 concentrated to give the title compound as a colorless oil (106 .mg, 1 H NMR (CDC1 3 8.02 J 8.4 Hz, 2H), 7.65(d, J 8.2 Hz, 2H), 7.55-7.35 7H), 6.84 1H), 4.43-4.31 4H), 2.36 J 7.0 Hz, 2H), 2.10-1.92 (m, 2H), 1.89-1.62 6H), 1.49 6H), 1.42-1.20 2H); MS: m/e 512.5 fM-H]; High Resolution MS: Calcd for C 30

H

36

N

5 0 3 514.2818, Found: 514.2819.

Part B: Preparation of 4 6 -diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)(1,2,3,4tetraazolyl))pentanamide

N',

NN* N NO N H

H

O Boc A solution of 5-(5-(S-(4,6-diphenyl(2-pyridyloxy))- 1 i,dimethylpentyl)-1,2,3,4 -tetraazolyl)pentanoic acid (90 mg, 0.175 mmol) and DIEA (122 uL, 0.70 mmol) in anhydrous DMF (8 mL) was treated with HBTU (73 mg, 0.192 mmol) and stirred at ambient temperatures for 1 min. A solution of aminopropoxy)ethoxy)ethoxy)propyl)(tert-butoxy)formamide (63.2 mg, 0.197 mmol) in DMF 4 mL) was added and the solution was stirred for 2.5 h. The DMF was removed by vacuum evaporation and the resulting thick oil was partitioned between EtOAc mL) and water (10 mL). The aqueous layer was adjusted to pH 3 with 1.0 N HC1, the layers were mixed thoroughly and separated. The organic phase was washed with 1N NaOH (2 x 15 mL) and sat. NaCl (10 mL), dried (MgSO 4 and concentrated to give the title compound as a pale amber oil (144 mg, 100%).

MS: m/e 816.6 High Resolution MS: Calcd for C45H 6 6

N

7 0 7 S 816.5024, Found: 816.5044.

20 Part C: Preparation of 4 ,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)(1,2,3,4tetraazolyl))pentanoylamino)propoxy)ethoxy)ethoxy)propyl)carbamoyl)(2-pyridyl))amino)vinyl)benzenesulfonic Acid N-(3-(2-(2-(3-((tert-Butoxy)carbonylamino)propoxy)ethoxy)ethoxy)propyl)-5-(5-(5-(4,6-diphenyl( 2 -pyridyloxy) 1,1l-dimethylpentyl)(1 ,2,3 1 4-tetraazolyl))pentanamide (146 mg, 0.179 nmmol) was dissolved in TFA (5 mL) and stirred at ambient temperatures for 45 min. The TFA was removed under vacuum and the thick amber oil was dissolved in anhydrous DMF (3 mL) and made basic. to pH paper with TEA (200 uL). The solution was treated with 2-(2-aza-2-((5-((2,5-dioxopyrrolidinyl)carbonyl)- (2-pyridyl))amino)vinyl)benzenesulfonic acid (94.6 mg, 0.215 mmol) and stirred at ambient temperatures for 18 h under a nitrogen atmosphere. .The reaction solution was concentrated to a volume of 1.0 mL, diluted with ACN (4 mL), and purified by preparative HPLC on a Vydac C-18 column (22 x 250 mm) using a 1.80%/min gradient of 18 to 72% ACN containing 0.05 M NH 4 0AC at a flow rate of 15 mL/min. The main product peak eluting at 24.7 min was collected and lyophilized to give the title compound as a colorless powder (131 mg, MS: m/e 1019..5 High Resolution MS: Calcd for C53H6.7Nl00 9

S

1019.4813, Found: 1019.4839.

Example 27 Synthesis of (5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)(1,2,3,5tetraazolyl))pentanoylamino)ethoxy)ethoxy)ethoxy)ethoxy) ethoxy)ethoxy)ethoxy)ethyl)carbamoyl)(2r pyridyl))amino)vinyl)benzenesulfonic Acid 7 NO N.ONN0 I o7 0 7

HO

3

S

NNN

20 Part A: Preparation of (tert-Butoxy)-N-(2-(2-(2-(2-(( 4 methylphenyl) sulfonyloxy)ethoxy)ethoxy)ethoxy)ethyl)formamide A solution of N-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)(tert-butoxy)formamide (5.87 g, 20 mmbl) and TEA (6.12 mL, 44 mmol) in ether was treated with p-toluenesulfonyl chloride (4.00 g, 21 mmol) and stirred at reflux under a nitrogen atmosphere for 24 h, and for another 24 h at ambient temperatures. The solution was concentrated and the oily residue was shaken with sat. NaCl (200 mL) and ether (400 mL), causing a crystalline solid to form in the aqueous layer. The aqueous layer was extracted with a second portion of ether (400 mL). The combined ether extracts were dried (MgSO 4 and concentrated to a dark oil. This oil was purified by flash .chromatography on silica gel (hexane:EtOAc) to give the title compound as a pale yellow oil (2.85 g, 1 H NMR (CDC1 3 7.78 J 8.0 Hz, 2H), 7.32 J 8.0 Hz, 2H), 4.18-4.08 2H), 3.71-3.46 12H), 3.32-3.22 2H), 2.43 3H), 1.42 9H); MS: m/e 465.4 [M+NH 4 Part B: Preparation of diazoprop-3-enyloxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl)(tert-butoxy)formamide A solution of 3 -aza-3-diazoprop-3enyloxy)ethoxy)ethoxy)ethan-1-ol (0.723 g, 3.30 mmol) in anhydrous THF (20 mL) was treated with NaH (144 mg of dispersion, 3.6 mmol) and stirred at ambient temperatures under a nitrogen atmosphere until gas evolution ceased.

A

solution of (tert-butoxy)-N-(2--(2-(2-((4 methylphenyl)sulfonyloxy)ethoxy)ethoxy)ethoxy)ethyl)formamide (1.61 g, 3.6 mimol) in anhydrous THF (20 mL) was added and the mixture was stirred 48 hr at.ambient temperatures under nitrogen. The THF was removed under vacuum and the residue was triturated with ether (3 x 50 mL). The combined triturants were concentrated to give an amber oil. This oil was purified by flash chromatography on silica gel (hexane:EtOAc:MeOH, 47.5:47.5:5) to give the title compound as a colorless oil (l.11.g, 1 H NMR (CDC1 3 5.00 1H), 3.67-3.51 26H), 3.49 J 5.2 Hz, 2H), 3.34 J 5.1 Hz, 2H) 3.30-3.20 2H), 1.40 9H); MS: m/e 512.4

[M+NH

4 High Resolution MS: Calcd for C 21

H

43

N

4 0 8 495.3030, Found: 495.3047.

Part C: Preparation of Aminoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl)(tert-butoxy)formamide Boc A solution of N-( 2 2 2-((2-(2-(2-(2-(3-aza-3-diazoprop-3enyloxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl)(tertbutoxy)formamide (960 mg, 1.94 mmol) in MeOH (100 mL) was hydrogenated over PtO 2 (100 mg) at a pressure of 60 psi for 2 hr at ambient temperatures. The catalyst was removed by filtration through filter aid and the filtrate was concentrated to give the title compound as a pale amber oil (953 mg). 1 H NMR (CDC1 3 5.06 1H), 3.67-3.40 28H), 3.28-3.18 2H), 2.79 J 5.2 Hz, 2H), 1.40 2H), 1.38 9H); MS: m/e 469.3 High Resolution MS: Calcd for C 2 1

H

45

N

2 0 9 469.3126, Found: 469.3125.

Part D: Preparation of.N-( 2 2 2 2 Butoxy)carbonylamino)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)- 15 ethoxy)ethoxy)ethyl)-5-(4-(5-(4,6-diphenyl(2-pyridyloxy))-1,1dimethylpentyl)(1,2,3, 0 NN O 0 NBoc 0 7 A solution of 5-( 4 -(5-(4,6-diphenyl(2-pyridyloxy))-1,1dimethylpentyl)-1,2,3,5-tetraazolyl)pentanoic acid (99 mg, 0.193 mmol) and DIEA (134 uL, 0.772 mmol) in anhydrous DMF (8 mL) was activated by treatment with HBTU (80.5 mg, 0.212 mmol) for 2 min at ambient temperatures. To this solution was added N-(2-(2-(2-(2-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl)(tertbutoxy)formamide (103 mg, 0.220 mmol) in DMF (4 mL) and the resulting solution was stirred 2 h at ambient temperatures under nitrogen. The DMF was removed under reduced pressure and the thick oil was partitioned between EtOAc (50 mL) and water (10 mL). The aqueous layer was adjusted to pH with 0.1 N HC1 and the layers were mixed. The organic phase was washed with sat. NaHCO 3 (10 mL) and sat. NaC1 (10 mL), dried (MgS0 4 and concentrated to give the title compound as an amber oil (208 mg, MS: m/e 981.7 (M+NH 4 ];.High Resolution MS: Calcd for C 5 1

H

7 8

N

7 0 1 1 964.5759, Found: 964.5788.

Part E: Preparation of (2-(2-(5-(4-(5-(4,6-diphenyl(2-pyridyloxy)11 dimethylpentyl)(i,2,3,5tetraazolyl))pentanoylamino)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethox) ethyi)-carbamoyl)(2pyridyl))amifo)vinyl)benzenesulfonic Acid tert-Butoxy) carbonylamino)ethoxy) ethoxy) ethoxy) ethoxy) ethoxy) ethoxy) ethoxy) ethyl)-5-(4- 5 4

I

6 -diphenyl(2-pyridyloxy) )-1,l-dimethylpentyl) (1,2,3,5tetraazolyl))pentanamide (170 mg, 0.193 nmol) was dissolved in TFA (5 mL) and stirred at ambient temperatures for 45 min.

The TFA was removed under reduced pressure and the resulting thick oil was taken up in anhydrous DMF and made basic to pH paper by the addition of TEA (315 uL, 2.32 mmol). This solution was treated with 2 dioxopyrrolidinyl) carbonyl)(2-pyridyl ))amino)vinyl)benzenesulfonic acid (;02 mg, 0.232 mmol) and stirred at ambient temperatures for 20 h. The DMF was removed under reduced pressure and the thick oil was dissolved in ACN (3 mL) 25 and purified by preparative HPLC on a Vydac C-18 column (22 x 250 mm) using a 1.80%/min gradient of 18 to 72% ACN containing 0.05:M NH40Ac at a flow rate of 15 iL/min. The main product peak eluting at 27.5 min was collected and lyophilized to give the title compound as a pale yellow powder (151 mg, 67.1%).

MS: m/e 1167.8 tM+H]; High Resolution MS: Calcd for 9

H

79

N

10

O

13 S 1167.5549, Found: 1167.5577.

Example 28 Synthesis of 2-(2-Aza-2-( (5-(4,6-diphenyl (2pYridyloxy))1,l.dimethylpentyl) (1,2,3,5tetraazolyl))pentanoylamino)-l-(6-deoxy-pcyclodextryl)carbamoyl)pentyl)carbamoyl)(2pyridyl))amino) vinyl) benzenesulfonic Acid Nr HHN' -Cyclodextrin A H

O

N 0 0 HN 0 H0 3 S

N

6 NrNH Part A: Preparation of 6-Amino-2-((tertbutoxy)carbonylamino)-N- (6-deoxy-0-cyclodextryl hexanamide A solution of 6-deoxy-6-amino-o-cyclodextrin (70 mg, 0.062 mmol), Boc-Lys(Z)-OSu (29.5 mg, 0.062 mmol), and TEA (12.6 uL, 0.092 mmol) in anhydrous DMF (3 mL) was stirred under a nitrogen atmosphere at ambient temperatures for 90 min. The solvent was removed under reduced pressure. The slightly green solid was taken up in MeOH (6 mL) and water (0.5 mL), treated with anisole (100 uL), and hydrogenolyzed over Pd/C (50 mg) at 30 psi and ambient temperatures for 18 h. The catalyst was removed by filtration through filter aid and the filtrate was concentrated under vacuum to give the title compound as a slightly green solid (87 mg). MS: 1362.7 Part B: Preparation of 2 (4-(5-(4,6-diphenyl(2-pyridyloxy))-1,1dimethylpentyl)(1,2,3,5-tetraazolyl))pentanoylaino)-N-(6deoxy-0-cyclodextryl)hexanamide HN' -Cyclodextrin NNU~(

N.N

NHN.

5 Boc 6-Diphenyl 2 -pyridyloxy))-1, i-dimethylpentyl)- 1, 2 ,3,5-tetraazolyl)pentanoic acid (31.6 mg, 0.062 mmol) was dissolved in anhydrous DMF (3 mL) and preactivated by the addition of HBTU (25.6 mg, 0.068 mmol) and DIEA (28 uL, 0.186 mmol). After 5 min a solution of 6 -amino-2-((tertbutoxy)carbonylamino)-N-(6-deoxy-f-cyclodextryl)hexanamide (84 mg, 0.062 mmol) and DIEA (28 uL, 0.186 mmol) in DMF (3 mL) was added and the resulting mixture was stirred at ambient temperatures under nitrogen for 18 h. Solvents were removed under reduced pressure and the residue was dissolved in MeOH:water:DMF, 10:2:2 (1.4 mL). This solution was used for preparative HPLC purification on a Vydac C-18 column (22 x 250 mm). using a 1.

8 0%/min gradient of 18 to 72% ACN at a flow rate of 15 mL/min. The main product peak eluting at 27.3 min was collected and lyophilized to give the title compound as a colorless powder (52 mg, MS: 1857.9 High Resolution MS: Calcd. for C 83

H

125 N80 39 1857.8044, Found: 1857.8068.

Part C Preparation of 2 diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)(1,2,3,5tetraazolyl))pentanoylamino)-1-(6-deoxy-pcyclodextryl)carbamoyl)pentyl)carbamoyl)(2pyridyl))amino)vinyl)benzenesulfonic Acid 2-((tert-Butoxy)carbonylaminolamino)-6-(5-(4-(5( 4 4 diphenyl( 2 pyridyloxy))-1,1-dimethylpentyl)(1,2,3,5tetraazolyl))pentanoylamino)-N-(6-deoxy- -cyclodextryl)hexanamide (52 mg, 0.028 mmol) was dissolved in TFA and stirred 45 min at ambient temperatures. The TFA was removed under vacuum, and the residue was dissolved in anhydrous

DMF

(3 mL) and made basic to pH paper with TEA (58 uL, 0.42 mmol).

The solution was treated with active ester 2 ((2,5-dioxopyrrolidinyl)carbonyl)(2-pyridyl))amino)vinyl)benzenesulfonic acid (14.8 mg, 0.034 mmol) and stirred under a nitrogen atmosphere at ambient temperatures. Additional active ester was added at 72 h (17 mg) and at 96 h (20 mg).

After a total reaction time of 8 days the solution was concentrated to give a thick oil. This oil was dissolve'd in MeCH and purified by preparative HPLC on a Vydac C-18 column (22 x 250 mm) using a 1.50%/min gradient of 18 to 63% ACN containing 0.05 M NH40Ac at a flow rate of 15 mL/min. The main product peak eluting at 27.1 min was collected and lyophilized to give the title compound as a colorless Powder 3 01mg, MS: 2061.6 Nigh Resoluticn MS: Calcd for C9 1

H

1 2 6

N

1 1

O

4 1 S 2060.7833, Found: 2060.7-874.

Example 29 Synthesis of diphenyl( 2 -pyridyloxy))-i,1-dimethylpentyl) (1,2,3,4tetraazolyl))acetylamino)propoxW)ethoxy)ethoxy)propyl)carbamoyl)(2-pyridyl))amino)vinyl)benzenesulfonic Acid NO0 C~

H

I 0 SHN N S0 3

H

Part A Preparation of Ethyl 2 -(5-(5-(4,6-diphenyl(2pyridyloxy)) -1,l-dimethylpentyl) 4-tetraazolyl) acetate and Ethyl 2 7( 4 -(5-(4,6-diphenyl(2-pyridyoxy)).l1 1dimethylpentyl)-1,2,3,5-tetraazolyl)acetatie

NH

NO

A solution of 6-(5-(2H-2,3,4,5-tetraazolyl)-5-methyihexyloxy)- 2 4 -diphenylpyridine (827 mg, 2.00 nmol) and bis-tri-nbutyltin oxide (596 mg, 1.00 mmol) in EtOH (50 mL) was stirred at reflux under a nitrogen atmosphere for 20 min and concentrated to a pale yellow oil under reduced pressure. The oil was dissolved in ACN (25 mL), treated with ethyl bromoacetate (333 uL, 3.00 mmol) and heated to reflux under nitrogen for 60 h. The ACN was removed under vacuum and the resulting amber oil was taken up in EtOAc (50 mL). This organic solution was washed consecutively with 0.1 N HCl mL), sat. NaHCO 3 (15 mL), sat. NaCl (15 mL), dried (MgS0 4 and concentrated to give an amber oil (1.662 The oil was dissolved in ether (60 mL) and washed with 10% KF (2 x 30 mL).

The precipitate was removed by filtration and the two layers of the filtrate were separated. The organic layer was dried (MgSO 4 and concentrated to give a yellow solid (0.957 g).

Flash chromatography on silica gel (20% EtOAc/hexanes) gave N2 isomer ethyl: 2 4 -(5-(4,6-diphenyl(2-pyridyloxy))-l,1dimethylpentyl)-1,2,3,5-tetraazolyl)acetate as a colorless solid (617 mg). Recrystallization from hexanes afforded S 15 product as colorless solid (490 mg, MP: 76-79 OC; 1

H

S9NMR (CDC1 3 8.06 J 6.8 Hz, 2H), 7.66 J 8.1 Hz, 2H), 7.58-7.34 7H), 6.86 1H), 5.33 2H), 4.42

J

6.6 Hz, 2H), 4.22 J 7.1 Hz, 2H), 1.90-1.72 4H), 1.50-1.28 8H), 1.22 J 7.1 Hz, 3H);-MS: m/e 500.3 High Resolution MS: Calcd for C 2 9

H

34

N

5 0 3 500.2662, Found: 500.2668; CHN Calcd: C, 69.72; H, 6.66; N, 14.02; Found: C, 69.43; H, 6.69; N, 13.90.

After eluting the above compound from the flash column the 25 eluting solvent was changed to 30% EtOAc/hexanes to give N1 isomer ethyl 2 -(5-(5-(4,6-diphenyl(2-pyridyloxy))-1,ldimethylpentyl)-1,2,3,4-tetraazolyl)acetate as a pale yellow oil (142 mg, 1 H NMR (CDC1 3 8.05 J 6.8 Hz, 2H), 7.66 J 6.5 Hz, 2H), 7.60-7.33 7H), 6.85 (s, 1H), 5.20 2H), 4.43 J 6.4 Hz, 2H), 4.22 J 7.1 Hz, 2H), 1.89-1.70 4H), 1.52-1.38 8H), 1.24 J 7.1 Hz, 3H); MS: m/e 500.3 [M+HI; High Resolution MS: Calcd for C2 9

H

34

N

5 0 3 500.2662, Found: 500.2653.

Part B Preparation of 2-(5-(5-(4,6-Diphenyl(2-pyridyloxy))- 1,1l-dimethylpentyl)-1,2,3, 4 -tetraazolyl)acetic Acid

NO

A mixture of ethyl 2 -(5-(5-(4,6-diphenyl(2-pyridyloxy))- 1,1-dimethylpentyl)-1,2,3,4-tetraazolyl)acetate (97 mg, 0.194 mmol) and 3N LiOH (1.2 mL, 3.6 mmol) in THF (2 mL) was stirred at 50 0 C for 23 h under a nitrogen atmosphere. The THF was removed under vacuum and the residue was dissolved in EtOAc mL), washed with dilute HC1 (pH 5 nL)) and then with water (5 mL). The organic solution was dried (MgSO 4 and concentrated to give the title compound as a colorless solid.

MS: 470.3 Part C Preparation of 4 ,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)(1,2,3,4i. tetraazolyl) )acetylamino)propoxy)ethoxy)ethoxy)propyl)carbamoyl)(2-pyridyl) amino)vinyl)benzenesulfonic Acid A solution of 2 -(5-(5-(4,6-diphenyl(2-pyridyloxy))-1,1dimethylpentyl)-1,2,3,4-tetraazolyl)acetic acid (76 mg, 0.161 mmol), TEA (181 uL, 1.30 mmol), N-( 3 -(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)(tert-butoxy)formamide (157 mg, 0.488 mmol), and HBTU (195 mg, 0.512 mmol) in anhydrous DMF (3 mL) was stirred at ambient temperatures under nitrogen for 27 h.

*,The solution was concentrated under reduced pressure and the resulting dark amber oil was dissolved in EtOAc (20 mL), washed with 0.1 N HC1 (10 mL) and sat. NaC1 (2 x 10 mL), dried (MgSO 4 and concentrated to give the crude linker conjugate as an amber oil (280 mg). The presence of the desired conjugate was confirmed by low resolution mass spedtroscopy (MS: 774.4 The above oil was dissolved in TFA (3 mL) and stirred at ambient temperatures for 45 min. The TFA was removed under vacuum, the resulting oil was dissolved in DMF (1 mL) and made basic to pH paper with TEA (385 uL, 2.76 mmol). The solution was treated with active ester dioxopyrrolidinyl) carbonyl)(2-pyridyl ))amino)vinyl)benzenesulfonic acid (264 mg, 0.598 nmol) and stirred at ambient temperatures for 48 h. The Solution was diluted with 50% ACN (2.5 rL) and purified by preparative HPLC on a Vydac C-18 column (22 x 250 mm) using a l.50%/min gradient of 18 to 63% ACN containing 0.05 M NH 4 0Ac at a flow rate of 15 mL/min.

The main product peak eluting at 29.4 mmin was collected and lyophilized to give the title compound as a pale yellow powder (49 mg, MS: 977.4 fM+HI; High Resolution MS: Calcd for C50H1Nloo 9 S 977.4344, Found: 977.4333.

Example Synthesis of 2-(2-Aza-2 diphenyl (2-pyridyloxy))-l.l-dimethylpdntyl)(*2,3,5 tetraazolyl))acetylamino)propoxy) ethoxy) ethoxy) propyl)carbamoyl) (2-pyridyl)) amino) vinyl) benzenesul-fonic Acid WNN" ZfgO KNH..

H

0\~2 S NOHN N S03H Part A: Preparation of 2-(4-(5-(4,6-Diphenyl(2-pyridyloxy))- 1, l-dimethylpentyl)-1,2,3, -tetraazolyl)acetic Acid 0 A mixture of ethyl 2 4 -(5-(,6-diphenyl(2pyridyloxy))-1,1 dimethylpentyl)-1,2,3, -tetraazolyl)acetate (370 mg, 0.739 mmol) and 3 N LiOH (3.6 mL, 10.8 nmol) in THF (1 mL) was stirred at 50 0 C for 17 h and concentrated to dryness. The residue was partitioned between EtOAc (20 mL) and dilute HCl (pH 2, 5 mL). -TThe organic phase was washed with water mL), dried (MgS0 4 and concentrated to give the title compound as a colorless solid (278 mg, MS: 470.3 [M-

H].

Part B Preparation of (5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl) (1,2,3,5tetraazolyl))acetylamino)propoxy)ethoxy)ethoxy)propyl)carbamoyl)(2pyridyl))amino)vinyl)benzenesulfonic Acid A solution of 2 4 -(5-(4,6-diphenyl(2-pyridyloxy))-1,1dimethylpentyl)-1,2,3,5-tetraazolyl)acetic acid (261 mg, 0.553 mmol), TEA (920 uL, 6.60 mmol), HBTU (754 mg, 1.99 mmol), and S 15 N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)(tertbutoxy)formamide (398 mg, 1.24 mmol) in anhydrous DMF 1.5 mL) was stirred at ambient temperatures under nitrogen for 21 h.

The solution was concentrated under reduced pressure and the o resulting dark amber oil was dissolved in EtOAc (20 mL), washed with 0.1 N HCl (10 mL) and sat. NaHCO 3 (2 x 10 mL), dried (MgSO 4 and concentrated to give the crude (3-((tert-butoxy)carbonylamino)propoxy)ethoxy)ethoxy)propyl)- 2-( 4 -(5-(4,6-diphenyl(2-pyridyloxy))-1,1dimethylpentyl)(1,2,3,5-tetraazolyl))ethanamide as a pale amber oil (430 mg). The presence of this conjugate was confirmed by low resolution mass spectroscopy IMS: 774.4 The above oil was dissolved in TFA and stirred at ambient temperatures for 45 min. The TFA was removed under reduced Spressure, the resulting oil was dissolved in DMF (2 mL) and made basic to pH paper with TEA (464 uL, 3.34 mmol.. The solution was treated with active ester dioxopyrrolidinyl)carbonyl)(2-pyridyl))amino)vinyl)benzenesulfonic acid (490 mg, 1.11 mmol) and stirred at ambient temperatures for 93 h. The solution was diluted with ACN (2.5 mL) and purified by preparative HPLC on a Vydac C-18 column (22 x 250 mm) using a 1.80%/min gradient of 18 to 72% ACN containing 0.05 M.NH 4 OAc at a. flow rate of 15 mL/min.

The main product peak eluting at 26.8 min was collected and lyophilized to give the title compound as a pale yellow powder (120 mg, MS: 977.4 High Resolution MS: Calcd for C50H 61

N

1 0 0 9 S 977.4344, Found: 977.4341.

Example 31 Synthesis (sulfophenyl)vinyl)amino)(3-pyridyl)) methoxypolyethylene(750)glycoxyethyl)carbamoyl)pentyl)carbamoyl)propoxy)2-(5-(4,6-diphenyl(2pyridyloxy) )pentyloxy)phenyl)propanoic Acid NO NH N N O 0 0

OHN

SCOOH

H S I

N.NH

*H03S Part A: Preparation of 3 -Aza-3-diazo-1-(Omethoxypolyethylene(750)glycoxy)prop-3-ene A 1000 mL 3-neck flask was equipped with a mechanical stirrer, 20 an addition funnel with nitrogen line, and a thermometer. The flask was charged with C-methoxypolyethylene- 7 50)glycoxyethanol (75 g, 0.10 mol), TEA (28 mL, 0.20 mol), anhydrous ether (300 mL), and anhydrous THF (200 mL). The solution was cooled to 5 OC in an ice bath. The addition funnel was charged with methanesulfonyl chloride (11.6 mL, 0.15 mol), ether (250 mL), and THF (250 mL). The contents of the addition funnel were added to the flask dropwise with stirring while maintaining the flask contents at 5-10 OC.

When addition was complete, the ice bath was removed and stirring was continued at ambient temperatures for 1 h. The mixture was filtered to remove TEA*HC1 salt and the filtrate was concentrated to give a pale yellow oil. This oil was triturated with hexanes (6 x 100 m.L) and dried under vacuum to give the mesylate as a pale yellow oil (86.8 g).

The mesylate was dissolved in anthydrous EtOH (600 m.L) and treated with sodium azide (6.8 g, 0.104 minol). The mixture was heated at reflux under nitrogen for 24 h, at which time additional sodium azide (20'0 g) was added, and heating was continued another 24 h. The EtOH was removed under vacuum giving a mixture of oil and solid. The oil was dissolved in ether (500 mL) and filtered, and the filtrate was concentrated to give the title compound as a pale yellow oil (74.6 g, 96%).

13C NMR (CDCl 3 58.8 (O-CH 2

CH

2

NH

2 50.5 (CH 2

-N

3

IR

(neat/KBr cm-1): 2100 Part Preparation of Methoxypolyethylene (7 50) glycoxy) ethylamine ~20 3 -Aza- 3-diazo -l1- (0O-methoxypolyethylene 7 5O) glycoxy)prop- 3-ene (14.0 g, 18.0 mmol) in MeOH (200 mL) was hydrogenated over, Pta 2 (1.0 g) at 60 psi and ambient temperatures for 15 h.

*Catalyst was removed by filtration through filter aid and the filtrate was concentrated to give the title compound as a pale yellow oil (11 3 g, 1 3 C NMR (CDCl 3 58-.8 (0- CH2CH 2

NH

2 41.4 (CH2-NH 2 IR (neat/KBr carl): 3350 M4S: 516.4 (n=11) 560.4 604.4 648.4 692.4 7,36.5 780.5 824.5 (n=18) Part Preparation of 2 -((tert-Butoxy)carbonylamino)-N..(O).

methoxypolyethylene (750).glycoxyethyl) -6- ((phenylme thoxy) carbonylamino) hexanamide 41I ,'NH

HN,.

A Solution -of 2- (c-methoxypolyethiylene (750)glycoxy) ethylmne (11.2 g, 14.9 mmol), Boc-Lys(Z)-OSu (6.2 g, 0.13.0 mmol), and TEA (2.7 mL, 0.19.5 mmol) in anhydrous THF (500 mL) was stirred at ambient temperatures for 24 h. The solution was diluted with 70:30 ether CHC1 3 (1200 mL) and washed with sat.

NaCi (500 mL). The NaCi wash was back extracted with 70:30 ether CHCl 3 (500 mL). The combined organic extracts were dried (MgSo 4 and concentrated to give a colorless oil (15.1

A

2.0 g sample of this .oil was purified by flash chromatography on silica gel (CHC1 3 :MeOH) to give the title compound as a colorless oil (1.30 g, MS: 939.5 983.7 *1027.7 1071.8 -1115.7 1159.7 (n=17), 1203.8.(n=18)

[M+NH

4 High Resolution MS: Calcd for C50H 9 2

N

3 0 2 0 (n=15) 1054. 6274, Found.: 105.4.6224; Calcd for C52H 9 6

N

3 0 2 1 (n=16) 1098.653.6, -Found: 1098.6476.

Part D: Preparation of 6-Amino-2-((tertbutoxy) carbonylahino) (0me thoxypo lye thyl ene 50.) gl1ycoxye thyl) hexanamide

H

2

N

HN.B

(tert-Butoxy) carbonylamino (O'-methoxypolyethylene(750) 25 gl ycoxye thyl) ((phenylmethoxy) carbonylamino) hexanamide (1.00' g, 0.86 mmol) in MeOH (20 mL) was hydrogenolyzed over .10% Pd/C (200 mg) at 1 atm and ambient temperatures for 4 h. The catalyst was removed by filtration through filter aid and the filtrate was concentrated to give the title compound as a colorless oil (0.79 g, MS: 832.6 876.7 (n=14), 920.8 964.8 1008.7 1052.6 (n=18), 1096.8 (n=19) Part E; Preparation of Methyl 3 Butoxy) carbonylamino) (cOmethoxypolyethylene(750)glycoxyethyl)carbamoyl)pentyli carbamoyl)propoxy)2-(5-(4,6-diphenyl(2pyridyloxy) pentyloxy)phenyl propanoate H0

NN

~N 0 0

HN,,

COOMe A solution of 4-(3-(5-(4,6-diphenyl(2-pyridyloxy))pentyloxy)- 2-(2-(methoxycarbonyl)ethyl)phenoxy)butanoic acid (27.5 mg, 0.045 mmol) and TEA (12 uL) in anhydrous DMF (2.5 mL) was 10 treated with HBTU (18.9 mg, 0.049 mol) under a nitrogen atmosphere. The solution was stirred 5 min at ambient temperatures and treated with a solution of 6-amino-2-((tertbutoxy) carbonylamino) .(O-methoxypolyethylene (750)glycoxyethyl)hexanamide (55.7 mg, 0057 mmol) in DMF (3.0 mL).

The solution was stirred 3 h at ambient temperatures under a nitrogen atmosphere and-concentrated to a colorless oil. This oil was dissolved in ACN (1.5 mL) and purified by preparative S* HPLC on a Vydac C-18 column (22 x 250 mm) using a 1.80%/min gradient of 36 to 90% ACN containing 0.1% TFA at a flow rate of 15 mL/min. The main product peak eluting at 20.4 min was .collected and lyophilized to give the title compound as a colorless oil (40 mg, MS: 1478.0 1521.8 1565.9 1610.0 1654.1 (n=18) [M+Na]; High Resolution MS: Calcd for C78H 1 2 3

N

4 0 2 4 (n=15) 1499.8527, Found: 1499.8579; Calcd for C 82

H

131

N

4 0 26 (n=17) 1587.9052, Found: 1587.9026.

Part F: Preparation of 3 6 3 methoxypolyethylene(750)glycoxyethyl)carbamoyl)pentyl)carbamoyl)propoxy)2-(5-(4,6-diphenyl(2pyridyloxy))pentyloxy)phenyl)propanoic Acid A mixture of methyl 3 3 carbonylamino)-5-(N-((o-methoxypolyethylene(750)glycoxyethyl)carbaoyl)pentyl)carbamoyl)propoxy)2-(5-(4,6diphenyl(2-pyridyloxy))pentyloxy)phenyl)propanoate (35.7 mg, 0.0226 mmol) and 3 N LiOH (609 uL) in THF (3.5 rL) was stirred at ambient temperatures under nitrogen for 96 h. The Solution was concentrated under reduced pressure and the colorless solid was taken up in TFA (4 niL) and stirred at ambient temperatures for 45 min. The TFA was removed under vacuum to give 3 3 -(N-(5-aino-5- (W.methoxypolyethylene (750) glycoxyethyl cabamoyl pentyl) carbamoyl)

L

propox 6-diphenyl(2-pyridyloxy))pentyloxy)phenyl)propanoic acid as an orange solid (32.2 mg).

A solution of the above orange solid (32.2 mg, 0.0245 nmol), TEA (101 uL), and 2 2 -aza-2-((5-(2,5-dioxopyrroldinyl) carbonyl) 2 -pyridyl))amino)vinyl)benzenesulionic acid (20.0 mg, 0.0454 mmol) in anhydrous DMF (2 mL) was stirred at ambient temperatures under nitrogen for 72 The DMF wasiremoved under vacuum and the resulting thick oil was dissolved in ACN (1.0 mL) .and purified by preparative HPLC on a Vydac C- 18 column (22 x 250 mm) using a 1.80%/min gradient of 18 to 72% ACN containing 0.05 M NH 4 0Ac at a flow rate of 15 iL/min.

The main product peak eluting at 25.7 min was collected and lyophilized to give the title compound as a pale yellow oil (21.0 mg, MS: *1643.5 1687.6 1731.7 1775.2 1819.2 1863.2 1907.5 Example 32 Synthesis of sulfophenyl)vinyl)amino) (3pyridyl)) carbonylamino) propoxy) ethoxy) ethoxy) propyl)carbamoyl)propoxy)2-(5-(4,6 -diphenyl( 2 pyridyloxy)) pentyloxy) phenyl) propanoic Acid Part A: Preparation of Methyl Butoxy)carbonylamino)propoxy)ethoxy)ethoxy)propyl)carbamoyl)propoxy)2-(5-(4,6-diphenyl(2pyridyloxy))pentyloxy)phenyl)propanoate H

H

N O "OO N, O O O,,0 N.Bo COOMe 0 00*0* 0 see: 10 A solution of 4 3 -(5-(4,6-diphenyl(2-pyridyloxy))pentyloxy)-2-(2-(methoxycarbonyl)ethyl)phenoxy)butanoic acid S(100 mg, 0.167 mmol) in anhydrous DMF (0.75 mL) was treated with HBTU (90 mg, 0.237 mmol) under a nitrogen atmosphere.

The solution was stirred 5 min at ambient temperatures and 15 treated with a solution of N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)(tert-butoxy)formamide (59 mg, 0.184 mmol) in anhydrous DMF (0.75 followed by DIEA (73 mg, 0.418 mmol). The solution was stirred 3 h at ambient temperatures under nitrogen. The reaction solution was purified directly by preparative HPLC on a Vydac C-18 column (22 x 250 mm) using a 1.80%/min gradient of 36 to 90% ACNat a flow rate of 15 nL/min. The main peak eluting at 33.9 min was collected and lyophilized to give the title compound as a colorless oil (105 mg, 1 H NMR (CDCl3): 8.10-8.06 (m, 2 7.70-7.62 2H), 7.56-7.35 (m 7H), 7.08 J 8.1 Hz, 1H), 6.89 J 1.2 Hz, 1H), 6.53-6.44(m, 3H), 4.95 (s, 1H), 4.51 J 6.5 Hz, 2H), 3.97 J 6.2 Hz, 2H), 3.62- 3.45 15H), 3.33 J 6.2 Hz, 2H), 3.23-3.15 2H), 3.05-2.95 2H), 2.59-2.34 4H), 2.16-2.04 2H), 1.98- 1.63 10H), 1.42 9H); MS: m/e 900.7 High Resolution MS: Calcd for CslH7oN 3 Oll 900.5010, Found: 900.5012.

Part B: Preparation of 3 3 Butoxy) carbonylamino) propoxy) ethoxy)ethoxy) propyl)carbamoyl)propoxy)2- 6-diphenyl(2- Pyridyloxy))pentyloxy)phenyl)propanoic Acid A mixture of methyl 3 3 butoxy) carbonylamino) propoxy) ethoxy) ethoxy) propyl) carbamoyl) propoxy)2 6-diphenyl (2!-pyridyloxy) )pentyloxy) phenyl).propanoate (107 mg, 0.119 imol) and 3M LiOH 57 mL, 1.72 mmol) in THF (5.8 mL) was stirred at ambient temperatures for 15 4 days. The THF was removed by vacuum evaporation and the resulting mixture was treatedwith water (20 mL). The aqueous mixture was adjusted to pH 2 with 1.0 N HCl, and extracted with EtOAc (3 x 40 mL). The combined organic layers were washed consecutively with water (20 mL) and sat'. NaCi (20 m), dried (MgS04), and concentrated to give the title compound'as a colorless oil (93.0 mg, MS: m/e 886.6 High Resolution MS: Calcd for C 50

H

6 8

N

3 0 1 1 886.4854, Found: 886.4872.

Part C Preparation of (l-Aza- 2-( 2 -sulfophenyl)vinyl)aino)(3pyridyl)) carbonylaino) propoxy) ethoxy) ethoxy) propyl)carbamoyl)propoxy)2-(5-(4, 6-diphenyl(2pyridyloxy)) pentyloxy) phenyl) propanoic Acid A solution of 3 3 -butoxy).

carbonylamino) propoxy) ethoxy) ethoxy) propyl) carbamoyl) propoxy)2 -(5-(4'6-diphenyl(2-pyridyloxy))pentyloxy)phenyl)propanoic acid (89 mg,-0.100 mmol) in TFA (4 mL) was stirred under a nitrogen atmosphere for 60 min at ambient temperatures. The TFA was removed by vacuum evaporation and the resulting oil was dissolved in DMF (0.7 mL). TEA was added until the solution was basic to pH paper (106 uL, 0.76 miol), and 2-(2aza-2-((5-((2,5-dioxopyrrolidinyl)carbnyl) (2-pyridyl)')amino)- .vinyl)benzenesulfonic acid (53.0 mg, 0.12 mmcl) was added.

The resulting solution was stirred 17 h at ambient temperatures under a nitrogen atmosphere. The solution was purified directly by preparative HPLC on a Vydac C-18 column (22 x 250 mm) using a l.80%/min gradient of 20 to 80% ACN containing 0.05 M NH 4 OAc at a flow rate of 15 mL/min. The main product peak eluting at 25.8 min was collected and lyophilized to give the title compound as a colorless solid (75.6 mg, MS: me 1087.5 High Resolution

MS:

Calcd-for C5 8

H

6 9

N

6 i 3 1S 1089.4643, Found: 1089.4661.

Example '33 Synthesis of (-Aza-2- (2sulfophenyl) vinyl) amino) (3 -pyridyl) carbonylamino)

(N-

E-pentahydroxhexyl )carbanoyl) pentyl) carbamoyl)propoxy) 2 -(S5(4...-diphenyl(2pyridyloxy))pentyloxy)phenyl)propanoic Acid

OH

O OH

OH

H

H

N O OH0

COOH

HOS O

NH

0

NNH

Part A: Preparation of 2 -((tert-Butoxy)carbonylamino)-N- (2,3,4,5,E-pentahydroxyhexyl)-6- ((phenylmethoxy)carbonylamino)hexanamide OH OH HO

OH

OH

H

NH

0

HN.B

Boc A mixture of l-amino-l-deoxysorbitol 1.99 g, 11.0 mmol), Boc-Lys-(Z)-OSu (4.77 g, 10.0 mmol), TEA (0.556 g, mmol), THF (50 mL), and water (10 mL) was stirred at ambient temperatures for 2 h followed by concentration to a volume of mL. Water (100 mL) was added, and the mixture was extracted with EtOAc (3 x 200 mL). The combined organic extracts were washed consecutively with 0.05 N HC1 (50 mL) water (50 mL), and sat. NaCl (50 mL), dried (MgSO 4 and S* concentrated by vacuum evaporation until crystals began to form. The mixture was diluted with ether, causing additional crystallization. The solid was collected by filtration and dried to give the title compound as colorless crystals (1.08 15 g, 1 H NMR (CD30D): 7.41-7.26 5H), 5.09 2H), 4.05-3.94 2H), 3.88-3.45 7H), 3.14 J 6.6 Hz, 2H), 1.87-1.31 16H); MS: m/e 544.4 High Resolution MS: Calcd for C25H 42

N

3 010 544.2870, Found: 544.2895.

Part B: Preparation of 6-Amino-2-((tertbutoxy)carbonylamino)-N-(2,3,4,5,6pentahydroxyhexyl)hexanamide 2-((tert-Butoxy)carbonylamino)-N-(2,3,4,5,6pentahydroxyhexyl) -6-((phenylmethoxy)carbonylamino)hexanamide (450 mg, 0.829 mmol) was dissolved in MeOH (10 mL) and hydrogenolyzed over 10% Pd/C (85 mg) at atmospheric pressure for 90 min. The catalyst was removed by filtration through filter aid and the filtrate was concentrated under reduced pressure to give the title compound as a pale yellow oil (331 mg, MS: m/e 410.3 Part C: Preparation, -of Methyl. 3 ((tert- Butoxy)carbonylamino)-5-(N-(2,3,4,5,6pentahydroxyhexyl) carbaxnoyl)pentyl) carbaxnoyl)propoxy) 6-diphenyl (2-pyridyloxy) )pentyloxy) phenyl )propanoate OH OH HO

OH

OH N

COOOH

A solution of 4 -(3-(5-(4.,6-diphenyl(2-pyridyloxy))pentyloxy) (methoxycarbonyl) ethyl).phenoxy)butanoic acid (90 mig, 0.152 nimol), and DIEA (66 uL, 0.380 mmol) in anhydrous DMF nit) was preactivated with HBTU (69.2 mg, 0.182 nimol) min at ambient temperatures, and then treated with a solution of 6-amino-2- ((tert-butoxy) carbonylamino) -N- 2 ,3,4,5,6-pentahydroxyhexyl)hexanamide (74.7 mg, 0.182 inmol) in anhydrous DMF (2 niL). The solution was stirred at ambient' temperatures for 45 min and purified directly by preparative :HPLC on a Vydac C-18 column (22 x 250 mim) using a 2.10%/mmn gradient of 27 to 90% ACN at a flow rate of 15 niL/mmn. The main product peak eluting at 29.5 min was collected and lyophilized to give the title compound as a colorless oil (88 mg, MS: m/e 989.5 High Resolution 145: Calcd for C 5 3

H

7 3

N

4 0 1 4 989.5123, Found: 989.5145.

Part D: Preparation of pentahydroxyhexyl) carbamoyl) pentyl) carbamoyl )propoxy) 6-diphenyl (2-pyridyloxy) )pentyloxy) phenyl) propanoic Acid A mixture of methyl 3 butoxy) carbonylamino) 6-pentahydroxyhexyl) carbamoyl)pentyl)carbamoyl)propoxy) 6-diphe nyl (2- PYridylPxy) )pen.tyloxy phenyl)propanoate (37 mg, 0.037 nmmol) and 3M LiOH (181 uL) in THF (1.8 mL) was stirred at ambient temperatures for 3 h and then concentrated to dryness under vacuum. The solid residue was cooled at -10 *C and treated with TFA (4 mL). The resulting solution was stirred 60 min at ambient temperatures and concentrated under reduced pressure to give the TFA salt of the title compound as an amber oil.

MS: m/e 875.5 Part E Preparation of (2,3,4,5, 6 -pentahydroxyhexyl) carbamoyl pentyl) carbamoyl)propoxy)-2-(5-(4,6-diphenyl(2pyridyloxy))pentyloxy)phenyl)propanoic Acid A solution of 3 3 -(N-(5-amino-5-(N-(2,3,4,5,6pentahydroxyhexyl)carbamoyl)pentyl) (4,6-diphenyl(2-pyridyloxy))pentyloxy)phenyl)propanoic acid in anhydrous DMF (0.5 mL) was treated with TEA until basic to pH paper (57 uL, 0.41 mmol). This solution was treated with 2- (2-aza-2-((5-((2,5-dioxopyrrolidinyl)carbonyl)(2-pyridyl) amino)vinyl)benzenesulfonic acid (18.2 mg, 0.041 mmol) and stirred at ambient temperatures for 17 h under a nitrogen atmosphere. The solution was diluted with 80% ACN (0.5 mL) and purified directly by preparative HPLC on a Vydac C-18 column (22 x 250 numm) using a 1.80%/min.gradient of 18 to 72% ACN containing 0.05 M NH 4 0Ac at a flow rate of 15 mL/min. The main product peak eluting at 23 min was collected and lyophilized to give the title compound as a colorless powder (11.5 mg, MS: m/e 1176.7 High Resolution

MS:

Calcd for C60H 72

N

7 0 16 S 1178.4756, Found: 1178.4792.

Example 34 Synthesis of 3 3 sulfophenyl)vinyl)amino)(3-pyridyl))carbonylamino)propyl)carbamoyl)propoxy)-2-(5-(5-oxo-1-prop-2-enyl(2-6,7,8trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid H H 0 a COOH HOS

N

N.NH

Part A: Preparation of tert-Butyl (Methoxycarbonyl)ethyl)-3-(5-(5-oxo-1-prop-2-enyl(2-6,7,8trihydronaphthyloxy))pentyloxy)phenoxy)butanoate 0 0 O O 't-Bu 0 COOMe A mixture of tert-butyl 4-(2-(2-(methoxycarbonyl) ethyl)- (482 mg, 0.959 mmol), 6-hydroxy-5-prop-2-enyl-2,3,4-trihydronaphthalen- 1-one (204 mg, 1.01 mmol), and anhydrous K 2

CO

3 (265 mg, 1.92 mmol) in anhydrous DMSO (4.5 mL) was stirred at ambient temperatures under a nitrogen atmosphere for 67 h. The 15 reaction mixture was diluted with 80% ACN and used directly for preparative HPLC purification on a Vydac C-18 column.(22 x 250 mm) using a 1.80%/min gradient of 36 to 90% ACN at a flow rate of 15 mL/min. The main product peak eluting at 32 min was collected and lyophilized to give the title compound as a pale yellow oil (330 mg, 1 H NMR (CDC13): 8.00 J 8.7 Hz, 1H), 7.08 J 8.3 Hz, 1H), 6.83 J 8.7 Hz, 1H), 6.48 J 8.3 Hz, 2H), 5.95-5.78 1H), 5F-00-4.84 2H), 4.05 J 6.2 Hz, 2H), 4.01-3.91 4H), 3.64 (s, 3H), 3.43 J 5.9 Hz, 2H), 2.98 J 8.2 Hz, 2H), 2.88 J 6.1 Hz, 2H), 2.57 J 6.5 Hz, 2H), 2.53-2.37 (m, 4H), 2.16-1.57 10H), 1.43 9H); MS: m/e 609.4 High Resolution MS: Calcd for C36H 49 0 8 .609.3427, Found: 609.3398.

Part B Preparation of 4-(2-(2-(Methoxycarbonyl)ethyl)-3- (5-(5-oxo-1-prop-2-enyl(2-6,7,8trihydronaphthyloxy))pentyloxy)phenoxy)butanoic Acid A solution of tert-butyl 4 2 2 -(methoxycarbonyl) ethyl) 3- (5-oxo--prop-2 -enyl(2-6,7,8-trihydronaphthyloxy)pentyloxy)phenoxy)butanoate (252 mg, 0.414 mmol) and anisole uL, 0.823.mmol) in TFA (6 mL) was stirred 15 min at ambient temperatures. The TFA was removed by vacuum evaporation, the resulting oil was dissolved in 70% ACN and lyophilized to give the title compound as a colorless powder (224 mg, 1 H NMR (CDC13): 7.99 J 8.7 Hz, 1H), 7.05 J 8.2 Hz, 1H), 6.83 J 8.7 Hz, 1H), 6.48

J

S8.2 Hz, 2H), 5.94-5.78 1H), 4.99-4.84 (mn, 2H), 4.10-3.92 S(m, 6H), 3.67 3H), 3.42 J =5.9 Hz, 2H), 3.01-2.84 (m, 48), 2.62-2.42 6H), 2.22-2.01 4H), 1.95-1.80 4H), 1.73-1.59 (mn, 2H); MS: m/e 553.3 High Resolution

MS:

Calcd for C 32

H

37 0 8 553.2801, Found: 553.2796.

Part C Preparation of Methyl 3 Butoxy)carbonylamino)propyl)carbamoyl)propoxy)-2-(5-(5-oxo-1- S: 25 prop-2-enyl(2-6,7, 8trihydronaphthyloxy))pentyloxy)phenyl)propanoate H H 0 NBoc COOMe A solution of 4 2 2 -(methoxycarbon)thyl)ethyl)-3-(5-(5oxo-1-prop-2-enyl(2-6,7,8-trihydronaphthyloxy) pentyloxy)phenoxy)butanoic acid (110 mg, 0.191 mmol) in anhydrous DMF (3 mL) was preactivated by treatment with HBTU (79.7 mg, 0.21 mmol) for 5 min at ambient temperatures. A solution of N-(3aminopropyl)(tert-butoxy)formamnide (33.3 mg, 0.191 mmol) and DIEA (83 uL, 0.478 rmmol) in anhydrous DMF (1 mL) was added and stirring was continued at ambient temperatures for 15 min.

The DMF was removed by vacuum evaporation and the resulting yellow oil was taken up in a mixture of EtOAc (40 mL) and water (30 mL). The aqueous phase was adjusted to pH with 0.2 N HC1 and the layers were thoroughly mixed. The organic phase was washed consecutively with sat. NaHCO 3 (30 mL), and sat NaCl (2 x 30 mL), dried (MgSO 4 and concentrated to give the title compound as a pale yellow oil (129 mg,

MS:

m/e 709.4 Part D Preparation of 3 Butoxy)carbonylamino)propyl)carbamoyl)propoxy)-2-(5-(5-oxo-lprop-2-enyl(2-6,7,8trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid A mixture of methyl 3-(6-(3-(N-(3-((tert-butoxy)carbonylamino)propyl)carbamoyl)propoxy)-2-(5-(5-oxo-1-prop-2enyl(2-6,7,8-trihydronaphthyloxy) pentyloxy)phenyl)propanoate (105 mg, 0.148 mmol), and 3 M LiOH (0.72 mL) in THF (7.2 rML) was stirred at ambient temperatures for 4 days and concentrated to dryness under vacuum. Water (20 mL) was added to the oily residue and adjusted to pH 2.0 with 1.0 N HC1.

S 25 The cloudy solution was extracted with EtOAc (3 x 40 mL). The combined organic extracts were-washed with water (20 mt) and with sat. NaC1 (20 mL), dried (MgSO4), and concentrated to give the title compound as a colorless solid (93.5 mg, 91%).

:30 MS: m/e 693.4 Part E Preparation of sulfophenyl)vinyl)amino)(3-pyridyl))carbonylamino)propyl)carbamoyl)propoxy)-2-(5-(5-oxo-1-prop-2-enyl (2-6,7,8trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid A solution of 3-(6-(3-(N-(3-((tert-butoxy)carbonylamino)propyl)carbamoyl)propoxy)-2-(5-(5-oxo-1-prop-2-enyl(2-6,7,8trihydronaphthyloxy))pentyloxy)phenyl)propanoic acid (72 mg, 0.104 mmol) in'TFA (3 nL) was stirred at ambient temperatures for 70 mi and concentrated to a viscous oil under reduced pressure. This oil was dissolved in anhydrous DAF (0.7 mL) and treated with TEA until basic (58 uL, 0.415 mmol). This solution was treated with dioxopyrrolidinyl) carbonyl)(2-pyridyl))amino) vinyl)benzenesulfonic acid (55 mg, 0.125 mmol) and stirred at ambient temperatures for 16 h under a nitrogen atmosphere.

The solution was diluted with 80% ACN (0.7 nL) and purified directly by preparative HPLC on a Vydac C-18 column (22 x 250 mm using a 1.

8 O%/min gradient of 18 to 72% ACN containing 0.05 M NH 4 OAc at a flow rate of 15 iL/min.. The main product peak'eluting at 20.7 min was collected and lyophilized to give the title compound as a colorless powder (52 mg,

MS:

m/e896.4 tM-H]; High Resolution MS: Calcd for C47H 5 6

N

5 0 1 1

S

898.3697, Found: 898.3699.

Example Synthesis of (2 -sulfophenyl vinyl) amino) (3 -pyridyl) carbonylamino) ethoxy) ethoxy) ethoxy) ethoxy) ethoxy) ethoxy) ethoxy) ethyl) carbamoyl)- .:.ipropoxy)-2-(5-(5-xo-prop-n12-+yl( -6,7 8 trihydronaphthyloxy) )pentyloxy)phenyl) propanoic Acid 0 0 01

NN

0 07 COOH H03SN Part A Preparation of Methyl 3 2(2(2.( 2 tert-Butoxy) carbonylamino) ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl)carbamoyl)propoxy)-2-(5-(5-oxo-l-prop-2-enyl(2-6,7,8trihydronaphthyloxy) )pentyloxy) phenyl) propanoate 0

H

0- N N.

S4+Boc I .0 COOMe A solution of 4 2 -(2-(methoxycarbonyl)ethyl.-3-(5-(5oxo-l-prop-2-enyl 8-trihydronaphthyloxy) )pentyloxy)phenoxy)butanoic acid (80 mg, 0.139 mmol) in anhydrous-Dmy (1 ML) was treated with HBTU (58 mg, 0.152 nmol). After 5 min a solution of N-(2-(2-(2-(2-(2-(2-(2-(2-aminoetoxy) ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl)(tertbutoxy)formamide (71.2 mg, .0.152 nmol) and DIEA (60.5 uL, 0.348 mmol) in anhydrous DMF (2 mL) was added and the resulting solution was stirred at ambient temperatures under a nitrogen atmosphere for 15 min. The DMF was removed by vacuum evaporation and the resulting oil was dissolved in a mixture of EtOAc (40 nL) and water (30,mL). The aqueous layer was adjusted to pH 2.0 with 0.2 N HCl and the phases were thoroughly mixed. The organ ic phase was washed consecutively with at. NaHC0 3 (30 mL), and sat. NaCl (2 x 30 rL), dried (MgSo 4 and concentrated to give the title compound as a colorless oil (114 mg, MS: x/e 1020.7

[M+NH

4 3.

Part B: Preparation of (2 ((tert-Butoxy) carbonylamino) ethoxy) ethoxy) ethoxy) ethoxy)ethoxy) ethoxy)ethoxy)ethyl)carbamoyl)propoxy)-2-(5-(5-oxo-lprop-2-enyl(2-6,7,8-trihydronaphthyloxy) pentyloxy)phenyl)propanoic Acid 0 0

B

COOH

A mixture of methyl ((tert-butoxy)carbonylamino)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl)carbamoyl)propoxy)-2-(5-(5-oxo-1prop-2-enyl(2-6,7, 8 -trihydronaphthyloxy))pentyloxy)phenyl)propanoate (110 mg, 0.11 mmol) and 3 M LiOH (0.53 mL, 1.59 mmol) in THF (5.3 mL) was stirred at ambient temperatures under a nitrogen atmosphere for 3 days and concentrated to dryness under reduced pressure. Water (20 mL) was added to the mixture and adjusted to pH 2.0 using 1.0 N HC1. The mixture was extracted with EtOAc (3 x 40 mL). The combined organic extracts were washed with water (20 mL) and with sat. NaCl mL), dried (MgSO 4 and concentrated to give the title compound as a colorless oil (93 mg, MS: m/e 1006.7

[M+NH

4 Part C Preparation of (.(6-((1-Aza-2-(2-sulfophenyl)vinyl)amino) (3pyridyl)) carbonylamino) ethoxy) ethoxy) ethoxy) ethoxy) ethoxy)ethoxy)ethoxy)ethyl)carbamoyl)propoxy)-2- (5-oxo-1-prop-2- 20 enyl(2-6,7,8-trihydronaphthyloxy))pentyloxy)phenyl )propanoic Acid A solution of butoxy)carbonylamino)ethoxy)ethoxy) ethoxy)ethoxy) ethoxy)ethoxy)ethoxy)ethyl)carbamoyl)propoxy)-2-(5-(5-oxo-1-prop-2enyl(2-6,7, 8 -trihydronaphthyloxy))pentyloxy)phenyl)propanoic acid (83 mg, 0.084 mmol) in TFA (4 nML) was stirred at ambient temperatures under a nitrogen atmosphere for 60 min. The TFA was removed under reduced pressure to give an amber oil. This oil was dissolved in anhydrous DMF (0.7 mL) and treated with TEA until basic to pH paper (71 uL, 0.511 mmol). This solution was treated with 2 dioxopyrrolidinyl)carbonyl)(2-pyridyl))amino)vinyl)'benzenesulfonic acid (45 mg, 0.102 nmmol) and stirred at ambient temperatures for 19 h under a nitrogen atmosphere. The solution was diluted with 80% ACN (0.7 mL) and purified directly by preparative HPLC on a Vydac C-18 column (22 x 250 mm) using a 1.80%/min gradient of 18 to 72% ACN containing 0.05 M NH- 4 0Ac at a flow rate of 15 mL/min. Th .e main Product peak was collected and lyophilized to give the title compound as a colorless powder (64 mg, MS: m/e 1209.7

[M+NH

4 High Resolution MS: Calcd for.C6OH8 2 N501 8 S 1192.5376, Found: -1192.5394.

Example 36 Synthesis of sulfophenyl) vinyl) amino) (3-pyridyl) )carbonylamino)

(N-

5, 6-pentahydroxyhexcyl) carbamoyl) pentyl) carbamoyl*)propoxy-2- (5-oxo-1-prop-2-enyl(2-6,7, 8trihydronaphthyloxy) )pentyloxy) phenyl )propanoic Acid OH OH HO

OH

OH

NH

I

IH

N

00 0 HN 0

COCH

HO

3 S NN C. CPart A Preparation of Methyl Butoxy)carbonylamino)-5-(N-.(23,4,5..

pen tahydroxyhexyl) carbamoyl) pen tyl )carbamoyl) propoxy-2 'C oxo-1-prop-2-enyl(2-6,7,8..

trihydronaphthyloxy) )pentyloxy) phenyl )propanoate OH OH HO

OH

OH

NH

I I

H

0 N0 -0 NH. Bo A solution of 4-(2-(2-(methoxycarbonyl)ethyi)-3-(5-(5oxo-1-prop-2-enyl(2-6,7,8-trihydronaphthyloxy))pentyloxy)phenoxy)butanoic acid (55 mg, 0.096 mmol) in anhydrous DMF (0.8 mL) was treated with HBTU (43.5 mg, 0.115 mmol) and the solution was stirred at ambient temperatures for 5 min. To this solution was added a solution of 6-amino-2-((tertbutoxy)carbonylamino)-N-(2,3,4,5,6-pentahydroxyhexyl)hexanamide (47 mg, 0.115 mnmol) and DIEA (42 uL, 0.239 mmol) in anhydrous DMF (0.8 mL) and stirring was continued at ambient temperatures for 45 min. The solution was concentrated to of its original volume and diluted with 80% ACN (1.2 mL).

This solution was purified directly by preparative HPLC on a Vydac C-18 column (22 x 250 mm) using a 2.10%/min gradient of 27 to 90% ACN at a flow rate of 15 mL/min. The main product peak eluting at 22.1 min was collected and lyophilized to give the title compound as a colorless powder (70 mg, 1

H

NMR (CDC13): 7.98 J 8.8 Hz, 1H), 7.25 1H), 7.07 (t, J 8.4 Hz, 1H), 6.90 1H), 6.83 J 8.8 Hz, 1H), 6.47 J 8.4 Hz, 2H), 5.94-5.77 (mn, 2H), 4.98-4.84 (mn, 2H), 4.40-3.10 27H), 3.05-2.81 4H), 2.61-2.36(m, 6H), 2.16- 1.98 4H), 1.94-1.25 (mn, 21H); MS: m/e 961.6 [M+NH 4 High Resolution MS: Calcd for C 49

H

74

N

3 0 1 5 [M+HJ: 944.5120, Found: 944.5117.

Part B Preparation of 3 sulfo (2,3,4,5,6-pentahydroxyhexyl)carbanoyl)pentyl)carbamoyl) propoxy-2-(5-(5-oxo-1-prop-2-enyl(2-6,7,8trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid A mixture of methyl 3-(6-(3-N-(5-((tert-butoxy)carbonylamino)-5-(N-(2,3,4,5,6-pentahydroxyhexyl)carbamoyl)pentyl)carbamoyl)propoxy-2-(5-(5-oxo-l-prop-2-enyl(2-6,7,8trihydronaphthyloxy))pentyloxy)phenyl)propanoate (55 mg, 0.058 mmol) and 3 M LiOH (280 uL) in THF (2.8 mL) was stirred at ambient temperatures for 2.5 h and concentrated to dryness under reduced pressure. The presence of the expected hydrolysis product was confirmed by low resolution mass spectroscopy. MS: m/e 928.5 fM-H].

The solid resulting from the above hydrolysis was cooled to 0 OC, dissolved in TFA (5 mL), and stirred at ambient temperatures 25 min. The TFA was removed under reduced pressure and the resulting amber oil was used directly in the next reaction.

The oil was dissolved in anhydrous DMF (0.75-mL) and made basic to pH paper with TEA (49 uL, 0.35 mmol). The solution was treated with 2 -(2-aza-2-((5-((2,5-dioxopyrrolidinyl)carbonyl)(2-pyridyl))amino)vinyl)benzenesulfonic acid (31 mg, 0.070 mmol) and stirred at ambient temperatures for 22. h. The solution was diluted with 80% ACN (0.75 mL) and purified directly by preparative HPLC on a Vydac C-18 column (22 x 250 mm) using a 1.80%/min gradient.of 18 to 72% ACN containing 0.05 M NH 4 0Ac at a flow rate of 15 mL/min. The main product peak eluting at 18.7 min was collected and lyophilized to give the title compound as a pale yellow powder (31.5 mg, 47.7%).

MS: m/e 1131.7 High Resolution MS: Calcd for 20 C 56

H

73

N

6 0 17 S fM+H): 1133.4753, Found: 1133.4722.

Example 37 Synthesis of 3 6 3 sulfophenyl) vinyl) amino) (3-pyridyl) carbonylamino)-5- (5-oxo-l-prop-2-enyl(2-6,7,8trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid

O

H -Cyclodextrin

H

0- 0 0 O HN O

COOH

HO N N3NH Part A Pr;eparation of Methyl 3 i--N(((rt Butoxy) carbonylanino) (6-deoxy-3cyclodextryl) carbainoyl pentyl) carbamoyl) propoxy-2 (5 (S -oxo-iprop-2-enyl trihydronaphthyloxW) )pentyloxy)phenyl)propanoate 0 HN- Cyclcodextrn 0K 0 COOMe Asolution of 4 2 2 -(methoxycarbonyl)ethyl)>..(5.( 5

S

oxo-l-prop-2-enyl 8-trihydronaphthyloxy))etlx phenoxy)butanoic. acid (21.3 mg, 0.0386 xmol) in anhydrous

DM.'F

0 mL).was preactivated by treatment with HBTU (14.6 mg, 0.0386 mmol) and TEA (80 uL, 0. 579 inmol) for 5 min at ambient temperatures. A solution of 6-amino-2-'((tertbutoxy) carbonylamino) -(6-deoxy-Jo-cyclodextryl )hexanamide (52.5 mg, 0.0386 inmol) in DMF (1.5 niL) was added and stirring was continued ofr 17 h at amrbient temperatures under a nitrogen atmosphere. The DMF was removed by vacuum evaporation and the resulting colorless solid. (90 mg) was dissolved in a combination of 80% ACN (800 UlL), MeOH (200 uL),, and DMF (300 This solution was purified by preparative HPLC on a Vydac C-18 column (22 x 250 mm) using a 1.80%/min gradient of 18 to 72% ACN at a flow rate of 15 mL/min. The main product peak eluting at 24.2 min was collected and lyophilized to give the title compound as a colorless powder (28.2 mg, MS: 1897.0 [M-iH].

Part B Preparation of sulfophenyl)vinyl) amino) (3-pyridyl) )carbonylamino) (6deoxy-J-cyclodextryl) carbamoyl) pentyl) carbamoyl )propoxy-2- (5-oxo-1-prop-2-enyl(2-6,7, 8trihydronaphthyloxy) )pentyloxy) phenyl )propanoic Acid A mixture of methyl 3- (tert-butoxy) carbonylamino)-5-(N-(6-deoxy-f-cyclodextryl)carbamoyl)pentyl)carbamoyl)propoxy-2-(5-(5-oxo--prop-2-enyl(2-6,7,8trihydronaphthyloxy))pentyloxy)phenyl)propanoate (28.2 mg, 0.0149 mmol) and 3 N LiOH (138 uL, 0.416 mmol) in THF was stirred at ambient temperatures under nitrogen for 4.5 h. The solution was concentrated and the colorless solid was dissolved in TFA (3 mL), and stirred at ambient temperatures under nitrogen for 1.5 h. The TFA was removed to give 3-(6- (3-N-(5-amino-5-(N-(6-deoxy-1-cyclodextryl)carbamoyl)pentyl)carbamoyl)propoxy-2-(5-(5-oxo-1-prop-2-enyl(2-6,7,8trihydronaphthyloxy) pentyloxy)phenyl)propanoic.acid as a pink oil (35.4 mg).

The above oil was dissolved in anhydrous DMF (500 uL), made basic to pH paper with TEA (130 uL), and treated with 2- 2 ,5-dioxopyrrolidinyl)carbonyl)(2-pyridyl))amino)vinyl)benzenesulfonic acid (20.1 mg, 0.0444 mmol). This solution was stirred under nitrogen at ambient temperatures for 7 days. The sample was concentrated under reduced pressure, the oily residue was dissolved in 50% ACN (1.5 mL), and purified by preparative HPLC on a Vydac C-18 column (22 x 250 mm) using a 1.50%/min gradient of 18 to 63% ACN containing 0.05 M NH 4 0Ac at a flow rate of 15 mL/min. The main product peak eluting at 18.4 min was collected and lyophilized to give 25 the title compound as a colorless powder (1.0 mg, MS: 1041.7 [M-2H].

Example 38 Synthesis of 3 6 sulfophenyl vinyl)amino)(3-pyridyl) -Gly-Lys-Lys- Lys)aminopropyl)carbamoyl propoxy)-2- (5-(5-oxo-l-prop-2enyl(2-6,7,8-trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid

NH

2 NH 2 0 H H 0 0 O O N N N N N o o H o

COOH.

HOWS

N

NH

2

H

Part A: Preparation of Boc-Gly-Lys(Dde)-Lys(Dde)-Lys(Dde)-OH To a 250.ml peptide reaction vessel was added

HMPB-BHA

resin (9.0 g, substitution level 0.86 mmol/g). The resin was pre-washed with anhydrous DMF (3 x 100 ml). The resin was suspended in DMF (60 mL), treated with Fmoc-Lys(Dde)-OH (8.25 g, 15.5 mmol), and after gentle mixing for 15 min was treated 10 with anhydrous pyridine (2.1 mL, 25.5 mmol) and 2,6dichlorobenzoyl chloride (2.36 mL, 15.5 mmol). The mixture 0" was gently shaken at ambient temperatures for 22 h and the resin was washed thoroughly with 180 mL portions of DMF (3X), MeOH DCM MeOH and DCM The 15 substitution level was determined to be 0.73 mmol/g by the fulvene-piperidine adduct test. Unreacted hydroxyl groups were blocked by treatment with benzoyl chloride (3 mL) and %0 pyridine (3 mL) in DCM for 2 hours, and the resin was washed with 180 mL portions of DCM MeOH DCM MeOH and DCM (3X).

The following steps were then performed: (Step 1) The S resin was washed with 70 ml portions of DMF (Step 2) The resin was washed with 80 mL of 20% piperidine in DMF, and the Fmoc group was removed using 80 ml of 20% piperidine in DCM for 30 minutes. (Step 3) The resin was washed thoroughly with 180 mL portions of DCM MeOH DCM MeOH and DMF (Step 4) Fmoc-Lys(Dde)-OH (8.0 g, mmol), HATU (5.7 g, 15 mmol), DIEA (5.0 ml, 28 mmol), and DMF ml) were added to the resin and the reaction was allowed to proceed for 18 hours. (Step 5) The completeness of the coupling reaction was monitored by the ninhydrin test. Steps were repeated until the desired sequence had beerr attained. The resin was washed thoroughly with 180 mL portions of DCM MeOH DCM MeOH and DCM and dried under reduced pressure to give 15.1 g of tan solid.

The fully protected linear peptide was cleaved from the resin using 1% TFA. Peptide-resin (3.0 g) was placed in a sintered glass funnel and washed with DCM (30 mL) to swell the resin. The resin was treated with 1% TFA in DCM (20 mL) for 2 min and filtered directly into 10% pyridine in MeOH (4 mL).

This procedure was repeated until all of the desired peptide had been cleaved from the resin. Filtrates were monitored by TLC (silica gel, CHC1 3 :MeOH, 10:1) with product peptide having an Rf 0.75. Fractions containing product were combined and concentrated to give a thick oil. Trituration with ether (3 x S 100 mL) gave an orange solid (1.5 Purification was Saccomplished using reversed-phase HPLC on a Vydac C-18 column 0 (22 x 250 mm) using a 2.10%/min gradient of 18 to 81% ACN at a 20 flow rate of 15 mL/min. The main product peak eluting at 22.7 min was collected and lyophilized to give the title compound as a colorless solid (350 mg, MS: m/e 1069.6 [M+NH 4 Part B: Preparation of Methyl 25 Butoxycarbonyl-Gly-Lys(Dde)-Lys(Dde)- Lys(Dde))aminopropyl)carbamoyl)propoxy)-2- (5-oxo--prop-2enyl(2-6,7,8-trihydronaphthyloxy))pentyloxy)phenyl)propanoate Ode, Dde, H NH NH H H 0

H

O 0 H 0 COOMe DdeNH 144 Methyl (tert-butoxy)carbonylamino)-.

(S-oxo-1-prop-2-enyl(2-6,7,8trihydronaphthyloxy))pentyloxy)phenyl)propanoate (100 mg, 0.141 mmol) was dissolved in TFA (2 mL) and stirred at ambient temperatures for 20 min. The TFA was removed under reduced pressure to give a pale yellow oil. This oil was dissolved in anhydrous DMF (1.5 mL) and preactivated by the addition of HBTU (58.8 mg, 0.155mmol). After 5 min the solution was treated with a solution of Boc-Gly-Lys(Dde)-Lys(Dde)-Lys(Dde)- OH (148 mg, 0..141 mmol) and DIEA (147 uL, 0.89 mmol) in DMF mL). After 10 min at ambient temperatures the DMF was removed and the pale yellow oil was dissolved in a mixture of EtOAc (50 mL) and water 40 mL). The aqueous layer was adjusted to pH 2.0 using 0.2 N HC1 and the layers were thoroughly mixed. The. organic phase* was washed with consecutively with sat,. NaHCO 3 (5 mL) and sat. NaCl (2 x 4 mL), dried (MgSO 4 and concentrated to give colorless solid (155.mg). This solid was purified by preparative HPLC on a Vydac C-18 column (22 x 250 mm) using a 1.80%/min gradient of 20 36 to 90% ACN at a flow rate of 15 mL/min. The main product peak eluting at 27.3 min was collected and lyophilized to give the title compound as a colorless solid. 1 H NMR (CDC13): S13.40-13.17 3H), 7.97 J 8.8 Hz, 1H), 7.82 1H), 7.55 J 8.3 Hz, 1H), 7.04 J 8.3 Hz, 1H), 6.97 (s, 1H), 6.90-6.70 2H), 6.47 J 8.3 Hz, 2H), 6.00-5.75 2H), 4.95-4.80 (m 2H), 4.29 3H), 4.15-3.90 6H), 3.90- 3.59 5H), 3.55-3.10 11H), 3.10-2.75 4H), 2.75-2.20 29H), 2.20-1.25 39H), 1.25-0.90 18H); MS: m/e 1660.9 [M+NH 4 High Resolution MS: Calcd for C 90

H

1 3 2

N

9 0 1 9 30 1642.9640, Found: 1642.9602; Part C: Preparation of sulfophenyl)vinyl)amino)(3-pyridyl))-Gly-Lys-Lys- Lys)aminopropyl)carbamoyl)propoxy)-2-(5-(5-oxo-1-prop-2enyl(2-6,7,8-trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid Methyl 3- (tert-butoxycarbonyl-Gly-Lys(Dde) Lys (Dde) -Lys (Dde))aminopropyl)carbamoyl)propoxy) 5 1-prop-2-enyl (2-6,7, 8 -trihydronaphthyloxy))pentyloxy)phenyl)propanoate (37 mg, 0.0225 mmol) was dissolved in TFA (3 mL) and stirred at ambient temperatures for 15 min. The TFA was removed under vacuum and the oily residue was taken up in anydrous DMF (0.5 mL) and made basic to pH paper with TEA (19 uL, 0.135 mmol). The solution was treated with 2 2 -aza-2- 5-dioxopyrrolidinyl) carbonyl) (2-pyridyl) )amino)vinyl)benzenesulfonic acid (10.9 mg, 0.025 mmol) and stirred at ambient temperatures for 20 h. The DMF was removed under vacuum. The residue was taken up in 3 M LiOH (110 uL) and THF (1.1 mL) and the mixture was stirred at ambient temperatures for 21 h. The THF was removed by vacuum evaporation, the mixture was dissolved in 50% ACN (1.0 mL) and adjusted to pH with acetic acid. The solution was purified by preparative HPLC on a Vydac C-18. column (22 x 250 mm) using a 1l.80%/min gradient of 18 to 72% ACN containing 0.05 M NH 4 0Ac at a flow rate of 15 mL/min. The main product peak eluting at 18.6 min was collected and lyophilized to give the title compound as a colorless powder (10 mg, MS: m/e 1339.6 Example 39 Synthesis of 2 -Sulfobenzaldehyde Hydrazinonicotinamido)propyl]-3-1[6- dichlorophenyl)thio]methyll-3-(2-phenylethoxy)-2-pyridinyll-2propenamide Hydrazone *7*7 ,N N 0

SO

3 H

N

NOY

0 0 Part A Synthesis of (E)-N-[N-(tert-Butyloxycarbonyl)-3aminopropyl] -3-[6-[[(2,6-dichlorophenyl)thio]lmethyl] phenylethoxy)-2-pyridinyl] -2-propenamide To a solution of S dichiorophenyl) thio]methyl] -3 -(2-phenylethoxy) 2 -pyridinyl]-2propenoic acid (702 mg, 1.52 mmol), tert-butyl N-(3amnopropyl)carbamate (341 mg, 1.96 nmol), and TBTU (596 mg, 1.86 nimol) in DMF (10 ml) was added diisopropylethylamine ml, 11.48-mmol). The reaction mixture was allowed to stir at room temperature for 3 hours, was concentrated, diluted with EtOAc, washed with water, saturated NaHCO, brine, dried (Na 2

SO

4 and concentrated. The residue was purified by column chromatography (silica'gel) using.3:1 EtOAc/CH 2 Cl 2 Recovered the title compound (805 mg, 86%) as a 15 dried white foam. 1 H NMR (D 6 -DMSO) 8.18 (br t, NH), 7.63 (d, 7.51 2Ar-H),. 7.45-7.10 8 Ar-H), 6.85

NH),

*6.79 4.23 0H 2 4.15 CH 2 3.16 CH 2

N),

3.07,(t,

CH

2 Ph), 2.95 CH1N) 1.57 (quintet,

CH

2 1.38 (s, t-Bu); ES-MS: 616.-2;.FAB-HRS: 616.1815 20 (Calcd for C3 1

H

3 6 C1 2

N

3

O

4 S 616.1804) Part B Synthesis of 2 -Sulfobenzaldehyde H ydrazihoniotinamido)upropyl] dichlorophenyl) thiolmethyl] (2-phenylethoxy) -2-pyridinyl] -2propenamide Hydrazone To a solution of (E)-N-[N-(tert-Butyloxycarbonyl) -3 aminopropyl] -3-[6-[[(2,6-dichiorophenyl) thiolmethyl]-3-(2phenylethoxy)-2-pyridinyl]- 2 -propenamide (502 mg, 0.81 mmol) in CH 2 Cl 2 (8 ml) was added TFA (4 ml, 51.92 imol). The reaction mixture was allowed to stir at RT overnight, then was concentrated, diluted with CH 2 C1 2 concentrated, and dried under high-vacuum for 3 hours.

The crude residue and .succinimidyl 2-sulfobenzaldehyde 6hydrazinonicotinate hydrazone (410 mg, 0.93 mmol) was dissolved in DMF (5 ml), followed by the addition of Et 3 N (1 ml, 7.18 mmol). The reaction mixture was allowed to stir at room temperature for 24 hours, and was concentrated to provide a dark oil. Purification of a portion of the crude product was accomplished by reversed-phase HPLC on a preparative Vydac C18 column (2.5 X 25 cm) using a gradient of 40 to 100% of solution B (90% acetonitrile 10% 0.05 M NH40Ac) over minutes, and solution A (100% 0.05 M NH40Ac) to give the title compound (306 mg) as a pale yellow powder. Proton NMR spectral data indicated the presence of some triethylammonium salts, therefore, a second preparative HPLC under identical conditions was run to provide the title compound (126 mg) as a pale yellow powder. 1 H NMR (DE-DMSO) 11.75 (br s, OH), 9.15 br 8.58 1H), 8.50 (br s, 1H), 8.27 1H), 8.15 2H), 7.80 1H), 7.64 7.55-7.00 6.90 1H), 6.81 4.23 CH20), 4.15 CH 2 3.31 2CH 2 3.07 CH 2 Ph), 1.74 (quintet,

CH

2 ES-MS: [M- .20 HI- 817.2; FAB-HRMS: 819.1577 (Calcd for C39H 37

C

2

N

6 06S 2 819.1593).

Example Synthesis of 2 -Sulfobenzaldehyde Hydrazinonicotinamido)propyl] -3-[6-[(phenylthio)methyl] phenylethoxy)-2-pyridinyl]-2-propenamide Hydrazone

H

N N

*SO

3 H NN

N

Part A Synthesis of (E)-N-[N-(tert-Butyloxycarbonyl)-3aminopropyl -3-[6-[(phenylthio)methyl]-3-(2-phenylethoxy)-2pyridinyl l -2-propenamide The title compound was prepared by the general procedure described above for (E)-N-[N-(tert-Butyloxycarbonyl)-3aminopropyl]-3-[6-[[(2,6-dichlorophenyl)hiolmethy -3(2phenylethoxy) -2-pyridinyl] -2-propenamide, substituting -3- [6-f(phenylthio)methyl -3-(2-phenylethoxy)-2-pyridinyl]-2propenoic acid. Recovered the titlecompound (773 mg, 98%) as a pale yellow solid which was used without further purification. 1 H NMR (D 6 -DMSO) 8.30 (br 7.71 (d, 7.48 Ar-H), 7 .40-7.10'(m, 11 Ar-H), 7.03 =CH), 6.80 NH), 4.28 CH 2 4.-25 CH 2 3.17 CH 2

N),

3.08 .CH 2 Ph), 2.96 CH 2 1.57 (quintet, CH 2 1.38 (s, ES-MS: 548.3.

Part B Synthesis of 2-Sulfobenzaldehyde Hydrazinonicotinamido)propyl -3-(6-f(phenylthio)methyl] (2phenylethoxy) -2-pyridinyl] -2-propenamide Hydrazone The title compound was prepared by the general procedure described above for 2-Sulfobenzaldehyde Hydrazinonicotinamide)propyl]-3-[.6-[ dichlorophenyl) thio]methyl -3-(2-phenylethoxy)-2-pyridinyl]-2propenaiide Hydrazone, substituting [N-(tert- 25 Butyloxycarbonyl) -3 -aminopropyl]-3 (phenylthio) methyl] -3- 2 -phenylethoxy)-2-pyridinylj-2-propenamide. Purification of a portion of the crude product was accomplished by reversedphase HPLC on a preparative Vydac C18 column (2.5 X 25 cm) using a gradient of 40 to 100% of solution B (90% acetonitrile 10% 0.05 M NH4Az) over 30 minutes, and solution A (100% 0.05 M NH4OAc) to give the title compound as a pale yellow powder. 1 H NMR (DE-DMSO) 11.75 (br s, OH), 9.11 br s, NH), 8.63 1H), 8.50 (br s, 1H), 8.39 1H), 8.12 2H), 7.81 1H), 7.74 7.50-7.00 18H), 6.91 1H), 4.28 CH- 2 .4.25. CH 2 3.34 2CH 2 N) 3.08

CH

2 Ph), 1.75 (quintet,

CH

2 ES-MS: 751.4; FAB-FfRMS: 751.2357 (Calcd for C 39

H

39

N

6 0 6

S

2 751.2372).

Example 41 Synthesis of 2 -Sulfobenzaldehyde Hydrazinonicotinamido)propyl) chiorophenyl) thiolmethyl] -3-(2-phenylethoxy) 2 -pyridinyij -2propenainide Hydrazone N 0 a SO 3 H NN N )NS' 0 0 Part A Synthesis of (tert-Butyloxycarbonyl) -3axinopropyil-3-[6-[ 2 -chlorophenyl)thiolmethyl-3-(2- -2-pyridinyl] -2-propenamide H H 00 The title compound was prepared by the general procedure described above for (E)-N-(N-(tert-Butyloxycarbonyl)..>.

aminopropyl] 6-dichlorophenyl) thiolmethyl] (2phenylethoxy) -2-pyridinyl] -2-propenamide, substituting -3- (6-E[C(2-chiorophen yl) thiolinethyl] (2-phenylethoxy) -2pyridinyll-2-propenoic acid. Recovered the title compound (847 mng, 97%) as a dried pale reddish foam which was used without further purification. 1H NMR (D 6 -DMSO) 8.31 7.72 7.55-7.40 (mn, 4Ar-H), 7.40-7.10 (in, 7 Ar-H), 7.04 6.85 NH), 4.33 01 2 4.26 CH 2 3.17

CH

2 3.09 CH 2 Ph), 2.96 (mn, CH2N), 1.57 (quintet,

CH

2 1.38 t-Bu); ES-MS: 582.3.

Part B Synthesis of 2-Sulfobenzaldehyde Hydrazinonicotinamido)propylI-3- chiorophenyl) thiolmethyl] (2-phenylethoxy) -2-pyridinyi 2propenaxnide Hydrazone The title compound was prepared by the general procedure described above for 2 -Sulfobenzaldehyde (6- Hydrazinonicotinamide)propyll] dichlorophenyl) thiolmethyl] (2-phnltoy 2 prdnl -2propenamide Hydrazone, substituting (tert- Butyloxycarbonyl) -3 -aminopropyl 1-3 6- chlorophenyl) thio] methyl] (2-phenylethoxy) -2 -pyridinyl 1-2propenamide. Purification of a portio .n of-the'crude product was accomplished by reversed-phase HPLC on a preparative Vydac C18 column (2.5 X 25 cm) using a gradient of 40 to 100% of.

solution B (90%,acetonitrile -1 10% 0.05 M NH4OA c) over minutes, and solution A (100% 0.05-M NH4OAc) to give the title compound as a p ale-yellow powder.' 1 H .NMR (D6E-DMSO).*. 1. 75 (b r s, OH), 9.13 br s, NH), '8.61 1H), -8.50 (br s, 1Hi), 8.40 8.13 (in, 2H), 7.81 1H), .7.75 =CH).I 7-.55-*7.00.

18H), 6.90 1H), 4.33

CH

2 4.26

CH

2 3.28 (n,'2-CH 2 3.08

CH

2 Ph), 1.75 (quintet,

CH

2

ES-MS:

785.3; FAB-HRMS: [M+HJ+ =.785.2013 (Calcd for C39H 38 C1N 6 0 6

S

2 =785.1983).

.Example 42 Synthesis of 2 -Sulfobenzaldehydle Hydrazinonicotinamido)propyl] diinethylphenyl) thiol methyl 1-3- (2-phenylethoxy) -2-pyridinyl] -2propenamide Hydrazone Part A Synthesis of (E)-N-[N-(tert7Butyloxycarbony aminopropyl 6-dimethylphenyl) thiolImethyl I (2phenylethoxy)-2-pyridinyl 2 -propenamide 0 P e~ Boe N N N 0MX The title compound was prepared by the general procedure described above for (E)-N-[N-(tert-Butyloxycarbonyl)-3aminopropyl 1-3 6.-dichiorophenyl) thio] methyl] (2phenylethoxy) -2-pyridinyl] 2 -propenanide, substituting 6-dimethyiphenyl) thioImethyl] (2-phenylethoxy) -2pyridinylj-2-propenoic acid. Recovered the title compound (847 mg, 97%) as a dried pale reddish foam which was used Without further purification. 1 H NMR (D6-DMSO) 8.25 (br t, NH), 7.69 15 7.40-7.15 6Ar-H), 7.15-7.00 3Ar-H), 6.95 (d, 6.88 Ar-H), 6.80 NH), 4.21

CH

2 3.89 (s,

CH

2 3.17

CH

2 3.07

CH

2 Ph), 2.96

CH

2 2.32 2Me), 1.57 (quintet,

CH

2 1.38 t-Bu);*ES-MS:

[M+H]

576.4.

Part B Synthesis of 2 -Sulfobenzaldehyde Hydrazinonicotinamido)propy] dimethyiphenyl) thiolmethyl] (2-phenylethoxy) -2-pyridinyl] -2propenamide Hydrazone The title compound was prepare by the general procedure described above for 2-Sulfobenzaldehyde Hydrazinonicotinamide)propy l dichlorophenyl)thiolmethyl]-3-(2-phenylethoxy)-2-pyridinyl]-2propenamide Hydrazone, substituting Butyloxycarbonyl)-3-aiinopropyl]-3-[6-[[(2,6dimethyiphenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2propenamide. Purification of a portion of the crude product was accomplished by reversed-phase HPLC on a preparative Vydac C18 column (2.5 X 25 cm) using a gradient of 40 to 100% of solution B (90% acetonitrile 10% 0 05 M4 NH4OAc) over minutes, and solution A -(160% *0.0 5 M NH4OAc) to give the title compound as a pale yellow powder. 1 H NMR (D6-DMSO) 11.75 (br S, OH), 9.12 br s, NH), 8.63 1H), 8.50 (br s, 1H), 8.36 1H), 8.13 (mn, 2H), 7.82 1H), 7.71 7.40-7.15 (mn, lOH), 7.15-6.85 (mn, 7H), 4.22

CH

2 3.89

CH{

2

S),

3.32 (in, 2CH 2 3.07

CH

2 Ph), 2.32 2CH 3 1.75 (quintet,

CH

2 ES-MS: 779.4; FAB-HRMS; 779.2691 (Calcd for C41H 4 3

N

6 0 6 5 2 =779.2686).

Example 43 Synthesis, of 2 -Sulfobenzaldehyde (6- Hydrazinonicotinaido)propylj tetrafluorophenyl) thiolmethyl 3- (2-phenylethoxy) -2 pyridinyl] 2 -propenamide Hydrazone :N 0~ *N N N

F

S

3 H

NNN

.0 0I

F

F

Part A Synthesis of (E)-N-[N-(tert-Butyloxcarbonyl)3aininopropyl] 6 -tetrafluorophenyl)thiolmethyl] (2 -phenylethoxy) -2 -pyridinyl] -2-propenamide H F **Boek NNN NN

F)

The title compound was prepared by the general procedure described above for (tert-Butyloxycarbonyl) -3aminopropyl] 6-dichiorophenyl) thiolmethyl] (2phenylethoxy) -2-pyridinyl] 2 -propenamide, substituting -3- 6 -tetrafluorophenyl) thiolmethyl] (2phenylethoxy) -yidinyl] -2 -propenoic acid.'.Recovered the title compound '(865 mg,* 98%) .as a dried .pale yellow foam which was used without further purification. 1 H NMR (D6-DMSO) 8.22 (br t, NH), 7.89 (in, Ar-H), 7.63 7.48 Ar-H), 7.35-7.20 (mn, 6Ar-H), 6.83 6.80 (in, NH), 4.26 (t,

CH

2 4.19

CH

2 3.16

CH

2 3.08

CH

2 Ph), 2.96 (mn, CH 2 1.57 (quintet,

CH

2 1.38 t-Bu); ES-MS: -620.3.

Part B Synthesis of 2 -Sulfobenzaldehyde Hydrazinonicotinamido)propylj [6-[11(2,3,5,6tetrafluorophenyl) thiolmethyl] (2-phenylethoxy) -2pyridinyl] -2 -propenaznide Hydrazone The. title compound was prepared by the general procedure described above for 2 -Sulfobenzaldehyde (6- Hydrazinonicotinamide)propyl3[6..( (2o6dichlorophenyl) thiolmethyl] (2-phenylethoxy) -2-pyridinyl] -2propenaxnide Hydrazone, substituting (E)-N-(N-(tert- Butyloxcarbonyl).3-ainopropyl.3..[6[[ (2,3,5,6tetrafluorophenyl) thiolmethyl] (2-phenylethoxy) pyridinyl]-2-propenamide. Purification of a portion of the crude product was accomplished by reversed-phase HPLC on a preparative Vydac C18 column (2.5 X 25 cm) using a gradient of 40 to 100% of solution B (90% acetonitrile 10%. 0.05 M NH4OAc) over 30 minutes, and solution A (100% 0.05 M NH4OAc) to give the title compound as a pale yellow powder. 1 H NMR (D6-DMSO) 11.75 (br s, OH), 9.11 br s, NH), 8.63 1H), 8.52 (br s, 1H), 8.32 1H), 8.12 (in, 2H), 7.90 (in, 2H), 7.65 7.50-7.15 (in, 1111), 7.10 1H), 6.90 1H), 6.87 4.25

CH

2 4.19

CH

2 3.34 (in, 2CH 2 3.08

CH

2 Ph), 1.75 (quintet,

CH

2 ES-MS: [M+HIl 823.4; FAB-HR4S: [M+H]1 823.2014 (Calcd for C39H 3 5

F

4

N

6 0 6

S

2 823.1996).

Example 44 Synthesis of 2-Sulfobenzaldehyae (6- Hydrazinonicotinamido)propyl] [6-[11(4h.Ydroxyphenyl) thiol methyl] 2 -phenylethoxy) 2 -pyridiny1l propenamide Hydraz one

H

NN N Ow.o H

H

a SO 3 H

N~

Part A Synthesis of (tert-Butyloxycarbony'l) -3aminopropyl]-3-(6-[ 4 -hydroxyphenyl) thiojmethyl]..3- (2phenylethoxy) -2 -pyridinyl] -2 -propenamide H

H

BocN

N

0 The title compound was prepared by the general procedure described above 'for (E)-N-[N-(tert-Butyloxycar,oyl)3..

aminopropyl]-3-.[6,-[ 2 ,6-dichloropheny,)thiomethyl.3(2-.

phenylethoxy) -2-rpyridinyl] -2-propenamide, substituting

-N-

(tert-Butyloxycarbonyl) -3-aminopropyl) hydroxypheny.) thio] methyl] (phnltoy--pyridinyl]-2propenaniide. Recovered the title comon .(675 mg,9%)aa dried pale reddish foam which was used without further purification. 1H NMR -(D 6 -DMSO) 9.55 OH), 8.28 (br t, NH), 7.71 7.44 Ar-H), 7.35-7.10 (in, 8Ar-H), 7.00 (d, too.. 6.82 NH), 6.68 Ar-H), 4.25

CH

2 4.08 (s,

CH

2 S) 3.17

CH

2 N) 3.08

CH

2 Ph) 2.96

CH

2 N) 1.56 (quintet,

CH

2 1.38 t-Bu); ES-MS: 564.4.

Part B Synthesis of 2 -Sulfobenzaldehyde Hydirazinonicotinamido)propyl] hydroxyphenyl) thiol methyl] (2 -phenylethoxy) -2-pyridinyl] -2propenainide Hydrazone The. title compound was prepared by the general procedure described above -for 2 -Sulfobenzalehyde Hydrazinonicotinamide)propyl]-3-[6-[[(2,6dichiorophenyl) thiolmethyl] -3-(2-phenylethoxy) 2 -pyridinyl-2propenanide Hydrazone, substituting (E)-N-[N-(tert- Butyloxycarbonyl)- 3 -aminopropyl]-3-f6-[[(4hydroxyphenyl) thio] methyl] -3-(2-phenylethoxy) -2-pyridinyl]-2propenaide. Purification of a portion of the crude product was accomplished by reversed-phase HPLC on a preparative Vydac C18 column (2.5 X 25 cm) using a gradient of 40 to 100% of solution B (90% acetonitrile 10% 0.05 M NH4OAc) over minutes, and solution A (100% 0.05 M NH4OAc) to give the title.

compound as a pale yellow powder. 1 H NMR (D6-DMSO) 11.75 (br s, OH), 9.57 C br s, OH), 9.13 br s, NH), 8.64 11), 8.50 Cbr s, 1H), 8.38 iH), 8.14 Cm, 2H), 7.82 1H), 7.73 (d, 7.45-6.90 Cm, 15H), 6.70 2H), 4.24 Ct, CH 2 4.07

CH

2 3.35 Cm, 2CH 2 3.08 Ct, CH 2 Ph), 1.75 Cquintet,

CH

2 ES-MS:(M+H]+ 767.3; FAB-HRMS: 767.2335 C: CCalcd for C39H 3 9

N

6 0 7

S

2 767.2322) Example Synthesis of 2 -Sulfobenzalaehyde CE)-N-[2-C6- Hydrazinonicotinamido)ethyl] dichlorophenyl) thio]methyl] -3-C2-phenylethbxy) 2 -pyridinyl] -2propananide Hydrazone *3H

C.

N

N

HH

Part A Synthesis of ()-N-N-(tert-ButyloxycarbonylY 2aminoethyl -dichlorophenyl) thio] methyl] phenylethoxy)-2-pyridinyll-2-propanamide Boc,, The title compound was prepared by the general procedure described above for (tert-Butyloxycarbonyl) aminopropyl] 6-dichiorophenyl) thiolmethyl] phenylethoxy) -2-pyridinyl 1-2 -propenamide, substituting CE) -N- (tert-Butyloxycarbonyl) -3-aminopropyl] 6dichloropheny.) thiolmethyl] (2-phenylethoxy) -2-pyridinyll -2propananiide and tert-butyl N-(3-axninoethyl)carbaate and was used without further purification. ES.-MS: [M+Hl+ 604.2.

Part B Synthesis of 2 -Sulfkobenzaldehyde Hydlrazinonicotinamido)ethyl.3-6.. dichiorophenyl) thio I methyl]1 -3 (2-phenylethoxy) -2 -pyridinyl) -2 *15 propanamide Hydrazone The title compound was prepare by the general procedure described above for 2 -Sulfobenzaldehyde. HYdrazinonicotinam'ide).propyl] dichlorophenyl) thiolmethyl] (2-phenylethoxy) -2-pyridinyl] -2propenamide Hydrazone, substituting e 0 Butyloxycarbonyl) -2-aminoethyj 2,6dichlorophenyl) thiolmethyl] (2-phenyleth6xy) -2-pyridinyl] -2propananide. Purification of a portion of the crude'product was accomplished by reversed-phase HPLC on a preparative Vydac C18 column (2.5 X 25 cm) using a gradient of 40 to 100% of solution B (90% acetonitrile 10% 0.05 M4 NH4OAc) over minutes, and solution A (100% 0.05 M NH4QAc) to give the title compound as a pale yellow powder. 1 H NNR (D6-DMSO) 11.75 (br s, OH), 9.01 br s, NH), 8.61.Cs, 1H), 8.40 Ct, 1H), 8.03 (t, 2H), 7.92 1H), 7.77 1H), 7.48 2H), 7.40-7.10 (in, 11H), 6.94 1H), 4.15 Ct, CH 2 4.08 Cs, CH 2 3.29 (m, 2CH 2 3.17

CH

2 Ph), 3.02 (in, CH 2 Ar), 2.26 Cm, CH 2 CO); ES- S4: 80.7..2; FAB-HR4S: [M.+HJl 807.169(ac o -C38H 3 7 Cl 2

N

6 0 6

S

2 =807.1593).

Example 46 Synthesis of 2 -Sulfobenzaldehyde Hydrazinonicotinamido)propyl 1- -biphenyl] -4ylmethyl) 2 H-1-benzopyran.7 -yl] -cyclopentanecarboxamide Hydrazone.

S0 3 H

P

r- N Part A Synth esis-of (trans)-N-(N-(tert-Butyloxcarbny).

3 aminopropylJ-1-[3-( [lll'-biphenyl]-4-ylethyl)..3,4.dihydr- 4 hydroxy-2H-1-benzopyrn7-yl]ccoetneabxmd

OH

Boc., The title compound was prepare by the general procedure described above for (tert-Butyloxycarbonyl) -3aminopropyl-3-[6.[ 2 6 -dichlorophenyl)thiomethyl.>.(2.

phenylethoxy) -2-pyridinyl]-2 -propenamide, substituting [3- -biphenyl] -4-ylmethyl) 4-dihydro-4-hydroxy-2H-lbenzopyran-7 -yl] -cyclopentanecarboxylic acid. Recovered the title compound (530 mg, 98%) as a colorless glass which was used without further purification. 1 H NMR (D 6 -DMSO)7 7.-62 (in, 4ArH), 7.50-7.30 (mn, 3Ar-H, NH), 7.25 (in, 3ArH), 6.86 (d, ArH), 6.74 ArH), 6.70 (mn, NH), 5.45 OH), 4.29 (t, CH0), 4.03 (d.ABq, CH 2 2.95 CH2N), 2.80

CH

2 2.70 (in, 1H), 2.45 (mn, CH 2 Ar), 2.10 1.80-1.50 (mn, 6H), .1.40 2H), 1.35(s. t-Bu) ES-MS: 585.4; FAB-Mz.

[M+Hl+ 585.3345 (Calcd for C3 6

H

45

N

2 0 5 585.3328).

Part B Synthesis of 2 -Sulfobenzaldehyde Hydrazinonicotinamido)propyl] l-[ 3 -biphenyl]-4ylmethyl)- 2 H-l-benzopyran-7yl-cyclopentnecarboxamide Hydrazone The title compound was prepared by the general procedure described above for 2 -Sulfobenzaldehyde Hydrazinonicotinamide)propyl] dichiorophenyl) thio]iethyl] (2-phenylethoxy) 2 -pyridinyl-2propenaide Hydrazone, substituting (trans)-N-(N- (tert+- Butyloxycarbonyl) 3 -aninopropyl] -biphenyl] -4ylImethyl) 4 dihydro 4 4hydroxy-2H-l -benzopyran-7 -yl] cylopentanecarboxamide. Purification of a portion of the crude product was accomplished by reversed-phase HPLC on a preparative Vydac C18 column X 25 cm) using a gradient of 100% of solution B (90% acetonitrile I 10% 0.05 M NH4OAc) over 30 minutes, and solution A (100% 0.05 M NH4OAc) to give the title compound as a pale yellow powder. 1 H NMR (D6-DMSO) 11.5.0 (br s, 9.00 br s, 8.56 1H), 8.30 (br s, 1H), 8.04 2H), 7.78 1H), 7.65 4H), 7.50-6.80 14H), 6.70 1H), 6.24 4.63 (s,

CH

2 3.08 2CH 2 2.45 2H), 1.80-1.50. 8H); ES- MS: 768.3.

Example 47 Synthesis of 2-Sulfobenzaldehyde+ 6- Hydrazinonicotinamido)pentyloxy] 2 -propenyl)-1,2,3,4tetrahydronaphthalen.1-one Hydrazone Part A .Synthesis of amfifopentyloxy] 2 -propenyl) 2,3, 4 -tetrahydronaphthalen-l one

H

To. a solution of 6 -hydroxy-5-(2-propenyl)..12,34.*.

tetrahydronAphthalen.1.-one (1.00-g, 4.94 rnmol), tert-butyl

N-

(5-hydroxypenty1)carbamate (1.10 g, 4.97 mmol), and PPh 3 (1.30 g, 4.96 mmol) in anhydrous THF. (31 ml), cooled in an ice-bath, was added diethyl. azodicarboxylate (2.00. ml, 11.48 'mMol) over 15 minutes. The reaction mixture was allowed to stir at 0 0

C

:.for 15 minutes, then slowly warm to room -temperature over 1 hour. The reaction mixture was concentrated, triturated with hexane/EtOAc cooled to 0 0 C, f iltered, and the f iltrate was concentrated. The residue was purified by column *a chromatography (silica gel) using 3:1 hexane/EtOAc. Recovered the title compound (1.55 g, 81%) as a white solid. 1 H NMR (CDCl 3 7.99 ArH), 6.81 ArH), 5.86 (in, 4.96 (dd, =CHHl), 4.89 (dd, =CHH), 4.50 (br s, NH), 4.01 CH 2 3.42 (in, CH 2 3.12

CH

2 2.*88

CH

2 Ar), 2.57

CH

2

CO).,

2.08 (quintet,

CH

2 1.81 (quintet,

-CH

2 1.51 (in, 2CH 2 1.43 t-Bu); ES-MS: [M+H]l 388.3.

Part B Synthesis of 2 -Sulfobenzaldehyde Hydrazinonicotinamido)'pentyloxy] (2-propenyl) 4tetrahydronaphthalen-1 -one Hydrazone To a solution of E-[N-(tert-Butyoxycarbonyl)..s.

aminopentyloxy] (2-propenyl) 2,3, 4 -tetrahydronaphthalen-lone (502 mng, 0. 81 inmol) in CH 2 Cl 2 (8 ml) was added TFA (4 ml, 51.92 inmol). The reaction mixture was allowed to stir at RT f or 3 hours, then, was concentrated, diluted with. CH 2 Cl 2 concentrated, -and dried unde .r high-vacuum overnight. 1 H NmR (CDC1 3 8.86 (br s, NH 3 7.94 ArH), 7.44 (br s, 2H), 6.77 Ar.H), 5.83 (mn, 4.94 (dd, =CHH), 4.84 (dd, =CHH), 4.01

CH

2 3.40 (Mn, CH 2 3.06

CH

2 2.86 (t, CH2Ar), 2.60 (ti CH 2 CO), 2.07 (quintet,

CH

2 1.80 (Mn, 2CH 2 1.51 (in, CM 2 ES-MS: 288.3.

The crude amine*TFA salt (100 mg, 0.25 inmol) and succinimidy.

2 -sulfobenzaldehyde 6-hydrazinonicotinate hydrazone (131.6 mg, 0.30 inmol) was dissolved in DMF (2 ml), followed by. the addition of Et 3 N (200 Igl, .1.44 mmol)..The reaction mixture was all owed to stir at room temperature for 48 hours., and was concentrated; Purification of-the crude product was accomplished by reversed-phase H4PLC on a preparative Vydac C18 column (2.5 X 25 cm) using a gradient of .40 to 100% of solution Bl (90% acetonitrile I10% 0.05 M4 NM4OAP) over minutes, and solution A (10'0% 0.05 M NH4OAc).to give the title compound (.39 mg) as a yellow solid. Proton NI4R spectral data indicated the presence of some triethylainmonium salts'. 1 H NMR -(D6-DMSO) 9.05.(br s, NH), 8.58 1Hi), 8.35 (br 1H), 8.05 (br d, 2H), -7.82 7.78 1H), 7.34 (in, 1H), 7.23 1H), 7.0.1 ArH), 5.81 4.90 (mn, =CHH), 4.07

CH

2 3.3 7 (in, CH 2

CH

2 N) 13. 10 (mn, CM 2 N salt), 2.85

CH

2 2.50 (in, CM 2 1.9.8 (quintet,*

CH

2 1.78 (quintet,

CH

2 1.55 2CM 2 1.18 CH3CH 2 N salt); ES-MS: [I4+H]+ 591..4;_ F.AB-HRMS: [M+H]l 591.2276 (Calcd for C3 1

H

35

N

4 0 6

S

Example 4.8 Synthesis of 2-Sulfobenzaldehyde (2-propenyl) -1,2,3,4tetrahydronaphthalen- 1-one Hydrazone Part A Synthesis of 6-[N-(tert-Butyoxycarbonyl).6aminohexyloxy] (2-propenyl) 2,3, 4 -tetrahydronaphthalenl one I

H

The title compound was prepare by the general procedure described above for 6 aminopentyloxy] 2 -propenyl) 4-tetrahydronaphthalenlone substituting tert-butyl N- (6-hydroxyhexyl) carbaxnate.

Recovered the title compound as a whit e solid. 1 H NMR (D 6 5 DMS0) 7.8.2 ArH), 6.99 ArH), 6.76 (br t, NH), 5.84 (in, =H),4.96 (dd, =CHH), 4.91 (dd, =CHH), 4.04 CH 2 O),,3.40

CH

2 2.86 (mn, 2CH 2 2.5.0 (mn, CH 2 1.98 (quintet,

CH

2 1.71 (quintet,

CE

2 1.36 (mn, 3CH 2 1.36 t-Bu); ES- MS: 402.5.

Part B Synthesis of 2-Sulfobenzaldehyde 6-f 6-(6- Hydrazinonicotinamido) hexyloxy] (2-propenyl) -1,2,3,4tetrahydronaphthajlen-l-one Hydrazone The title compound-was prepare by the general procedure described above for. 2-Sulfobenzaldehyde 6- (6- Hydrazinonicotinamido)pentyloxy] 2 -propenyl) -1,2,3,4tetrahydronaphthalen-1-one Hydrazone, substituting 6- (tert- Butyloxyjbarbonyl) -6-aminohexyloxYJ-5- (2-propenl -l.2,3,4.

tetrahydronaphthalen...lone. Purification of the crude product was accomplished by reversed-phase HPLC on a preparative Vydac C18 column (2.5 X 25 cm) using a gradient of 40 to 100% of solution B acetonitrile 10% 0.05 M NH4OAc) over mintes an so uti n A (100% .0.05 M NH40A.C) to give the title compound as a pale yellow powder. Proton NMR spectral data indicated the presence of some triethylanmionium. salts. IH NMR (D6-DMso) 11.4.5. br s, OH), 9.04 Cbr s, NH), 8.57' 1H), 8.35 (br s, 8.06 (br d, 2H), 7 .82 ArH), 7.78 -(dd, 1H1),.7.34 1Hi), 7.22 1H), 7.00 ArH), 5.83 (in, =CH), 4.94 (in, =CHH), 4..06 tCH 2 3.38 (in, CH2c=), 3.26*(q,

CH

2 3.1-0

CH

2 N salt),. 21.85 Ct., CH 2 2.5-0 Cm, CH 2 1.98 (quintet,

-CH

2 1.75 (quintet, CH4 2 1 .0 (mn, 3 CH 2 1.17 Ct,

CH

3

CH

2 N salt) ES-MS: =03.2;

FAB-HRMS:.[M+H]+

605.2433 CCalcd for C32H 3 7

N

4 0 6 S 6 05.2434).

Example 49 Synthesis of 2 -Sulfobenzaldehyde 220 Hydrazinonicotinamido) 4 -dim +ethylpentyloxy] (2 -propenyl) 1,2,3, -era~rnphhl~-l oE Hydrazone *H03

NN

HO

3 N NN artA Snthsisof 5-Ctert-ButYldimethylsilyl,x,).

2 2 dimethylpentanenjtri le To a solution of LDA*THF in cyclohexane 100 Ml, 1-50 minol) and anhydrous THF (100 ml) cooled to -78*C was added isobutyronjtrile (10.00 g, 144.70 mmiol) over 15 minutes. The reaction mixture was allowed to warm to -40 0 C over 30 minutes, recooled to -78 0 C, then 3 (tert-butyldimethylsilyloxy)propyl bromide (26.08 g, 102.98 mmol) was added dropwise over minutes. The reaction mixture was allowed to warm to 0°C over 1 hour, quenched with 1 N HC1, extracted with ether, and the combined extracts were washed with H20, saturated NaHC0 3 brine, dried (Na2S0 4 and concentrated. Recovered the title compound (22.23 g, 89.4%) as a pale yellow liquid which was used without further purification. 1 H NMR (CDC13) 3.64 (t,

CH

2 1.60 2CH 2 1.34 2CH 3 0.88 t-Bu), 0.04 2CH 3 Si); ES-MS: [M+H- 242.1.

Part B Synthesis of (5-Hydroxyl-2,2-dimethylpentyl)ammonium chloride To a solution of 5-(tert-Butyldimethylsilyloxy)-2,2dimethylpentanenitrile (5.00 g, 20.71 mmol) in MeOH (50 ml) H20 (5 ml) was added concentrated HC1 (2.5 ml, 30.0 mmol) followed by Pt02 (100 mg). The mixture was hydrogenated on a Parr apparatus at 60 psi for 36 hours, the catalyst was removed by filtration, and the reaction mixture was concentrated. Recovered the title compound (4.72 g, contained 20 residual methanol) as a colorless oil which which was used without further purification. 1 H NMR (D 6 -DMSO) 7.97 (br s,

NH

3 3.36 CH 2 2.59 CH 2 1.30 2CH 2 0.90 (s, 2CH 3 ES-MS: [M+H] 132.0.

25 Part C Synthesis of N-(tert-Butyloxycarbonyl)-5-amino-4,4dimethylpentanol To a suspension of (5-Hydroxyl-2,2dimethylpentyl)ammonium chloride (crude, 20.78 mmol) in CH 2 C12 (50 ml), cooled in an ice-bath, was added Et 3 N (3 ml, 21.52 mmol) followed by Boc20 (5.1 ml, 22.20 mmol). The cooling bath was removed and the reaction mixture was allowed to stir at room temperature for 18 hours, the reaction mixture was concentrated, partitioned between EtOAc H 2 0, and the organic layer was washed with 5% citric acid, H20, saturated NaHCO3, brine, dried (Na2S04), and concentrated. The residue was purified by column chromatography (silica gel) using 3:1 to 1:1 hexane/EtOAc. Recovered the title compound (4.45 g, 93%) 164 as a colorless oil. 1 H'NMR (CDC 3 .4.60 (br s, NH), -3.60 (t,

CH

2 2.92

CH

2 1.74 (br s, OH), 1.51

CH

2 1.42 t-Bu), 1.25 CH 2 0.84 2CH 3 ES-MS: 232.1.

Part D Synthesis of (tert-Butyloxycarbonyl)-5-amino-4, 4dimethylpentyloxyl-5-(2-propenyl)-1,2,3,4tetrahydronaphthalen..l-one The title compound was prepared by the general procedure described above for 6-[N-(tert-Butyloxycarbonyl) aminopentyloxy] (2-propenyl) 4 -tetrahydronaphthalen-lone, substituting N-(tert-Butyloxycarbonyl)-5-amino-4,4dimethylpentanol. Recovered the title compound as a crude pale yellow oil. ES-MS: [M+H]l 416.2.

Part E Synthesis of 2 -Sufobenzaldehyde Hydrazinonicotinamido)-4, 4-dimethylpentyloxy] 2 -propenyl)- 1,2,3, 4 -tetrahydronaphthalen-lone Hydrazone The title compound was prepare by the general procedure described above for 2 -Sulfobenzaldehyde Hydrazinonicotinamido)petyloxyl -5-(2-propenyl)-1,2,3,4tetrahydronaphthalen-l-o ne Hydrazone, substituting 6-N-(tert- Butyloxycarbony) -5-amino-4 ,4-dimethylpentyloxy) (2propenyl)-1,2,3, 4 -tetrahydronaphthalen-lone Purification of the crude product was accomplished by reversed-phase HPLC on a preparative Vydac C18 column (2.5 X 25 cm) using a gradient of 40 to 100% of solution B (90% acetonitrile 10% 0.05 M NH4OAc) over 30 minutes, and solution A (100% 0.05 M NH4OAc) to give the title compound as a pale yellow powde;. 1 H NMR (D6-DMSO) 11.40 (br s, OH), 9.01 NH), 8.61 8.17 (br t, 1H), 8.03 2H), 7.82 ArH), 7.78 (dd, 1H), 7.40- 7.20 3H), 6.99 ArH4), 5.82 4.89

=CHH),

4.03 (br t, CH 2 3.36

CH

2 3.14

CH

2 2.84 (m,

CH

2 2.50

CH

2 1.97

CH

2 1.75 CH 2 1.40 (m,

CH

2 0.89 s, -2CH 3 ES-MS: 619.3; FAB-HRMS: [M+P]l 619.2610 (Calcd for C 33

H

3 9

N

4 0 6 S 619.2590).

Example Synthesis of 2 -Sulfobenzaldehyde Hydrazinonicotinamido) 5-dimethylhexyloxyj 2 -propenyl)- 1,2,3, 4 -tetrahydronaphthalen--1 one Hydrazone 0 0 H0 3

S

H

N.N

H

0 Part A Synthesis of E-(tert-Butyldimethylsilyloxy)-2,2 dimethyihexanenitrile The title compound was prepare using the procedure described above for 5-(tert-Butyldimethysiyloxy)-2,2dimethylpentanenitrile Recovered the title compound as a pale yellow liquid which was used without further purification. 1

H

NMR (CDCl 3 3.62 (br t, CH 2 1.52 (br s, 3CH 2 1.32 (s, 2CH 3 0.88 t-Bu), 0.04 2CH 3 Si); ES-MS:fM-H]+ 256.1.

Part B Synthesis of (6-Hydroxy1-2,2 -dimethylhexyl)ammonium chloride The title compound was prepare using the procedure described above for (5-Hydroxyl-2, 2 -dimethylpentyl) ammonium chloride. Recovered the title compound as a colorless oil which which was used without further purification. 1 H NMR

(D

6 -DMSO) 8.02 (br s, NH 3 3.38

CH

2 2.58

CH

2

N),

1.38

CH

2 1.22 2CH 2 0.89 2CH 3 ES-MS: 146.0.

Part C Synthesis of N-(tert-.Butyloxycarbonyl)-6-aininio-s.,Sdime thyl hexano 1 The title compound was prepare using the procedure described above for N-(tert-Butyloxycarbonyl)-.5-amino-44.

dimethylpen-tanol. Recovered the title compound as a colorless oil. 1 H NMR (CDCl 3 4.60 (br s, NH), 3.58 (to CH 2 2.88 (d,

CH

2 2.19- (br so OH),1 1.49 (in, OH 2 1.40 t-Bu), 1.40- 1.10 (in, 2CH 2 0.81 (so 2CH 3 ES-MS: 246.1.

Part D Synthesis of 6- (tert-Butyloxycarbonyl) -6-amino-S 1 dimethylhexyloxy] (2-propenyl) -1,2,3 ,4-tetrahydronaphthalen- 1-one The title compound was prepare by the general procedure described above for 6- (tert-Butyloxycarbonyl) aminopentyloxy] (2-propenyl) 4-tetrahydronaphthalen-1one substituting N- (tert-Butyloxycarboniyl) -6-amino-S 1 dimethyihexanol. Recovered the title comon asapleylo oil. 1.H NMR (CDCJ.

3 7. 69 ArH), 6. 81 ArH), 6.75,(br mn, NH), 5.85 (mn, 4.94 (mn, =CHH), 4.04 (to CH 2 3.37 (in, C H 2 3. 35 (in, -CH 2 N) 2.8.2 OH 2 2 46 (to O.H 2 1.9 6 (quintet, CH 2 1.68 CH 2 1.36 t-Bu), 1.17 (mn, 2CH 2 0.76 0.74 (2s, 2CH 3 ES-MS: fM+H]+ 430.3.

Part E Synthesis of 2-Sulfobenzaldehyde Hydrazinonicotinamido) 5-dimethylhexyloxy] (2-propenyl) 1,2,3,4 -tetrahydronaphthalen-1-one Hydrazone The title compound was prepare by the general procedure described above for 2-Sulfobenzaldehyde Hydrazinonicotinamido) pentyloxy] (2-prop'enyl) -1 3,4tetrahydronaphthalen-1-one Hydrazone, substituting- 6- (tert- Butyloxycarbonyl) -6-amino-S. 5-dimethyihexyloxy] (2propenyl) 4-tetrahydronaphthalen-1-one. Purification of the crude product was accomplished by reversed-phase HPLC on a preparative Vydac C18 column (2.5 X 25 cm) using a gradient of to 100% of solution B (90% acetonitrile 10% 0.05 M over 30 minutes,*and solution A (100% 0.05 M NH4OAC) to give the title compound as a pale yellow powder. 1 H NMR (D6-DMSO) 11.50 (br s, OH), 9.09 (br s, NH), 8.56 1H), 8.20 (br s, 1H), 8.09 2H), 7.82 ArH), 7.78 (dd, lH), 7.40-7.15 4H), 7.08 1H), 6.99 ArH), 6.89 1H), 5.85 4.94 =CHH), 4.06 (br t, CH 2 3.35 (m,

CH

2 3.13

CH

2 2.84 (br t, CH 2 2.50

CH

2 1.98

CH

2 1.71

CH

2 1.45

CH

2 1.30

CH

2 0.86 2CH 3 ES-MS: fM+H]+ 633.3; FAB-HRMS: 633.2752 (Calcd for C34H 4 1

N

4 0 6 S 633.2747).

Example 51 Synthesis of 2 -Sulfobenzaldehyde Hydrazinonicotinamido) butoxy) (2-propenyl) tetrahydronaphthalenl-one Hydrazone i .4 :i N II'i

I

N N

H

0 Part A Synthesis of 6-[N-(tert-Butyloxycarbonyl)-.4 aiinobutoxy 2 -propenyl)-1,2,3, 4 -tetrahydronaphthalen..l.one The title compound was prepare by the general procedure described above for 6 2 -propenyl)-1;2,3, 4 -tetrhydronaphthalen-lone, substituting N-(tert-Butyloxycarbonyl)- 4 -aminobutanol.

Recovered the title compound as a white solid. 1 H NMR (CDCl 3 7.98 ArH), 6.80(d, ArH), 5.85 4.94 (dd, =CHH), 4.88 (dd, =CHH), 4.55 (br s, NH), 4.03

CH

2 3.42 (m,

CH

2 3.17

CH

2 2.87

CH

2 2.57

CM

2 2.07 (quintet,

CM

2 1.82 (quintet,

CM

2 1.68 (quintet,

CM

2 1.43 t-Bu); ES-MS: 374.4.

Part B Synthesis of 2-Sulfobenzaldehyde Hydrazinonicotianido)butoxcy] -5-(2'-propeniyl) -1,2,3,4tetrahydonaphthalen-l. -one Hydrazone The title compound was prepare by the general procedure described above for 2 -Sulfobenzaldehyde (2-propenyl) -1,2,3,4tetrahydronaphthalen-1.-one Hydrazone, substituting 6- (tert- Butyloxycarbonyl) -4-aininobutoxy] (2-propenyl) 2,3,4tetrahydronaphthalen-l-.one. Purification of the crude product was accomplished by reversed-phase HPLC on a preparative Vydac C18 column (2.5 X 25 cm) using a- gradient of 40 to 100% of solution.B (90% acetonitrile /10% 0.05 M MHOMc) over minutes, and solution A (100.% 0.05 M NH4OAc) to give the title compound-as a pale yellow powder. Proton NMR spectral data indicated the presence of some triethylainmonium salts. 1 H NMR (D6-DMSO) 11.45 (br s, 9.04 (br s, NH), 8.56 1H), 8.40 (br s, 1H), 8.05 (br s, 2H), 7.82 ArH), 7.77 (dd, iN), 7.35 (mn, 7..22 1H) 7. 02 ArH) 5. 84 (in, =CH), 4.93 =CHH), 4.10 CH 2 3.40 (in, CH 2 3.25 (in,

CH

2 3.10 (mn, :CH 2 N salt), 2.84

CE

2 2.50 (in, CE 2 1.98 (quintet,

CH

2 1.80-1.55 (in, 2CH 2 1.17 CH 3

CH

2 N salt); .ES-KS: [M-HJ- 575.3; FAB-ERMS: (M H+H1 577.2130 (Calcd for C3OH 3 3

N

4 0 6 S =577.2121).

Example 52 Synthesis of 2-Sulfobenzaldehyde Hydrazinonicotinamido)propoxy] 5(2-propenyl) 12,,4 tetrahydronaphthalen-1-one Hydrazone 0 Part A Synthesis of 6-(N-(tert-Butyloxycarbony1)-3- 2 -propenyl) 4 -tetrahydronaphthalen-lone The title compound was prepare by the general procedure described above for 6- 2 -propenyl)-1,2,3, 4 -tetrahydronaphthalen-lone, substituting N-(tert-Butyloxycarbony -3 -aminopropanol Recovered the title compound as a white solid. 1 H NNR (CDC1 3 8.0.0 ArH), 6.82 ArH), 5.90 4.98 (dd, =CHH), 4.86 (dd, =CHH), 4.75 (br s, NH), 4.08

CH

2 3.43 (d,

CH

2 3.32

CH

2 2.88

CH

2 2.58

CH

2 2.08 (quintet,

CH

2 2.02 (quintet,

CH

2 1.43 t-Bu);

ES-MS:

360.3.

Part B Synthesis of 2 -Sulfobenzaldehyde 6-f3-(6- Hydrazinonicotinamido)propoxyl-5- (2-propenyl) -1,2,3,4- 9: tetrahydxonaphthalen-1-one Hydrazone The title compound was prepare by the general procedure described above for 2 -Sulfobenzaldehyde Hydrazinonicotinamido)pentyloxyl-5-(2-propenyl)-1,2,3,4tetrahydronaphthaen-..one Hydrazone, substituting 6-fN-(tert- Butyloxycarbonyl) 3 -aminopropoxy 2 -propenyl) -1,2,3,4tetrahydronaphthalenl.one. Purification of the crude product was accomplished by reversed-phase HPLC on a preparative Vydac C18 column (2.5 X 25 cm) using a gradient of 40 to 100% of solution B (90% acetonitrile 10% 0.05 M NH4OAc) over 99 9. minutes, and solution A (100% 0.05 M NH4OAc) to give the title compound as an off-white powder. Proton NMR spectral data indicated the presence of some triethylammonium salts. 1 H NMR (D6-DMSO) 9.04 (br s, NH), 8.58 1H), 8.45 (br s, 1H), 8.05 (br t, 2H), 7.83 ArM), 7.77 (dd, 1H), 7.34 1H), 7.23 1H), 7.02 Ar), 5.82 4.97 =CHH), 4.13

CH

2 3.44 (br d, CH 2 3.32

CH

2 3.10 CH2N salt), 2.87

C!

2 2.50 CH2), 2.01 2CH2), 1.17 (t,

CH

3

CH

2 N salt); ES-MS: 563.4; FAB-HRMS: 563.1978 (Calcd for C29H31N40 6 S 563.1964).

Example 53 Synthesis of 2 -Sulfobenzaldehyde 6- (6- Hydrazinonicotinamido) ethoxy] 2 -propenyl) -1,2,3,4tetrahydronaphthalen..1-one Hydrazone N N

H

0 Part A Synthesis of 6 -[N-(tert-Butyloxycarb1).... aminoethoxy] (2-propenyl) 2,3, 4 -tetrahydronaphthalenl.one The title compound was prepared by the general. procedure described above for. 6- (tert-Butyloxycarbony.) aminopentyloxy] (2-propenyl) 2,3, 4 tetrahydonaphthalen-..

on, substituting N- (tert-Butyoxycrbnyl) 2 -azninoethanol.

Recovered the title compound as a white solid. 1 H NMR (CDCl 3 8.00 Ar.H) 6.81 Ar-H), 5.90 (in, 5.00 (dd, =CHH), 4.90 (br s, NH), 4.89 (dd, =CHH), 4.08

CH

2 3.54 (q,

CH

2 3.44

CH

2 2.88

CH

2 2.58

CH

2 2.09 20 .(quintet,

CH

2 1.36 (in, 3CH 2 1. 43 t-Bu); ES-MS: 346.2.

Part B Synthesis of 2 -Sulfobenzaldehyde B Hydrazinonicotinamido) ethoxy 5- 2 -propenyl) -1,2,3,4tetrahydonaphthalen.l-.one Hydrazone The title compound was prepare by the generaV procedure described above for 2 -Sulfobenzaldehyde Hydrazinonico'tinanddo)pentyloxy] -5.-(2-propenyl) -1,2,3,4tetrahydronaphthlen..1one Hydrazone, substituting 6- (tert- Butyloxycar,ony1) 2 -aminoethoxy] (2-propenyl) -1,2,3,4tetrahydroaphthale..1..one. Purification of the crude product Was accomplished by reversed-phase HPLC on a preparative Vydac C18 column (2.5 X 25 cm) using a gradient of 40 to 100% of solution B 90% acetonitrile 10% 0.05 M NH4OAc) over minutes, and solution A (100% 0.05 M NH4OAc) to give the title compound as a pale yellow powder. Proton NMR spectral data indicated the presence of some triethylammonium salts. 1 H NMR (D6-DMSO) 9.21 (br s, NH), 8.80 (br s, 1H), 8.52 IH), 8.18 (br m, 2H), 7.82 ArH), 7.79 1H), 7.41 1H), 7.22 1H), 7.05 ArH), 5.80 4.88 =CHH), 4.21

CH

2 3.67

CH

2 3.40

CH

2 3.10

CH

2

N

salt), 2.85

CH

2 2.50

CM

2 1.97 (quintet,

CH

2 1.17

CH

3

CH

2 N salt); ES-MS: 549.2; FAB-HRMS: [M+Hl 549.1792 (Calcd for C28H 29

N

4 0 6 S 549.1808).

Example 54 Synthesis of 2 methylenedioxyphenyl)-6-phenyl-2-pyridinyl) oxy hexanaiino] carbonyl] -2 -pyridinyl] hydrazonol methyl]benzenesulfonic acid I A NNI A o,

H

2 0-' Part A Preparation of 2,2-Dimethyl-6-((4-(3,4methylenedioxyphenyl) 6-phenyl-2-pyridinyl)oxy]-hexanenitrile NN 0 CNN 0-i 4-(3,4 -Methylenedioxyphenyl)- -phenyl--pyridone (1.1 g, 3.77 mmol) was dissolved in dimethylformamide (60 mL). 6- Bromo- 2,2-dimethylhexanenitrile (1.54 g, 7.54 mmol) and silver carbonate (1.04 g, 3.77 mmol) were added, and the reaction was refluxed in the dark for 36 h. The reaction was then cooled, filtered, and concentrated under high vacuum. The residue was brought-up in methylene chloride and passed through silica gel. The filtrate was concentrated under high vacuum. The resulting residue was recrystallized from hexane:ethyl acetate to give 1.18 g of product.

ESMS: Calcd. for C26H26N203, 414.19; Found 415.3 [M+H]+1 Part B Preparation of l-Amino-2,2-dimethyl-6-[(4-(3,4methylenedioxyphenyl)-6-phenyl-2-pyridinyl)oxy]-hexane -To a dry flask was added aluminum chloride (0.707 g, 5.30 mmol). The flask was cooled to less than O'C with an ice/ethanol bath. Ether (10 mL) was added, and the reaction was stirred for 5 minutes until the aluminum chloride dissolved. Lithium aluminum hydride (0.201 g, 5.30 mmol) was then added, and the reaction was heated to reflux. 2,2- Dimethyl-6-[ (4-(3,4-methylenedioxyphenyl) -6-phenyl-2pyridinyl)oxy]-hexanenitrile (1.0g, 2.41 mmol) was dissolved in ether mL) and added dropwise to the refluxing solution.

S 20 After addition was complete, the reaction was stirred for hours at room temperature. The reaction was then quenched with water. Aqueous sulfuric acid (6 N) was added until a clear solution formed. This mixture was then extracted with ether The aqueous layer was then cooled in an ice bath 25 and basified to pH 14 with 50% aq. sodium hydroxide. The resulting solution was then extracted with ether The organic layer was washed with saturated NaC1, dried over magnesium sulfate, and evaporated to give an oil. The oil was crystallized from hexane:ethyl acetate to give 0.3184 g (31%) of product. ESMS: Calcd. for C26H30N203, 418.23; Found, 419.3 [M+H]+1 j Part C Preparation of 2-[[[5-[[2,2-dimethyl-6--(4-(3,4methylenedioxyphenyl)-6-phenyl-2-pyridinyl)oxy]-1hexanamino] carbonyl] -2 -pyridinyl hydrazono methyl] benzenesulfonic acid l-Amino-2,2-dimethyl-6-[ 4 -methylenedioxyphenyl) -6phenyl-2-pyridinyl)oxyl-hexane (0.100 g, 0.239 mmol) was dissolved in dimethylformamide (5 mL). Triethylamine (99.7 4L, 0.717 mmol) was added and the reaction was stirred for minutes. 2 ,5-Dioxo-l-pyrrolidinyl)oxycarbonyl]-2pyridinyl] hydrazonoj methyll -benzenesulfonic acid, monosodium salt 0.126 g, 0.287 mmol) was added and the reaction was stirred for 24 hours under nitrogen. The reaction was then concentrated to an oil under high vacuum. The oil was triturated with ethyl acetate. The crude product was then purified by preparative HPLC Method 1 to give 16 mg of product. HRMS: Calcd. for C39H39N 5 07S H, 722.2648; Found, 722.2669.

Example Synthesis of N- [2,2-Dimethyl-6- 4 -methylenedioxyphenyl)- 6-phenyl-2-pyridinyl)oxy]-hexyl] -bis-S-(l-ethoxyethylmercaptoacetyl)pentanoate NH HN S

S

I OO1 0-/ I -Amino-2,2-dimethyl-6-[(4-(3,4-methylenedioxyphenyl)-6phenyl-2-pyridinyl)oxy]-hexane (0.010 g, 0.0238 mmol), as described in Example 54, Part B, was dissolved in dimethylformamide (1 mL). Triethylamine (10.0 jiL, 0.0286 25 mmol) was added and the reaction was stirred for 5 minutes.

Tetrafluorophenyl bis-S-(1-ethoxyethylmercaptoacetyl)pentanoate (MAPT, 0.015 g, 0.0262 mmol) was added and the reaction was stirred for 24 hours under nitrogen. The reaction was then concentrated to an oil under high vacuum.

The oil was triturated with ethyl acetate to give 20.0 mg (100%) of product. HRMS: Calc. for C43H60N408S2

H,

825.3931; Found, 825.3959.

Example 56 Synthesis.of 2 [[5[(N6.-l(4.6-diphenyl.2:pyridiyl hexanoyl]-glycine-alpha-amino]carbonyl]-2- PYridinyl]hydrazono)-methyll-benzenesulfonic acid +H2N'

O

N

3 SOHN O N NO N O6H H

O

Part A Preparation of 2 -amino-[2'-N'-16-[((4,6-diphenyl-2- .pyridinyl)oxy] -hexanoyl] -amino] ethanoic acid trifluoroacetic acid salt 1: 1 N Q NH 2

.TFA

O

Wang Resin (0.60 mmol/g) (5 g, 3.0 mmol) was placed in a reaction vessel. To this was added dimethylformamide (100 mL) and the reaction was rotated for 10 min.. The DMF was removed, and the following were added: Fmoc-Gly(NH-Boc)-0H (2.46 g, Mmol); HATU (2.85 g, 7.5 mmol); diisopropylethylamine (3.13 mL, 18.0 mmol); dimethylformamide (50 mL). The reaction was rotated for 24 h. The resin was then washed with 100 mL of DMF 3X, MeOH lX, DCM 3X, MeOH 2X, DCM 3X. The resin was dried under vacuum. The new substitution was determined using the Picric acid assay (0.495 mmol/g). The resin was then capped to the resin was added pyridine (3 mL), benzoyl chloride (3 mL), in dichloroethane (80 mL), and the reaction was rotated for 2 h. The resin was then washed with 100 mL of DCE 3X, DCM 3X, MeOH lX, DCM 2X, MeOH 2X, DCM 2X. The resin was dried under high vacuum.

To a teabag (5x5cm polypropylene filter, 0.75 Am mesh) was added 0.50 g of Fmoc-Gly(NH-Boc)-Wang Resin prepared above. The teabag was washed with the following (10 ml/bag) DMF 2 x 3 min, 20% piperidine in DMF solution 1 x 3 min, piperidine in DMF solution 1 x 30 min, DCM 8 x 3 min, and DMF 3 x 3 min. To the reactor was added 3 equivalents of diphenyl-2-pyridinyl)oxy]-hexanoic acid, five equivalents of each of the following; HBTU, HOBT, diisopropylethylamine(DIEA) and DMF (10ml/bag). The bag was then shaken overnight for about 18 hours. The bag was then washed with the following (10ml/bag): DMF 3 x 3 min, DCM 8 x 3min. The bag was dried under high vacuum. The contents of the bag was then placed in a small erlenmeyer flask. To the flask was added cleavage cocktail (10 mL) (95% trifluoroacetic acid, 2.5% triisopropylsilane, and 2.5% water). The resin was allowed to sit for two hours while occasionally being swirled.

After each swirl the side of the flask was rinsed with additional cocktail until the total volume of cocktail added was 15 mL. After two hours, the resin was filtered and washed 20 with TFA 2x4 mL. The filtrate was concentrated to an oil under high vacuum. The oil was triturated with ether to give 96 mg of product. ESMS: Calcd. for C25H27N304,433.20; Found, 434.3 [M+H]+1 Part B Preparation of 2-[[[5-[[N-[6-[(4,6-diphenyl-2pyridinyl)oxy]-hexanoyl]-glycine-alpha-amino]carbonyl] -2pyridinyl]hydrazono]-methyl]-benzenesulfonic acid 2-Amino-[2'-N'-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexanoyl]-amino]ethanoic acid trifluoroacetic acid salt (0.040 g, 0.0731 mmol) was dissolved in dimethylformamide (2 mL).

Triethylamine (30.6 pL, 0.219 mmol) was added and the reaction was stirred for 5 minutes. pyrrolidinyl)oxy]carbonyl]-2-pyridinyl]hydrazono]methyl]benzenesulfonic acid, monosodium salt (0.0386 g, 0.0877 mmol) was added and the reaction was stirred for 24 hours under nitrogen. The reaction was then concentrated to an oil under high vacuum. The oil was triturated with ethyl acetate. The 176 crude product was then purified by preparative HPLC Method 3 to give 12-mg of product. HRMS: Calcd. for C38H3 6

N

608

S

H,7372394; Found,737.2420.

HPLC Method 3 Instrument: Column: Detector: Flow Rate: Column Temp: Mobile .Phase: Gradient: Rainin Rabbit; Dynaax software Vydac C-18 (21.2 mm x 25 cm) Knauer VWM 1iml/min

RT

A: B: ACN/H 2 0 (9:1) Time (min) %A

%B

0 60 20 40 21 0 100 0 100 31 60 Example 57 Synthesis of 2 -Acetyl-4-ethyl sulfonyiphenyl) methylenel hydrazino]-3pyridinyl] carbonyl] amino] hexyl] oxy phenol OHH2+ N N. 3 -S0 Part A Preparation of 2-Hydroxy-5-ethyl-4- [6-(N-tertbutyloxycarbonyl) aminohexyll oxy] acetophenone 0L 2, 4-Dihydroxy-5-ethyl-acetophenone (1.5 g, 8.32 mmol) and N-tert-butyloxycarbonyl-6-bromohexylamine (2.45 g, 8.73 mmol) were dissolved in methylethylketone (5.5 mL). Potassium carbonate (2.01 g, 14.6 nmol), potassium iodide (0.276 g, 1.66 mmol) and methyl suifoxide (1.2.mL) were added and the reaction was heated to reflux for 30 h. The reaction was cooled, brought up in water, and extracted with toluene. The organic layer was washed with 1.0 N NaOH LN HCl (1X), and water. The organic layer was then stirred with silica gel for 15 min. The silica was removed by filtration. The filtrate was concentrated. The resulting solid was brought up in hexane and filtered and dried to give 1.63 g of product.

ESMS: Calcd. for C21H33N 5 379.24; Found, 380.3 [M+H]+1 Part B Preparation of 2-Hydroxy-5-ethyl-4-[6aminohexyll oxyl]acetophenone trifluoroacetate salt 2 -Hydroxy-5-ethyl-4-[[6-(N-tert-butyloxycarbonyl)aminohexyl]oxy]acetophenone (0.100 g, 0.264 mmol) was dissolved in methylene chloride (1.5 mL). Trifluoroacetic acid (1.5 mL) was added, and the reaction was stirred for 2 h.

The reaction was concentrated under high vacuum. The 20 resulting oil was brought up 50:50 acetonitrile/water and lyophilized to give 100.2 mg of product.

ESMS: Calcd. for C16H25NO 3 279.18; Found, 280.2 [M+H]+1 Part C Preparation of 2-Acetyl-4-ethyl-[5-[6-[[6-ll(2- 25 sulfonylphenyl)methylene]hydrazino]-3pyridinyl] carbonyl amino] hexyl] oxy] phenol 2-Hydroxy-5-ethyl-4-[[6-aminohexyloxylacetophenone trifluoroacetate salt (0.095 g, 0.241 mmol) was dissolved in dimethylformamide (5 mL). Triethylamine (100.

9 fL, 0.723 mmol) was added and the reaction was stirred for minutes. 2-[f5-[[(2,5-Dioxo-l-pyrrolidinyl)oxy]carbonyl] -2pyridinyl] hydrazono] methyl] -benzenesulfonic acid, monosodium salt (0.127 g, 0.289 mmol) was added and the reaction was stirred for 24 hours under nitrogen. The reaction was then concentrated to an oil under high vacuum. The oil was triturated with ethyl acetate. The crude product was then purified by preparative HPLC Method 2 to give 3.1 mg of product. HRMS: Calcd. for.C29H34N40 7 S H, 583.2226; Found, 583.2213.

Example 58 Synthesis of 2 4 -Diethyl-15-[5,5-dimethyl-6-([6-[[[( 2 sulfonylphenyl)methylene]hydrazino]-3pyridinyl] carbonyl amino] hexyl] oxy] phenol OHH2 N N

SO

3 -03 Part A: Preparation of 2 -Benzyloxy-5-ethyl-4[((5.-methyl-5 cyanohexyl)oxy-acetophenone .0 0 6--~XCN 2-Hydroxy-5-ethyl-4- acetophenone (2.8 g, 9.22 mmol), as described in Example 13, Part A, was dissolved in dimethylformamide (40 mL). Potassium carbonate (2.04 g, 14.8 mmol) and benzyi bromide (2.19 mL, 18.4 mmol) were added and the reaction was heated to 75'C for 18 h. The reaction was cooled, filtered and concentrated.

S 20 The resulting oil was brought up in ethyl acetate. The organic layer was washed with water, brine, dried over magnesium sulfate, filtered and concentrated. The crude product was purified by flash chromatography using 6:1 hexane:ethyl acetate followed by 3:1:0.05 hexane:ethyl acetate:methanol to give 1.79 g (49%)of product. ESMS: Calcd.

for C25H31N3, 393.23; Found 394.3 [M+H]+1 Part B: Preparation of 1-Benzyloxy-2,4-diethyl-5-[(5,5dimethyl-6-aminohexyl)oxy] benzene To a dry flask was added aluminum chloride (0.186 g, 13.9 nmmol). The flask was cooled to less than O'C with an ice/ethanol bath. Ether (5 mL) was added, and the reaction 179 was stirred for 5 minutes until the aluminum chloride dissolved. Lithium aluminum hydride (0..0531 g, 13.9 mmol) was then added, and the reaction was heated to reflux. 2- Benzyloxy-5-ethyl-4-[(5-methyl-5-cyanohexyl)oxy-acetophenone (0.250 g, 0.635 mmol) was dissolved in ether (2 mL) and added dropwise to the refluxing solution. After addition was complete, the reaction was stirred for 5 hours at room temperature. The reaction was then quenched with water. hydrosulfuric acid was added until a clear solution formed.

This mixture was then extracted with ether The aqueous layer was then cooled in an ice bath and basified to pH 14 with 50% aq. sodium hydroxide. The resulting solution was then extracted with ether The organic layer was washed with water, saturated NaC1, dried over magnesium sulfate, and evaporated to give 0.140 g of product as an oil. ESMS: S: Calcd. for C25H37N0 2 383.28; Found, 384.4 [M+H]+1 *o Part C Preparation of 2 ,4-Diethyl-5-[(5,5-dimethyl-6aminohexyl) oxy]phenol o 2 0 A small round bottom was purged with nitrogen. To this was added palladium on carbon (10 mg, 10%w/w) followed by ethanol (5 mL). l-Benzyloxy-2,4-diethyl-5-[(5,5-dimethyl-6aminohexyl)oxy]benzene (0.100 g, 0.527 mmol) was dissolved in 25 ethanol (5 mL) and added to the reaction. The reaction was evacuated and purged with nitrogen twice, and then evacuated and opened to hydrogen twice. The reaction was stirred under hydrogen for 1 h. The reaction was filtered through celite, washed with ethanol. The filtrate was concentrated under high vacuum to give 67.4 mg as an oil. ESMS: Calcd. for C18H31N02, 293.24; Found, 294.3 [M+H]+1 Part D Preparation of 2 4 -Diethyl-[5-[5,5-dimethyl-6-[[6- 2 -sulfonylphenyl)methylene]hydrazino]-3pyridinyl] carbonyl] amino] hexyl] oxy] phenol 2,4-Diethyl-5- [(5,5-dimethyl-6-aminohexyl)oxy]phenol (0.040 g, 0.136 mmol) was dissolved in dimethylformamide (2 mL). Triethylamine (56.8 J±L, 0.'408 mmol) was added and the reaction'-was stirred for 5 minutes. 2- S-Diox0.

pyrrolidinyl) oxyl carbonyl] -2-pyridinyl] hydrazono] methyl] benzenesulfonic acid, monosodium salt (0.072 g, 0.163 nunol) was added and the reaction was stirred for 24 hours under nitrogen. The reaction was then concentrated to an oil under high vacuum. The oil was triturated with ethyl acetate.. The -crude product was then purified by preparative HPLC Method 2 to give 15.1 mg of product. Mg: Calcd. for C31H40ON40 6 S 597.2747; Found, 597.2754 Example 59 Synthesis of 2- (S-Carboxypentyloxy) [6-f 4 hydroxyphenyl] oxy] hexyl )benzenepropnc aid 0 OH 0. 0 A OH

'NOH

0 *Part.A *Preparation of 2 6 -Methoxy-6-oxohexyoxy)6-[6..f[4.

acetyl-2-ethyl.5-.hydroxyphenyl] oxy] hexyl Jbenzenepropanoic* acid methyl ester 0 OH *0 0 00 0 2, 4 -Dihydroxy"5-*ethyl-acetophenione (20.8 mg, 0.117 Inmol)and 2- 6 -Methoxy-6-oxohexyoy) 6 -iodohexyllbenzenepropanoic acid methyl ester (0m, .96molwe dissolved in acetonitrile (5 znL). Potassium carbonate (53.3 mg, 0.386 inmol) was added, and the reaction was he ated to overnight. The reaction was concentrated under high vacuum.

The resulting residue was brought up in ethyl acetate and washed with water, brine, dried over magnesium sulfate, filtered, and evaporated. The resulting crude product was purified by flash column chromatography (5:1 hexane:ethyl acetate) to give 38.1 mg of product. MS: Calcd. for C33H 46 0 8 570.32; Found, 571.4 [M+H]+1 Part B Preparation of 2 -(5-Carboxypentyloxy)-[6-[6-[ 4 oxy]hexyl]benzenepropanoic acid 2-(6-Methoxy-6-oxohexyloxy)-6-[6-[[4-acetyl-2-ethyl-5hydroxyphenyl] oxy]hexyl]benzenepropanoic acid methyl ester (25.8 mg, 0.0452 mmol) was dissolved in tetrahydrofuran mL). Lithium hydroxide monohydrate (18.9 mg, 0.452 mmol) was dissolved in water (1 mL) and added to the reaction. The reaction was stirred for 18 h. The reaction was then concentrated, brought up in water, acidified to pH 5 with 1N HCl, and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over magnesium sulfate, filtered, and evaporated. The resulting oil recrystallized with hexane:ethyl acetate to give 24.5 mg (100%) of product.

MS: Calcd. for C31H420 8 H, 543.2958; Found, 543.2946 Example Synthesis of 2-((tert-butyl)oxycarbonyl)-7-(5-(4,6-diphenyl(2pyridyloxy))pentyloxy)-1,2,3,4-tetrahydro-isoquinoline-3- 2 carboxylic acid S

O

OCO

Part A: Preparation of 5-( 4 ,6-diphenyl-2-pyridyloxy)pentyl acetate 182 A mixture of 4 ,6-diphenyl-2-pyridone (2.5 g, 10.1 mmol), N,N-dimethylformaide (137.5 mL), methyl 6-bromohexanoate (3.17 g, 15.15 mmol) and silver carbonate (2.9 g, 7.58 mmol) was heated at 110 'C in the dark for 48 h. The mixture was allowed to cool to room temperature, filtered, and concentrated under high vacuum. The residue was purified by silica gel flash chromatography (hexane/ethyl acetate, 10:1) to give 2.85 g of product. 1H NMR (CDC13): 8.12-6.90 (m, 12H), 4.52 2H), 4.18 2H), 2.05 3H), 1.98-1.50 (m, 6H); ESMS: Calculated for C24H25N03, 375.18 Found 376.3 Rt= 21.013 min (88.5% pure, Vydac C18 column; gradient 20 to 100% acetonitrile/water 0.1% TFA over min) Part B: Preparation of 5-(4,6-Diphenyl-2-pyridyloxy)pentan-1-ol A solution of 5-(4,6-diphenyl-2-pyridyloxy)-pentyl 20 acetate (2.85 g, 7.59 mmol) in MeOH (107 mL)was treated with IN NaOH (26.82 mL) and stirred at room temperature for 16 h.

The.solvent was evaporated in vacuo, and the residue was acidified with 10% KHS04 and extracted with EtOAc The combined organic extracts were washed with saturated NaC1, dried over MgSO4, filtered and concentrated under high vacuum to afford 2.3 g of a yellowish solid. The product was used without further purification. 1 H NMR (CDC13): 8.15-6.90 12H), 4.56 2H), 3.76 2H), 1.95-1.50 (mp 7H); ESMS: Calculated for C22H23N02, 333.17 Found 334.3 Rt= 17.468 min (96.6% pure, Vydac C18 column; gradient 20 to 100% acetonitrile/water 0.1% TFA over 30 min).

Part C: Preparation of (5-(4,6-diphenyl(2pyridyloxy))pentyl)(methylsulfonyl)oxy.

A mixture of 5-(4, 6 -diphenyl-2-pyridyloxy)-pentan-1-ol (2.3 g, 6.9 mmol), ethyl acetate (50 mL), triethylamine (7.4 mL) and methanesulfonyl chloride (3.4 g, 29.7 mmol) was stirred at 0-5'C for 4 h and refrigerated for 24 h. The mixture was acidified with 1N HC1 and extracted with ether.

The ether extract was washed with water and brine, dried over MgSO 4 filtered and concentrated in vacuo to give 2.8 g (98%) of a yellowish solid which was used without further purification. 1 H NMR (CDC13): 8.14-6.90 (mi 12H), 4.56 (t, 2H), 4.34 2H), 3.05 3H), 1.98-1.52 7H); ESMS: Calculated for C23H25NO4S, 411.15 Found 412.3 Rt= 15 18.935 min (97.0% pure, Vydac C18 column; gradient 20 to 100% acetonitrile/water 0.1% TFA over 30 min).

Part D: Preparation of 2-((tert-butyl)oxycarbonyl)-7hydroxy-1,2,3,4-tetrahydroisoquinoline-3- arboxylic acid

CO

2

H

HO

HO

To a solution of L-1,2,3,4-tetrahydro-7hydroxylisoquinoline-3-carboxylic acid (1g, 5.18 mmol) in DMF (5.3 mL) was added triethylamine (0.87 nimL, 6.23 mmol) followed 25 by di-t-butyl-dicarbonate (1.13 g, 5.18 mmol). The mixture was stirred at room temperature for 17 h, evaporated in vacuo, dissolved in a minimum amount of ethyl acetate and filtered through silica gel using ethyl acetate as eluent. The filtrate was concentrated under high vacuum to give 1.2 g of a yellowish solid which was used without further purification. ESMS: Calculated for C15H19NO5, 293.13 Found.292.2 Rt= 9.091 min (92.1% pure, Vydac C18 column; gradient 20 to 100% acetonitrile/water 0.1% TFA over min).

Part Preparation of 2(:etbt!OXCabOy)7 6 -diphenyl(2-pyridvloxy) )pentyloxy) 2,3, 4 -tetrahydo isqioie3croyi acid A solution of 2- ((tert-butyl) oxycarbonyl) 7 -hydroxy- 1,2,3, 4 -tetrahydroisoqinoline-3-carboxylic acid.(72 mg, 0.244 rmol) in DMdF (0.'53 mL) was treated with NaH (50% dispersion in oil;. 6.4 mg,. 0.268 nMol) and stirred at 0 OC for 1 h. A solution'of (5-(4,.6-diphenyl(2pyridyloxy))pentyl) (rethylsulfonyl)ox (50 mg, 0.122 Inmol) in DMF 2 0 mL) was added dropwise and the mixture Was stirred at room temperature for 24 h. 'The solvent was removed in vacuc,-and the residue' was purified by reverse-phase

HPLC

(Water-acetonitrile gradient containing 0.1% TFA) to afford 47 mg of "a whi te powdered-solid. 1 H NMR (CDC13): 8.18-1 6.60 .4.50-4.38 (in, 3H), 4.0.5 (in, 1lH), 3.18 2H), 1.98-1.60- (in, .1.50 (mn, 9H). ESM'S: Calculated for' C37H40N20 6 1 608.29' Found .607.3 Rt=*22.403 min pure, Vydac C18 column;.gradient 20- to 100% acetonitrile/water 0.1% TFA .over 30 min).

,..Example.61 *Synthesis of 3- 6-diphenyl (2-pyridyloxy) )pentyloxy) -3ethoxyphenyl) ((6-hydrazino (3 -pyridyl) )sulfonyl) prop-2 25 enanuide

NN

02 IN 0.

Part A: Preparation of 4- 6-diphenyl (2-pyridyloxy) )pentyloxy) -3 -ethoxybenzaldehyde

-CHO

A mixture of G-dipheny.( 2 -pyridyloxy) )pentyl) (methylsulfoflyl)oxy (0.5 g, 1.21 xnmol), 3 -ethoxy-4-hydroxi benzaldehyde (0.2 g, 1.21 mmol), N,N-dimethylforamide (17 mL,) and cesium carbonate (0.79 g, 2.43 nimol) was heated at 60 *C for 18 h. The mixture was concentrated under high vacuum,.

taken up in water, and extracted with EtOAc The combined organic extracts were'washed with saturated NaCi, dried over MgSo 4 filtered and evaporated in vacuo to afford 0.38 g (65W) of product which was used without further purification. ESMS: Calculated-for C31IH3lNO 4 481.23 Found 482.4 Rt= 22.024 min (83'.4%.pure, Vydac C18 column; gradient 20 to 100%.acetonjtrile/water 0.1% TFA over Part B: Preparation of ethyl 3 4 -(5-(4,*6-.diphenyl(2pyridyloxy)) pentyloxy) 3 -ethoxyphenyl )prop-2-enoate 0

V,.

A mixture of NaH (50% dispersion in oil, 29 mg, 1.22 inmol), tetrahydrofuran (3.75 rnL), triethyl phosphonoacetate (0.24 niL, 1.18 inmol)*was stirred at 0 for 15 min.

A

solution of 6-diphenyl (2-pyridylox) )pentyloxy) -3 ethoxybenzaldehyde (380 mig, 0.789 nimol) in tetrahydrofuran (2 niL) was added. The mixture was stirred at room temperature for 18 h, concentrated under high vacuum, and partitioned between EtOAc and water. The organic phase was washed with brine, 'dried over MgSO4, filtered and evaporated in -Vacua.

Purification by silica gel flash chromatography (hexane/ethyl acetate, 4:1) yielded 310 mng of a white solid. 1 H NMR (CDCl3): 8.14 2H), 7.73-6.30 (in, 15H), 4.58 2H), 4.30 2H), .4.04 (in, 5H), 2.00 (in, 5H), 1.78 (mn, 2H), 1.45 (mn, 12H); ESMS: Calculated for C35H37N05, 551.27 Found 552.4 23.450 mmn (96.5% pure', Vydac C18 column; gradient 20 to 100% acetonitrile/waiter TFA over min).

Part C: Preparation of 3-(4-(5-(4,6.-diphenyl(2pyridyloxy) )pentyloxy) -3-ethoxyphenyl )prop-2-enoic acid To a solution of ethyl 3-(4-(5-(4,6-diphenyl(2- 15 pyr~idyloxy))pentyloxy)-3-ethoxhenyl)prop2-.enoate (250 mg.

0.453 minol) in ethanol (7 mL) was treated with. KOH (2.24 M, 0.68 mfL) and heated toSO 'Cfor 72 The mixture was concentrated under high vacuum,. diluted with water, acidified to PH 7 with IN HCl and extracted'with ether The ether 999 20 extract was washed with saturated.NaCl, dried over MgSO.4, filtered and concentrated in vacuo+ to give 140 mng of produc .t which was used without further purification. 1 H NM (DMSO-d6)': 8.25 2H),'7.98-6.30 (mn, 15H), 4.50 .2H) 1.90-1.25 (mn, ESMS: Calculated for C33H33N05, 523.24 Found 524.3 Rt= 20.4.36 min (96.5% pure, Vydac C18 column; gradient 20 to 100% acetonitrile/water 0.1%.TFA over 30 min).

Part D Preparation of 3-(4-(5-(4,6-diphenyl(2pyridyloxy) )pentyloxy) -3-ethoxyphenyl) ((6-hydrazino(3pyridyl) )sulfonyl)prop-2-enamide To a solution of 3-(4-(5-(4,6-diphenyl(2-pyrtdyloxy) pentyloxy) 3 -ethoxyphenyl)prop-2-enoic acid (0.231 inmol) in methylene chloride, is added 2-chioro- (0.243 inmol), dimethylaminopyridine (0.300 nunol), 1- (3-dimethylaminopropyl) -3-ethyl carbodiimide hydrochloride (0.231 mmol), and 4 A molecular sieves. The reaction mixture is stirred overnight for 18 h and is then filtered. The filtrate is washed with IN HC1, water, brine.

The organic layer is dried over magnesium sulfate, filtered, and concentrated to a small volume. The resulting concentrated solution is triturated with hexane. The product is filtered, washed with hexane and dried under high vacuum to give the chloropyridine intermediate. This intermediate (0.164 mmol) is brought up in hydrazine hydrate (5 mL). The reaction is heated to 70 "C for 18 h. The precipitate is dissolved in ethanol (10 mL) and the reaction is heated at 'C for another 20 h. The reaction is then concentrated under high vacuum to give the crude product, which is purified by flash chromatography.

Example 62 o:Synthesis of 2 ((6-((l-aza-2-(2-sulfophenyl)vinyl) -amino) (3pyridyl))carbonyl)-7-(5-(4,6-diphenyl(2-pyridyloxy))pentyloxy) -1,2,3, 4 -tetrahydro-isoquinoline-3-carboxylic acid

SO

3

H

N'-NH

^COH

Part A Preparation of 7 -(5-(4,6-diphenyl(2-pyridyloxy) )pentyloxy)-1,2,3, 4 -tetrahydroisoquinoline-3-carboxylic acid (trifluoroacetic acid salt) 0,,r NN0

CO

2

H

A solution of 2-((tert-butyl)oxycarbonyl)-7-(.5-(,6diphenyl 2 -pyridyloxy) )pentyioxy) -1,2,3 ,4-tetrahyroisoquinoline-3-carboxylic acid (30 mg, 0.049 mmol), the compound of Example 60, in dichioromethane (2.5 inL) was treated with trifluoroacetic acid mL) and stirred at room temperature for 2 h. The solution was concentrated under high vacuum, and the residue was lyophilized to afford 21 mg (84%) of a white powdered solid. 1 H IM (CD3OD): 8.20-6.80 (in, 16H), 4.61 2H), 4.42 2H)' 4.14 3H), 3.70 2H), 2.02-1.66 6H); ESMS: Calculated for C32H32N204, 508.24 9:9 Found 509.3 Rt= 16.871m (85.2% pure, Vydac C18 column; gradient.20 to 100% acetonitrile/water 0.1% TFA over min).

Part B Preparation of 2 6 sulfophenyl) vinyl).amino)( 3 -pyridyl))carbonyl)-7-.5-(4,6- S0., diphenyl(2-pyridyl-oxy))pentyloxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid A mixture of 7 4 ,6-diphenyl(2-pyridyloxy) )pentyloxy) 4 -tetrahydroisoquinoline- 3 -carboxylic acid (trifluoroacetic acid salt) (0.0805 mmol),'N,N-dimethyl formanide (2 miL), and triethylamine (0.2478 mmol) is stirred at room temperature for 15 min. 2 [5[-(((2,5-Dioxo-lpyrrolidinyl) oxy] carbonyl] -2-pyridinyl] hydrazono methyl] benzenesulfonic acid, monosodium salt (0-.0991 mmol) is added and the mixture is stirred under nitrogen. After 24 h, the mixture is concentrated under high vacuum. Purification by reverse-phase HPLC (water-acetonitrile gradient containing 0.1% TFA) yields the desired product.

Example 63 Synthesis of 2- (1-aza-2-(2.-sulfophenyl) vinyl)..

amino) 3 -pyridyl)carbonylamino)-3-(4-(5-(4,6-.diphenyl(2 pyridyloxy) )pentyloxy)phenyl)propanoic acid 0 H

S

3 Part A: Preparation of benzyl. 2-((tert-'butoxy)carbonylamino) 6-diphenyl (2-pyridyloxy) pentyloxy) phenyl) propanoate 0 0 6@6600 0.010 04:10A mixture of 6-diphenyl (2-pyridyloxy) )pentyl) (methylsulfonyl)oxy (200.mg, 0.487 mmol), Boc-Tyr-OBzl (181mg, 0.487 mmol), N,N-dimethylforamide.(7 niL) and cesium carbonate 0*0 0 (317.mg, 0.974 nimol) was heated to 60 'C for 18*h. The 15 mixture was concentrated under high vacuum, diluted with water 0 00 Sand extracted with EtOAc -The combined organic extracts 00 were washed with water and saturated NaCi, dried over MgSO4, and concentrated in vacuo. Purification by reverse-phase

HPLC

(wat er-acetonitrile gradient containing 0.1% TFA) Yielded 140 20 mg (42%).of a white powdered solid. 1 H NMR (CDC13): 8.14- 6.66 (in, 22H), 5.11 (in, 3H), 4.59 2H), 4.00 2H), 3.08 2H), 1.88 (in, 10H), 1.40 (in, 12H); ESMS: Calculated-for C43H46N206, 686.34 Found 687.4 Rt= 23.460 min (99.6% *pure, Vydac C18 column; gradient 20 to 100% acetonitrile/water 0.1% TFA over 30 min).

Part B: Preparation of 2-((tert-butoxy)carbonylamino)-3-(4- 6-diphenyl(2-pyridyloxy)) pentyloxy) phenyl) propanoic acid A mixture of 10% Pd on carbon (13 mg) and ethyl acetate xnL) was added to a dry flask and stirred at room temperature for 10 min. A solution of benzyl 2 -((tertbutoxy) -carbonylamino) (5-v 6-diphenyl 2 -pyridyloxy) pentyloxy)phenyl)propanoate (130 mg, 0.189 mmol) in 5 niL of ethyl acetate was added'dropwise. The mixture was stirred under atmospheric hydrogen for 24 h and filtered through Celite using ethyl acetate as eluent. The filtrate concentrated under high vacuum to give 52 mg of a yellowish oil which was* used without further purif ication.

ESMS: Calculated fr314N0,596.29 Found 597.3 Rt= 20.989 min (100% pure,. Vydac C1 8 column; gradient to 100% acetonitrile/water 0.1% TFA over 30 min).

Part Preparation of 2.-amino-3-(4-(5-(4,6dipheniyl(2 -pyri'dyloxy) )-pentyloxy) phenyl )propanoic acid (trifluoroacetic acid salt) A solution of 2- ((tert-butoxy) -carbonylamino) (4-1(5- 7. 6.-dipheny. (2-pyridyloxy) )-pentyloxy) phenyl) propanoic acid (53 mg, 0.088 nimol) in dichloromethane (49m)was treated with trifluoroacetic acid (4.9 mL) and stir .red at room temperature for 1 h. The- solution was-concentrated under high vacuum, and the residue was lyoph .ilized to give 43 mg of a white powdered solid. 1H1 NMR (DMSO-d6): 8.25-6.80 (in, *1611), 4.54 4.12 (in, 3H), 3.06 1.80 (mn, 6H); *ESMS:. Calculated for C31H32N 2 0 4 496.24 Found 497.3 Rt= 16.257 min (100% pure, Vydac C18 column; gradient 20 to 10O0% acetonitrile/water 0.1% TFA over 30 min).

Part D: Preparation of 2 sulfophenyl) vinyl) amino) (3-pyridyl) carbonylamino) -3L 6-diphenyl (2-pyridyloxy)) pentyloxy) phenyl )propanoic acid A mixture of 2 -amino- 3 -(4-(5-(4,6-diphenyl(2.

pyridyloxy) )-pentyloxy)phenyl) propanoic acid (40 mng, 0.0805 inmol), N,N-dimethyl fommamide (2 mL), and triethylamine (34.5 mL, 0.2478 mniol) was stirred at room temperature for 15 min.

2 ,S-Dioxo-l-pyrrolidinyl)oxcyI carbonyl]-2pyridinyl ]hydrazono] methyl] -benzenesulfonic acid, monosodium salt (43.6 mg, 0.0991 mmol) was added and the mixture was stirred under nitrogen. After 24 h, the mixture was concentrated under high vacuum. Purification by reverse-phase HPLC (water-acetonitrile gradient containing 0.1% TFA) yielded 25 mg of a white powdered solid. IH NMR (DMS0d6): 9.40 1H), 9.02 1H), 8.54 1H), 8.30-6.76 (in, 26H), 4.58 (in, 3H), 4.00 2H), 3.10 (mn, 2H), 1.78 (in, 6H); ESMS: Calculated for C44H41N50 8 S, 799.26 Found 800.3 Rt= 16.691 min (98.0% pure, Vydac C18 column; -adient 20 -to 100% acetonitrile/water +.0.1%-TFA over ruinf).

Example 64 Synthesi s of (-aza-2-+(2-sulfophe nyl)vinyl) amino) 3 -pyridyl)carbonyamino.3(2-(5-.(46-dipheny(2.

pyridyloxy) )pentyloxy) phenyl) propanoic acid 0 2

H

_oHN- N6 Part A: Preparation of methyl 2-amino-3-(2- *hydroxyphenyl) propanoa te (hydrochloride)

NH

2 25 OH 0 A solution of DL-o-tyrosine (2g, 11.04 minol) in methanol niL) was treated with concentrated HCl (0.67 niL, 22.08 ~mol) and refluxed for 24 h. The solution was cooled to room temperature and concentrated under hi gh vacuum to give 2 g 30 of a brownish solid which was used without further purif ication. 1 H NMR (DS-6:7.15-6.12-(in, 4H1),-42(t lH), 3.75 3H), '3.08 2H); ESIMS: Calculated for ClOH13NO 3 195.09 Found 196.1 [M+HI+l; Rt- 2.956-3.850 min (100% pure, Vydac C18 column; gradient 20 to 100% acetonitrile/water 0.1% TFA over 30 min).

Part B: Preparation of methyl 2-((tert-butoxy)carbonylamino) (2 -hydroxyphenyl )propanoate To a solution of methyl 2 -amino -3 -hydroxyphenyl)..

propanoate (1.5 g, 7.68 nunol) in- DMF (10 inL) was added triethylamine (2.14 mL, 15.36 nimol) followed by di-tert-butyl.

di-.carbonate (1.68 g, 7.68 nimol)-, and the mixture was stirred at room-temperature for 18 h. The mixture was concentrated 15 under high vacuum dissolved ina minimal amount ofEtOAc, filtered through silica gel using EtOAc as. eluent. The :filtrate was concentrated in vacuo and puri -f ied' by silica gel flashcrmtozah (hexane/ethyl acetate, 7:3) to provide *1.1 g of a-white. solid. 1 H NMR (CDCl3): 7.20-6.76 (mn, 4H), 4.47 1H), 3.77 3H), 3.12 2H), 1.47 (mn, 9H); ESMS: Calculated for C15H21N0 5 295.14 Found 294.2 Rt= 11.471 min (89.1l% pure, Vydac C18-:column; gradient- 20 to 100% acetonitrile/water 0.1% TFA over 30 min).

Part+ C: Preparation of methyl 2 ((tert-butoxy)carbonylamino) 6-diphenyl (2-pyridyloxy pentyloxy) phenyl )propanoate- I ~HNtO> 0- 0 A mixture of 6-diphenyl (2-pyridyloxy) )pentyl) (methylsulfonyl)oxy (400 mng, 0.972 mmol) and methyl-2-((tertbutoxy) -carbonylamino) (2-hydroxyphenyl.) propanoate (287 mng, 0.972 mmol), N,N-dimethylforamide (20 mL), cesium carbonate (633 mg, 1.944 mmol) was heated to 79 'C for 18 h. The mixture was concentrated under high vacuum, diluted with water and extracted with EtOAc The combined organic extracts were washed with water and saturated NaCI, dried over MgSO 4 filtered and concentrated in vacuo. Purification by reversephase HPLC (water-acetonitrile gradient containing 0.1% TFA) yielded 350 mg of a white powdered solid.

ESMS:

Calculated for C37H42N 2 0 6 610.30 Found 611.3 (M+HI+1; Rt= 23.124 min (100% pure, Vydac C18 column; gradient 20 to 100% acetonitrile/water 0.1% TFA over 30 min).

Part D: Preparation of 2 -((tert-butoxy)carbonylamino)-3-(2-(5-(4,6-diphenyl( 2 -pyridyloxy))- 15 pentyloxy)phenyl)propanoic acid

HNO

A solution of methyl 2-((tert-butoxy)-carbonylamino)-3- (2-(5-(4,6-diphenyl(2-pyridyloxy))pentyloxy)phenyl)propanoate (145 mg, 0.237 mmol) in THF (15.8 mL) was treated with lithium .hydroxide monohydrate (0.6 M, 4 mL) and stirred at room temperature for 18 h. The mixture was concentrated under high vacuum, diluted with water, acidified to pH 3 with IN HC1 and extracted with EtOAc The EtOAc extract was washed with water and brine, dried over MgS04, filtered and concentrated in vacuo to yield 125 mg of a white solid which was used without further purification. ESMS: Calculated for C36H40N 2 0 6 596.29 Found 597.3 Rt= 21.353 min (95.8% pure, Vydac C18 column; gradient 20 to 100% acetonitrile/water 0.1% TFA over 30 min).

Part E: Preparation of 2 amin0-3-(2 (5-(4,6-dipheflyl.( 2 pyridyloxy) )-pentylor) phenyl )propanoic acid (trifluoroacetic acid salt) A solution of 2-((tr-uoy)croyain)3(-5 6 -diphenyl(2-pyridyloxy) )-pentyloxy) phenyl )propanoic acid mng, 0.159 mxnol) in dichioromethane (5 mL) was treated-with trifluoroacetic acid (5 niL) and stirred at room temperature 'for 30 min. The solution was concentrated under high vacuum, and the residue lyophilized-to give 79 mg (100%) of a white powdered solid. ESMS: Calculated for.C31H32N20 4 496.24 Found 497..3 Rt= 16.002 min.(97.1% pure, Vydac 018 column; gradient 20 to 100% Acetohitrile/water TFAover min).

*-Part F: Preparation of -(-1az2(- E+-diphenyl (2 -pyridy .loxy).).pentyloxy )phe nyl).propanoic acid A solution of 2 -mio-3-(2(5..(46.diphenyl(2pyiylx) petlxphnlroaicacid (53 mg, 0.106 inmol) in DMF (2 mL) was added triethylamine (44.3 roL, 0.318 nimol) and stirred at room temperature for 15 min. 2-1[[5- U -i'x--yroidnloxyI carbonyl) 2 -pyridinyl] 25 hydriazonolmethyl].benzenesulfonicacid,. monosodium salt (56.4 mg, 0.128.nimol) was added. The mixture was stirred for 4 h, coincentrated under high vacuum, ,and purified by, reverse-phase HPLC (water-acetonitrile gradient containing TFA) to afford 41 mg of a white powdered solid. IH NM~R (DMSOd6): 8.54 1H), 8.28-6.70 (in, 22H), 4.80 1H), 4.55 (t, 2H), 4.12 2H), 3.00 1H), 1.85 (in, 6H);

ESMS:

Calculated for C44H41N 5 0 8 S, 799.27 Found 800.3 Rt= 16.407 min (100% pure, Vydac C18 column; gradient 2,0 to 100% acetonitrile/water 0.1% TFA over 30 min).

Example 195 Synthesis of (6-((l-aza-2-(2-sulfophenyl) vinyl) amno) 3 pyridyl) carbonylamino) 6-diphenyl (2-pYridyloxcy) 2,2 -dimethyihexyl) carbainoyl )propanoic acid.

0 C0 2 H H S0 3

H

N N N-N-

N

"0 H HN 0 Part A: Preparation of tert-butyl 3'-((tertbutoxy)carbonylamino) 6-diphenyl(2-pyridylo,) 2,2 -diLmethyihexyl) carbamoyl )propanoate

N

H

-0 0 A solution of 6- 6-diphenyl(2-pyridyloxy) dimethylhexylamine (100 mng, 0.267 mmol), as described in Example 10, Part C, in DMF (5 niL) was added triethylamine (112 mL, 0.8.01 inmol) and stirred at room temperature for min. Boc-Asp(OtBu)-OSu.(124 mg, 0.320 mmol) was added, and the mixture was stirred for 4 h. The mixture was concentrated under high vacuum, taken up in water and extracted with EtOAc.

The EtOAc extract was washed with water and saturated NaCi,dried over MgSO4, fil tered and eVporated in vacuo. The resulting residue was lyophilized to give 155 mg of product. The product was used without further purification.

ESMS: Calculated for C38H51N306, 645.38 Found 646.3 At= 23.397 min (94.1% pure, Vydac C18 column; gradient 20 to 100% acetonitrile/water 0.1% TFA over 30 min).

Part -rPrtoof .3..amino3- i...(N-(46(diphenl PYridyloxy) -dimethyihexyl) carbamoyl) propanoic acid (trifluoroacetic acid salt) A solution of tert-butyl 3 -((tert-butoxy)carbonylajmf 0 3- 6-diphenyl 2 -pYridyloxy) -2,.2-dimethyihexyl)carbamoY1)propanoate (150 mg, -0 .232 inmol) Yin dichioromethane niL) was treated with trifluoroacetic acid (7 MnL) and stirred at room temperature for 30 min. The solution was concentrated under high vacuum, and the residue was lyophilized to give. 180 mg of product which was used without further purification. ESMS: Calculated for*C29H35N 3 0 4 489.26 Found 490.3 [MH+;R=1.8 m (95.2% pure, Vydac C18 column; gradient 20.to 100O%*acetonitrile/water 15 0.1% TFA over 30 min).

Part C: Preparation ~of 3 6 aza-2-(2- Sulfophenyl )vinyl) amino)*(3-yrdl aroymi)-3- 6-diphena. 2 -pyridyl oxy) 2-dimethyihexyl) carbamoyl)propanoic acid A mtixture of 3 -amino-3 6 7-diphenyl pyridyloxy) 2-dimethylhexyl) carbainoyl) propanoic acid 0.040.8 inmol), N,N-dimethylformamide zL) and triethylamine (17 mL, 0.122 nimol) was stirred at room, temperature for 15 min. 2 pyrrolidinyl) oxyl carbonyl] -2-pyridinyl] hydrazono] methyl] *benzenesulfonic acid, monosodium salt (21.6 mg, 0.0492 nimol) was added, and the mixture was stirred for 25 h. The mixture was concentrated under high vacu .um, and the residue was purified by reverse-phase HPLC (waters-acetonitrile gradient containing 0.1% TFA) to afford 15 mg of a white powdered solid. 1 H NMR (DMSO-d 6 9.45 1H), 9.00 1H), 8.50- 7.15 (in, 19H), 7.10 1H), 4.95 lH), 4.51 2H), 3.25- 2.50 (in, 4H), 1.80-1.25 (mn, 6H), 0.80 6H); ESMS: Calculated for C42H44N60 8 S, 792.29 Found 793.4 [M+HU+1; Rt= 15.488 min (98.3% pure, Vydac C18.column;.gradient 20 to .100% acetonitrile/wate r 0.1% TFA over 30 min).

S~ntheEXaMPle 66 S n h s i s o f 2 a a 2 5 3 2 me thyl 2 -phenyl ethyl) carbarnoyl) me thyl) (phenylmetho,) indol-2.yl) carbonylamilo) propoxcy) ethoy) ethoxy) propyl carbaxnoyl) (2 -pyridyl) min0o vinyl) benzenesulfonic acid.

Part A: Preparation Of 2-2H 10 buto'cy) carbonylminlo) propoy) ethox-y) eNho(3y) 'rpl carbamoyl) er 5- (phenylImetho,) indolyl) )N-methyl...N 2 -Pheylethyl) ethanamide eh -N 2-hn ety 0 N

-N

To a solution~ of 1:(N-rnethy.N-( 2 eyltyicarbamnoy methyl -5-(benzyloxy) ifdole.2ca...lci d 13 mg, 1 0.3 mnOl), as described in Example 25, Part c, nDF( mL as a ded isoprOPylethYl .m n (130 ML, 0.75 xruol) followed by 2 -(1H-benzotriazoi yl-14,,3,3- tetramethylurnu hexafluorophosphat (114 mng, 0.3 flmfol).

The solution was stirred at room temperature for 5 min, and

N-

3 -amino)Pr0poxy) ethoxy) ethoxcy)prOPYl) -(tertbutoxyl)fOrmamde (80 mg, 0.250 Xfmol) Was added. The mixture was stirred for 18 h, concentrated under high vacuunl~and purified by reverse-phase HPLC (water-acetonitrile gradient containing 0.1% TFA) to afford 140 mg (75 of product.

ESMS: Calculated for C42H-56N 4 0 8 744.41 Found 745.S Rt= 18.006 min (96.2% pure, Vydac C18 column; gradient 20 to 100% acetonitrile/water TFA over min).

Part B: Preparation of2-(2-(-Q-2-(2-3 aminopropoxy) ethoxy) ethoxy) propyl) carbainoyl) (phdnylmetho,) indolyl) -N-me-thyl-N- (2 -phenylethyl) -ethanamide -(trifluoroacetic acid salt) A solution of 2 2 (N(3(2(2(3.((tert-butoxcy)- 15 ca'rbonylamino) propoxy)ethoxy)'ethoxy) propyl) carbamoyl) (phenylmethoxy) indolyl) -N methyl,-N-( 2 -phenylethyl) -ethanamide (140.mg, 0.188 inmol) in-dichioromethane.(7 mL) was treate~d *.with trifluoroacetic acid niL) and stirred at room' temperature for 30 min. The. soluti.on -was concentrated -under high vacuum, and the residue was lyophilized to give 13.0 rng of a white.'powdered solid.. ESMS: -Calculated for C37H48N 4 0 6 644.36 'Found 645. 4' Rt= 13.737 min (94.6% pure, Vydac C18 column;.gradient. 20 to 100%.

acetonitr*ile/water 0.1% TFA over 30 min).

Part C: Preparation of ((N-methyl-N- (2 -Phenylethyl) carbamoy))methyl) (phenylmethoxy) -indol-2-y1) carbonylamnino)propoxy) ethoxy) ethoxy) propyl) -carbamoyl) (2 -pyridyl) )amino) vinyl)boenzenesulfonic acid.

A solution of 2 2 (N(3-.(2-(2(3-.an1.nopropoy)thox)' ethoxy) propyl) carbamoyl) (phenylmethoxy) indolyl) 4 -methy1

-N-

2 -phenylethyl)..ethami (130 mg, 0.171 nmmol) in DMF (4 mL) was added triethylamine (84 niL, 0.606 nunol) and stirred at room temperature for 15 min. 21 pyrrolid inyl) oxy] carbonyl] -2 -pyridinyl] hydrazono] methyl] benzenesulfonic acid, monosodium salt (107 mg, 0.242 inmol) was 199 added, and the mixture was stirred for 24 h. The mixture Was concentrated under high vacuum and purified by reverse-phase HPLC (water-acetonitrile gradient containing 0.1% TFA) to provide 116 mg of a white powdered solid. 1 H NMR (DMSOd6): 8.60-6.75 24H), 5.5 1H), 5.36 1H), 5.18 (t, 2H), 3.60 16H), 3.15-2.64 7H), 1.80 4H), 1.25 (t, 1H); ESMS: Calculated for C5QH57N70 10 947.39 Found 948.4 Rt= .13.750 min (98.1% pure, Vydac C18 column; gradient 20 to 100% acetonitrile/water 0.1% TFA over min).

Example 6.7 Synthesis-of 2-(2-((6-((l-aza-2-(2-sulfophenyl)vinyl).

amino) (3-pyridyl) carbonylamino) -3-carboxypropanoylamino) (2- (4,6-diphenyl(2-pyridyloxy))pentyloxy)phenyl)propa 0 ji acid a H0 3

S

0 2 H 0 N

HN-N

C02H Part A: Preparation of 2-3-((tert-butyrl) oxycarbonyl)diphenyl(2-pyridyloxy))-pentyloxy)phenylpoao 200 A mixture of 2 mi0-3- 4...-dip .h enyl.(2 pyridyloxy)) -pentyloxy)phenyl)propan 0 j~ acid (166 mg, 0.334 nunol), N,N-dimethylformanide (4 mL) and triethylamine (0.14 mL, 1.00 rnrol) was stirred at room temper .ature for 15 min.

Boc-Asp(OtBu)..oSu (155 mg, 0.401 nimol) was added and the mixture was stirred for 2h.. The mixture was concentrated under~high vacuum" diluted with water and extracted'with EtOAc The combined organic extracts were washed -with water and saturated NaCi, dried over MgSO4 and filtered. The filtrate was concentrated in vacuo and lyophilized to give 228 mg of product- which was used without further purification. ESMS: Calculated for C,44H53N30 9 767.38 Found 768.4 Rt='17.484 min pure, Vydac'C18 column; gradient. 20 to 100%.acetonitrile/water- 0.1%'TFA min).

T art B: Preparation of 2 (amino-.3-carboxypropanoylamino) 6-diphenyl(2-pyridyloxy) )pentyloxy) .pheny1) pr'opanoic acid.(trifluoroacetic acid. salt) A solution of 2- (tert-butyl)oxcycarbonyl) (tertbutoxy) -carbonylamino)propanoylamino) 6-diphenyl.(2yr'yoy)pnyox~hnlpoaot (205 mg, 0.267 nimol) in dichloromethane (5 niL) was treated with trifluoroacetic 25 acid (7 niL) and stirred at room temperature for 1 h, The solution was concentrated under high vacuum, and the residue was Jlyophilized to give 210 mg of product. ESNS: :Calculatedfor C35H37N 3 0 7 611.26 Found 612.4 Rt= 15.413 min a (91.0% pure, Vydac CiB column; gradient 20 to 100% acetonitrile/water 0.1% TFA over 30 min)-.

Part C: Preparation of sulfophenyl) vinyl) amino) 3 -pyridyl) carbonylamino) -3carboxypropanoylamino) 6-diphenyl (2-pyridyloxy) )pentyloxy)phenyl~propanoic acid A solution of 2- (aino-3-carboxypropanoy1amino) 6 -diphenyl 2 -pyridyloxy) )pentyloxy) phenyL )propanoic acid (84 mg, 0.137 mmol) in DMF (2 mL) was added triethylamine (57 mL) and stirred at room temperature for 15 min. [[(2,5-Dioxo-l-pyrrolidinyl)oxylcarbonyl-2-pyridinyl] hydrazonolmethyl] -benzenesulfonic acid, monosodium salt (73 mg, 0.165 mmol) was added and the mixture was stirred for 48 h. The reaction was monitored by analytical HPLC, and the chromatogram showed that there were two diastereoisomers in the reaction. The mixtuire was concentrated under high vacuum, and the two diasteroisomers were separated by reverse-phase HPLC (water-acetonitrile gradient containing 0.1% TFA) to afford 11mg of each isomer. ESMS: Calculated for C48H46N 6 0 11 S, 914.29 Found 915.4 For SK983: Rt= 14.686 min (88.5% pure, Vydac Cl8 column; gradient 20 to 100% acetonitrile/water 0'.l%+TFA over 30 min); For SK894: Rt= oS 15 .15.129 min (95.7% pure, Vydac C18 column; gradient.20 to 100% acetonitrile/water 0.1% TFA over 30 min).

S..

Example 68 Synthesis of 2 2 2 dioxoimidazolidin-4-y)acetylamino)-propoxy)ethoxy)ethbxy)propyl carbamoyl)-1- 6-diphenyl (2-pyridyoxy)) -2,2dimethylhexyl)carbamoyl) -ethyl) carbamoyl(2 -pyridyl))amino)vinyl)benzenesulfonic acid 0

H

H OD NH 0 00 N

HN\"

HNH

NH

H

S0 3

H

Part A: Preparation of butoxy)carbonylamino)propoxy) ethoxy) ethoxy) propyl-2-(2,5dioxoimidazolidin- 4.yl) ethanamide.

202 0

HH

A mixture of S-hydrantoinacetic acid (0.44 g, 2.78 nunol, N,N-dimethylfomaide (10 rnL), diisopicopylethylamine (1.2 mL, 6.96 mmol) and 2- (lH-benzotriazole.1.yl) -li 3 3 -tetramethy1l uronium hexafluoro- phosphate ,(2.64 g,:6-.96 mmol) was. stirred at room temperature for.5 min. amino) propoxy) ethoxcy) ethoxy) propyl) (tert-butoxyl) formamide (0.744 g, 2'.32 mmol) was added and the mixture was stirr-ed for 24 h. The mixture was concentrated under-high vacuum, and the residue was. .Purified by silica'gel flash chromatography (chloroform/methanol, 4:1)'to give 0.75 g of a brownish oil.. ESMS: Calculated for C20H36N40 8 460.25 -Found 461.3 M+H]+1 Preparation'of

N-(

3 -(2-(2-(3-amnopropoxy, ethoxy) ethoxy)propyl2..(2, S-dioxoimidazolidin-4.yl) ethanamide. (trifluoroacetic acid salt) *A solution of N-( 3 2 -(2-(3-((tert-butoxy)_ carbonylamno)prop,,) ethoxy) ethoxy)propyl-2-(2,5dioxoimidazolidin4y)ethanamjde (0'.75 g,.1.6-4 imoal) in dichloromethane (10 mL) was treated with trifluoroacetic acid MiL) and stirred-at room temperature for 1 h. The solution was concentrated under high vacuum, and the residue was 25 lyophilized to give 0.75 g of product.

ESMS.

Calculated for C15H28N40 6 360.20 Found 361.2 [M+H]+l Part C: Preparation of 3 -((tert-butoxy)carbonylamino- 3- (41 E-di phenyl+ (2-pyridyloxy) 2 2 -dimethylhexyl) 'carbainoyl) -propanoic acid To a solution of 3-amino-3- 6-diphenyl (2- Pyridyloxy) 2 -dimethylhexyl,)carbamoyl )propanoic acid (120 mg, 0.253 nmol) in acetonitrile (3 mL) was added triethylamine 5(42.4 mL) followed by di-tert-butyl.dicabnate (55 mg, 0.253 .Mmol). The mixture was stirred at room temerature for 4 h, concentrated under high vacuum and filtered through silica gel using'ethy. acetate as eluent. The filtrate was evaporated in vacuo and lyophilized to provide.163 mg of 'product. which was used without further purification. ESMS: Calculated for C34H43N 3 0 6 589.32 Found 590.2. Rt= 20.268 min (94.2% -pure,.Vydac C18 column; gradient 20 to 100% acetonitrile/water TFA over 30 min).

Part D: Preparation of 2-((tert-butoxy)carbonylamino 0 N' S-dio*oimidazolidin..4..yl)acetylamfino)propoxy) ethoxy) ethoxy)propyl) 6-dipheniyl (2iylyoxy))-22dmtyhxlbtn-, 4-diamide NN 0

J

4 0 00

*NH

HN

)NH 0 0 A mixture of 3- ((tert-butoxy)cabonylamino 3 (4,6diphenyl 2 -pyridyloxy) -dimethylhexyl) carbamoyl) -propanoic acid (141 mg, 0.239 Inmol), N,N-dimethylfomamide (6 mL), diisopropylethylamne (0.1 mL, 0.60 mmol) and 2-(1Hbenzotriazole-1-yl) 3 -tetramethyluronium 204 hexafluorophosphate (90. mg, 0.2-39 inmol) -was stirred -at room temperature for 15' min. 3 -aminopropoxy) ethoxy) ethoxy)propyl 2 S-dioxoimidazolidin.4.yl) ethanamide (94 mg, 0.199 mmol) was added and the mixture was stirred for 18 h.

The mixture was concentrated under high vacuum and Purified by reverse-phase HPLC (wa ter-acetonitrile containing 0.1% TFA) to afford 68 mg of a white powdered solid.

'ESMS:

Calcul 'ated for.C49H6 9

N

7

O

11 931.50 Found 932.6 fM+Hl+l; Rt= .17.822 nun (S2.3% pure, Vydac C18 'column; gradient 120 to 100% acetonitrile,'water.+ 0.1% TFA over 30 min).

Part E: Preparation of 2(25- diOxoimidazoidin 4 .Yl) acetylamino) -poxyehxyethoxy)propyl) 6 -diphenyl 2 -pyridyloxy) dimethylhexyl)butanel1 4 diide (trifluoroacetic acid salt) X solution of 2--((tert-butoXY) carbonylamino-N, (2- Sdioxoinidazolidin.4 yl)act1 -in).

o ~propoxy.) ethoxy) ethoxyypropyl) 6- 6-diphenyl (2o: 20 -Pyridyloxy)-) 2 2 dine thylhexy)butane 1 4-diainide' (6 8 mg, 0..07.3 mmol) indichloromethane.(4 mnL trated with oooo trifluoroacet ic acid (4 mL) and stirred at room temperature for 1 h. The solution was concentrated under high vacuumn, and the residue was lyophilized to give 60 mg of 25 product. ESMS: Calculated for C44H61N 7 0 9 831.45 Found 832.5 (M+HJ+1; Rt= 14.308 min (75.8% pure,- Vydac C18 column; *gradient 20 to 100%+ acetonitrile,'water t-0.1% TFA over Part F: Preparation of S-dioxoimidazolidin4.yl) acetylanino) propoxy) ethoxy) ethoxy)propyl) carbamoyl) (4,6diphenyl 2 -pyridyloy) 2 -dimethylhexyl) carbamoyfl ethyl) carbamoyl (2-pyridyl) )amino) vinyl) benzenesulfonic acid A solution of 2aioN-3(-2(3(-25 dioxoimidazolidin4.yl) acetylamino) -propoxy) ethoxy) ethoxy) propyl) 6-diphenyl (2-pyridyloxy) 205 dim thlheyl)butne-1, iaide(60 mg, 0.072. imol). in DMF (2 m.L) was added triethylamine (30 xnL, 0.216 mmol)* was added and stirred at room temperature for 15 min. 2 pyrrolidinyl )oxy] carbonyl] 2 -pyridinyl] hydrazono] -methyl] benzenesulfonic acid, monosodium salt (73 mg, 0.165 Inmol) was added and the mixture was stirred for 48 h. The mixture was concentrated under high vacuum, and the residue was Purified by reverse-phase HPLC (water-acetonitrile gradient containing 0.1% TFA) to afford 12.8 mg of a white' powdered solid.

ESMS: Calculated for C57H70NI 0 0 1 3 S, 1134.48 Found 1135.6 Rt= 14.167 min (86.1% pure, Vydac C18 column; gradient .20 to 100% acetoni tril1e /water 0.1% TFA over min).

Example 69 Synthesis of (l-aza-2-(2-sulfophenyl)..

vinyl). amino) Q3-pyridyl) carbonylamino) -2 ((N-methyl (2 phenylethyl)carbamoyl) methyl) (phenylmethoxy) indol-2 yl) carbonylami no) hexanoic acid.

0

HN

'k l N N-N_ S0 3

H

0 N C02H-

H

fN 00 20Part A: Preparation of tert-butyl -((tert-butoxy)carbonylamino) ((N-methyl-N- (2-phenylethyl) carbamoyl) methyl) (phenylmethoxy) indol-2-yl) carbonylamino) hexanoic acid .206

_-N

To 'a mixture of l 1-((N-methy-N- (2 phenylethy)..

indole-2-carboxylic acid (180 mg, 0.407 mol), N;N-dimethylfomaide (4 rnL)..

diisopropylethy1amine (0.18 mL, 1.02 mmol.) wasadded .2-(1Hbenzotriazole-1-yl) -1,1I,3, 3 -tetramethyluronium hexafluoro'phosphate'(154 mg, 0.407 nimol.). .After stirring at.

*room. temperature for .5 min,' H-Ly (Boc) -OtBu.HCl. (103 mg, 0.339 mmol) was added and the mixture was 'stirred for 24*h.

The mixture was concentrated under high vacuum and purified by reverse-phase HPLC (water-acetonitrile gradient containing 0.1%'TFA) to afford 137 mg A white powdered solid., ESMS: Calculated for C42H54N 4 6 7 726.40 Found 744.6 [M+NH4]+1; Rt= 19.783 min (98.6% pure, Vydac C18 column;, gradient 20 to 100%*acetonitrile/water 0.1% TFA over min).

Part B: Preparation of 6 -amino-2-((-((N-methylN-(2- ~phenylethyl) carbamoyl) methyl) (phenylmethoxy) indol-2 yl)carbonylamino)hxanoi acid (trifluoroacetic acid salt) A solution of tert-butyl 6-((tert-butoxy)carbonylamno)- 2- ((1-((N-methyl-N- 2 -phenylethyl) carbamoyl)methyl) (phenylmethoxy) indol-2-yl) carbonylamino) hexanoic acid.(137 mg, 0.188 mmol) in dichioromethane (7 mL) was treated with trifluoroacetic acid (7 ml,).and stirred at room temperature for 1 h. The solution was concentrated under high-vacuum, and -207 the 'residue was lyophilized. to give 103 mg of product.

ESMS: Calculated for C33H38N 4 0 5 570.28 Found 569.3 Rt= 12.423 min (93.1% pure, Vydac C18 columnn; gradient 20 to 100% acetonitrile,water 0.1% TFA over 30 min).

Part C: Preparation of sulfophenyl)vinyl)amino) (3-pyridyl) carbonylanino) methyl-N- 2 -phenyle'thyl) carbamoyl) methyl) (phenylmethoxy) indoJ.-2-yl) carbonylamino) hexanoic acid A solution of 6-amino-2-((-(N-methylN(2phenylethyl) carbamfoyl)methyl) (phenylinethoxy) indol-2yl)carbonylamino)hexanoic acid .(68 mg, 0.119 inmol) in DMF ML) .was. Added triethylamine (50 i, 0.357 inmol) and stirred at -room temperature for 15 min. pyrrolidinyl) oxy] carbonyll -2-pyridiiyl] hydrazono] methylbenzenesulfonic acid, monosodium, salt .(63 mg, 0.143 mmol) was added and the mixture was stirred for 24 h. The mixture was concentrated under high vacuum and purified by reverse-phase HPLC (water-.acetonitrile gradienit containing 0.1% TFA) to afford of a white powdered'solid.. ESMS:- Calculated for C46H47N 7

O

9 S, 873.31 Found 87 2.3 Rt= 11.569 min (100% pure, Vydac C18 column; gradient 20 to 100% acetonitrile/water 0.1%6 TFA over 30 min).

.Example *Synthesis of (6-((l'-aza-2-(2-sulfophenyl)vinyl)amn)- ~pyridyloxy) -2,2 -dimethylhexyl) carbamoyl.) propanoylamino) 30 'ethane-l,2-.dicarboxylic acid.

A mixture of 3-((tert-butoxy)carbonylamino-3-(N-(6- (4,6diphenyl(2-pyridyloxy))-2,2-dimethyihexyl)carbamoyl)-propanoic acid (50 mg, 0.0847 mmol), N,N-dimethylformamide (2 diisopropylethylamine (45 mnL, 0.254 mmol) and -(1Hbenzotriazole-l1-yl)-1,1,3, 3 -tetramethyluronium hexafluorophosphate (32 mg, 0.0847 mmol) was stirred at room temperature for 10 min. H-Asp-OH (11.4 mg, 0.084 7 ummol) was 1 added in portions and the mixture was stirred for 18 h. The 10 mixture was concentrated under high vacuum and purified by reverse-phase HPLC (water-acetonitriie gradient containing 0.1% TFA) to provide the intermediate product. A solution of this intermediate in dichloromethane (4 mL) was treated with trifluoroacetic acid (4 mL) and stirred at room temperature 15 for 1 h. The solution was concentrated under high vacuum, and the residue was lyophilized to give the deprotected amine salt. To a solution of this amine salt in DMF (1.5 mL) was added triethylamine (35 mL). After stirring for 10 min, 2- [[[5-[[(2,5-Dioxo-1l-pyrrolidinyl)oxy] carbonyl]-2-pyridinyl] hydrazono] methyl]-benzenesulfonic acid, monosodium salt (44.76 mg, 0.102 mmol) was added. The mixture was stirred for 24 h and concentrated under high vacuum. Purification by reverse-phase HPLC (water-acetonitrile gradient containing 0.1% TFA) yielded 7 mg of a white powdered solid.

ESMS: Calculated for C46H49N70 11 S, 907.32 Found 908.3 Rt= 14.158 min (100% pure, Vydac C18 column; gradient to 100% acetonitrile/water 0.1% TFA over 30 min).

Example 71 Synthesis of (l-aza-2-(2-sulfophenyl)vinyl)amino) 3 -pyridy1)carbonyamino)-.(N(6.(46..diphenyl( 2 pyridyloxy) -dirnethyihexy1) carbamoyl )propanoylamino) -3carboxypropanoylamino) ethane-l, 2-dicarboxylic acid H S0 3

H

0 NNN NH He H- C0 2

H

H HO 2 liii:C0 2

H

A mixture of' 3- (tert-butoxy) carbonylamino-3- (4,6diphenyl 2 -pyridyloxy) -dimethyihexyl) carbamoyl) -propanoic acid (50 mg. 0.0847 inmol)., N,N-dimethylformamide (2 mL), diisopropylethyl'amine (45 mL, 0..254 mrmol) and 2-(1H- *benzotriazole1..yl) 3 -tetramethyluronium *hexafluorophosphate (32 mg, 0:.0847. mmol) was. stirred at room temperature'for 10 min. H.-Asp-Asp-OH -(11.4 mg, 0.0847 mmol) was added in portions and the mixture was stirred for 18 h.

15 The mixture was concentrated under high vacuum and purified by reverse-phase HPLC (water-acetonitrile gradient containing 0.1% TFA) to provide the desired intermediate product.

A

solution of this intermediate in dichioromethane (4 niL) was treated with trifluoproacetic acid (4 niL) and stirred at room temperature for 1 h. The solution was concentrated under high vacuum, and the residue was lyophilized to give the deprotected amine salt. To a solution of this amine salt in DMF (1.5 niL) was added triethylamine (35 niL). After stirring for 10 min, 2 ,5-Dioxo-1-pyrrolidinyl)oxyI carbonyl]- 2-pyridinyl] hydrazono] methyl]-benzenesulfonic acid,.

monosodium salt (44.76 mig, 0.102 nimol) was added. The mixture was stirred for 24 h and concentrated under high vacuum.

Purification by reverse-phase HPLC (water-acetonitrile gradient containing 0.1% TFA) to give 13 mg of a white powdered solid. ESMS: Calculated for C5OHS4N801 4 S, 1022.35 210 Found.10,23.3 Rt= 13.5710 mi (90.6%'pure, Vydac c18 column; gr adient 20 to 100% acetonitri le /water 0.1% TFA over min).

Example 72 Synthesis of 2 (5-N7(ilN.(6(4,6-diphenyl( 2 pyridyloxy))-2,2-dimethylhel)caramoyl) 2 3 trihydroxy-3 -(hydroxymethyl) 2 -oxanyl) )amino) carbonylamino) propanoylamino) ethyl) carbamoyl (2-pyirdyl) )amino) vinyl) benzenesulfonic acid

C.

C

C

C C

C

Part Preparation of 2- (ter~t-butboxy) carboonylamino) (6- 6-diphe'nyl.( 2 -pyridyrloxy) 2-dimethyihexyl) ((fluoren-9ylmethoxy) carbonylamnino) propanamide To a solution of 6- 6-diphenyl (2-pyridyloxy) dimethyihexylamine (130 mg, 0.347 mmol) in DMF (6 niL) was added diisopropylethylamine (0.18 mL, 1.04 mmol) followed by 2-(lH-Benzotriazolel.yl)-1,1,3, 3 -cetramethyluronju hexafluorophosphate (158 mg, 0.416 nmol). After Stirring at room temperature for 15 min, Boc-DAP(Fmoc)-OH.(178 mg, 0.416 mmol) was added. The mixture was stirred for 24 h, Concentrated under high vacuum and purified by reverse-phase HPLC (water-acetonitrile gradient containing 0.1% TFA) to afford 171 mg of a white powdered solid.

ESMS:

Calculated for C48H54N 4 0 6 782.40 Found 783.5 [M+HI+l; Rt= 23.382 min (87.9% pure, Vydac C18 column; gradient 20 to 100% acetonitrile/water 0.1% TFA over 30 min).

Part B: Preparation of 3 -amino-2-(-(tert-butoy) carbonylanino) -N-(6-(4,6-diphenyl (2-pyridyloxy)) -2,2dimethyihexyl) propanamide A solution of 2-((tert-butoxy)carbonylamino) diphenyl (2-pyridyloxy)) 2-dimethyihexyl) -3-((fluoren-9ylmethoxy) carbonylamiJo)Jpropanamide (171 mg,- 0.218 mmol) in DMF.(5 mL) was'added piperidine (1.25 mL) .and stirred at room 'temperature for-1.5 h. The solution was concentrated under high vacuum, and the residue was purified by reverse-phase S HPLC (water-acetonitrile containing 0.1% TFA) to give 70 mg of product. ESMS: Calculated for C33H44N40 4 560.34 Found 561.4 Rt= 17.715 min (98.3%pure, Vydac C18 column; gradient 20 to 100% acetonitrile/water 0.1% TFA over min).

Part C: Preparation of 2 -((tert-butoxy)carbonylamino)

N-(

6 4 ,6-diphenyl(2 -pyridyloxy) )-2,2-dimethylhexyl)-3-(3.

(((4,5,6-trihydroxy-3-(hydroxymethyl)(2-oxanyl))amino)carbonylamino)propanoylamino)propanamide 212 A solution of 3-amino-2- ((tert-butoxy) carbonylamijno)

-N-

(4,.6-diphenyl 2 -pyridyloxy 2, 2 -dimethylheyl)propanairide mg, 0.125 mmol) in DMFt (2mL) was added triethy lamine (52 iL, 0-.375 nimol) and stirred for S mm. -(b-D-Glucoseamido) carbonyl-b-alanine*.OSu '(58.7*mg, 0..15 irimol) was added and the.

mixture was stirred for 18 h. The mixture was-concentrated under high vacuum,: and the residue was lyophilized-to provide .93 mg of product w~hich was used without further.

10 purifi'.cation' ESMS: Calculated for C43H6ON601l, 836.43' Found 835.3 Rt= 16.154. min pure, Vydac C18 column; gradient 20 to 100% acetonitrile/water 0.1%-TFA over Part D: Preparation of 2 -amino-N-(6-(4,6-dipheny(2.

pyridyloxy) -22-dimethyhel~-t,3...(3'(4,5,6-trihydroxy"3 (hYdroxyrnethyl) (2 -oxanyl) )amino) carbonylanino) propanoyl amino)propanamide (trifluoroacetic acid-salt) A solution of 2 -((tert-butoxy)carbonylamno)-.N-.(-(4, 6 diphenyl(2-pyridyloxy) )-2,2-dimethyhexy)-3(3-(((4 5 6 trihydroxy-3 -(hydroxymethyl) (2 -oxanyl) )amino) carbonylamino) propanoylalnino)propanamide (93 mg, 0.111 nimol) in dichioromethane (4 niL) was treated with trifluoroacetic acid (5 niL) was added and stirred at room temperature-for 1 h. The solution was concentrated under high vacuum, and the residue was lyophilized to give 82 mg (100%) of product.. The product was used without further purification. EST{S: Calculated for C38H52N 6 0 9 736.38 Found 737.5 Rt= 13.320 min (80.5% 213 pure, Vydac C18 column.;-gradient 20 to 100% acetonitrile,'water 0.1% TFA over 30 min).

Part E: Preparation of -2a--(5N(lN(6 6-diphen'yl (2-pyridyloxy) 2-dimethyihexyl) carbamoyl) -2- 3 4 ,5,6-.trihydroxc-3-(hydroxcymethyl),(2-oxanyl))amino) carbonylamino) propanoylamino) ethyl) carbamzoyl (2pyridyl) )amino) vinyl) benzenesulfonic acid A solution of 2-amino-N- 6-diphenyl 2 -pyridyloxcy) (hydroxymethyrl) (2-oxanyl) )amino) carbonylaminio) propanoylamino) propanamide (82 mg, 0.111 mrmol) in DMF (2 mL) was added triethylamine (46 mL, 0.333 mmol) and stirred at- room temperature for 10 min.- 2 oxy] carbonyl J-2-pyridinyl] hydrazono] methyl] -benzenesulfonic acid, monosodium salt (68 mg, 0.155 mmol) was'added and the mixture was stirred for 24 The mixture was concentrated under high vacuum and purified by reverse-phase HPLC (water- 20 acetonitrile gradient containing'0.1% TFA) to afford 20 mg of a white powdered solid. ESMS: Calculated for *C51H6lN90 13 1039.41 Found 1038.2 Rt= 13.149 min (92.5% pure, Vydac t18 column; gradient 20 to 100% acetonitrile/water 0.1% TFA over 30 min).

*Example 73 *Synthesis of 3 6 4 ,6-diphenyl(2-pyridyloxy))-2,2dimethylhexyl) carbamoyl) (3 -pyridylcarbonylamino) propanoic acid.

214 A 'mixture of 3 -amino-3-(N-6-(4,6-diphenyl(2pyridyloxy) 2 -dimethylhexyl) carbamoyrl)-propanoic acid (100 mg, 0.204 mmol), N,N-dimethYlformamide (2 mL), and triethylamine (0.1 niL) was stirred at room temperature for min. Succinimidyl nicotinate (69 mg, 0.315 inmol) was added, and the mixture was stirred for 18 h. The mixture was concentrated under high vacuum, and the residue was Purified using reverse-phase HPLC (water -ac etoni tri le gradient containing 0.1% TFA).to afford 23 mg of a white powdered solid. ESI4S: Calculated for C35H38N40 5 594.2842 Found 595.2. [M+HI+1; Rt= 15.597 min (10.0% pryacC18 colun; gradient 20 to 100% acetoni trile /water!+ 0.1I% TFA over min).

Example 74 Synthesis of. N-(6.-(4.,6-diphenyl (2-pyridyloxy).) -2,2dimethylhexyl 3 -pyridyl f ormamjde 0 0N 0 G .oes's N 0 0000

N

00* 20 A mixture of 6-( 4 6 -diphey1(2-pyridyoxr))-2,2dimethylhexylamine (0.14 g, 0.373 inmol), N,N-dimethylfomaide **0o0 (4mL), and triethylamine (0.3 mL) was stirred at room temperature for 10 mmn. Succinimidyl nicotinate (0.1 g, .4 000mmol) was added, and the mixture was stirred for 18 h. The :6.6 25 mixture was concentrated under high vacuum, and the residue was purified using reverse-phase EPLO (water-acetonitrile containing 0.1 TFA) to afford 0.114 mg of a white powdered solid. 1 H NMR (CDC13): 8.12-6.80 (in, 16k1), 4.54 (t, 2H), 3.43 2H), 1.90 (in, 6H), 1.05 6H1);

ESMS:

Calculated for C311133N30 2 479.2573 Found 480.2 Rt= 17.096 min (100% pure, Vydac C18 column; gradient 20 to 100% acetonitrile/water 0.1%.TFA over 30 min).

215 Example Synthesis of 2 6 -(4-benzo[d]ll3-dioxolan-5-yl- 6-phenyl(2-pyridyloxy) 2 -dimethylhexanoylamino)sulfonyl)- (2-pyridyl))amino) vinyl) benzenesulfonic acid 0

H

N XJS03H

NIN

Part A: Preparation of 6 4 -benzo.[d]1,3 -dioxolan-5-yl-6phenyl (2-pyridyloxy) 6 -chloro(3-pyridyl) )sulfonyl) -2,2dimethyihexanamide .:.iTo a solution of 6- (8-benzo[d] 1, 3-dioxdlan"5-*yl-6phenyl (2-pyridyloxy))-2,.2-dimethylhexa'noic acid (0.100 g 0.231 mmnol) in methylene chloride, -was added 2-chloropyridine- (0.0466 g, 0.243 mmol), dimethylaminopyridine (0.0367 g, OAOO mmmol), 1- (3 dimethylamin4propyl -3 -ethyl carbodiimide hy2rochloride (0.0443 g, 0.231 mmol)., and 4 A molecular sieves.- The reaction mixture was stirred overnight for 18 h and then filtered. The filtrate was washed with 1N HC1, water, brine. The organic layer was dried over magnesium sulfate, filtered, and concentrated to a small volume. The resulting concentrated solution was triturated with hexane.

The product was filtered, washed with hexane and dried under high vacuum to give 51.7 mgs of product. ESMS: Calcd.

for C31H30N306S, 607.15; Found, 608.4 [M+H+ll HPLC Method 5. Rt =19.226 min Purity 78% 216 Part B: Preparation-of 6--(4-ben'zo(d]1,3-dioxoan-5y..

6 phenyl (2-pyridyloW) ((6-hydrazino(3-pyridyl)) suifony.) 2,2 -dime thyihexanamide 6- (4-Benzo[d] 1, 3 -dioxolan- 5-yl-6-phenyl(2..pyridyloxy)

)-N

((6-chioro (3-pyridyl) )sulfonyl) 2 -dixnethylhexanamide (0.100 g, 0.164 minol) was brought up in hydrazine hydrate (5 mL.).

The reaction was heated to 70 *C for 18 h. A precipitate was still in the reaction so ethanol (10-n'L) was added. The precipitate dissolved and the reaction was heated at 80*c for another 20 h. The reaction was then concentrated under high vacuum to. give the crude product.. The crude'product was purified by flash chromtography chloroform:methanol) to give 54.8 mgs of product. ESMS: Calcd. for.

C31H33N50 6 S, 603.21;. Found, 604.4.(M+H+1] HPLC Method 5.Rt .=15'.285 min Purity =98%.

Part C:-Preparation 'of 2 2 aza-2-((5-((6-(4-benzo[d1,3 dioxolan"5-yl-6-phenyl (2--pyridyloxy)') -2 ,2-dimethylhexanoyl.

amino) sulfonyl) (2-pyridyl) )amino)vinyl)benzenesulfonic acid 6- (4-Benzofd 1, 3 -dioxolan-5-yl-6.-phenyl (2-pyridyloxy) ((6-hydrazino (3-pyridyl) )sulfoniyl) 2-dimethylhexanamiide (0.050 g, 0.082.8 mmol) was dissolved in dimethylformamide (1 mL). Triethylamine (34.6 gL, 0.248 mmol) was added, and the rea ction'was 'stirred for 5'mmn. 2-Formylbenzenesul .foni.acid monosodium salt (0.0181 g, 0.0869 mmol) was'added, and the reaction was stirred overnight for 18 h. The reaction was *concentrated to-an oil under high vacuum. The crude product was purified by preparative HPLC Method 2 to give 6.4 mg of product. ESMS: Calcd. for C38H37N509S2, 771.20; Found, 772.3 [M+H+1] HPLC Method 5.Rt =15.431 min Purity =97% Example 76 Synthesis of 6-(4-benzo~d]l, 3 -dioxolan-5-yl-6-phenyl(2pyridyloxy) ((6-hydrazino(3- 217 pyridyl)) sulfonyl)cabamoyl) -2-(4-hydroxyphenyl)ethyl) -2,2dimethyihexanamide H V ~NHNH2

H

N,

0* 0-N' Part A: Preparation of tert-butyl 2-(6-(4-benzo(d]1,3dioxolan-5-yl-6-phenyl (2-pYridyloxy))-2, 2 -dinethylhexanoylamino)-3-(4-(tert-butoxy)'phenyl)propanoate 6-( 4 -Benzo[d]1,3-dioxolan-5-yl-6-phenyl (2-pyridyloxy))- 2, 2 -dimethylhexanoic acid (0.100 g, 0.231 mmol) was dissolved in dimethylformamide (5 rL). Diisopropylethylamine (100.5 ILL, 0.578 mmol) was added, and the reaction was stirred for 5 min.

H-Tyr(OtBu)-OtBu.HCl (0.0838 g, 0.254 nmol) and berizotriazole-ly1) -1,1,3,3 -tetramethyluronium hexafluorophosphate (0.0964 g, 0.254 mmol) were added, and the reaction was stirred under nitrogen for 24 h. The -reaction was concentrated to a residue under high vacuum to give 190.5 mg (116%) of product. The crude product was utilized in the next step. ESMS: Calcd. for C43H52N20 7 708.38; Found 709.5 [M+H]+1 HPLC Method 5.Rt 23.043 min Purity 87% Part B: Preparation of 2-(6-(4-benzo[d]1,3-dioxolan-5-yl-6phenyl (2-pyridyloxy)) 2-dimethylhexanoyl-amino) hydroxyphenyl) propanoic acid Tert-butyl 2-(6-(4-benzofl,3-dioxolan-5-yl-6-phenyl(2pyridyloxy))- 2 ,2-dimethylhexanoyl-amino)-3-(4-(tertbutoxy)phenyl)propanoate (0.144 g, approx.0.223 mmol) was dissolved in methylene chloride (3.0 mL). Trifluoroacetic acid (3.0 mL) was added, and the reaction was stirred for 2 h.

The reaction was concentrated under high vacuum. The resulting oil was brought up in 50:50 acetonitrile/water and lyophilized to give the product as an oil. The product was purified by preparative HPLC Method 2 to give 119.1 mg (98%) of product. HRMS: Calcd. for C35H36N20 7 H, 597.2600; Found, 597.2617.

HPLC Method 5.Rt =15.729 min .Purity 100% Part C Preparation of 6-( 4 -benzo.dl,3-diooolan-5-yl-6 phenyl 2 -pyridyloxy))-N- (6-hydrazino(3pyridyl))sulfonyl) cabamoyl)-2-(4-hydroxyphenyl)ethyl)-2,2dinmethylhexanamide 20 To a solution of 2 6 -(4-benzo[d]l1,3-dioxolan-5-yl-6phenyl 2 -pyridyloxy))-2, 2 -dimethylhecxanoyl-amino)-3-(4hydroxyphenyl)propanoic acid (0.231 mmol) in methylene chloride, is added 2 -chloro-pyridine-5-sulfonamide (0.243 nmmol), dimethylaminopyridine (0.300 mmol), 1-(3dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (0.231 mmol), and 4 A molecular sieves. The reaction mixture is stirred overnight for 18 h and is then filtered. The filtrate .is washed with 1N HC1, water, brine. The organic layer is dried over magnesium sulfate, filtered, and concentrated to a small volume. The resulting concentrated solution is triturated with hexane. The product is filtered, washed with hexane and dried under high vacuum to give the chloropyridine intermediate. This intermediate (0.164 mnmol) is biought up in hydrazine hydrate (5 mL). The reaction is heated to 70 *C for 18 h. The precipitate is dissolved in ethanol (10 mL) and the reaction is heated at 80 'C for another 20 h. The reaction is then concentrated under high vacuum to give the crude product, which is purified by flash chromatography.

219 Example 77 Synthesis of 4 4 6 -diphenyl(2-pyridyloxy))-N-(1-(N-(1-(N-((6hydrazino( 3 -pyridyl)) sulfonyl)cabamoyl) (4hydroxyphenyl) ethyl) -carbamoyl) -isopropyl) butanamide 0 H 02 S0OH

NHNH,

Part A: Preparation of 4 -(4,6-diphenyl-2pyridyloxy)butanenitrile 4,6-Diphenyl-pyridone (1.5 g, 6.07 zmmol) was dissolved in dimethylfOrmamide (40 mL). 4 -Bromobutyronitrile (1.81 mL, 18.2 mmol) and silver carbonate (1.67 g, 6.07 mmol) were added, and the reaction was refluxed in the dark for 72 h.

15 The reaction was then cooled, filtered, and concentrated under high vacuum. The residue was brought up in ethyl acetate and passed through silica gel. The filtrate was concentrated under high vacuum. The resulting residue was purified by flash chromatography (5:1 hexane:ethyl acetate) to give 1.77 g of product.

ESMS:

Calcd. for C21H18N20, 314.14; Found 315.3 [M+H]+1 HPLC Method 5.Rt =18.715 min Purity 97% Part B: Preparation of 4-(4,6-diphenyl-2-pyridyloxy)butanoic 25 acid 4-(4,6-Diphenyl-2-pyridyloxy)butanenitrile (0.813 g, 2.59 mmol) was dissolved in conc. hydrochloric acid (10 mL), glacial acetic acid (6 mL), and water (4 mL), and heated to reflux for 20 h. The reaction was diluted with water, and extracted with methylene chloride. The organic layer was washed with water, brine, dried over magnesium sulfate, filtered, and evaporated. The resulting oil was purified kbr flash chromatography 4:1 hexane:ethyl acetate, 2. 2:1 220 methylene chloride:ethyi acetate) to'give 109.1 mg of product. ESMS: Calcd. for C21H19N0 3 333.14, Found 332.3 H]-1 HPLC Method 5. Rt =15.884 min Purity 100% Part C: Preparation of 2 2 4 -(4,6-diphenyl-2pyridyloxy) butanoylamino) -2-methylpropanoy1amno) hydroxyphenyl )propanoic acid N

HA

0 To a teabag.(5x5 cm polypropylene filter, 0-.75 Jim mesh)wa saddd .50 gofFmoc-Tyr(otBu)-wang resin. The teabag was washed with the following (10ml./bag) DME' 2'x min,- piperidine in DMF solution 1.x 3 mmn,'20% piperidine in' DMF -solution Ix 30 min, DCM 8 x3min, and .DMF '3 x 3min. To.

the reactor was added.-five equivalents of each of the following; Fmoc-Aib-O0H, HBTU, HOBT, diisopropylethylamine (DIEA) and DMF (l0ml/bag). The bag was shaken overnight for *about.16 h. The bag was then washed-with the following (l0mi/bag): DMiF 3 x 3 min, DCM 8 x 3 min.and dried under high vacuum. The coupling yield was determined, using the picric acid assay. Then 0.200.g 'of this Fmoc-Aib- 'IYr(OtBu) -wang resin was transfered to a teabag (5x5 cmpolypropylene filter, 0.75 pim mesh). The teabag was washed 25 with the following (10 ml/bag) DMF 2 x 3 min, 20% piperidine in DMF'solution 1 x 3 min, 20% piperidine in DMF solution 1 x 3 0Omin, DM 8 x"3min, and DM 3 x 3min. To the reactor was added 2.5 equivalents of 4 7( 4 ,6-diphenyl-2-pyrdylox,) butanoic acid and five equivalents of each of the feallowing; HBTJ, HOBT, diisopropylethylamine'(DIEA) and DMF (lOml/bag).

The bag was then shaken overnight for about 18 h. The bag was then washed with the following (l0ml/bag): DMF 3 x 3 min, DCM 8 x 3 min. The bag was dried under high vacuum. The contents of the bag was then placed in a small erlenmeyer flask and a cleavage cocktail (10 mL) (95% trifluoroacetic acid, 2.5% triisopropylsilane, and 2.5% water) added. The resin was allowed to sit for two hours while occasionally being swirled. After each swirl the side of the flask was rinsed with additional cocktail until the total volume of cocktail added was 15 mL. After two hours, the resin was filtered and washed with TFA (2x4 The filtrate was concentrated to an oil under high vacuum. The oil was purified by preparative HPLC Method 2 to give 14.1 mg of product. HRMS: Calcd. for C34H35N30 6 H, 582.2604; Found, 582.2606.

HPLC Method 5. Rt 13.912 min Purity 98% Part D Preparation of Preparation of 4-(4,6-diphenyl(2- 15 pyridyloxy))-N-(1-(N-(1-(N-((6-hydrazino(3pyridyl))sulfonyl)cabamoyl)-2-(4-hydroxyphenyl)ethyl)carbamoyl)-isopropyl)butanamide To a solution of 2 2 -(4-(4,6-diphenyl-2-pyridyloxy)butanoylamino)- 2 -methylpropanoylamino).-3 (4h..ydroxyphenyl)propanoic acid (0.231 mmol) in methylene chloride, is added 2 -chloro-pyridine-5-sulfonamide (0.243 mmol), dimethylaminopyridine (0.300 mmol), 1-(3dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (0.231 25 mmol), and 4 A molecular sieves. The reaction mixture is stirred overnight for 18 h and is then filtered. The filtrate is washed with 1 N HC1, water, brine. The organic layer is dried over magnesium sulfate, filtered, and concentrated to a small volume. The resulting concentrated solution is triturated with hexane. The product is filtered, washed with hexane and dried under high vacuum to give the chloropyridine intermediate. This intermediate (0.164 mmol) is brought up in hydrazine hydrate (5 mL). The reaction is heated to 70 'C for 18 h. The precipitate is dissolved in ethanol (10 mL) and the reaction is heated at 80 'C for another 20 h. The reaction is then concentrated under high vacuum to give the crude product, which is purified by flash chromatography.

222 Synt esi ofExamp e .78 Sulfophenyl)'Vinyl) amino) (3 -pyridyl) )carbonylamino) propoxy)phenyl) 2-dimethyl-6..(5-oxo-1-prop2-enyl (2- 6,7, S-trihydronaphthylo,) hexanoylamino) propanoic acid 0

NN

N N

H&

*S03H (2in dimethylom.ie (5 mol,). Diisoprpy-ethyla(n (126.3

IL

acmid(.100 0290 mol an hexfluroste (0.12-H1 g, 0.19 nmiol were4 mlad d thled re2 ml a addAdteracti on was stirred udrntoe for 60 h.Tereci n concentrated to a residue under high vacuum. The oil was dissolved in 50:50

ACN:H

2 0 and lyophilized to give 0.457 g of product, however, as an oil. ESMS: Calcd. for C38H53N0 6 619.39, Found 620.5 LM+H]I+1 25 HPLC Method 5. Rt 21.882 min Purity 94% 223 Part B: Preparation of 2- 2-dimethyl-6- (5-oxo-l-prop-2enyl 8-trihydronaphthyloxy) )hexanoylamino) (4hydroxyphenyl)propanoic acid tert-Butyl 3- (tert-butoxy)phenyl) (2,2-dimethyl....

(5-oxo-l-prop-2.-enyl 7,.8-trihydronaphthyloxy) hexanoylaznino.)propanoate (0.457 g) was diss olved in methylene chloride znL). Trifluoroacetic acid (3.0 znL) was added, and the reaction was stirred for 2 h. The reaction was concentrated under high vacuum. The resulting oil was purified by preparative HPLC Method 2 to give 126.5 mg (86% over 2 steps.) of-product. HRMS: Calcd. for C30H37N0 6 508.2699; Found, 508.2703.

15 HPLC Method 5. Rt =13'.743 min Purity =98% *Part C Preparation of 3 sul fophenyl) vinyl) amino) (3 -pyridyl) carbonylamino) propoxy)phenyl-)-2- 2-dimethyl-6- (5-oxo-l-prop-2-enyl (2- 6,7, 8-trihydronaphthyloxy) )hexanoylamino) propanoic acid H- r (-CH2-CH2-CH2-NH-boc)_OtBu (0.348 mmol) i .s dissolved in dimethylformamide (5 mL). *Diisopropylethylamine (0.725 mmol) is added,'and the reaction-is stirred for 5 mmn.

naphthyloxy)).hexanoic acid (0.290 mmol) and :2(lH-benzotriazole-1-yl) -1,1,3,3-tetramethyluroniwn hexafluorophosphate (0.319 mmol) is added, and the reaction is stirred under nitrogen for 60 h. The reaction mixture is concentrated to a residue under high vacuum and is disso lved in methylene chloride (5 niL). Trifluoroacetic acid (5.0 znL) is added, and the reaction is stirred for 2 h. The reaction is concentrated under high vacuum to give the amine product. A mixture of this product (0.0805 nimol), N,N-dimethyl formamide (2 niL), and triethylamine (0.2478 nimol) is stirred at room temperature for min. 2 2 ,S-Dioxo-1-pyrrolidinyl)oxy] carbonyl]-2pyridinyl]hydrazono]methyl) -benzenesulfonic acid, monosodium salt (0.0991 mmol) is added and the mixture is stirred under nitrogen. After 24 h, the mixture is concentrated Under high vacuum. Purification by reverse-phase HPLC (wateracetonitrile gradient containing 0.1% TFA) yields the desired product.

Example 79 Synthesis of (l-aza-2- 2 -su1fophenyl)vinyl)amino) (3pyridyl) carbonylamino) (6-(4-benzo [dl1, 3 -dioxolan-5-yl-6phenyl 2 -pyridyloxy))'-2, 2 -dimethylhexyi) carbamoyl) propanoic acid 0 ~V H2+ Part A: Preparation-of tert-butyl (4-beno d] 3 dioxolan-5-yl-6-phefly( 2 -pyridyloxy)) -2,2jI.l.I1..a..i dimethylhe I)crbanoyl)-3-((tettbutoxy)carbonylamino propanoate N. 0 IH 0 l-Amino-2,2-dimethyi-6- 3 4 -methylenedioxcpbenyl) -6phenyl-2 -pyridiny:L)oxy]-exane (0.100 g, 0.239 mmol) was dissolved in dimethylformamide (5 nL). Triethylamine (0.'100 x:L, 0.717 nmol) was added, and the reaction was stirred for min. Boc-Asp(OtBu)-OSu (0.110 g, 0.287 mmol) was added, and the reaction was stirred under nitrogen for 48 h. The reaction was concentrated to an oil under high vacuum. The oil was dissolved in 50:50

ACN/H

2 o and lyophilized to givet-0.219 g (133%) of product. ESMS: Calcd. for C39H5 1

N

3 0 8 689.37; Found 690.5 HPLC Method 5. Rt=21.930 min Purity 97% 225 Part B: Preparation'of 3-amino-3-(N-(6-(-benzo[d]1,3 dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2dimethyihexyl)carbamoyl)propanoic acid Tert-butyl 3 -(N-(6-(4-benzo[d)1,3-dioxolan -5-yl-6phenyl (2 -pyridyloxy) -2,2 -dimethyihexyl) carbamoyl) -3- ((tertbutoxy)carbonylamino)propanoate (0.145 g, 0.210 mmol) was dissolved in methylene chloride (3.0 mL). Trifluoroacetic acid (3.0 mL) was added, and the reaction was stirred for 2 h.

The reaction was concentrated under high vacuum. The resulting oil was brought up 50:50 acetonitrile/water and lyophilized to give 242.0 mg (177%) of product. ESMS: Calcd.

for C30H35N30 6 ,'533.25; Found 53-2.3 [M-H]-1 HPLC Method 5. Rt 13.921 min Purity.= 96% Part C: Preparation of 3 sulfophenyl vinyl )amino) (3-pyridyl)carbonylamino) (4benzo[d]1, 3-dioxolan-5-yl-6-phenyl (2-pyridyloxy) -2,2dimethylhexyl)carbamoyl)propanoic acid 3-Amino-3- (4-benzo'(dli, 3-dioxolan-5-yl-6-phenyl(2pyridyloxy)) -2,2-dimethyihexyl)carbanoyl)propanoic acid (0.100 g, 0.154 nmol) was dissolved in dimethyiformamide (5 mL).

Triethylamine (64.4 gL, 0.462 nmol) was added and the reaction was stirred for 5 min. 2-([[5-fl[(2,5-Dioxo-lpyrrolidinyl) oxy] carbonyl] -2 -pyridinyl] hydrazono] methyl]benzenesulfonic acid, monosodium salt 0.082 g, 0.185 nmol) was added and the reaction was stirred for 24 hours under nitrogen. The reaction was then concentrated to an oil under high vacuum. The oil was triturated with ethyl acetate. The, crude product was then purified by preparative HPLC Method 2 to give 31.1 mg of product. HRMS: Calcd. for C43H44N601S H, 837.2917; Found, 837.2901.

HPLC Method 5. Rt 14.279 min Purity 93% Example Synthesis of 2-(2-aza-2-((5-(N-(1-(N-(6-(4-benzo~dl,3dioxolan-5-yl-6-phenyl (2-pyridyloxy) 2-dimethyl- 226 hexYl) carbainoYl) -hydrox~yphenyl) ethyl) carbamoylU(2 N NK N

HO

0 Part A: Preparation of N-(G-(4-benzofdll,3-.di xlan5 ylE6 phenyl (2-pyridyloxy) -dirnethyihexyl) (te .rtbu toxy) carbonylamino) (4 -hyd~roxyphenyl) propanamide 0 H

H

1-'m'4no 1 (4-.(3,'-metnylenedioxyphel)6phenl.-2-yrdiyl) x-exan.e. (0.l0g, 0'.239 nimol). was dissolved in dimethYlforamde.( i) ispoyeh1n (5m4) ii*royety*mn (104.1 pt, 0.598 nimol) was added, and the reaction was-stirred 4for .5 min. Boc-Tyr-OH (0.081 g, 0.287 nunol) and 2(1H-* benzotriazole-1.yl) 3 -tetramethyluroniu hexafluorophosphate (0.100 g, 0.263 mmol) were added, and the 4..reaction was stirred under nitrogen for 2 4 h. The reaction was concentrated to an oil under high vacuum. The oil was dissolved in 50:50 ACN/H 2 o and lyophilized. The crude product 20 was then purified by preparative EPLO Method 2 to give 67.9 mg of product. ESMS: Calcd. for C4047N 3 0 7 681.34.; Found, 680.3 LM-H]-1 HPLC Method Rt 19.238 min Purity =98% Part B: Preparation-of 2-amino-N- (4-benzo [dll, 3-dioxolan-Syl-6-phenyl 2 -pyridyloxy) 2-dimethyihexyl) (4hydroxyphenyl )propanamide 227 N- (4-Benzo (dj.1, 3 -dioxolan 5-yl..6-pheny.1 (2- Pyridyloxy) 2-dimethyihexyl) ((tert-butoxy)carbonyiamn)3(- doxpey~rpnmd (0.058 g, 0.0851 mxnol) was dissolved in methylene chloride (3.0 ML). Trifluoroacetic acid (3.0 mL) -was added, and the reaction was stirred for 2 h.

The reaction was concentrated under high vacuum. The resulting oil was brought up-in 50:50 acetonitrile/water and lyophilized to give 53.6 mg of product. ESMS: Calcd for C35H39N30 5 581.29; Found,.582.5 HPLC Method 5.Rt 14.92.0 min Purity 9 98% Part Preparation of benzo[dll,3-dioxolan-5.yl..6phenyj (2-pyridyloxy) Sdimethylhexyl) carba moyl) (4-hydroxyphenyl) ethyl) carbamnoyl (2 -pyridyl) amino) vinyl benzenesulfoni.c acid -G0pyridyloxy) -dimethylhexy.) (4 -hydrox yphenyl) proanmie.0.20g, 0.0287 nunol) wasdisle in dimethylformamide (2 znL).* Triethylanine (12 gLL,. 0.861 inmol) was-added and'-the reaction was stirred for 5 mim. S-Dioxo-l-pyrrolidinyl) oxy] carbonyl] -2-pyridinyl] 0 hyJtznlehl~eznsloi acid, monosodium salt (0.0152 g, 0.0344 Inmol) was added and the reaction was stirred for 48 0 25 h under nitrogen. The reaction was then concentrated to an e o il under high vacuum. The oil was then purified by preparative HPLC Method 2 to give 15.6 mg of product.

HRMS: Calcd. for C48H48N60 9 S H, 885.3282; Found, 885.3268.

*HPLC Method 5.RL 1543minPrt 94% Example 81 Synthesis of (l-aza- 2 -(2-sulfophenyl)vinyl)amino) (3pyridyl) carbonylamino) 2-dimethyl.-6- (5-oxo-1-prop-2enyl 8-trihydronaphthyloxy) )hexanoylamino) acetic acid H2+N -03S Part A: Preparation of ethyl 6-(5-oxo-1-prop-2-enyl(2-6,7,8trihydronaphthyloxy))hexanoate 6-Hydroxy-5-prop-2-enyl-2,3,4 -trihydronaphthalen-1-one g, 4.97 mmol) was dissolved in dimethylforamide (15 mL).

Ethyl-6-bromohexanoate (1.33 mL, 7.45 mmol) was dissolved in dimethylformamide (15 mL), and added to the reaction.

Potassium carbonate (i.20 g, 8.70 mmol) and potassium iodide (0.206 g, 1.24 mmol) were added, and the reaction was heated to 100 *C for 16 h. The reaction was concentrated under high vacuum. The resulting oil.was brought up in ethyl acetate. and washed with water, brine, dried over. magnesium sulfate, filtered, and evaporated. The resulting crude product was dissolved in 90:10 hexane:ethyl acetate and passed through ***silica gel. The filtrate was then concentrated to give 1.218 g of product. ESMS: Calcd. for C21H280 4 344.20; Found, 345.2 [M+H]+1 HPLC Method 5. Rt-17.662 min Purity =.96% Part B: Preparation of 6-(5-oxo-1-prop-2-enyl(2-6,7,8trihydronaphthyioxy))hexanoic acid Ethyl 6 -(5-oxo-l-prop-2-enyl(2-6,7,8-trihydronaphthyloxy))hexanoate (1.10 g, 3.19 mmol) was dissolved in ethanol (20 mL). Potassium hydroxide pellets (0.Z68 g, 4.78 mmol) were dissolved in water (1 mL), and added to the reaction. The reaction mixture was heated to reflux for 18 h then concentrated to an oil under high vacuum. The residue was brought up in water. The solution was adjusted to pH with 1N hydrochloric acid. The solution was extracted with 229 ethyl acetate. The organic layer was washed with water, brinei, dried over magnesium sulfate, filtered, and concentrated to an oil under high vacuum. The oil was recrystallized from hexane:ethyl acetate to give 0.842 g (83%) of product. ESMS: Calcd. for C19H 24 0 4 316.17; Found, 315.2 HPLC Method 5. Rt 13.339 min-1 HPLC Method 5. Rt 13.339 min Purity 98% *c Part C: Preparation of.2-amino-2-(6-.(S-oxo-1-prop2-enyl(2- 6,7, 8 -trihydronaphthyloxy))hexanoylamino)acetic acid To a teabag (5x5 cm polypropylene filter, 0.75 ;Lmmesh) was added 0.50 g of Fmoc-Gly(NH-Boc)-Wang Resin. The teabag was washed with.the following (10 mi/bag) DMF 2 x 3 min, piperidine in DMF solution 1 x 3 min, 20% piperidine in DMF solution 1-x 30 min, DCM 8 x 3 min, and DMF 3 x 3 min. To the reactor was added 3 equivalents of the 6-(5-oxo-1-prop-2enyl( 2 -6,7,8-trihydronaphthyloxy))hexanoic acid, five equivalents of each of the following; HBTU,

HOBT,

diisopropylethylamine(DIEA) and DMF (10ml/bag). The bag was then shaken overnight for about.20 h. The bag was then washed with the following (lOml/bag): DMF 3 x 3 min, DCM 8 x 3 min.

The bag was dried under high vacuum. The contents of the bag was then placed in a small erlenmeyer flask. To the flask was added cleavage cocktail (10 mL) (95% trifluoroacetic acid; triisopropylsilane, and 2.5% water). The resin was allowed to sit for two hours while occasionally being swirled.

After each swirl the side of the flask was rinsed with additional cocktail until the total volume of cocktail added was 15 mL. After two hours, the resin was filtered and washed with TFA (2x4 mL). The filtrate was concentrated to an oil under high vacuum. The oil was triturated with ether to give 0.0792 g of product. ESMS: Calcd. for C21H28N 2 05, 388.20; o'unr, 389.2 [M+HJ+1 HPLC Method 5. Rt =9.020 min Purity 230 *Part Preparation o .f 2 -a a 2 .s~oh vinyl) amino) 3 -pyridyl) carbonylamino) (Soxo-lprop.2 enyl 8 -trihydronaphthyloy) hexanoylamino) acetic acid 2 -Amino-2 (6 5 -oxo- 1-prop-2..enyl (2 7,8 trihydronaphthyloy) ).hexanoylamino)acetic acid (0.040 g, 0.-0796 mmol) was dissolved in dimethyf omide -(3'rni) Triethylanmine (33.2 JIIL, 0.239 nimol) was added 'and the reaction was stirred for 5 minutes.* 2 -([(5-[(2,5Dioxo-1pyrrolidinyl) oxy] -carbonyl] 2 -pyridinyl] hydrazonoj methyl]benzenesulfonic acid, monosodim salt (0.0421 g, 0.0955 nimol) was added and.-the reaction- was stirred for 24. hours under nitrogen. The reaction was then concentrated to an oil under high vacuum. the oil was then purified by preparative HPLC Method. 2 to give 14.9 mig of *product:.' IRMS: Calcd.

for C34H37N 5 0 9 5S H, 692.2390; Found, 692+.2404.

*HPLC Method 5. Rt =9.976 Min Purity'= 92% Example*82 Synthesis *of 2- 2 -sulfophenyl) vinyl) amino) (3pyr idyl) carbonylai 0 -2 (2,2-dimethyl-,6- (5-oxo-4-prop-2 enyl S-trihydronaphthyloy) hexanoylanino) acetic. acid -710 *0

NN

H2N7 -0 3

S

Part A: Preparation of ethyl 2 2 -dimethy..(5oxo...prop-.

2 enyl (2 -trihydronaphthyloxy) )hexanoate 6-Hydrioxy-s-prop-2-enyl-2, 3, 4 -trihydronaphthalen.1.-one g, 4.97 inmol) was dissolved in dimethylformamide (15 xnL).

Ethyl 6 -bromo-2,2-.dimethylhexanoate (1.87 g, 7.45 mmol) was dissolved in dixethyforamid (15 znL), and added to the reaction. Potassium carbonate (1.20 g, 8.70 mmol) and potassium iodide (0.206 g, 1.24 mmol) were added, and the reaction was heated to 100'C for 16 h. The reaction was concentrated under high vacuum. The resulting oil was brought up in ethyl acetate and washed with water, brine, dried over magnesium sulfate, filtered, and evaporated. The resulting crude product was dissolved in 90:10 hexane:ethyl acetate and passed through silica gel. The filtrate was then concentrated to give 1.595 g of product. ESMS:* Calcd. for C23H 32 0 4 372.23; Found, 373.3

[M+H]+I

HPLC Method 5. Rt 19.756 min Purity 98% Part B: Preparation of 2 ,2-dimethyl-6-(5-oxo-l-prop-2-enyl(2- 6,7, 8 -trihydronaphthyloxy))hexanoic acid Ethyl 2 2 -dimethyl-6-(5-oxo-l-prop-2-enyl(2-6,7,8trihydronaphthyloxy))hexanoate (1.40 g, 3.76 mmol) was dissolved in ethanol (20 mL). Potassium hydroxide pellets (0.316 g, 5.64 nmmol) were dissolved in water (1 mL), and added 0 to the reaction. The reaction was heated to reflux for 4 days. The reaction was concentrated to an oil under high vacuum. The residue was brought up in water. The solution was adjusted to pH 5 with 1N hydrochloric acid. The solution was extracted with ethyl acetate. The organic layer was 25 washed with water, brine, dried over magnesium sulfate, filtered, and concentrated to an oil under high vacuum. The oil was purified by flash chromatography 7:1 methylene chloride:ethyl acetate to give 0.635 g of product as an Soil. ESMS: Calcd. for C21H 2 8 04, 344.20; Found, 345.2 [M+H+1 HPLC Method 5. Rt 15.644 min Purity 92% Part C: Preparation of 2 -amino-2-(2,2-dimethyl-6-(5-oxo-lprop-2-enyl(2-6,7, 8 -trihydronaphthyloxy))hexanoylamino)acetic acid To a teabag (5x5 cm polypropylene filter, 0.75 pm mesh) was added 0.50 g of Fmoc-Gly(NH-Boc)-Wang Resin. The teabag was washed with the following (10 ml/bag) DMF 2 x 3 min, 232 p iperidijne in DMF solution. 1 xc 3: -mi, piperidine in DNF solution I x 30 min, DCM 8 x 3 min, and'DMF 3 x 3 min. To the reactor was added 3 equivalents of the 2 ,2-dimethyl....(S oxo-l-prop2enyl 8 -trihydronaphthyloxy) )hexanoic acid, five equivalents of each of the following; HBTJ,

HOBT_

diisopropylethyamne(DIEA) and DMF (10Ml/bag). The bag was then shaken overnight for. about 20 h. The bag was then washed with the following (l0mi/bag): DNF 3 x 3 mi, DCM 8 x 3 min.' The bag was dried'under high vacuum. The 'contents .of the bag was then placed in a small erlenmeyer flask. Tothe flask was added-cleavage cocktail (10 mL) (95% trifluoroacetic acid, triisopropylsilane, and 2.5% water). The resin was allowed to sit for two hours while occasionally being swirled.

Af ter each swirl'the side of the flask was rinsed with.

additional cocktail-until the total volume of- cocktail added was 15 ML. After two hours, the resjIn was filtered And. washed *.with TFA (2x4 mL). The filtrate was' cnetad oan i under high vacuum.* The oil was triturated with ether to give 0.0560 g of product. _ESMS: Calcd. f or 0213N0,416.23 Found, 417.,3 HPLC Method 5. Rt =10..429,mmn Purity+= 97% Part D: Preparation of sulfophenyl) vinyl) amino) 3 -pyridyl) carbonylamino) (2,2 dimethyl-6-.(5oxlo..pr-en 2 6 ,7 trihydronaphthyloxy) )hexanoylamino) acetic ai 2-Amino-2- 2-dimethyl-6-(5-oxo-1-prop-2..enyl (2-6,7,8trihdr~aphtylpy))hxanylamn L1ci acid (0.025 g,. 30 0.0471 nunol) was dissolved in dimethy1formamide (2 xnL).

Triethylamine (19.7 JiL, 0.141 !nmol) was added and the reaction was stirred for 5 minutes. 2[[-[25DooI pyrrolidinyl) oxy] -carbonyl] 2 -pyridinyl]hydrazono&]methyl] benzenesulfonic acid, monosodium salt (0.0249 g, 0.0565 nunol) was added and the reaction was stirred for 24 hours under nitrogen. +The reaction was then concentrated to an oil under high vacuum. The oil was then purified by-preparative HPLc 233 Method 2 to give 8.9 mg of product. HRMS: Calcd. for C36H41N50 9 S H, 720.2703; Found, 720.2727.

HPLC Method 5. Rt 11.243 min Purity 100% Example 83 Synthesis of 3-((6-((1-aza-2-(2-sulfophenyl)vinyl)amino)(3pyridyl)carbonylamino)-3- (N-(6-(6-ethyl-3-hydroxy-4phenylphenoxy)-2,2-dimethylhexyl)carbamoyl)propanoic acid

H

o0 N SOj 2 Part A: Preparation of 6 2 (benzyloxy)phenoxy) -2, 2 -dimethylhexanenitrile 4*

NN

Benzene boronic acid (0.851 g, 6.98 mmol) was dissolved in ethanol (5.82 mL) (1.2 mM solution). 6-(4-Bromo-2-ethyl-5- (benzyloxy)phenoxy)-2, 2 -dimethylhexanenitrile (1.5 g, 3.49 mmol) was dissolved in toluene (17.4 mL) (0.2 mM solution), and added to the ethanol solution. Sodium bicarbonate was dissolved in water (5.24 mL) (2 mM solution), and added to the reaction. The reaction was heated to reflux overnight. The reaction was cooled to room temp and diluted with ethyl acetate. The organic layer was washed with sat. ammonium chloride. The organic layer was concentrated to an oil and purified by flash column chromatography (10:1 hexane:ethyl acetate) to give 1.24 g of product. ESMS: Calcd. for C29H33N2, 427.25; Found, 445.3 [M+NH4]+1 HPLC Method 5.Rt =21.888 min Purity Part B: Preparation of 6-( 2 (benzyloxy)phenoxy)-2,2-dimethylhexylamine 234 To a dry flask was added aluminum chloride (0.589 g, 4.11 mmol). The flask was cooled to less than O'C with an ice/ethanol bath. Ether (10 mL) was added, and the reaction was stirred for 5 minutes until the aluminum chloride dissolved. Lithium aluminum hydride (0.156 g, 4.11 mmol) was then added, and the reaction was heated to reflux. 6-(2- -2,2 -dimethylhexanenitrile (0.800 g, 1.87 mmol) was dissolved in ether (5 mL) and added dropwise to the refluxing solution. After addition was complete, the reaction was stirred for 5 hours at room temperature. The reaction was then quenched with water. Hydrosulfuric acid was added until a clear solution formed.

This mixture was then extracted with ether The aqueous layer was then cooled in an ice bath and basified to pH 14 with 50% aq. sodium hydroxide. The resulting solution was then extracted with ether The organic layer was washed with saturated NaC1, dried over magnesium sulfate, and :0 evaporated to give 0.982 g (121%) of product as an oil. ESMS: Calcd. f o r C29H37NO2, 431.28; Found, 432.3 [M+H]+1 20 HPLC Method 5.Rt =17.226 min Purity 91% ooe* Part C: Preparation of tert-butyl 3-((tertbutoxy) carbonylamino) -3-(N-(6-(2-ethyl-4-phenyl-5- (benzyloxy)phenoxy) -2,2 -dimethylhexyl) carbamoyl) -propanoate

SH..

0 0o 6-( 2 -Ethyl-4-phenyl-5-(benzyloxy)phenoxy)-2,2dimethylhexylamine(0.100 g, 0.232 mmol) was dissolved in dimethylformamide (5 mL). Triethylamine (0.097 mL, 0.696 mmol) was added, and the reaction was stirred for min. Boc- Asp(OtBu)-OSu (0.107 g, 0.278 mmol) was added, and the reaction was stirred under nitrogen for 60 h. The reaction was concentrated to an oil under high vacuum. The oil was dissolved in 50:50 ACN/H20 and lyophilized to give 0.239 g (147%) of product as -an oil. ESMS: Calcd. for C42H58N 2 0 7 702.42; Found, 703.5 [M+H]+1 HPLC Method 5. Rt =24.125 min Purity 89% Part D: Preparation of 3 -amino-3-(N-(6-(6 ethYl-3-hydroxy- 4 Phenyiphenoxy) -2,2-dimethylhexyl) carbamoyl) propanoic acid tert-Butyl 3-((tert-butoxy)carbonylamino) (2- (benzyloxy) phenoxy) -2,2-dimethyihexyl) carbamoyl)propanoate (0.200.g, 0.284 mmol) was dissolved in anisole (0.937 tL, 8.63 mmol), and cooled to 0 *Cin an ice bath. Trifluoroacetic acid (6.25 nL, 81.1 imol) was added, and the reaction was stirred for 10 min at 0 *C.

Trifluoromethanesulfonic acid (0.625 mL, 7.06 xmol) was added dropwise. The reaction was stirred at 0 *C for 1.5 h. The reaction was concentrated under high vacuum. The resulting oil was purified using the following method to give 48.5 mg of product. ESMS: Calcd. for 26H36N20 5 45.6.26; Found, 455..3 (M-H]-1 HPLC Method 5.Rt =13.395 min Purity 87% Part E: Preparation of 3 sulfophenyl)vinyl)amino) 3 -pyridyl)carbonylamino)-3- ethyl-3 -hydroxy-4-phenylphenoxy) -2,2-dimethyihexyl)- 25 carbamoyl)propanoic acid 3-Amino-3- 6 -ethyl-3-hydroxy- 4 -phenylphenoxy) -2,2dimethylhexyl)carbamoyl)propanoic acid (0.0315 g, 0.0533 mmol) was dissolved in dimethy1formamide (5 mL). Triethylamine (22.3 ALL, 0.160 nmol) was added and the reaction was stirred for 5 min. 2-[[[5-[1(2,5-Dioxo-l-pyrrolidinyl)oxylcarbonyll- 2-pyridinyl] hydrazon6]'-methyl] benzenesulfonic acid, monosodium salt 0.0281 g, 0.0640 nmol) was added and the reaction was stirred for 24 hours under nitrogen. The reaction was then concentrated to an oil under high vacuum. The oil was then purified by preparative HPLC Method 2 to give 14.4 mg of product. HRMS: Calcd. for C40H45N 5 0 9 S H, 760.3016; Found, 760.2997.

236 HPLC Method 5. -Rt=13.874 min Purity =83% Example 84 Synthesis of (l-aza- 2 -(2-sulfophenylviny1)amin) (3pyridYl)carbonylamino) (4-benzo [dl l, 3 -dioxolan-5..y 6 phenyl 2 -pyridyloxy) 2 -dimethylhexanoylamino) acetic acid so 3 H H' H S.

acid 0 NH 2

.TFA

S.H.

H

0 To a teabag (5x5 cm polypropylene filter, 0.75 9n 'Mesh) -15 was added 0.50 g of Fmoc-Gly(NH-Boc)-Wang Resin. The teabag .**was washed with the following (10 ml/bag).DMF 2 x 3 mint piperidine in.DMF solution 1 x 3 min, 20% piperidine in DHF solution lx 30 min, DOM 8x 3min, andDMF 3 x3 min. To the reactor was added 2 equivalents of the 6-(4-benzofd 1,3dioxolan--5-yl-6phenyl 2 -pyrkidyloxy) 2 -dimethylhexanoic acid, five equivalents of each of the following; RBTU,

HOBT,

diisopropylethylamine(DIEA) and DMF (l0mi/bag).. The bag was then shaken overnight for about 20 h. The bag was then washed with the following (l0ml/bag).: DMF 3 x 3 min, DCZM 8 x 3 min.

The bag was dried under high vacuum. The contents of the bag 237 was then placed in a small erlenmeyer flask. To the flask was added cleavage cocktail (10 mL) (95% trifluoroacetic acid, triisopropylsilane, and 2.5% water). The resin was allowed to sit for two hours while occasionally being swirled.

After each swirl the side of the flask was rinsed with additional cocktail until the total volume of cocktail added was 15 mL. After two hours, the resin was filtered and washed with TFA (2x4 mL). The filtrate was concentrated to an oil under high vacuum. The oil was triturated with ether to give 0.0460 g of product. ESMS: Calcd. for C28H31N30 6 505.22; Found, 506.3 fM+H]+1 HPLC.Method 5. Rt =13.477 min Purity Part B: Preparation of 2 sulfophenyl)vinyl)amino)(3-pyridyl)carbonylamino)-2-(6-(4benzo(d]1,3-dioxolan-5-yl -6-phenyl(2-pyridyloxy))-2,'2dimethylhexanoylamino)acetic acid 2-Amino-2-(6-(4-benzold],3-dioxolan-5-yl-6-phenyl(2pyridyloy))-2,2-dimethylhexanoylamino)acetic acid (0.035 g, 0.0560 mmol) was dissolved in dimethylformamide (3 mL).

Triethylamine (23.4 IL, 0.168 mmol) was added and the reaction was stirred for 5 minutes. PYrrolidinyl)oxy]carbonyl] -2-pyridinyl] hydrazono]lmethyl]benzenesulfonic acid, monosodium salt (0.030 g, 0.0672 mmol) was added and the reaction was stirred for 24 hours under nitrogen. The reaction was then concentrated to an oil under to. high vacuum. The oil was then purified by preparative

HPLC

Method 2 to give 11.2 mg of product. HRMS: Calcd. for C41H40N6010S H, 809.2605; Found, 809.2578.

HPLC Method 5.Rt =13.711 min Purity 98% Example Synthesis of 2-(2-aza-2-(( 5 5 -((3-((N-(6-(4,6-diphenyl(2pyridyloxy))-2,2-dimethylhexanoylamino)-3-(4hydroxyphenyl)propanoylamino)-1-(N-(2,3,4,5,6pentahydroxyhexyl)carbamoyl)pentyl)carbamoyl(2pyridyl))amino)vinyl)benzenesulfonic acid 238 Part A: Preparation of methyl 2 -,(6-(4,6-diphenyl(2pyridyloxy) 2-dimethylhexanoylamino) (4hydroxyphenyl.) propanoate' I H 6- (4 SDpey 2-yiyl -diehlhx i aci 6 6-Diophoyeyl (2pyidyly )2 -2L, 1.5dimehyiheanoicd aid the reaction was stirred for 5 min. H-Tyr(OBzl)-OMe (0.198 g, 0.61.6 inmol) and 2(lH-bentotriazoe-1-yl)1,1,3,3..

tetramethyluronium hexafluorophosphate (0.214 g, 0.564 nmol) see. were added, and the reaction was stirred under nitrogen for h. The-reaction was concentrated to an.oil under high vacuum.

The oil was dissolved in 50:50 ACN/H20 and lyophilized.' The crude product was then purified by preparative HPLC Method 2 to give 322.9 mg of product. ESMS: Calcd. for C42H44N20 5 656.33; Found, 657.5 [M+H]+1 HPLC Method 5.Rt =22.768 min Purity =100% Part B: Preparation of (6 6.-diphenyl (2 -pyridyloxy) dimethylhexanoylamino) (4 -hydroxyphenyl) propanoic acid 239 Methyl 2-(6-(4,6-diphenyl(2-pyridyloxy) dimethylhexanoylamino)-3-(4-hydroxyphenyl)propanoate (0.150 g, 0.228 mmol) was dissolved in tetrahydrofuran (10 mL). Lithium hydroxide monohydrate (0.0958 g, 2.28 nmol) was dissolved in water (2 mL) and added to the reaction. The reaction was stirred for 18 h. The reaction was then concentrated, brought up in water, acidified to pH 5 with IN HC1, and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to give 138.6 mg of product. ESMS: Calcd. for C41H42N205, 642.31; Found, 643.4 [M+H]+1 HPLC Method 5.Rt =21.258 min Purity Part C: Preparation of S 15. butoxy)carbonylamino)-5-(N-(2,3,4,5,6pentahydroxyhexyl)carbamoyl)pentyl-)carbamoyl)-2-(4benzyloxyphenyl)ethyl)-6-(4,6-diphenyl(2-pyridyloxy))-2,2dimethyihexanamide

N

?H

.0.0

H

H 0 r,,O NH OH OH 00 0 0.

6-Amino-2-((tert-butoxy)carbonylamino)-(N-(2,3,4,5,6pentahydroxyhexyl)hexanamide (0.050 g, 0.122 mmol) was 0 dissolved in dimethylformamide (3 mL). Diisopropylethylamine (63.8 gL, 0.366 mmol) was added, and the reaction was stirred for 5 min. 2-(6-(4,6-Diphenyl(2-pyridyloxy))-2,2dimethylhexanoylamino)-3- (4-hydroxyphenyl propanoic acid (0.0942 g, 0.146 mmol) and 2(1H-benzotriazole-l-yl)-1,1,3,3tetramethyluronium hexafluorophosphate (0.050 g, 0.134 mmol) were added, and the reaction was stirred under nitrogen for 72 h. The reaction was concentrated to an oil under high vacuum.

The oil was then purified by preparative HPLC Method 2 to give 79.2 mg of product. ESMS: Calcd. for C58H75N5012, 1033.54; Found, 1034.5 [M+H]+1 240 HPLC Method 5. Rt =19.290.min Purity 84% Part D: Preparation of butoxy) carbonylanino)-5- pentahydroxyhexyl) carbamoyl) pentyl) carbanoyl) hydroxyphenyl)ethyl)-6- (4,6-diphenyl( 2 -pyridyloxy))-2,2dimethylhexanamide A small round- bottom was purged with nitrogen.To this was added palladium on carbon (30 mg, 10%w/w) followed by methanol N- (-(Tert-butoxy) carbonylmino) 3,4,5, 6 -pentahydroxyhexyl)carbamoyl)pentyl)carbamoy (4benzyloxyphenyl)ethyl) 6- diphenyl 2 -pyridyloxy.)y-2,2'dimethylhexnamide (0.065 g, 0.0628 Imol) was dissolved in methanol (5*mL) and added to the reaction. 'Te reaption was evacuated and purged with nitrogen twice.. and then evacuated and opened to hydrogen twice. The reaction was stirred under hydrogen -for 4 h. The reaction was not complete so more palladium on carbon was added (30 mg). The reaction was stirred overnight for 18 h. The reaction was filtered through -celite, washed with methanol. The filtrate was concentrated to an oil under high vacuum to give-57.0 mg of product.

ESMS: Calcd. for C51H69N5O 12 943.49; Found, 944.5 [M+H+l HPLC Method 5. Rt =15.990 min Purity Part E: Preparation of (5-aminol5-(N-(2- 3,4,5,6pentahydroxyhexyl) carbanoyl) pentyl) carbamoyl) hydroxyphenyl)ethyl) -6-(4,6-diphenyl( 2 -pyridyloxy))-2,2dimethylhexanamide 5-(N 2 3 4,5,6pentahydroxyhexyl) carbamoyl) pentyl) carbamoyl) hydroxyphenyl) ethyl) -6-(4,6-diphenyl( 2 -pyridyloxy))-2, 2dimethylhexanamide (0.054 g, 0.0572 mmol) was dissolved in methylene chloride (1.5 mL). Trifluoroacetic acid (1.5 mL) was added, and the reaction was stirred for 2 h. The reaction was concentrated under high vacuum. The resulting oil was triturated'with ether to give 40 mg of product.

ESMS:

Calcd. for C46H6lN50lO, 843.44; Found, 844.6 [M+H +I HPLC Method 5. Rt =13.804 min Purity 89% Part F: Preparation of 2 2aa2 5 N 5 diphenyl (2-pyridyloxy) 2, 2 -dimethylhexanoyl amino) (4hydroxpheny)propanoylamno).I.(N-.( 2 3 4 5 6 pen tahydroxyhexyl) carbamoyl pentyl) carbamoyl (2 pyridyl) )amino)vinyl)benzenesulfonic acid N- (5-Amino-5- 6-pentahydroxyhexyl) carbamoyl)pentyl)carbamoyl) (4-hydroxyphenyl) ethyl) (4,6- .diphenyl 2 -pyr idyloxy) 2, 2 -dime thyihexanamide (0.040 g, 0.0418 rnmol-) was dissolved in dimethylformamide (3 mL).

Triethylamine (17.5. iL, 0.125 xruol) was added*.and the. reaction was stirred for 5 minutes. .2-t[[5-[[(2,5-Dioxo-1pyrrolidinyl) oxy] carbonyl] -2-pyridinyl] hydrazonolmethyl] *benzenesulfonic acid,. monosodium salt (0.0221 g, 0.0501 nmnol) was added and the reaction was' stirred for 24 hours under nitrogen. The. reaction. was then concentrated to an oil under high vacuum. The oil was then purified by preparative

H.PLC

Method 2 to give 12.1 mg of product-. HRMS: Calcd. for C59H70N8O 14 S H, 1147.4810; Found, 1147.4826.

HPLC Method 5.Rt =13.358 min Purity Example 86 Synthesis of 2 z N 6 e z l dioxolan-5-yl-6-phenyl (2-pyridyloxy) 2-dimethylhexyl) carbamoyl) E-pentahydlroxyhexyljcarbamoyl) ethyl) carbarnoyl (2-pyridyl) )amino) vinyl) benzenesulfonic acid OH OH Part A: Preparation of benzyl 2-((tert-butoxy)carbonyamino)- 3- (N-(2,3,4,5,6-pentahydroxyhexyl) carbamoyl) propanoate

NH

O H OH OH 0 OH OH Boc-Asp(OSu)-OBzl (2.00 g, 4.76 mmol) was dissolved in tetrahydrofuran (25 mL). 1-Amino-desoxysorbitol (0.948 g, 5.24 mmol) was dissolved in water (5 mL), and added to the reaction. Triethylamine (0.265 mL, 1.90 mmol) was added, and the reaction was stirred for 3 h under nitrogen. The reaction was concentrated under high vacuum. The residue was brought up in water and extracted with ethyl acetate. The ethyl acetate was washed with 0.1 N hydrochloric acid, water, brine, dried over magnesium sulfate, and filtered. As the filtrate was evaporated the product precipitated out of the solution.

15 The precipitate was filtered, washed with hexane, and dried under high vacuum to give 0.384 g of product. ESMS: Calculated for C22H34N2010, 486.22; Found, 487.3 [M+H]+1 HPLC Method 5.Rt =8.724 min Purity 100% Part B: Preparation of 2-((tert-butoxy)carbonylamino)-3-(N- (2,3,.4,5,6-pentahydroxyhexyl) carbamoyl) propanoic acid A small round bottom was purged with nitrogen. To this was added palladium on carbon (100 mg, 10%w/w) followed by 25 ethanol (5 mL). Benzyl 2-((tert-butoxy)carbonylamino)-3-(N- 2 3 ,4,5,6-pentahydroxyhexyl)carbamoyl)propanoate (0.300 g, 0.617 mmol) was dissolved in ethanol (5 mL) and added to the reaction. The reaction was evacuated and purged with nitrogen twice, and then evacuated and opened to hydrogen twice. The reaction was stirred under hydrogen for 20 h. The reaction was filtered through celite, washed with ethanol. The filtrate was concentrated to an oil under high vacuum to give 266 mg (109%) of product. ESMS: Calcd. for C15H28N2010, 396.17; Found, 397.2 [M+H]+1 243 Part C: Preparation Of N- 4 -benzo [djl, 3 -dioxolan-5-Y.. 16 Phenyl 2 -Pyridylo,) 2 -dimethylhexyl)' 2 -((tertbutoxy) carbonylamno) -N -(2,3,4,56-ethdoxeyl buae 1, 4 dianjde OH OH 00IT H OH OH HNfA< 1-Amino-2, 2 -dimethyl-.6. 4 -methylenedioxphenyl)-6 phenyl-2-PYridiflyl)oxy-exn (0.,100 g, 0.239molwa dissolved in dimethylfOrmaide (5 mL). DiisoprMOpylethwai 0. 1 n o a a d d and the reaction was stirred for 5 m i. 2 'T r u o y c r o y a i o N 4 ,5 6 enta hydrohyl)carbol~poao' acid(0.14go xnmol) and 2U(H-benzotizlell -1,1,,7 JJUJOfospflate(0.109.g, 0.287' mmol)' Iwere addedi and the reaction was-stirred under nitroge fo 8h herato concentrated to an oil under high vacuum. The oi 'Was thenwa Purified by preparative HPLC Method 3 to give 98.9 mg (52% of product. ESMS: Calcd. for C41H56N 4 0 12 796.39; Found, 797.5 +1 I{PLC Method 5.Rt =15.13 min Purity =100% Part I):Preparation of 2 -amino-N..(6- (4-benzo [dli, 3 -dioxolan-..

petbdoxhxl uae1 4 -diamide N- (4-BenzofdIll13 -diOxolan.s yl-6phen1 (2- PYridyloxy) 2 -dimethylhe,l) ((tert-butoxy) carbonylamino) E-pentahydrOxhe,l) butane-i, 4 -diamide (0.090 g, 0.113 mmol) was dissolved in miethylene chloride MiL). Trifluoroacetic acid (1.5 MiL) was added, and the reaction was stirred for 2 h. The reaction was concentrated under h +igh vacuum. The resulting oil was triturated with ethe r 'to* give 8.0.5 mg -of product.. ESMS:' Calcd. for C36H48N4O 10 696.34; Found, 697.4 [M-sH]+1 HPLC Method 5. Rt =12.776 min Purity 88% Part E: Preparation of benzod)l,3-dioxolan-..y..6phenyl(2-pyridyloxcy) dimethyhexy)carbamoyl...>.(N-(2,3,4,5,6-.

pentahydroxyhexyl) carbamnoyl) ethyl) carbamnoyl (2 pyridyl) )amino) vinyl) benzenesulfon'ic acid .2AioN(-4rezfl,-ixln5y--hnl2 pyridyloxy) )-2,2-dimethylhexyl)-N*1-(2,3,4,5,6pentahydroxyhexyl) butane-.1, 4 -diamide 047 g, 0.0580 mmot)wa dissolved in dimethylformanide (3 rnL). Triethylamine (24.3 15 ILL, 0.174 mmol) was added and the reaction was stirred minutes. 2- 5-Dioxo-1-pyrrolidinyl)oxyl -carbonyl] -2pyridinyl] hydrazono]I methyl I-benzenesul fonic 'acid, monosodium salt (0.030.6 g, 0.0696 nimol) was added and the reaction was stirred for 72 hours under nitrogen. The reaction was then .concentrated to an oil-under high -vacuum. Theoil. was then purified by preparative HPLC Method 3 to give 25.2' mg of product.* HR MS: Calcd.. fo r C49H57N7014S H, 1000.3762; Found, 1000.3732.

HPLC Method 5.Rt =12.730 min Purity =96% Example 87 Synthesis of 2 2 d1,3dioxolan-5-yl-6-phenyl (2-pyridyloxy) dimethylhexyl) carbamoyl) amino) phenyl) carbonylamino) 6-pentahydroxyhexyl) carba moyl) pentyl) carbamoyl (2pyridyl) )amino) vinyl) benzenesulfonic acid Part A: Preparation of methyl 3-((N-(6-(4-benzo[d]1,3dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2dimethylhexyl)carbamoyl)amino)benzoate H H 1-Amino-2,2-dimethyl-6-l (4-(3,4-methylenedioxyphenyl) -6phenyl-2-pyridinyl)oxy]-hexane (0.300 g, 0.717 mmol) was *dissolved in dimethylformamide (10 mL). Diisopropylethylamine (642 pL, 3.58 mmol) was added, and.the reaction was stirred for 5 min. 3-Ethoxycarbonyphenyl isocyanate (0.548 g, 2.87 mmol) was added, and the reaction was stirred under nitrogen for 36 h. The reaction was concentrated to an oil under high vacuum. The oil was then purified by preparative HPLC Method 3 to give 431.6 mg of product. ESMS: Calcd. for C36H39N306, 609.28; Found, 610.4 [M+H]+1 HPLC Method 5.Rt =20.452 min Purity 99% Part B: Preparation of 3-((N-(6-(4-benzo[d]1,3-dioxolan-5-yl- 6-phenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)amino)benzoic acid Methyl 4 -benzo [d]1,3-dioxolan-5-yl-6-phenyl(2pyridyloxy) 2-dimethylhexyl)carbamoyl)amino)-benzoate(0 .400 g, 0.656 mmol) was dissolved in ethanol (10 mL). Potassium hydroxide pellets (0.0736 g, 1.31 mmol) were dissolved in water (1 mL), and added to the reaction. The reaction was heated to reflux for 16 h. The reaction was concentrated to 246 an oil under high vacuum. The residue was brought up-*in.

water. The solution was adjusted to pH 5 with 1N hydrochloric acid. The solution was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over magnesium sulfate, filtered, and concentrated to an oil under high vacuum. The oil was recrystallized from hexane:ethyl acetate-to give 0.212 g of product. HRMS: Calcd. for C34H35N306 H, 582.2604; Found, 582.2604.

HPLC Method 5.Rt =17.966 min Purity 100% Part C: Preparation of 6 1,3-dioxolan-5yl.-6-phenyl 2 -pyridyloxy) -2,2-dimethyihexyl) carbamoyl) amino) phenyl) carbonylamino) 2-((tert--butoxy) carbonylamino)-

(N-

(2,3,4,5, 6 -pentahydroxyhexyl.)hexanamide I H HdH OH OH

N

6-Amino-2-((tert-butoxy)carbonylamino)-(N-(2,3,4,5,6pentahydroxyhexyl)hexanamjde (0.040 g, 0.0977 mmol) was dissolved in dimethylformamide (2 niL). Diisopropylethylamine (46.4 gIL, 0.266 mnol) was added, and the reaction was stirred for 5 min. 3( 6 4 -Benzo[d-1,3-dioxolan-5-yl-6-phenyl(2 pyridyloxy)) -2,2-dimethylhexyl) carbamoyl) amino) -benzoic acid (0.-0516 g, 0.0888 mmol) and 2 (1H-benzotriazole-1-yl)-1,1,3,3.

tetramethyluronium hexafluorophosphate (0-.0404 g, 0.106 nmol) were added, and the reaction was stirred under nitrogen for 48 h. The reaction was concentrated to an oil under high vacuum.

The oil was then purified by preparative HPLC Method 3 to give 55.0 mg of product. ESMS: Calcd. for C51H68N6O 13 972.48; Found, 973.6 (M+H]+l HPLC Method 5.Rt=16.354 min Purity 97% Part D: Preparation of 2-amino-6-((3-((N-(6-(-benzod]1,3 dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2- 247 dime thyihexyl) carbamoyl) amino) phenyl) carbonylamino) -N--r 6-pentahydroxyhexy1)hexaamide pyridyloxy) -dimethyihexyl) carbaxnoyl) amino) phenyl) carbonylanino) ((tert-butoxy)carbonylamino) (2,3,4,5,6pentahydxoxyhexyl)hexanamjde (0.045 g,.0.0462 nunol) was dissolved in methylene chloride (3.0 xnL). Trifluoroacetic acid (3.0 rnL) was added, and the reaction was stirred for 2 h.

The reaction was concentrated under high vacuum. The resulting oil was triturated with ether to give 34.2 mg of product. ESMS: Calcd. for C46H60N6011, .872.43;Found, 873.6 [M+H]+1 HPLC IMeth od 5.Rt=14.610 mi Purity Part-E: Preparation of benzofd]1, 3 -dioxolan-5-yl-6-phenyl(2-pyridyloxy) dimethyihexyl) carb:amoyl) amino) phenyl) carbonylamino) 6-pentahydroxyhexyl) carbamoyl) pentyl) carbamoyl (2pyridyl) )amino)vinyl)benzenesulfonic acid ~2-Amino-6- (4-benzo [dli, 3-dioxolan-5-yl-6phenyl (2-pyridyloxy) 2-diniethylhexyl) carbainoyl) amino) phenyl) carbonyl amino) 6-pentahydroxyhexyl) 25 hexanamide (0.029 g, 0.0294 nimol) was dissolved in dimethylformamide (3 niL). Triethylamine.(12.3 ILL, 0.0882 zumol) was added and the reaction was stirred for 5 minutes.

((2,5-Dioxo- -pyrrolidiyl)oxycarbony.2.

pyridinyllhydrazonolmethyl.]-benzenesulfonic acid, monosodium salt (0.0155 g, 0.0353 inmol) was added and the reaction was stirred for 72 hours under nitrogen. The reaction was then concentrated to an oil under high vacuum. The oil was then purified by the preparative HPLC Method 4 to give 4.0 mig (12%) of product. ESMS: Calcd. for C59H69N9015S, 1175.46; Found, 1176.4 (M+H]+1 HPLC Method 5.Rt=13.898 min Purity =94% Preparative HPLC Method 4 248 Instrument: Column: Detector: Flow Rate: Column Temp: Mobile Phase: Gradient: Rainin Rabbit; Dynamax software Vyadac C-18 (21.2 mm x 25 cm) Knauer VWM i1mi 1m

RT

A: 0. 1% TFA in H2 0 B: 0.l%TFA in AdN/H20 (9:1) Time (min) %A %B 0 60 12 32 68 32 20 33 60 we we. 0

C

C

.Example 88 15 Synthesis of 2- (l-aza-2-.(2-sulf ophenyl) vinyl) amino) (3pyridyl) )carbonylamino*) (4-benz'o dl1, 3-diox 6-phenyl (2-pyridyloxy -dimethylbexyl) carbamoyl) propanoy lamino) -3-carboxypropanoyl.amino) -3carboxy(propanoylamino) -ethane-1, 2-dicarboxylic acid

OH

0 (6-((l-Aza-2-(2-sulfophenyl)vinyl)amino) (3pyridyl) carbonylamino) (4-benzo [dl 1,3-dioxolan-5-yl-6phenyl (2 -pyridyloxy) -dimethyihexyl) carbamoyl )propanoic acid (0.044 g, 0.0526 nimol) was dissolved in dimethylformamide (3 nL). Diisopropylethylamine (27.5 ;LL, 0.158 inmol) was added, and the reaction was stirred for 5 min. Triaspartic acid (Asp-Asp-Asp-OH, 0.0229 g, 0.0 631 nimol) and 2(1Hbenzotriazole-l-yl) 3 -tetramethyluronium .249 hexaf luorophosphate 023.9 g,-..0631 inmol) were added, and the reaction was stirred under nitrogen for 18 h. The reaction was concentrated to an oil under high vacuum. The oil was then purified by preparative HPLC Method 3 to give 22.6 mg of product. HRMS: Calcd. for C55H59N90 19 S H, 1182".3726; Found 1182.3765.

HPLC Method 5.Rt =12.612.min Purity Example 89 Synthesis of 6 -((l-aza-2-(2-sulfophenyl)vinyl)amino) (3pyridyl) )carbonylamino) (4-benzo (dli, 3 -dioxola1--yl.

6-phenyl 2 -pyridyloxy) )pentyloxy)phenyl)propanoic acid N O N* S03

N

H2 0.

e Prea:tiPrepaatin d o 4h ofe reez~ 3dooaction.lwas..quenyched..

(1,h sa.amnu hoie h ecinwscnetae un e i h v c um h e a n ng a u o s l y r a x r c e wit ety ctt.TeognclyrwswseSihbie dr e v r m g es u u f t fi t r d n on e t a e o a 250 oil under high vacuum. The oil was brought up in 90-10 hexane:ethyl acetate and passed through silica gel. The filtrate was concentrated to an oil under high vacuum to give 1.068 g (108%) of product. ESMS matches if TBDMS group ionizes during mass spec. Calcd. for C23H22N04, 376.15; Found, 377.3 [M+H]+1 HPLC Method 5.Rt =25.623 min Purity Part B: Preparation of 5-(4-benzo[d]l,3-dioxolan-5-yl-6phenyl-2-pyridyloxy)pentan-l-ol A small round bottom was purged with nitrogen.To this was added palladium on carbon (200 mg, 10%w/w).followed by ethyl acetate (7 mL). 4 -Benzo[d]1,3-dioxolan-5-yl-6-phenyl-2-( 5 15 (1,1,2,2-tetramethyl-l-silapropoxy)pentyloxy)pyridine (1.04 g, 2.12 mmol) was dissolved in ethyl acetate (8 mL) and added to the reaction. The reaction was evacuated and purged with nitrogen twice, and then evacuated and opened to hydrogen twice. The reaction was stirred under hydrogen for 3 h. The reaction was not complete so more palladium on carbon was added (200 mg), and the reaction was stirred for 3 h more. The reaction was still not complete so more palladium on carbon was added (500 mg) was added, and the reaction was stirred overnight for 16 h. The reaction still was not done, so more palladium on carbon (600 mg) was added, and the reaction was stirred for 3 h. The reaction was filtered through celite, washed with ethyl acetate. .The filtrate was concentrated to S* an oil under high vacuum. The oil was recrystallized from hexane:ether to give 421.8 mg of product. ESMS: Calcd.

for C23H23N0 4 377.16; Found, 378.2 [M+H]+1 HPLC Method 5. Rt =16.203 min Purity 99% iI- Part C: Preparation of methyl 3-(2-(5-(4-benzo[d]1, 3-dioxolan- 5-yl-6-phenyl(2-pyridyloxy))pentyloxy) phenyl)-2-((tertbutoxy) carbonylamino)propanoate 5-(4-Benzo(d]1,3-dioxolan-5-yl-6-phenyl-2-pyridyloxy)pentan-1-ol (0.153 g, 0.406 mmol) and methyl 2-((tert-butoxy)carbonylamino)-3-(2-hydroxyphenyl)propanoate (0.100 g, 0.338 mmol) were brought up in tetrahydrofuran mL). Triphenylphosphine (0.177 g, 0.676 mmol) and diethylazodicarboxylate (0.118 g, 0.676 mmol) were added, and the reaction was stirred for 3.h. The reaction was quenched with sat. ammonium chloride. The reaction was concentrated under high vacuum. The remaining aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, filtered, and concentrated to an oil under high vacuum. The oil was purified by flash chromatography (5:1 hexane:ethyl acetate) to give 0.111 g of.product. ESMS: Calcd..for C38H42N208; 654.29; Found, 655.4. M+H]+1 HPLC Method 5.Rt =21.986 min Purity Part D: Preparation of 3-(2-(5-(4-benzo[d]1,3-dioxolan-5-yl-6- .phenyl(2-pyridyloxy))pentyloxy)phenyl)-2-((tertbutoxy)carbonylamino)propanoic acid

N

L~,Et~p~ c

H

0 Methyl 3-(2-(5-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2pyridyloxy) pentyloxy)phenyl)-2- (tert-butoxy)carbonylamino)propanoate (0.098 g, 0.150 mmol) was dissolved in tetrahydrofuran (5 mL). Lithium hydroxide monohydrate (0.0628 g, 1.50 mmol) was dissolved in water (1 mL) and added to the reaction. The reaction was stirred for 18 h. The reaction was then concentrated, brought up in water, acidified to pH with 1N HC1, and extracted with ethyl acetate. The organic layer was washed brine, dried over magnesium sulfate, 252 -filtered. and evarporated to give .93.9 mg of Product.

ESMS: Calcd. for C37H40N208, 640.27; Found, 641.4 [M+H]+1 HPLC Method 5. Rt =20.109 min Purity 91% Part E: Preparation of 2-anino-3-(2-(5-(4 benzod]l,3- -dioxolan-5-yl-6-phenyl 2 -pyridyloxy) )pentyloxy)phenyl) propanoic acid To a solution of 3 -(2-(5-(4-Benzod],3-dioxolan-5-yl-6pheyl(2-pyridyloxy))pentyloxy)phenyl) -2-((tert-butoxy)carbonylamino)-propanoic acid (0.083 0.130 mmol) in methylene chloride (3.0 mL) was added trifluoroacetic acid mL), and the reaction stirred for 2 The. reaction was concentrated under high vacuum .to give 85 mg (100%) of product as an oil. ESMS: Calcd. for C32H32N206, 540.23; Found, 541.3 S[M+H] +1.

HPLC Method 5Rt =15.04*1 min Purity 96% Part F: Preparation of 2 (2sulfophenyl) vinyl) amino) (3-pyridyl) )carbonylamino)-3- benzo 1, 3 -dioxolan-5.-yl-6-phenyl (2pyridyloxy) )pentyloxy)phenyl)propanoic acid To a solution of 2 -amino-3-'(2-(5-(-benzo[dl,3-dioxolan- 5-yl-6-phenyl (2-pyridyloxy))pentyloxy)phenyl) -propanoic acid (0.080 0.122 mmol) in dimethyformamide (3.mL) was added triethylanine (85.0 gIL, 0.610 nmol) and the reaction stirred for 5 min. 2 -Dioxo-1I-pyrro1idinyl) oxy IcarbonylJ 2-pyridinyl] hydrazonolmethyl] -benzenesulfonic acid, monosodium salt (0.0646 g, 0.146 nmol) was added and the reaction was stirred for 96 hours under nitrogen. The reaction was concentrated*.to an oil under high vacuum. The oil was then purified by preparative HPLC Method 3 to give 36.4 mg of product. HRMS: Calcd. for C45H41N5010S H, 844.2652; Found, 844.2667.

HPLC Method 5.Rt =15.161 min Purity 96% HPLC Method Instrument: HP1050 Column: Vydac C18(4.6 x 250 mm) Detector: Diode array detector 220nm/500ref Flow Rate: 1.0 mL/min.

Column Temp: 50 'C Sample Size: 15 uL Mobile Phase: A: 0.1% TFA in water B: 0.1% TFA in ACN/Water (9:1) Gradient: Time(min) %A %B 0 80 0 100 0 100 15 31 80 Examples 90-166 The reagents of examples 1 58, 61 72, and 75 89 are LTB4 antagonist compounds which incorporate a chelator or bonding unit for Tc-99m. The following procedures (A D) describe the synthesis of radiopharmaceuticals of the present invention (Examples 90 166). The reagents comprised of a hydrazinonicotinamide group, present either as the free ."hydrazine or in protected form as a hydrazone react to form 25 ternary ligand complexes with Tc-99m, designated by the formulae 9 9 mTc(LTB4) (tricine) (phosphine) anid 9 9 mTc(LTB4) (tricine)(L) (L Imine-Nitrogen Containing Heterocycle), in which (LTB4) represents the LTB4 antagonist compound bonded to the Tc through a diazenido or hydrazido moiety. The other two ligands in the Tc coordination sphere are tricine and either a phosphine or an imine-nitrogen containing heterocycle. The reagents comprised of a diamidedithiol or monoamidemonoaminedithiol chelator form complexes with Tc-99m of the formula 9 9 mTc(0)(LTB4) in which the designation (LTB4) represents the LTB4 antagonist compound bonded to the Tc through two nitrogen donors and two sulfur donors forming a Tc(O) (N 2

S

2 coordination sphere. Procedure A Synthesis of Tc-99m LTB4 Antagonist Complexes of the Formula 99 mTc(LTB4)(tricine)(phosphine) Using Stannous Reducing Agent (Examples 90-93, 95-97, 99, 100, 105, 111, 126, and 145-150.) 10 30 jg (0.2 0.4 mL) of LTB4 antagonist in saline or aqueous ethanol, 40 mg (0.4 mL) of tricine in water, 1-7 mg (0.10 0.30 mL) of phosphine dissolved in water or ethanol, 25 gg (25 IL) SnCl 2 2H 2 0 dissolved in 0.1 M HCl, 0 0.25 mL ethanol and 50 150 mCi 99 mTcO 4 in saline were combined in a 10 cc vial. The kit was heated in a 100°C water bath for 10 20 minutes, then a 50 JIL sample analyzed by HPLC Method 6. If necessary, the complex was purified by performing a 300 400 gL injection on the HPLC and collecting the fraction into a shielded flask. The collected fraction 15 was evaporated to dryness, redissolved with a 0.05 solution of Tween 80 in saline, and then re-analyzed using HPLC Method 6.

Procedure B Synthesis of Tc-99m LTB4 Antagonist Complexes of the Formula 99 mTc(LTB4) (tricine) (TPPTS) Without Using Stannous Reducing Agent (Examples 93, 97, 100-103, 105-109, 111-124, 126-143.) To a lyophilized vial containing 4.84 mg TPPTS, 6.3 mg tricine, 40 mg mannitol and 0.25 M succinate buffer, pH 4.8, was added 0.2 0.4 mL (20 40 jig) LTB4 antagonist in saline or .50% aqueous ethanol, 50 100 mCi 99 mTcO 4 in saline, and additional saline to give a total volume of 1.3 1.5 mL. The kit is heated in an 100°C water bath for 10 15 minutes, and a sample was then analyzed by HPLC Method 6 or 7. If necessary, the complex was purified by performing a 300 400 1L injection on the HPLC and collecting the fraction into a shielded flask. The collected fraction was evaporated to dryness, redissolved with a 0.05-5% solution of Tween 80 in saline, and then re-analyzed using HPLC Method 6 or 7.

Procedure C Synthesis of Tc-99m LTB4 Antagonist Complexes of the Formula 99 mTc(LTB4) (tricine) (L Imine-Nitrogen Containing Heterocycle) (Examples 151 164) To a 10 mL vial was added 0.4 mL of tricine solution (100 mg/mL in 25 mM succinate buffer, pH 0.2 mL of LTB4 antagonist solution (100 gg/mL in EtOH), 0.2 0.4 mL of coligand solution (10 50 mg/mL in 25 mM succinate buffer, pH 5.0, depending on the type of coligand (for pyridine analogs, the coligand concentration was 5 10 mg/mL while the concentration of imidazole, thiazole or triazole analogs was 1 5 mg/mL), 0.2 0.5 mL of 99 mTcO4- solution (100 200 mCi/mL in saline), and 25 JL of SnCl 2 -2H 2 0 solution (1.0 mg/mL in 0.1 N HC1). The reaction mixture was heated at 100 oC for 10 min. After cooling at room temperature, the reaction mixture was analyzed by HPLC Method 6 If necessary, the complex was purified by performing a 300 400 JiL injection on the HPLC and collecting the fraction into a shielded flask. The collected fraction was evaporated to dryness, redissolved.with a 0.05-5% solution of Tween 80 in saline, and then re-analyzed using HPLC Method 6.

Procedure D Synthesis of Tc-99m LTB4 Antagonist Complexes of the Formula 99 mTc() (LTB4) (Examples 165, 166) A commercial Glucoscan® kit (containing 200 mg sodium glucoheptonate and -60 jg stannous chloride dihydrate) was reconstitituted with 1.25 mL saline. To 0.5 mL of the reconstituted Glucoscan® was added: 150 LL 1:7 glacial acetic acid:0.2 M HCl(aq), 0.25 mg (0.5 mL) of the respective conjugate dissolved in ethanol and ca. 50 150 mCi 99 mTc0 4 in saline. The kit was heated in an 80 0 C water bath for minutes, then a 50 LL sample analyzed by HPLC Method 6. If necessary, the complexes were purified by performing a 300 400 gL injection on the HPLC and collecting the fraction into a shielded flask. The collected fraction is evaporated to dryness, redissolved with 0.05-5% solution of Tween 80 in saline, and then re-analyzed by HPLC Method 6.

256 Analytical Methods HPLC Method 6 Column: Zorbax C18, 25 cm x 4.6 mm or Vydac C18, 25 cm x 4.6 mm Column Temperature: ambient Flow: 1.0 mL/min Solvent A: 10 mM sodium phosphate buffer pH 6 Solvent B: 100% Acetonitrile Detector: sodium iodide (Nal) radiometric probe Gradient A (Ex. 99, 100): t (min) 0 20 30 31 %B 15 5 .50 75 15 Gradient B (Ex. 90-93, 95, 96): t (min) 0 20 30 31 %B 0 90 90 0 0 Gradient C (Ex. 94, 97, 98, 101-109, 111-144, 147-166): t (min) 0 20 30 31 %B 0 75 75 0 0 Gradient D (Ex. 145, 146): t (min) 0 20 30 31 %B 0 80 .80 0 0 HPLC Method 7 (Ex. 110) Column: Cosmosil C18, 25 cm x 4.6 mm Column Temperature: 50 0

C

Flow: 1.0 mL/min Solvent A: 25 mM sodium phosphate pH 6 Solvent B: 100% Acetonitrile Detector: Nal radiometric probe Gradient: t (min) 0 20 30 31 %B 40 80 80 40 257 *0 0 0 Table 1. Analytical and Yield Data for 99 mTc(LTB4) (tricine) (TPPTS) Complexes Complex Ex. No. Reagent Ex. No.

1 91 2 92 3 93 4 94 6 7 96 8 97 10 98 12 99 14 100 15 101 17 102 18 103 19 104 20 105 21 106 23 107 26 108 27 109 28 110 31 111 32 112 33 113 34 114 35 115 36 116 37 117 38 118 39 119 40 120 41 121 42 122 43 123 44 124 45 125 49 126 54 127 56 128 58 129 64 130 65 131 67 132 67 133 68 134 70 135 72 136 75 137 79 138 80 Yield 75 92 83 88 91 91 59 70 68 60 83 47 60 77 72 54 73 41 80 83 51 58 83 80 85 47 44 90 76 85 79 82 87 87 87 92 85 33 46 86 94 79 82 83 67 57 87 82 47 RT (min) 12.7 12.0 12.4 15.2 12.8 15.1 12.9 15.0 16.0 18.7 15.0 12.4 15.3 16.0 14.1 12.1 13.5 15.6 16.4 15.0 16.0 15.8 16.0 13.3 14.1 13.8 15.7 14.0 14.6 13.8 12.8 13.6 13.3 12.2 12.6 10.9 17.5 13.9 13.3 13.9 13.9 12.9 13.2 14.5 12.9 11.7 12.5 13.3 15.7 139 84 94 12 .S9 140 85 50 14.7 141 86 93 14.2 142 87 44 15.7 143 88 94 12.2 144' 89 82 13.8 Table 2. Analytical and Yield Data for 99 mTc (LTB4) (tricine) (TPPDS) and 9 9 mTc (LTB4) (tricine) (TPPMS) Com iexes Usincy the Re ,-rni of Ex 1 IComplex Ex. No. Phosphine Yield RT(min) 145 TPPDS 96 17.7 146 TPPMS 97 20.9 Table 3.*Analytical and Yield Data for 99 rnTc (LTB4) (tricine) (TFP) .Complexes 'Complex Ex. No.- Reagent. Ex. No. Yield RT(min) 147 15 70- 19.6 148 33 62 19.5 149 34 75 18.7 150 79 75 1.

S

S

S

S

A

table HPLC and Yield Data 99 mrc (LTB4) (tricine) Complexes (L =Imine-Nitrogen Containing Heterocycle) Complex Reagent Imine Yield RT Ex.. No. Ex.- No. Ligand (min) 15I A .75 16.7 152 14 A 90 16.6 153 14 B 88 17.1 .154 15 B 57 13.8 155 15 C 89 14.5 156 15 D 28 13.8 157 15 A 67 14. 8 158 15. E 64 16.0 1915 F 25 15.6 160 15 G 62 16.1 161 15 H 86 17.5 162 15 1 66 14.8 163 21 A 64 13.9 164 34 H 71 16.4 Imine-nitrogen containing coligands,

L:

A 3-pyridinesulfonic acid B 3 5 -pyridinedicarboxylic acid C Isonicotinic acid D Nicotinic acid E Hydroxyethylisonicotinmide~ F 4 G 4 H pyridine I 4-pyridylethylsulfonic acid 259 Table 5. Analytical and Yield Data for 99 mTcO(LTB4) Reported retention times are the average of the two diastereomeric complexes when resolvable.

Utility The radiopharmaceuticals of this invention are useful for imaging sites of infection and/or inflammation in mammals.

The reagents of this invention are useful in the treatment of diseases associated with infection and inflammation.

Representative compounds were tested in the in vitro and in vivo tests described below and found to be active.

LTB4 Human NeutroDhil (PMN) Binding Assay Heparinized blood was placed on a ficol gradient followed by its sedimentation with dextran. This resulted in preparations containing 95% neutrophils (PMN). The PMN 20 solution was adjusted to achieve a concentration of 8 X 106 PMN/ml. In this assay the test agent will actively compete with 3[H] LTB4 for the PMN LTB4 receptor. Very briefly, the assay was performed as follows; [3H]LTB4 (1 nM) and test agent were placed into a 96 well microplate with filters (0.65 pm 25 pore size). PMN solution (8 x 10 6 /ml) was added and the microplate incubated for 10 min at 4 C. The microplate was then placed on Millipore filtration system; the wells washed with cold saline (3 x) and dried. The filters were removed from the microplate; placed into scintillation fluid and the concentration of [3HILTB4 determined.

The compounds of Examples 1 89 were tested in this assay and all were found to be active.

Guinea Pia Focal Infection Model The function of the model is to rapidly assess an agent's ability to detect inflammation/infection as well as determine 260 the biodistribution. Very briefly, the procedure was-as follows: A #10 trochar needle was used to introduce a piece of umbilical tape immersed in a 6% sodium caseinate solution into the right flank and placed on the left side of the peritoneal cavity of anesthetized guinea pigs. The placement of the immersed string served as the focal site for white blood cell recruitmeAt over the next eighteen hours. Eighteen hours later the guinea pigs were anesthetized and the test agent administered via the lateral saphenous vein. At the appropriate time postinjection, the animals were euthanized and the focal uptake determined. Throughout the course of the study blood was withdrawn via cardiac puncture. Uptake and target-/background ratios were determined via well counting.

The radiopharmaceuticals of Examples 90, 92 95, 97, 99, 15 100, 102, 106 118, 126, 130, 133 134, 137 141, 143 and 166 were evaluated in this model and all were found to have focal uptake at the site of the sterile inflammation ranging from 0.1 to 2.1 Rabbit Focal Infection Model The function of the model is to rapidly assess. an agent's ability to detect inflammation/infection via scintigraphy as well as determine the biodistribution. The protocol takes place over 2 days and is comprised of induction of an 25 infection, imaging, followed by a biodistribution. Very briefly, the procedure was as follows: On day 1, 2x10 9 colonies of E.coli was administered intramuscularly in the thigh to anesthetized rabbits. The infection was permitted to fulminate for 24 hrs prior to the intravenous administration of the test agent. Prior to the administration of the test agent, the animal was anesthetized, intubated and monitored to assess arterial pressure and heart rate and hematology.

Anterior 5 min serial images were performed over a4 hr period. At the end of the protocol the animal was euthanized with a pentobarbital overdose and the uptake of the test agent in various organs assessed via well counting.

The radiopharmaceuticals of Examples 90, 93, 94, 97, 99, 100, 102, 107, 108, 113, 114, 118, 127, 129, 130, 133, 137, 140, and 157 were evaluated in this model and all were found to give a target-to-background ratio (infection site to contralateral muscle regions of interest) of ranging from 1.3 to 15.9.

Dosage and Formulation The anti-infection and anti-inflamation compounds of this invention can be administered as treatment for infection and inflamation by any means that produces contact of the active agent with the agent's site of action. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents.

They can be administered alone, but preferably are 15 administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage administered will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the age, health and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired. A daily dosage of active ingredient can be 25 expected to be about 0.001 to about 1000 milligrams per kilogram of body weight, with the preferred dose being about 0.1 to about 30 mg/kg.

Dosage forms of compositions suitable for administration contain from about 1 mg to about 100 mg of active ingredient per unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition. The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets and powders, or in liquid dosage forms, such as elixirs, syrups and suspensions. It can also be administered parenterally, in sterile liquid dosage forms.

262 Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like.

Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet.from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.

In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols 15 such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts, and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben and 25 chlorobutanol. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, supra, a standard reference text in this field.

Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows: Capsules A large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with 100 mg of powdered active ingredient, 150 mg of lactose, 50 mg of cellulose, and 6 mg magnesium stearic.

Soft Gelatin Capsules A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil can be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules should then be washed and dried.

Tablets A large number of tablets can be prepared by conventional procedures so that the dosage unit is 100 mg of active ingredient, 0.2 mg of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch and 98.8 mg of lactose. Appropriate coatings 15 may be applied to increase palatability or delay absorption.

0 Suspension An aqueous suspension can be prepared for oral administration so that each 5 mL contain 25 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, and 0.025 mg of vanillin.

S. Iniectable 25 A parenteral composition suitable for administration by injection can be prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution is sterilized by commonly used techniques.

Where the terms "comprise", "comprises", "comprised" or "comprising" are used in this specification, they are to be interpreted as specifying the presence of the stated features, integers, steps or components referred to, but not to preclude the presence or addition of one or more other feature, integer, step, component or group thereof This application is a divisional of Australian Patent Application No. 52381/98 the disclosure of which is incorporated herein by way of reference.

264

Claims (7)

1. A compound having the formula: WeO-(CR 54 R 55 wherein We' is selected from the group: OH R 47 N N R 4 N 06 So K 000*0, andR 0 wherein, S0 R 47 is selected from the group: CI-C 6 alkyl 00000:substituted with 0-3 R 50 C 1 -C 6 alkoxy 9806substituted with 0-3 R 50 aryl substituted with 0-3 R 5 1, and heterocycle substituted with 0-3 R 51 R48 and R 49 are selected from the group: CI-C3 alkyl, C

2 -C 3 alkenyl, cyclopropyl, cyclopropylmethyl, and aryl substituted with 0-3 R 51 R 50 is independently selected from the group: -F, -Cl, -Br, -N(R 5 2 (R 5 3 and -CF 3 R 51 is independently selected from the group: -F, -Cl, -Br, -N(R 5 2 (R 5 3 -CF3, C 1 -C 3 alkyl, CI-C 3 alkoxy, and methylenedioxy; R 5 2 and R 53 are independently H or Cl-C 3 alkyl; 265 R 54 and R 5 5 are independently selected at each occurrence from the group: H, C 1 -C 5 alkyl, and CI-C 5 alkoxy, or alternatively, R 54 and R 55 may be taken together to form a 3-6 membered cycloalkyl; k" is 4-7; Y' is selected from the group: C(=O)NHR 5 6 NHC(=O)R 5 6 and NHC(=0)NHR 57 R 56 is selected from the group: aromatic heterocycle substituted with 0-3 R 58 aryl substituted with 0-3 R 58 and C 1 -C 5 alkyl substituted with 1-3 R 5 9 R 57 is selected from the group: heterocycle substituted with 0-3 R 58 aryl substituted with 0-3 R 5 8 and C l C 5 alkyl substituted with 0-3 R 60 20 R 58 is independently selected at each occurrence from the group: -Cl, -Br, COOR 61 OR 61 C(=O)N(R 61 2 and C 1 -C 3 alkyl substituted with 0-3 R 62 R 59 is independently selected at each occurrence from the group: -Cl, -Br, COOR 6 1 OR 6 1 SC(=O)N(R 61 2 N(R 6 1) 2 and NHC(=) R 63 provided that at least one R 5 9 is NH(CFO)R 63 R 60 is independently selected at each occurrence from the group: -Cl, -Br, COOR 6 1 OR 6 1 C(=O)N(R 61 2 N(R 61 2 and NHC(=0)R 63 R 61 is independently selected at each occurrence from the group: H, and C1-Cs alkyl; R 62 is independently selected at each occurrence from the group: -Cl, -Br, COOR 64 OR 64 2 and NH(C=0)R 64 266 R 6 3 is independently selected at each occurrence from the group: aryl substituted with 0-3 R 65 and heterocycle substituted with 0-3 R 65 R 6 4 is independently selected at each occurrence from the group: H, and C 1 -C 5 alkyl; R 65 is independently selected at each occurrence from the group: -Cl, -Br, COOR 66 OR 66 and C(=O)N(R 66 2 and -R 66 is independently selected at each occurrence from the group: H, and C 1 -C 5 alkyl; A compound of claim 1, wherein: R 50 is independently selected from the group: -Cl, -N(R 52 )(R 53 and -CF 3 R 51 is independently selected from the group: -Cl, -CF 3 C 1 -C 3 alkyl, C 1 -C 3 alkoxy, and methylenedioxy; R 5 4 and R 5 5 are independently elected at each occurrence from the group: H, C 1 -C 3 alkyl, and CI-C 3 alkoxy; k" is 5-6; R 5 6 is selected from the group: pyridine substituted with 0-3 R 5 8 aryl substituted with 0-3 R 5 8 and Ci- C 3 alkyl substituted with 1-3 R 59 R 57 is selected from the group: pyridine substituted with 0-3 R 58 aryl substituted with 0-3 R 58 and C1- C 3 alkyl substituted with 0-3 R 60 267 8 i s Th pd~dfdeZItlY selected -at each occurrence from the group: -Cl, C00R 6 1 OR 6 1 and C(=O)N(R61) 2 R 5 9 is independently selected at each occurrence from the group: C00R 6 1 OR 6 1 C(=O)N(R 6 1 2 and NHC(=O)R 6 3 provided that at least one R 59 is NH R 6 3 R 60 is independently selected at each occurrence from the group: COOR 6 1 OR 6 1 C(=O)N(R 6 1 2 and NHC (=0)R 6 3 R 61 is independently selected at each occurrence from the group: H, and CI-C 5 alkyl; R 6 1 3 is independently selected at each occurrence from the group: phenyl substituted with 0-3 R 6 5 and pyridine substituted 'with 0-3 R 6 5 and, 20 R 65 is independent-ly selected at each occurrence. from the group: -Cl, C00R 66 and OR 6 6

3. A compound of claim 2, wherein: R 47 is phenyl or p-f luorophenyl; *R 4 8 is phenyl substituted- with 0-1 R 51 R 49 is C 2 -C 3 alkyl; R 51 is -F or methyle nedioxcy; R 5 4 and R 5 5 are independently H or methyl; R 56 is selected from the group: pyridine substituted with 0-1 R 58 phenyl substituted with 0-1 R 5 8 and Cl-C 3 alkyl substituted with 1-3 R 5 9 268 R 57 is selected from the group: pyridine substituted with 0-1 R 58 phenyl substituted with 0-1 R 5 8 and C 1 -C3 alkyl substituted with 0-3 R 60 R 58 is independently selected at each occurrence from the group: COOH, and OH; R 59 is independently selected at each occurrence from the group: COOH, OH, and NHC(=O)R 63 provided that at least one R 5 9 is NH(C=O)R 6 3 R 60 is independently selected at each occurrence from the group: COOH, OH, C(=O)NH2, and NHC(=)R 6 3 R 61 is independently selected at each occurrence from the group: H, and CI-C3 alkyl; 20 R 63 is independently selected at each occurrence from the group: phenyl substituted with 0-1 R 65 and pyridine substituted with 0-1 R 65 and R 65 is independently selected at each occurrence from the group: -Cl, COOH, and OH.

4. The compounds of claim 3 that are: N N H 269 COOH and, NN O N- COOH H H O-'

5. The method of treating disease in a mammal associated with infection and inflammation comprising administering to said mammal a therapeutically effective amount of a compound of claim 1. S*

6. A compound having the formula: We* -O-(CR 5 4 R 5 5 wherein We' is selected from the group: OH R 47 N R 4

7 R 48 and R49 wherein, R 4 7 is selected from the group: C 1 -C 6 alkyl substituted with 0-3 R 50 C 1 -C 6 alkoxy substituted with 0-3 R 50 aryl substituted with 0-3 R 5 1 and heterocycle substituted with 0-3 R 51 270 R 4 8 and R 49 are selected from the group: Cl-C3 alkyl, C2-03 alkenyl, cyclopropyl, cyclopropylmethyl, and aryl substituted with 0-3 R 51 R 50 is independently selected from the group: -F, -Cl, -Br, -N(RS 2 (R 5 3 and -OF 3 R 51 is independently selected from the group: -F, -Cl, -Br, -N(R 5 2 (R 5 3 -CIF3, 01-03 alkyl, 01-03 alkoxy, and methylenedioxy; R 5 2 and R 5 3 are independently H or 01-03 alkyl; R 5 4 and R 55 are independently selected at each occurrence from the group: H, 01-05 alkyl, and Cl-C5 alkoxy, or alternatively, R 54 and R 55 may be taken together *to form a 3-6 membered cycloalkyl; k" is 4-7; is selected from-the group: C(=0)'HR 5 6 NHC(=0)R 5 6 and NHC NHR 5 7 R 56 is selected from the group: aromatic heterocycle substituted with 0-3 R 5 8 aryl substituted with 0-3 R 5 8 and 0j-C5 alkyl substituted with 1-3 R 5 9 R 57 is selected from the group: heterocycle substituted with 0-3 R 5 8 aryl substituted with 0-3 R 5 8 and Cs.- alkyl substituted with 0-3 R 60 R 58 is independently selected at each occurrence from the group: -Cl, -Br, C00R 6 1 OR 61 'CV0O)N(I 6 1 2 and 01-03 alkyl substituted with 0-3 R 62 R 59 is independently selected at each occurrence from the group: -Cl, -Br, COOR 6 1 OR 6 1 C(=0)N(R 6 1 N(R 6 1 2 and NHCC'O)R 6 3 provided that at least one R 5 9 is NHIC;=)R 6 3 271 R 60 is independently selected at each occurrence from the group: -Cl. -Br, COOR 6 1 OR 6 1 C(=O)N(R 6 1 2 N(R 6 1 2 and NHC(=O)R 6 3 R 61 is independently selected at each occurrence from the group: H, and CI-C 5 alkyl; R 62 is independently selected at each occurrence from the group: -Cl, -Br, COOR 6 4 OR 6 4 2 and NH(C=0)R 6 4 R 6 3 is independently selected at each occurrence from the group: aryl substituted with 0-3 R 6 5 and heterocycle substituted with 0-3 R 65 R 6 4 is independently selected at each occurrence from the group: H, and CI-C 5 alkyl; *o• R 6 5 is independently selected at each occurrence from the group: -Br, COOR 6 6 OR 6 6 and C(=O)N(R 6 6 2 and R 66 is independently selected at each occurrence from the group: H, and CI-C 5 alkyl; substantially as herein described with reference to any one of the accompanying Examples. S 7. A method of treating disease in a mammal associated with infection and inflammation comprising administering to said mammal a therapeutically effective amount of a compound of claim 1, substantially as herein described with reference to the accompanying Examples. DATED this 29 th day of May, 2001. DUPONT PHARMACEUTICALS COMPANY By their Patent Attorneys: CALLINAN LAWRJE 272